{"4a48b64a87ac1e581cf2ac73dbecb18271c2d5a5": [["IntroductionNatural swimming ponds (NSPs) are artificially created bodies of water intended for human recreation, characterised by the substitution of chemical disinfection with natural biological processes for water purification.", [["human", "ORGANISM", 96, 101], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["human recreation", "TREATMENT", 96, 112], ["chemical disinfection", "TREATMENT", 151, 172], ["natural biological processes", "TREATMENT", 178, 206], ["water purification", "TREATMENT", 211, 229]]], ["The first NSP in recent times was built in Austria in the early 1980s, and by 2010 more than 20,000 NSPs had been constructed of which a hundred were open to the public (Littlewood 2005) cited in (Casanovas-Massana and Blanch 2013) .IntroductionDespite the growing popularity of these natural systems, little is known regarding the adequacy of the natural processes for enteric pathogen removal to provide adequate water quality for swimmers.", [["enteric pathogen removal", "TREATMENT", 370, 394], ["growing", "OBSERVATION_MODIFIER", 257, 264], ["popularity", "OBSERVATION_MODIFIER", 265, 275], ["natural systems", "OBSERVATION", 285, 300]]], ["Also, it is well known by health authorities that most recreational disease is not identified in normal health surveillance programs (Fewtrell and Kay 2015) , hence the majority go unreported even though there may be significant impacts on society including lost work days (Dwight et al. 2005) .", [["significant", "OBSERVATION_MODIFIER", 217, 228], ["impacts", "OBSERVATION", 229, 236]]], ["In general, the chlorine-resistant parasitic protozoan, Cryptosporidium hominis is the leading cause of gastroenteritis in swimming pools, and results from faecal accidents/releases (Suppes et al. 2016 ) referred to in this paper as bather shedding.", [["chlorine", "CHEMICAL", 16, 24], ["parasitic protozoan", "DISEASE", 35, 54], ["Cryptosporidium hominis", "DISEASE", 56, 79], ["gastroenteritis", "DISEASE", 104, 119], ["faecal accidents", "DISEASE", 156, 172], ["chlorine", "CHEMICAL", 16, 24], ["chlorine", "SIMPLE_CHEMICAL", 16, 24], ["Cryptosporidium hominis", "ORGANISM", 56, 79], ["faecal", "ORGANISM_SUBDIVISION", 156, 162], ["Cryptosporidium hominis", "SPECIES", 56, 79], ["Cryptosporidium hominis", "SPECIES", 56, 79], ["the chlorine", "TEST", 12, 24], ["resistant parasitic protozoan", "PROBLEM", 25, 54], ["Cryptosporidium hominis", "PROBLEM", 56, 79], ["gastroenteritis", "PROBLEM", 104, 119], ["Cryptosporidium hominis", "OBSERVATION", 56, 79], ["gastroenteritis", "OBSERVATION", 104, 119]]], ["Human faeces may contain pathogens and is a known pathway of infection in recreational water environments (Chalmers 2012 , Dale et al. 2010 , Graciaa et al. 2018 , Pond 2005 .", [["faeces", "ANATOMY", 6, 12], ["infection", "DISEASE", 61, 70], ["Human", "ORGANISM", 0, 5], ["faeces", "ORGANISM_SUBDIVISION", 6, 12], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human faeces", "PROBLEM", 0, 12], ["pathogens", "PROBLEM", 25, 34], ["infection", "PROBLEM", 61, 70], ["pathogens", "OBSERVATION", 25, 34], ["infection", "OBSERVATION", 61, 70]]], ["Hence, in a natural pool, without chemical disinfectant residual, expected bather shedding of pathogens will go untreated until the pool water is passed through sufficient 'natural' barriers, with human enteric viruses the most numerous and infectious of these enteric pathogens (Ashbolt 2015) .IntroductionWhile the social and health benefits associated with recreational water environments are well recognized, various outbreaks have been associated with microbiological contamination of recreational waters in natural ponds and lakes (Blostein 1991 , Paunio et al. 1999 , Sinclair et al. 2009 ) and inadequately disinfected swimming pools (Barna and K\u00e1d\u00e1r 2012, Sinclair et al. 2009 ).", [["human", "ORGANISM", 197, 202], ["enteric viruses", "ORGANISM", 203, 218], ["human", "SPECIES", 197, 202], ["human", "SPECIES", 197, 202], ["chemical disinfectant residual", "PROBLEM", 34, 64], ["pathogens", "PROBLEM", 94, 103], ["human enteric viruses", "TREATMENT", 197, 218], ["most numerous", "OBSERVATION_MODIFIER", 223, 236], ["infectious", "OBSERVATION_MODIFIER", 241, 251]]], ["Hence, the efficacy and reliability of disinfection treatments (natural or artificial) is central to maintaining the microbial safety of recreational waters.IntroductionThe design and operation of the first Canadian NSP in Edmonton was the focus of this microbial risk assessment.", [["disinfection treatments", "TREATMENT", 39, 62], ["natural or artificial)", "TREATMENT", 64, 86], ["operation", "TREATMENT", 184, 193], ["this microbial risk assessment", "TEST", 249, 279]]], ["The NSP treatment system designed by Polyplan Kreikenbaum Group GMBH (www.polyplan-umwelt.de) was part of a municipal pool upgrade.", [["GMBH", "CHEMICAL", 64, 68], ["The NSP treatment system", "TREATMENT", 0, 24], ["a municipal pool upgrade", "TREATMENT", 106, 130]]], ["As part of the planning process, potential faecal pathogen risks were evaluated, using a Quantitative Microbial Risk Assessment (QMRA) framework.", [["potential faecal pathogen risks", "PROBLEM", 33, 64]]], ["It is recommended to undertake QMRA at increasing levels of detail referred to as a tiered approach (WHO 2016) , beginning simply and only increasing complexity as needed.", [["QMRA", "TREATMENT", 31, 35]]], ["The objective of the screening level assessment, was to characterize the system in a very simplistic way, based on average flow rates (within a simple box flow model) and using available literature data assess factors driving illness risks from accidental ingestion of enteric viruses, bacteria and parasitic protozoa, and to identify future data collection needs for the purpose of quantify risks adequately to support health protection.Materials and MethodsThe NSP is part of a redevelopment of a public pool at Borden Park, Edmonton, Canada (https://www.edmonton.ca/activities_parks_recreation/borden-park-outdoor-pool.aspx).Materials and MethodsThe design consists of a large rectangular main pool, a shallow children's pool (referred to as kiddie pool), and an area of floor nozzles designed for children's water play.", [["illness", "DISEASE", 226, 233], ["parasitic protozoa", "DISEASE", 299, 317], ["children", "ORGANISM", 713, 721], ["children", "ORGANISM", 801, 809], ["children", "SPECIES", 713, 721], ["children", "SPECIES", 801, 809], ["the screening level assessment", "TEST", 17, 47], ["average flow rates", "TEST", 115, 133], ["a simple box flow model", "TREATMENT", 142, 165], ["enteric viruses", "PROBLEM", 269, 284], ["bacteria", "PROBLEM", 286, 294], ["parasitic protozoa", "PROBLEM", 299, 317], ["health protection", "TREATMENT", 420, 437], ["Methods", "TREATMENT", 452, 459], ["Methods", "TREATMENT", 642, 649], ["floor nozzles", "TREATMENT", 774, 787], ["enteric viruses", "ANATOMY", 269, 284], ["redevelopment", "OBSERVATION_MODIFIER", 480, 493], ["large", "OBSERVATION_MODIFIER", 674, 679], ["rectangular", "OBSERVATION_MODIFIER", 680, 691], ["main", "OBSERVATION_MODIFIER", 692, 696], ["pool", "OBSERVATION_MODIFIER", 697, 701], ["shallow", "OBSERVATION_MODIFIER", 705, 712]]], ["The water flow is connected between all pools (see Figure 1 ) via the pump well (B1) and is directed to external filtration units (Neptune filter, Hydrobotanic and submerse filters) for purification.Materials and MethodsThe public pool is fenced from wildlife, and fed by potable water from the mains drinking water supply, therefore the significant only source of faecal contamination considered in the assessment was from bathers.", [["faecal", "ANATOMY", 365, 371], ["water", "SIMPLE_CHEMICAL", 4, 9], ["Hydrobotanic", "SIMPLE_CHEMICAL", 147, 159], ["faecal", "ORGANISM_SUBSTANCE", 365, 371], ["The water flow", "TREATMENT", 0, 14], ["the pump well (B1)", "TREATMENT", 66, 84], ["external filtration units", "TREATMENT", 104, 129], ["Neptune filter", "TREATMENT", 131, 145], ["Hydrobotanic and submerse filters", "TREATMENT", 147, 180], ["purification", "TREATMENT", 186, 198], ["Methods", "TREATMENT", 213, 220], ["faecal contamination", "PROBLEM", 365, 385], ["the assessment", "TEST", 400, 414], ["water flow", "OBSERVATION", 4, 14], ["faecal contamination", "OBSERVATION", 365, 385]]], ["The first step in any QMRA is to undertake a problem formulation, defining clearly the purpose and scope of the assessment (WHO 2016).", [["the assessment", "TEST", 108, 122]]], ["To address each class of microbial pathogen (viral, bacterial, parasitic protozoan) for the first tier in the QMRA process, the following reference pathogens were selected to represent each microbial group: Norovirus, Campylobacter jejuni and Cryptosporidium hominis; with Norovirus and C. jejuni representing some of the most prevalent pathogenic enteric viruses and bacteria reported in Edmonton sewage (Banting et al. 2016 , Qiu et al. 2015 and known to infect recreational swimmers (Guy et al. 2018) ; C. hominis was selected as oocysts are known to be far more resistant to environmental decay processes than Giardia cysts (Hamilton et al. 2018 ).", [["Norovirus", "DISEASE", 207, 216], ["Campylobacter jejuni", "DISEASE", 218, 238], ["Cryptosporidium hominis", "DISEASE", 243, 266], ["Norovirus and C. jejuni", "DISEASE", 273, 296], ["enteric viruses", "DISEASE", 348, 363], ["Giardia cysts", "DISEASE", 614, 627], ["Norovirus", "ORGANISM", 207, 216], ["Campylobacter jejuni", "ORGANISM", 218, 238], ["Cryptosporidium hominis", "ORGANISM", 243, 266], ["C. jejuni", "ORGANISM", 287, 296], ["C. hominis", "ORGANISM", 506, 516], ["Campylobacter jejuni", "SPECIES", 218, 238], ["Cryptosporidium hominis", "SPECIES", 243, 266], ["C. jejuni", "SPECIES", 287, 296], ["C. hominis", "SPECIES", 506, 516], ["Campylobacter jejuni", "SPECIES", 218, 238], ["Cryptosporidium hominis", "SPECIES", 243, 266], ["C. jejuni", "SPECIES", 287, 296], ["C. hominis", "SPECIES", 506, 516], ["microbial pathogen", "PROBLEM", 25, 43], ["viral, bacterial, parasitic protozoan", "PROBLEM", 45, 82], ["Norovirus", "PROBLEM", 207, 216], ["Campylobacter jejuni", "PROBLEM", 218, 238], ["Cryptosporidium hominis", "PROBLEM", 243, 266], ["Norovirus", "PROBLEM", 273, 282], ["C. jejuni", "PROBLEM", 287, 296], ["pathogenic enteric viruses", "PROBLEM", 337, 363], ["bacteria", "PROBLEM", 368, 376], ["C. hominis", "PROBLEM", 506, 516], ["oocysts", "PROBLEM", 533, 540], ["Giardia cysts", "PROBLEM", 614, 627], ["Norovirus", "OBSERVATION", 207, 216], ["Campylobacter jejuni", "OBSERVATION", 218, 238], ["most prevalent", "OBSERVATION_MODIFIER", 322, 336], ["enteric viruses", "OBSERVATION", 348, 363]]], ["Risk to adults and children were considered separately and compared with the gastrointestinal benchmark of the U.S. EPA for freshwaters of 35 cases of gastroenteritis per 1000 swimming events (EPA.", [["gastrointestinal", "ANATOMY", 77, 93], ["EPA", "CHEMICAL", 116, 119], ["gastroenteritis", "DISEASE", 151, 166], ["EPA", "CHEMICAL", 193, 196], ["children", "ORGANISM", 19, 27], ["gastrointestinal", "ORGAN", 77, 93], ["children", "SPECIES", 19, 27], ["gastroenteritis", "PROBLEM", 151, 166], ["gastroenteritis", "OBSERVATION", 151, 166]]], ["2012).Materials and MethodsExposure scenarios included in the risk assessment were for unintentional shedding during normal operation (nominal load = 252 adults and 17 children;Materials and Methodshigh bather load estimated as 1.5 times the nominal value =378 adults and 26 children) andMaterials and Methodslarger faecal release events.Materials and MethodsFirst the magnitude of pathogen contamination due to unintentional bather shedding was estimated; and the level of treatment required in order to achieve the benchmark risk was quantified.", [["children", "ORGANISM", 275, 283], ["children", "SPECIES", 168, 176], ["children", "SPECIES", 275, 283], ["the risk assessment", "TEST", 58, 77], ["unintentional shedding", "PROBLEM", 87, 109], ["normal operation", "TREATMENT", 117, 133], ["Methodslarger faecal release events", "PROBLEM", 302, 337], ["Methods", "TREATMENT", 352, 359], ["pathogen contamination", "PROBLEM", 382, 404], ["unintentional bather shedding", "PROBLEM", 412, 441], ["treatment", "TREATMENT", 474, 483]]], ["The capacity of the designed filtration system for treating the pathogen load at the benchmark risk level was then assessed, including the system response to larger pathogen release incidents.", [["the designed filtration system", "TREATMENT", 16, 46], ["the pathogen load", "PROBLEM", 60, 77], ["larger", "OBSERVATION_MODIFIER", 158, 164], ["pathogen", "OBSERVATION", 165, 173]]], ["The overall objective of the assessment was to assess the adequacy of the proposed treatment system for managing pathogen risks to bathers, and to identify future research needs to better characterize safety.Magnitude of pathogen contamination due to unintentional bather sheddingEnteric pathogens are transmitted by the faecal-oral route, and therefore the presence of pathogens in the water column is caused by shedding of faecal material by swimmers.", [["oral", "ANATOMY", 328, 332], ["faecal", "ORGANISM_SUBDIVISION", 321, 327], ["oral", "ORGANISM_SUBDIVISION", 328, 332], ["faecal material", "MULTI-TISSUE_STRUCTURE", 425, 440], ["the assessment", "TEST", 25, 39], ["the proposed treatment system", "TREATMENT", 70, 99], ["pathogen contamination", "PROBLEM", 221, 243], ["unintentional bather sheddingEnteric pathogens", "PROBLEM", 251, 297], ["pathogens in the water column", "PROBLEM", 370, 399], ["shedding of faecal material", "PROBLEM", 413, 440], ["pathogen contamination", "OBSERVATION", 221, 243], ["pathogens", "OBSERVATION", 370, 379], ["water column", "OBSERVATION", 387, 399]]], ["In this model, the pathogen loading under typical operating conditions was estimated asMagnitude of pathogen contamination due to unintentional bather sheddingwhere N is the discrete number of people visiting the facility per day infected with a reference pathogen, f s is the amount of faecal material (grams) shed per person per day, and c rp is the concentration of reference pathogens in the faeces of infected individuals (organisms.g -1 ).", [["faeces", "ANATOMY", 396, 402], ["pathogen contamination", "DISEASE", 100, 122], ["people", "ORGANISM", 193, 199], ["c rp", "GENE_OR_GENE_PRODUCT", 340, 344], ["faeces", "ORGANISM_SUBDIVISION", 396, 402], ["organisms.g -1", "CELL", 428, 442], ["people", "SPECIES", 193, 199], ["person", "SPECIES", 320, 326], ["the pathogen loading", "PROBLEM", 15, 35], ["pathogen contamination", "PROBLEM", 100, 122], ["reference pathogens", "PROBLEM", 369, 388], ["infected individuals", "PROBLEM", 406, 426], ["infected", "OBSERVATION", 406, 414]]], ["Given the number of visitors (n), and the point prevalence (pp) of shedding in the general population the discrete number of shedders on any given day was modelled using a binomial distribution with parameters n and pp.", [["discrete", "OBSERVATION_MODIFIER", 106, 114], ["number", "OBSERVATION_MODIFIER", 115, 121]]], ["A sample of the number of shedders was generated using Monte Carlo simulation (10, 000 iterations).Magnitude of pathogen contamination due to unintentional bather sheddingFaecal shedding: Unintentional shedding of faecal material by bathers is widely documented (Elmir et al. 2009 , Elmir et al. 2007 , Gerba 2000 .", [["faecal material", "MULTI-TISSUE_STRUCTURE", 214, 229], ["pathogen contamination", "PROBLEM", 112, 134], ["Unintentional shedding of faecal material", "PROBLEM", 188, 229]]], ["The amount of faeces shed per person is highly uncertain and was estimated relying on measurements from the literature of faecal indicator concentrations in bathing waters.", [["faeces", "ORGANISM_SUBSTANCE", 14, 20], ["faecal", "ORGANISM_SUBSTANCE", 122, 128], ["person", "SPECIES", 30, 36], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["faeces", "OBSERVATION", 14, 20]]], ["Details of this analysis is included in supplementary material.", [["this analysis", "TEST", 11, 24]]], ["Given the uncertainty in shedding mass, a reference distribution to describe the variability in faecal excretion was implemented in the model.", [["faecal", "ANATOMY", 96, 102], ["faecal", "ORGANISM_SUBSTANCE", 96, 102], ["shedding mass", "PROBLEM", 25, 38], ["faecal excretion", "TEST", 96, 112], ["shedding", "OBSERVATION_MODIFIER", 25, 33], ["mass", "OBSERVATION", 34, 38], ["faecal excretion", "OBSERVATION", 96, 112]]], ["We chose a triangular distribution (a distribution often used as a rough modelling tool where the range and most likely value within that range can be estimated (Vose, 2008) ) for faecal excretion with a mode equal to 0.6 and lower and upper bounds of 0.06 and 6 grams.Magnitude of pathogen contamination due to unintentional bather sheddingPathogen shedding density: Reported concentrations of pathogens in the faeces (shedding density) is variable.", [["faecal", "ANATOMY", 180, 186], ["faeces", "ANATOMY", 412, 418], ["faecal", "ORGANISM_SUBSTANCE", 180, 186], ["faeces", "ORGANISM_SUBDIVISION", 412, 418], ["faecal excretion", "TEST", 180, 196], ["pathogen contamination", "PROBLEM", 282, 304], ["unintentional bather sheddingPathogen shedding density", "PROBLEM", 312, 366], ["pathogens in the faeces", "PROBLEM", 395, 418], ["triangular", "OBSERVATION_MODIFIER", 11, 21], ["distribution", "OBSERVATION_MODIFIER", 22, 34], ["most likely", "UNCERTAINTY", 108, 119], ["upper", "ANATOMY_MODIFIER", 236, 241], ["pathogen contamination", "OBSERVATION", 282, 304], ["faeces", "ANATOMY", 412, 418], ["variable", "OBSERVATION_MODIFIER", 441, 449]]], ["The shedding density appears to vary between individuals, and over the course of an infection.", [["infection", "DISEASE", 84, 93], ["The shedding density", "PROBLEM", 0, 20], ["an infection", "PROBLEM", 81, 93], ["shedding", "OBSERVATION_MODIFIER", 4, 12], ["density", "OBSERVATION", 13, 20], ["to vary", "OBSERVATION_MODIFIER", 29, 36], ["infection", "OBSERVATION", 84, 93]]], ["Bambic et al. (2011) reviewed the published data and reported the following relevant to our chosen reference pathogens: a median Campylobacter concentration of 10 7 CFU.g -1 , ranging 10 1 -10 8 ; for Norovirus the median was 10 8 copies.g -1 , and a range of 10 4 -10 10 ; and for Cryptosporidium the median was 10 5 oocysts.g -1 , ranging 10 3 -10 6 .", [["Norovirus", "DISEASE", 201, 210], ["Norovirus", "ORGANISM", 201, 210], ["Cryptosporidium", "ORGANISM", 282, 297], ["a median Campylobacter concentration", "TEST", 120, 156], ["CFU.g", "TEST", 165, 170], ["Norovirus", "PROBLEM", 201, 210], ["Cryptosporidium", "TEST", 282, 297]]], ["The range limits and medians were used to define triangular distributions for the shedding density of each reference pathogen.Magnitude of pathogen contamination due to unintentional bather sheddingUsing a model constructed in Mathematica\u00ae (Wolfram International, version 11.1) a Monte Caro simulation (10, 000 random samples) was undertaken to obtain a random sample of the concentration of each reference pathogen in the main pool and the kiddie pool, assuming complete mixing.", [["triangular distributions", "PROBLEM", 49, 73], ["the shedding density of each reference pathogen", "PROBLEM", 78, 125], ["pathogen contamination", "PROBLEM", 139, 161], ["triangular", "OBSERVATION_MODIFIER", 49, 59], ["pathogen contamination", "OBSERVATION", 139, 161]]], ["The sensitivity of the estimated concentration to each of the model input variables (number of shedders, pathogen density in faeces and magnitude of faecal shedding by bathers) was evaluating using the Spearman Rank Correlation Coefficient to compare each of the input random samples with the generated concentration sample.Assessment of treatment requirements (QMRA)Quantitative microbial risk assessment (QMRA) was used to assess the amount of treatment required in order to achieve the U.S. EPA benchmark risk.", [["faeces", "ORGANISM_SUBDIVISION", 125, 131], ["faecal", "ORGANISM_SUBDIVISION", 149, 155], ["the model input variables", "TEST", 58, 83], ["pathogen density in faeces", "PROBLEM", 105, 131], ["the generated concentration sample", "TEST", 289, 323], ["treatment requirements", "TREATMENT", 338, 360], ["Quantitative microbial risk assessment", "TEST", 367, 405], ["treatment", "TREATMENT", 446, 455]]], ["Using the approach illustrated in Figure 2 and the sample of pathogen concentrations from unintentional bather shedding, the required Log 10 reduction was estimated.", [["pathogen concentrations", "PROBLEM", 61, 84], ["Log 10 reduction", "TREATMENT", 134, 150]]], ["A random sample representing the variability in the treatment requirements was generated using the pathogen concentration samples described in the previous section.", [["A random sample", "TEST", 0, 15], ["the treatment requirements", "TREATMENT", 48, 74], ["the pathogen concentration samples", "TREATMENT", 95, 129]]], ["A summary of the model input assumptions is included in Table 2 .Pathogen reduction capacity of designed natural treatment systemA simple box model was applied, assuming complete mixing within each component of the model over each time step, to evaluate the overall pathogen reduction capacity of the treatment system.", [["the model input assumptions", "TEST", 13, 40], ["Pathogen reduction capacity", "TREATMENT", 65, 92], ["natural treatment systemA simple box model", "TREATMENT", 105, 147], ["the treatment system", "TREATMENT", 297, 317], ["pathogen", "OBSERVATION", 266, 274]]], ["Given the flow paths represented in Figure 1 and the standard and maximum flow rates included in Table 3 , together with the assumed Log 10 removal capacity of each of the barriers, the change in pathogen concentration over time was estimated.Pathogen reduction capacity of designed natural treatment systemFive removal barriers were considered in the scoping of the QMRA: a wetland system consisting of zooplankton filtering, a hydro-botanic filter and submerse sand/root filter; a commercial designed Neptune\u2122 surface spray gravel media filter; and UV disinfection ( Figure 1 ).", [["surface", "ANATOMY", 512, 519], ["the flow paths", "TEST", 6, 20], ["maximum flow rates", "TEST", 66, 84], ["the barriers", "TREATMENT", 168, 180], ["the change in pathogen concentration", "PROBLEM", 182, 218], ["Pathogen reduction capacity", "PROBLEM", 243, 270], ["natural treatment systemFive removal barriers", "TREATMENT", 283, 328], ["a wetland system", "TREATMENT", 373, 389], ["zooplankton filtering", "TREATMENT", 404, 425], ["a hydro-botanic filter", "TREATMENT", 427, 449], ["submerse sand/root filter", "TREATMENT", 454, 479], ["a commercial designed Neptune\u2122 surface spray gravel media filter", "TREATMENT", 481, 545], ["UV disinfection", "TREATMENT", 551, 566], ["change", "OBSERVATION_MODIFIER", 186, 192], ["pathogen concentration", "OBSERVATION", 196, 218], ["root filter", "OBSERVATION", 468, 479], ["media filter", "OBSERVATION", 533, 545], ["UV disinfection", "OBSERVATION", 551, 566]]], ["However, there is very limited published data on the performance of these NSP barriers (Bruns and Pepper, 2019) , so in combination with related literature estimates we provided reasonable point estimate and plausible ranges in Log 10 removals for each barrier to be applied within the Screening level QMRA model (Table 4 ).", [["Log 10 removals", "TREATMENT", 228, 243], ["each barrier", "TREATMENT", 248, 260], ["very", "OBSERVATION_MODIFIER", 18, 22]]], ["As such, triangular distributions (defined by mode [min and max]) were selected to describe the variability and uncertainty associated with the Log 10 removals.Pathogen reduction capacity of designed natural treatment systemZooplankton filtering: Zooplankton grazing is proposed to provide important in-situ disinfection in NSPs (Bruns and Peppler, 2019 ), yet requires careful consideration as to how well it may be expected to perform as a barrier for protection of human health.", [["systemZooplankton", "CHEMICAL", 218, 235], ["Zooplankton", "CHEMICAL", 247, 258], ["NSPs", "SIMPLE_CHEMICAL", 324, 328], ["human", "ORGANISM", 468, 473], ["human", "SPECIES", 468, 473], ["human", "SPECIES", 468, 473], ["the Log 10 removals", "TREATMENT", 140, 159], ["Pathogen reduction capacity", "PROBLEM", 160, 187], ["natural treatment systemZooplankton filtering", "TREATMENT", 200, 245], ["Zooplankton grazing", "TREATMENT", 247, 266], ["a barrier for protection of human health", "TREATMENT", 440, 480], ["triangular", "OBSERVATION_MODIFIER", 9, 19]]], ["Studies have shown that free-living environmental protozoa can ingest human enteric bacteria and protozoan pathogens including Cryptosporidium oocysts (Agasild and N\u00f5ges 2005 , Connelly et al. 2007 , Stott et al. 2003 , Trout et al. 2002 ).", [["Cryptosporidium oocysts", "DISEASE", 127, 150], ["human", "ORGANISM", 70, 75], ["Cryptosporidium oocysts", "ORGANISM", 127, 150], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["Studies", "TEST", 0, 7], ["human enteric bacteria", "PROBLEM", 70, 92], ["protozoan pathogens", "PROBLEM", 97, 116], ["Cryptosporidium oocysts", "PROBLEM", 127, 150]]], ["Yet very little is known regarding the rate that zooplankton can clear (oo)cysts from the surrounding water, however rates of 22-24 mL\u00b7grazer -1 \u00b7day -1 and 15-19 mL\u00b7grazer -1 \u00b7day -1 for Cryptosporidium oocysts and Giardia cysts respectively have been reported (Connelly et al. 2007 ).", [["cysts", "ANATOMY", 75, 80], ["cysts", "ANATOMY", 224, 229], ["Cryptosporidium oocysts", "DISEASE", 188, 211], ["Giardia cysts", "DISEASE", 216, 229], ["Cryptosporidium oocysts", "ORGANISM", 188, 211], ["Giardia cysts", "PATHOLOGICAL_FORMATION", 216, 229], ["cysts", "PROBLEM", 75, 80], ["rates", "TEST", 117, 122], ["mL\u00b7grazer", "TEST", 132, 141], ["Cryptosporidium oocysts", "PROBLEM", 188, 211], ["Giardia cysts", "PROBLEM", 216, 229], ["cysts", "OBSERVATION", 75, 80], ["oocysts", "OBSERVATION", 204, 211], ["Giardia cysts", "OBSERVATION", 216, 229]]], ["The filtration capacity of zooplankton reported by (Eydeler and Spieker 2010) cited in (Bruns and Peppler 2019) ranged from 8.5 to 64.8 mL\u00b7grazer -1 \u00b7day -1 for Rotatoria, Copepoda and Cladocera protozoa.Pathogen reduction capacity of designed natural treatment systemThe more pressing issue relates to the poorly documented fate of ingested pathogens within zooplankton and their faecal pellets.", [["Rotatoria", "SIMPLE_CHEMICAL", 161, 170], ["Copepoda", "SIMPLE_CHEMICAL", 172, 180], ["Cladocera protozoa", "ORGANISM", 185, 203], ["The filtration capacity", "TEST", 0, 23], ["Rotatoria", "TREATMENT", 161, 170], ["Pathogen reduction capacity", "PROBLEM", 204, 231], ["natural treatment system", "TREATMENT", 244, 268]]], ["Rather than inactivate and digest all ingested pathogens, there is growing evidence that pathogens may be concentrated within zooplankton, where they may be protected from external environmental stressors ultimately favoring their survival (Bichai et al. 2010 , Bichai et al. 2014 , Bichai et al. 2008 , Folkins et al. 2020 , Tang et al. 2011 .", [["all ingested pathogens", "PROBLEM", 34, 56], ["pathogens", "PROBLEM", 89, 98]]], ["So, while faecal pellets may accumulate within sediments and on plant surfaces, and unknown fraction may stay suspended or be resuspended.", [["faecal pellets", "ANATOMY", 10, 24], ["faecal", "ORGANISM_SUBSTANCE", 10, 16], ["faecal pellets", "TREATMENT", 10, 24]]], ["For these reasons, zooplankton filtering was not included as a barrier for pathogen removal within this screening-level assessment of the NSP system.Hydro-botanic and Submerse filter:Two parallel filters were proposed in the design of the NSP including: 1.", [["zooplankton filtering", "TREATMENT", 19, 40], ["pathogen removal", "TREATMENT", 75, 91], ["this screening", "TEST", 99, 113], ["level assessment", "TEST", 114, 130], ["Hydro-botanic and Submerse filter", "TREATMENT", 149, 182], ["Two parallel filters", "TREATMENT", 183, 203], ["NSP system", "ANATOMY", 138, 148], ["Submerse filter", "OBSERVATION", 167, 182], ["parallel", "OBSERVATION_MODIFIER", 187, 195], ["filters", "OBSERVATION", 196, 203]]], ["Hydro-botanic filter with a bed thickness of 2.00 m and a design retention time of 6-8 hours; and 2.", [["Hydro-botanic filter", "TREATMENT", 0, 20], ["a bed thickness", "TREATMENT", 26, 41], ["botanic filter", "OBSERVATION", 6, 20]]], ["Submerse filter with a bed thickness of 2.00 m; and a design retention time of 4-5 hours.Hydro-botanic and Submerse filter:While these two filters operate in parallel, regarding their likely removal efficiency they are considered here together due to the similarity of mechanisms.", [["Hydro-botanic", "CHEMICAL", 89, 102], ["Hydro-botanic", "CHEMICAL", 89, 102], ["Hydro-botanic", "SIMPLE_CHEMICAL", 89, 102], ["Submerse filter", "TREATMENT", 0, 15], ["a bed thickness", "TREATMENT", 21, 36], ["filter", "OBSERVATION", 9, 15], ["bed thickness", "OBSERVATION_MODIFIER", 23, 36], ["Submerse filter", "OBSERVATION", 107, 122], ["filters", "OBSERVATION", 139, 146], ["removal efficiency", "OBSERVATION", 191, 209]]], ["Mechanisms of pathogen removal within these filters include adsorption to soil and filter substratum, predation (noting issues identified for zooplankton filtering above), sedimentation, physical filtering of larger organisms and inactivation due to environmental exposure (pH, temperature, sunlightHydro-botanic and Submerse filter:[only for the hydro-botanic filter]).", [["pathogen removal", "TREATMENT", 14, 30], ["these filters", "TREATMENT", 38, 51], ["adsorption to soil and filter substratum", "TREATMENT", 60, 100], ["sedimentation", "PROBLEM", 172, 185], ["larger organisms", "PROBLEM", 209, 225], ["inactivation", "PROBLEM", 230, 242], ["environmental exposure", "PROBLEM", 250, 272], ["pH", "TEST", 274, 276], ["temperature", "TEST", 278, 289], ["sunlightHydro-botanic and Submerse filter", "TREATMENT", 291, 332], ["the hydro-botanic filter", "TREATMENT", 343, 367], ["pathogen", "OBSERVATION", 14, 22], ["filter substratum", "OBSERVATION", 83, 100], ["larger organisms", "OBSERVATION", 209, 225]]], ["Both filters have been estimated to achieve 10%Hydro-botanic and Submerse filter:reduction of E. coli (Bruns and Peppler 2019) .Hydro-botanic and Submerse filter:Limited data is available in the literature specifically for hydro-botanic and submerse filters however a range of removal performances for microorganisms have been reported for wastewater systems using subsurface wetlands, rock filters and reed beds (reviewed byHydro-botanic and Submerse filter:Verbyla (2015)).", [["Hydro-botanic", "CHEMICAL", 47, 60], ["Hydro-botanic", "CHEMICAL", 128, 141], ["byHydro-botanic", "CHEMICAL", 423, 438], ["Hydro-botanic", "SIMPLE_CHEMICAL", 47, 60], ["E. coli", "ORGANISM", 94, 101], ["Hydro-botanic", "SIMPLE_CHEMICAL", 128, 141], ["hydro-botanic", "SIMPLE_CHEMICAL", 223, 236], ["E. coli", "SPECIES", 94, 101], ["E. coli", "SPECIES", 94, 101], ["Both filters", "TREATMENT", 0, 12], ["Submerse filter", "TREATMENT", 65, 80], ["E. coli", "PROBLEM", 94, 101], ["Hydro-botanic", "TREATMENT", 128, 141], ["Submerse filter", "TREATMENT", 146, 161], ["hydro-botanic and submerse filters", "TREATMENT", 223, 257], ["a range of removal", "TREATMENT", 266, 284], ["microorganisms", "PROBLEM", 302, 316], ["subsurface wetlands", "TREATMENT", 365, 384], ["rock filters", "TREATMENT", 386, 398], ["filters", "OBSERVATION", 5, 12], ["Submerse filter", "OBSERVATION", 65, 80], ["reduction", "OBSERVATION_MODIFIER", 81, 90], ["E. coli", "OBSERVATION", 94, 101], ["Submerse filter", "OBSERVATION", 146, 161]]], ["Bacterial reductions are in the range of 1.25 -2.5 Log 10 ; viruses 0.5 to 2Hydro-botanic and Submerse filter:Log 10 and parasitic protozoa between 0.4 and 3 Log 10 (Adhikari et al. 2013 , Bastos et al. 2010 , Garcia et al. 2010 , Gerba et al. 1999 , Jackson and Jackson 2008 , Karim et al. 2004 , Reinoso et al. 2008 , Stevik et al. 2004 , Vidales-Contreras et al. 2012 , Vidales et al. 2003 , Vymazal 2005 ; however noting that a key driver of removal is often the retention time within the filter, and retention times in these studies were typically in the order of days rather than hours proposed for the NSP.", [["2Hydro-botanic", "CHEMICAL", 75, 89], ["2Hydro-botanic", "SIMPLE_CHEMICAL", 75, 89], ["Bacterial reductions", "TEST", 0, 20], ["viruses", "TEST", 60, 67], ["2Hydro", "TEST", 75, 81], ["Submerse filter", "TREATMENT", 94, 109], ["parasitic protozoa", "PROBLEM", 121, 139], ["removal", "TREATMENT", 446, 453], ["the filter", "TREATMENT", 489, 499], ["these studies", "TEST", 524, 537], ["reductions", "OBSERVATION_MODIFIER", 10, 20], ["filter", "OBSERVATION", 493, 499]]], ["While the design only assumes 10% removal for each of these filters, it seems reasonable to assume that at least 1 Log 10 would be achieved for bacteria and protozoa, with a lower value of 0.5 Log 10 for viruses.Hydro-botanic and Submerse filter:Neptune filter: The Neptune filter system has a gravel medium depth of 2.00 to 2.20 m; and a retention time of 20 min was assumed by designers to have a higher E. coli removal efficacy of 90% in comparison to the hydro-botanic and submerse filters.", [["Hydro-botanic", "CHEMICAL", 212, 225], ["Hydro-botanic", "SIMPLE_CHEMICAL", 212, 225], ["E. coli", "ORGANISM", 406, 413], ["hydro-botanic", "SIMPLE_CHEMICAL", 459, 472], ["E. coli", "SPECIES", 406, 413], ["E. coli", "SPECIES", 406, 413], ["10% removal", "TREATMENT", 30, 41], ["these filters", "TREATMENT", 54, 67], ["bacteria", "PROBLEM", 144, 152], ["protozoa", "PROBLEM", 157, 165], ["a lower value", "TEST", 172, 185], ["viruses", "PROBLEM", 204, 211], ["Hydro-botanic", "TREATMENT", 212, 225], ["Submerse filter", "TREATMENT", 230, 245], ["Neptune filter", "TREATMENT", 246, 260], ["The Neptune filter system", "TREATMENT", 262, 287], ["a gravel medium depth", "TREATMENT", 292, 313], ["a higher E. coli removal efficacy", "TREATMENT", 397, 430], ["the hydro-botanic and submerse filters", "TREATMENT", 455, 493], ["Submerse filter", "OBSERVATION", 230, 245], ["Neptune filter", "OBSERVATION", 246, 260], ["gravel", "OBSERVATION_MODIFIER", 294, 300], ["medium", "OBSERVATION_MODIFIER", 301, 307], ["depth", "OBSERVATION_MODIFIER", 308, 313], ["coli removal", "OBSERVATION", 409, 421], ["submerse filters", "OBSERVATION", 477, 493]]], ["Challenge studies with coliphage (assumed to be a reasonable human enteric virus surrogate to mimic their) on similar filters has shown between 95 and 99% reduction (Bruns and Peppler 2019) .Hydro-botanic and Submerse filter:UV disinfection: UV disinfection is considered as an option in the design of the treatment system.", [["Hydro-botanic", "CHEMICAL", 191, 204], ["human", "ORGANISM", 61, 66], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["Challenge studies", "TEST", 0, 17], ["coliphage", "PROBLEM", 23, 32], ["a reasonable human enteric virus surrogate", "TREATMENT", 48, 90], ["similar filters", "TREATMENT", 110, 125], ["Hydro-botanic", "TREATMENT", 191, 204], ["Submerse filter", "TREATMENT", 209, 224], ["UV disinfection", "TREATMENT", 225, 240], ["UV disinfection", "TREATMENT", 242, 257], ["the treatment system", "TREATMENT", 302, 322], ["Submerse filter", "OBSERVATION", 209, 224], ["UV disinfection", "OBSERVATION", 225, 240], ["UV disinfection", "OBSERVATION", 242, 257]]], ["The most extensive meta-analysis review of data relating to pathogen sensitivity to UV has is by Hijnen et al. (Hijnen et al. 2006 Hijnen et al. (2006) , it is noted that if human adenovirus results were used, the Log 10 would be 0.5, rather than 2.6.Hydro-botanic and Submerse filter:Given a starting level of contamination of 500 Campylobacter per L; 10 000 Norovirus per L and 10 Cryptosporidium oocysts per L; the flow path model was run to estimate the decrease in concentration over time, and the subsequent Log 10 reduction in the main pool and the kiddie pool, at 1 minute time steps for 24 hours.", [["UV", "CHEMICAL", 84, 86], ["Hydro-botanic", "CHEMICAL", 251, 264], ["Hydro-botanic", "CHEMICAL", 251, 264], ["human", "ORGANISM", 174, 179], ["adenovirus", "ORGANISM", 180, 190], ["Hydro-botanic", "SIMPLE_CHEMICAL", 251, 264], ["human", "SPECIES", 174, 179], ["human", "SPECIES", 174, 179], ["pathogen sensitivity", "PROBLEM", 60, 80], ["human adenovirus", "TEST", 174, 190], ["Hydro-botanic", "TREATMENT", 251, 264], ["Submerse filter", "TREATMENT", 269, 284], ["Cryptosporidium oocysts", "PROBLEM", 383, 406], ["the flow path model", "TEST", 414, 433], ["the subsequent Log 10 reduction", "TREATMENT", 499, 530], ["Submerse filter", "OBSERVATION", 269, 284], ["decrease", "OBSERVATION_MODIFIER", 458, 466], ["concentration", "OBSERVATION_MODIFIER", 470, 483], ["main", "OBSERVATION_MODIFIER", 538, 542]]], ["The model was run with and without the proposed UV disinfection units.Hydro-botanic and Submerse filter:Given the importance of system water turnover time through treatment on the overall estimated pathogen reduction, estimated Log 10 reductions were evaluated for turnover periods of 1, 2, 4, 6 and 8 hours.", [["Hydro-botanic", "CHEMICAL", 70, 83], ["Hydro-botanic", "CHEMICAL", 70, 83], ["Hydro-botanic", "SIMPLE_CHEMICAL", 70, 83], ["the proposed UV disinfection units", "TREATMENT", 35, 69], ["Hydro-botanic", "TREATMENT", 70, 83], ["Submerse filter", "TREATMENT", 88, 103], ["treatment", "TREATMENT", 163, 172], ["the overall estimated pathogen reduction", "TREATMENT", 176, 216], ["UV disinfection", "OBSERVATION", 48, 63], ["Submerse filter", "OBSERVATION", 88, 103], ["pathogen", "OBSERVATION_MODIFIER", 198, 206], ["reduction", "OBSERVATION_MODIFIER", 207, 216]]], ["Noting that current design turnover of the main pool was specified at 11 and 7.4 hours for standard and maximum flow rates respectively; and in the kiddie pool, 4 and 2.7 hours respectively.Event scenariosIn addition to regular contamination, the response of the system to a larger scale faecal release event was investigated.", [["faecal", "ANATOMY", 288, 294], ["faecal", "ORGANISM_SUBSTANCE", 288, 294], ["maximum flow rates", "TEST", 104, 122], ["a larger scale faecal release", "TREATMENT", 273, 302], ["contamination", "OBSERVATION", 228, 241]]], ["The flow model was applied to assess the response to an accidental release by an ill swimmer.", [["The flow model", "TREATMENT", 0, 14], ["an accidental release", "TREATMENT", 53, 74], ["flow model", "OBSERVATION", 4, 14]]], ["The fate of a large pathogen release (faeces or vomitus) 10 10 Campylobacter; 10 12 Norovirus and 10 8 Cryptosporidium oocysts occurring in either the main pool, kiddie pool or at the floor nozzles was modelled in all three locations over 24 hours.Normal operation: estimated distribution of pathogen contaminationThe Monte Carlo sample of the number of shedders visiting the pool per day is illustrated for the main pool and the kiddie pool in Figures 3 & 4 , respectively.", [["oocysts", "ANATOMY", 119, 126], ["Norovirus", "DISEASE", 84, 93], ["Cryptosporidium oocysts", "DISEASE", 103, 126], ["faeces", "ORGANISM_SUBDIVISION", 38, 44], ["a large pathogen release (faeces or vomitus)", "PROBLEM", 12, 56], ["Campylobacter", "TEST", 63, 76], ["Norovirus", "PROBLEM", 84, 93], ["8 Cryptosporidium oocysts", "PROBLEM", 101, 126], ["pathogen contamination", "PROBLEM", 292, 314], ["large", "OBSERVATION_MODIFIER", 14, 19], ["pathogen", "OBSERVATION", 20, 28], ["oocysts", "OBSERVATION", 119, 126], ["operation", "OBSERVATION", 255, 264], ["distribution", "OBSERVATION_MODIFIER", 276, 288], ["pathogen contamination", "OBSERVATION", 292, 314]]], ["When prevalence was low, the estimated concentration was primarily driven by the number of shedders present in the pool.", [["the estimated concentration", "PROBLEM", 25, 52]]], ["As the prevalence of infection increased (for example from Cryptosporidium to Norovirus), and hence the likelihood of one or more shedders increased, the modelled concentration was then driven by the pathogen density in faeces.Pathogen removal capacity of the treatment systemThe estimated decrease in average pathogen concentration over time, and subsequent Log 10 reduction in the main swimming pool is illustrated for Norovirus in Figure 9 (Campylobacter and Cryptosporidium are illustrated in Figures S.2 and S.3) .", [["faeces", "ANATOMY", 220, 226], ["infection", "DISEASE", 21, 30], ["Cryptosporidium to Norovirus", "DISEASE", 59, 87], ["Norovirus", "DISEASE", 421, 430], ["faeces", "ORGANISM_SUBDIVISION", 220, 226], ["infection", "PROBLEM", 21, 30], ["Cryptosporidium", "PROBLEM", 59, 74], ["Norovirus", "PROBLEM", 78, 87], ["Pathogen removal", "TREATMENT", 227, 243], ["the treatment system", "TREATMENT", 256, 276], ["The estimated decrease in average pathogen concentration", "PROBLEM", 276, 332], ["subsequent Log 10 reduction", "TREATMENT", 348, 375], ["Norovirus", "PROBLEM", 421, 430], ["Campylobacter", "PROBLEM", 444, 457], ["Cryptosporidium", "PROBLEM", 462, 477], ["infection", "OBSERVATION", 21, 30], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["increased", "OBSERVATION_MODIFIER", 139, 148], ["pathogen density", "OBSERVATION", 200, 216], ["decrease", "OBSERVATION_MODIFIER", 290, 298], ["average", "OBSERVATION_MODIFIER", 302, 309], ["pathogen", "OBSERVATION_MODIFIER", 310, 318], ["concentration", "OBSERVATION_MODIFIER", 319, 332], ["main", "OBSERVATION_MODIFIER", 383, 387]]], ["The lower 2.5% and upper 97.5% quantiles of the Monte Carlo simulation are illustrated with dashed lines around the solid median line.", [["the Monte Carlo simulation", "TREATMENT", 44, 70], ["dashed lines", "TREATMENT", 92, 104], ["the solid median line", "TREATMENT", 112, 133], ["lower", "ANATOMY_MODIFIER", 4, 9], ["upper", "ANATOMY_MODIFIER", 19, 24], ["solid", "OBSERVATION", 116, 121], ["median line", "OBSERVATION", 122, 133]]], ["In all cases, the maximum Log 10 reduction that could be achieved over a 24 h period in the main pool, both with and without the application of UV disinfection, was around 1 Log 10 .", [["the maximum Log 10 reduction", "TREATMENT", 14, 42], ["UV disinfection", "TREATMENT", 144, 159], ["UV disinfection", "OBSERVATION", 144, 159]]], ["In each case the achievable Log 10 reduction was limited by the flow rate through the external filtration/treatment system.", [["the flow rate", "TEST", 60, 73], ["the external filtration/treatment system", "TREATMENT", 82, 122]]], ["The dashed lines (95% quantile interval of the Monte Carlo sample) represent the influence that the uncertainty in assumed pathogen removal performance by treatment had on the overall estimated reduction in pathogen concentration, and hence the achieved Log 10 reduction.", [["dashed lines", "CELL", 4, 16], ["dashed lines", "CELL_LINE", 4, 16], ["The dashed lines", "TREATMENT", 0, 16], ["the Monte Carlo sample)", "TREATMENT", 43, 66], ["pathogen removal performance", "TREATMENT", 123, 151], ["treatment", "TREATMENT", 155, 164], ["pathogen concentration", "TREATMENT", 207, 229], ["the achieved Log 10 reduction", "TREATMENT", 241, 270], ["reduction", "OBSERVATION_MODIFIER", 194, 203], ["pathogen concentration", "OBSERVATION", 207, 229]]], ["This uncertainty was highest for viruses, since a low reduction was assumed across treatment barriers, and the plausible range included in the stochastic analysis was broad.", [["viruses", "PROBLEM", 33, 40], ["a low reduction", "PROBLEM", 48, 63], ["treatment barriers", "TREATMENT", 83, 101], ["highest", "OBSERVATION_MODIFIER", 21, 28], ["viruses", "OBSERVATION", 33, 40], ["low reduction", "OBSERVATION_MODIFIER", 50, 63]]], ["However, the addition of UV disinfection eliminated the impact of this uncertainty on estimated pathogen reduction in all cases, clearly demonstrating the limiting factor of system return flow rate and pool water dilution.", [["UV disinfection", "TREATMENT", 25, 40], ["estimated pathogen reduction", "TREATMENT", 86, 114], ["pool water dilution", "TREATMENT", 202, 221], ["UV disinfection", "OBSERVATION", 25, 40], ["pathogen", "OBSERVATION_MODIFIER", 96, 104], ["reduction", "OBSERVATION_MODIFIER", 105, 114], ["water dilution", "OBSERVATION", 207, 221]]], ["For the Kiddie pool, a higher overall Log 10 reduction could be achieved within the kiddie pool, in comparison to the main pool, due to the decrease in turnover time (4 h in comparison to 11 h for the main pool) for the system flow rates (illustrated in Figures S.4 ,S.5 and S.6) The maximum achievable reduction in concentration with UV disinfection was more than 3.5 Log 10 for all pathogens (with the maximum flow rate) over 24 hours.Pathogen removal capacity of the treatment systemThe relationship between turnover time and achievable Log 10 reduction for each reference pathogen is illustrated in Figure 9 .", [["UV", "CHEMICAL", 335, 337], ["a higher overall Log 10 reduction", "TREATMENT", 21, 54], ["the system flow rates", "TEST", 216, 237], ["Figures", "TEST", 254, 261], ["The maximum achievable reduction in concentration", "TREATMENT", 280, 329], ["UV disinfection", "TREATMENT", 335, 350], ["all pathogens", "PROBLEM", 380, 393], ["the maximum flow rate", "TEST", 400, 421], ["Pathogen removal", "TREATMENT", 437, 453], ["the treatment system", "TREATMENT", 466, 486], ["achievable Log 10 reduction", "TREATMENT", 529, 556], ["decrease", "OBSERVATION_MODIFIER", 140, 148], ["maximum", "OBSERVATION_MODIFIER", 284, 291], ["achievable", "OBSERVATION_MODIFIER", 292, 302], ["reduction", "OBSERVATION_MODIFIER", 303, 312], ["concentration", "OBSERVATION_MODIFIER", 316, 329], ["UV disinfection", "OBSERVATION", 335, 350]]], ["Reducing the turnover time increases the achievable Log 10 reduction.", [["the achievable Log 10 reduction", "TREATMENT", 37, 68]]], ["Nevertheless, achieving greater than 3 Log 10 reduction in concentration over 8 h, regardless of treatment barriers, would require an hourly turnover time.Event analysisAside from the unintentional faecal wash-off assumed by normal bathing, accidental faecal releases (AFR) or vomitus releases can and do occur in public swimming pools.", [["faecal", "ANATOMY", 252, 258], ["faecal", "ORGANISM_SUBSTANCE", 198, 204], ["faecal", "ORGANISM_SUBSTANCE", 252, 258], ["treatment barriers", "TREATMENT", 97, 115], ["the unintentional faecal wash", "TREATMENT", 180, 209], ["vomitus", "PROBLEM", 277, 284]]], ["This situation was modelled as an event that could occur in one of three locations: the main pool, the kiddie pool or the floor nozzles ( Figure 2 ).", [["the floor nozzles", "TREATMENT", 118, 135]]], ["The full results for event analysis are included in the Supplementary Material.", [["event analysis", "TEST", 21, 35]]], ["Highest risks and hence greatest removal performance was required for Norovirus, followed by Campylobacter.", [["Norovirus", "DISEASE", 70, 79], ["Highest risks", "PROBLEM", 0, 13], ["greatest removal performance", "TREATMENT", 24, 52], ["Norovirus", "PROBLEM", 70, 79], ["Campylobacter", "PROBLEM", 93, 106], ["Campylobacter", "OBSERVATION", 93, 106]]], ["Even under the modelled event scenarios, the risks from Cryptosporidium were calculated to be low.", [["Cryptosporidium", "DISEASE", 56, 71], ["Cryptosporidium", "ORGANISM", 56, 71], ["Cryptosporidium", "PROBLEM", 56, 71]]], ["When the release occurred within the kiddie pool or the main pool, the recovery of the system was slow within that pool.", [["main", "OBSERVATION_MODIFIER", 56, 60]]], ["UV disinfection did not improve this recovery period.", [["UV disinfection", "TREATMENT", 0, 15], ["disinfection", "OBSERVATION", 3, 15]]], ["Nevertheless, UV disinfection reduced or prevented the risks being carried across the entire system.", [["UV disinfection", "TREATMENT", 14, 29], ["UV disinfection", "OBSERVATION", 14, 29]]], ["For example for Norovirus risks following an event in the kiddie pool ( Figure S.8) , UV disinfection reduced the peak reduction requirements in the main pool from over 4 Log 10 to below 2 Log 10 , and the risk at the floor nozzles was reduced from requiring around 5 Log 10 to just over 2 Log 10 .", [["Norovirus", "DISEASE", 16, 25], ["UV", "CHEMICAL", 86, 88], ["Norovirus risks", "PROBLEM", 16, 31], ["UV disinfection", "TREATMENT", 86, 101], ["the peak reduction requirements", "PROBLEM", 110, 141], ["Norovirus", "OBSERVATION", 16, 25], ["UV disinfection", "OBSERVATION", 86, 101], ["reduced", "OBSERVATION_MODIFIER", 102, 109], ["peak", "OBSERVATION_MODIFIER", 114, 118], ["reduction", "OBSERVATION_MODIFIER", 119, 128], ["requirements", "OBSERVATION_MODIFIER", 129, 141], ["main", "OBSERVATION_MODIFIER", 149, 153], ["pool", "OBSERVATION_MODIFIER", 154, 158]]], ["For Campylobacter, for a pathogen release in the main pool (Event 3), the inclusion of UV disinfection totally mitigated the risk in the kiddie pool or at the floor nozzle ( Figure S.13 ).DiscussionIt is well established that the prime source of pathogen risks in artificial swimming pools are the swimmers, who unintentionally or accidentally (due to illness) shed pathogens into the water column.", [["illness", "DISEASE", 352, 359], ["Campylobacter", "PROBLEM", 4, 17], ["a pathogen release", "PROBLEM", 23, 41], ["UV disinfection", "TREATMENT", 87, 102], ["Campylobacter", "OBSERVATION", 4, 17], ["UV disinfection", "OBSERVATION", 87, 102], ["water column", "ANATOMY", 385, 397]]], ["Hence, we estimated the likely level of pathogen contamination of the Edmonton natural swimming pool under normal operation and during potential event situations to explore how events and which pathogen groups may drive risk.", [["pathogen contamination", "PROBLEM", 40, 62], ["pathogen contamination", "OBSERVATION", 40, 62], ["normal operation", "OBSERVATION", 107, 123]]], ["Therefore, risks were summed on a Log scale and the combined risk of illness was driven by the highest risk group (enteric viruses).DiscussionThe approach applied for normal operation was based on the number of visitors to the pool and relied on assumptions regarding the incidence of infection in Alberta, and estimates of faecal and pathogen shedding from the literature.", [["faecal", "ANATOMY", 324, 330], ["illness", "DISEASE", 69, 76], ["infection", "DISEASE", 285, 294], ["faecal", "ORGANISM_SUBSTANCE", 324, 330], ["a Log scale", "TREATMENT", 32, 43], ["illness", "PROBLEM", 69, 76], ["normal operation", "TREATMENT", 167, 183], ["infection", "PROBLEM", 285, 294], ["faecal and pathogen shedding", "PROBLEM", 324, 352], ["infection", "OBSERVATION", 285, 294]]], ["The estimated concentration was variable and uncertain, given the extreme ranges of values reported in the literature (for example shedding of noroviruses was estimated to range from 10 1 to 10 7 copies.g -1 ).", [["noroviruses", "DISEASE", 143, 154], ["noroviruses", "ORGANISM", 143, 154], ["The estimated concentration", "TEST", 0, 27], ["noroviruses", "PROBLEM", 143, 154], ["concentration", "OBSERVATION_MODIFIER", 14, 27]]], ["Furthermore, our prevalence calculations were likely to be an overestimate given that we assumed that all people would be equally likely to attend the pool, regardless of their health status or whether they were recovering from an infection.", [["infection", "DISEASE", 231, 240], ["people", "ORGANISM", 106, 112], ["people", "SPECIES", 106, 112], ["our prevalence calculations", "TEST", 13, 40], ["an infection", "PROBLEM", 228, 240], ["infection", "OBSERVATION", 231, 240]]], ["It is unlikely that an individual who was actively ill, would desire to attend the NSP, yet asymptomatic carriers would.", [["asymptomatic carriers", "PROBLEM", 92, 113], ["unlikely", "UNCERTAINTY", 6, 14]]], ["In the absence of quantitative estimates on this, and recognizing that asymptomatic and extended shedding of pathogens (over weeks post illness) has been widely reported in the literature, it seemed wise to be cautious with the prevalence estimates and include all cases.", [["asymptomatic", "PROBLEM", 71, 83], ["pathogens", "PROBLEM", 109, 118]]], ["It is important to note that the variability in the number of shedders is a critical driver of the pathogen risk, and additional attention may be needed during periods of known higher community infection rates (e.g. during an outbreak).", [["infection", "DISEASE", 194, 203], ["known higher community infection rates", "PROBLEM", 171, 209], ["higher", "OBSERVATION_MODIFIER", 177, 183], ["community", "OBSERVATION_MODIFIER", 184, 193], ["infection", "OBSERVATION", 194, 203]]], ["This points to the importance of public education programs that encourage those who are or who have been unwell, to avoid swimming (as signposted at the Edmonton NSP).", [["public education programs", "TREATMENT", 33, 58]]], ["A message perhaps made easier given the COVID-19 pandemic.DiscussionWhen shedders were present and engaged in water activities the pathogen concentration and hence treatment requirements to maintain safety of other swimmers was estimated.DiscussionRisk from Cryptosporidium were consistently low in the calculations, however a reduction of up to 2 Log 10 and 4 Log 10 were estimated to be required within the main pool for The Alberta Health swimming pool standards (Alberta Health 2014) stipulate that a traditional chlorinated swimming pool constructed after November 2006 must have a turnover time of four hours.", [["Cryptosporidium", "ORGANISM", 258, 273], ["the COVID", "TEST", 36, 45], ["pandemic", "PROBLEM", 49, 57], ["the pathogen concentration", "TREATMENT", 127, 153], ["hence treatment requirements", "TREATMENT", 158, 186], ["Cryptosporidium", "PROBLEM", 258, 273], ["a reduction", "TEST", 325, 336], ["Cryptosporidium", "OBSERVATION", 258, 273]]], ["While the turnover time for a recirculating water spray park is lower at two hours, the standards also state that if 'a wading pool or recirculating water spray park is connected to a swimming pool, the turnover time for the swimming pool shall apply to the wading pool or water spray park'.", [["a recirculating water spray", "TREATMENT", 28, 55]]], ["Under the assumptions of the presented model, a four hour turnover time would achieve less than 1 Log 10 reduction for all reference pathogens.", [["all reference pathogens", "PROBLEM", 119, 142]]], ["Recently the provincial agency undertaking recreational water quality testing (ProvLab) moved to qPCR testing for Enterococcus spp. to indicate potential faecal contamination along with molecular testing for a human faecal marker (HF183) to detect faecal loadings, which are used on a daily basis at the Edmonton NSP to inform management.DiscussionGiven that the full-scale efficiency of the external filtration system is limited by turnover time, lack of knowledge regarding the impact of zooplankton grazing on viable pathogen numbers in the water column is a critical data gap in assessing the safety of the system.DiscussionSeveral studies have highlighted that pathogens are internalized by zooplankton in freshwater systems (Burnet et al. 2017 , Connelly et al. 2007 , Hahn and H\u00f6fle 2001 .", [["faecal", "ANATOMY", 154, 160], ["faecal", "ANATOMY", 216, 222], ["faecal", "ANATOMY", 248, 254], ["Enterococcus spp", "ORGANISM", 114, 130], ["faecal", "ORGANISM_SUBSTANCE", 154, 160], ["human", "ORGANISM", 210, 215], ["faecal", "ORGANISM_SUBSTANCE", 216, 222], ["faecal", "ORGANISM_SUBSTANCE", 248, 254], ["human", "SPECIES", 210, 215], ["Enterococcus spp", "SPECIES", 114, 130], ["human", "SPECIES", 210, 215], ["qPCR testing", "TEST", 97, 109], ["Enterococcus spp", "PROBLEM", 114, 130], ["potential faecal contamination", "PROBLEM", 144, 174], ["molecular testing", "TEST", 186, 203], ["a human faecal marker", "TEST", 208, 229], ["faecal loadings", "PROBLEM", 248, 263], ["the external filtration system", "TEST", 388, 418], ["zooplankton grazing", "TREATMENT", 490, 509], ["DiscussionSeveral studies", "TEST", 618, 643], ["pathogens", "PROBLEM", 666, 675], ["faecal contamination", "OBSERVATION", 154, 174]]], ["The question however remains as to whether internalization leads to permanent removal/inactivation of the pathogen, or whether pathogens are actually protected and their survival enhanced by internalization (Bichai et al. 2014 , Bichai et al. 2008 , Neogi et al. 2014 ).", [["permanent removal/inactivation", "TREATMENT", 68, 98], ["the pathogen", "PROBLEM", 102, 114], ["pathogens", "PROBLEM", 127, 136]]], ["Therefore, not only is an approach for quantifying the internalization rate of pathogens by zooplankton under full scale conditions needed, but also an understanding of the ultimate fate of internalized pathogens and what health risk they may pose to bathers.DiscussionIn addition, other internal inactivation processes including predation (considering now the entire microbiome/biofilm rather than zooplankton alone) and sunlight disinfection may be important health protection mechanisms.", [["biofilm", "ANATOMY", 379, 386], ["the internalization rate of pathogens", "TREATMENT", 51, 88], ["the entire microbiome/biofilm", "TREATMENT", 357, 386], ["sunlight disinfection", "TREATMENT", 422, 443]]], ["Unfortunately, the role of the natural microbiome in inactivation of pathogens is poorly understood, and at this stage not quantifiable.", [["pathogens", "PROBLEM", 69, 78]]], ["Investigation of the microbial inactivation within the site-specific water matrix of the NSP would be of great value.DiscussionWhile data does exist on sunlight inactivation of pathogens in fresh water (Bolton et al. 2010 , Dahl et al. 2017 , Davies-Colley et al. 1999 , Fujioka and Yoneyama 2002 , Mendez-Hermida et al. 2005 , Silverman et al. 2015 , Sinton et al. 2007 , Sinton et al. 2002 , the relevance of these data to the NSP situation is uncertain.", [["the microbial inactivation", "PROBLEM", 17, 43], ["microbial inactivation", "OBSERVATION", 21, 43]]], ["Sunlight is expected to be effective at the very surface, however the extent that solar radiation can penetrate the water column is variable and likely to be affected by site specific water quality and resuspension of particulates due to bather activities.", [["surface", "ANATOMY", 49, 56], ["solar radiation", "TREATMENT", 82, 97], ["resuspension", "TREATMENT", 202, 214], ["effective", "OBSERVATION_MODIFIER", 27, 36], ["solar radiation", "OBSERVATION", 82, 97], ["water column", "OBSERVATION_MODIFIER", 116, 128], ["likely to be", "UNCERTAINTY", 145, 157]]], ["In-situ measurement of solar radiation during pool operation, at appropriate depths, would facilitate incorporation of sunlight disinfection kinetics from literature values.DiscussionTo improve the safety of the system, UV disinfection was a design suggestion for the pool water return lines.", [["solar radiation", "TREATMENT", 23, 38], ["pool operation", "TREATMENT", 46, 60], ["sunlight disinfection kinetics", "TREATMENT", 119, 149], ["literature values", "TEST", 155, 172], ["UV disinfection", "TREATMENT", 220, 235], ["the pool water return lines", "TREATMENT", 264, 291], ["solar radiation", "OBSERVATION", 23, 38]]], ["However, the inclusion of UV had limited benefit on overall performance during normal operation, but could reduce the spread of infectious pathogens between pools following a faecal accident.", [["UV", "CHEMICAL", 26, 28], ["faecal accident", "DISEASE", 175, 190], ["faecal", "ORGANISM_SUBSTANCE", 175, 181], ["normal operation", "TREATMENT", 79, 95], ["infectious pathogens", "PROBLEM", 128, 148], ["infectious", "OBSERVATION", 128, 138]]], ["The UV disinfection units are considered to be particularly valuable on the outflow of the floor nozzles, given the higher likelihood of faecal contamination by children in this zone, and the need to protect the larger pools from this contamination.", [["faecal", "ANATOMY", 137, 143], ["faecal", "ORGANISM_SUBSTANCE", 137, 143], ["children", "ORGANISM", 161, 169], ["children", "SPECIES", 161, 169], ["The UV disinfection units", "TREATMENT", 0, 25], ["the floor nozzles", "TREATMENT", 87, 104], ["faecal contamination", "PROBLEM", 137, 157], ["the larger pools", "PROBLEM", 208, 224], ["this contamination", "PROBLEM", 230, 248], ["UV disinfection", "OBSERVATION", 4, 19], ["faecal contamination", "OBSERVATION", 137, 157], ["larger", "OBSERVATION_MODIFIER", 212, 218]]], ["The Log 10 reduction value assumed for viruses was based on calicivirus results reviewed by Hijnen et al. (2006) representative for human noroviruses (2.6 Log 10 ), but not as conservative as expected from some human adenovirus (0.5 Log 10 ).", [["human noroviruses", "DISEASE", 132, 149], ["calicivirus", "ORGANISM", 60, 71], ["human", "ORGANISM", 132, 137], ["human", "ORGANISM", 211, 216], ["adenovirus", "ORGANISM", 217, 227], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 211, 216], ["human noroviruses", "SPECIES", 132, 149], ["human", "SPECIES", 211, 216], ["The Log 10 reduction value", "TEST", 0, 26], ["viruses", "PROBLEM", 39, 46], ["human noroviruses", "PROBLEM", 132, 149], ["some human adenovirus", "PROBLEM", 206, 227]]], ["Hence the protection provided by UV disinfection may be less for some human enteric viruses than shown by these preliminary modelling results for Norovirus.DiscussionThe predicted performance of the UV units was based on a review of published laboratory studies for a range of different pathogens (Hijnen et al. 2006 ).There are two important limitations linked with using this laboratory data.", [["Norovirus", "DISEASE", 146, 155], ["human", "ORGANISM", 70, 75], ["Norovirus", "ORGANISM", 146, 155], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["the protection", "TREATMENT", 6, 20], ["UV disinfection", "TREATMENT", 33, 48], ["some human enteric viruses", "PROBLEM", 65, 91], ["Norovirus", "PROBLEM", 146, 155], ["the UV units", "TREATMENT", 195, 207], ["published laboratory studies", "TEST", 233, 261], ["different pathogens", "PROBLEM", 277, 296], ["this laboratory data", "TEST", 373, 393]]], ["Firstly, the performance of UV disinfection in natural waters will be suppressed by the variable organic content of the water.", [["UV", "CHEMICAL", 28, 30], ["water", "SIMPLE_CHEMICAL", 120, 125], ["UV disinfection", "TREATMENT", 28, 43], ["natural waters", "TREATMENT", 47, 61], ["UV disinfection", "OBSERVATION", 28, 43]]], ["Validation of the UV units would be required to ensure that the required effective UV dose is achieved using an approach similar to that recommended for drinking water treatment (USEPA 2006b) Secondly, the impact of UV disinfection on the natural biome of the water column and hence the natural elimination efficiency of the overall system is poorly understood.DiscussionDisrupting the natural biome through UV disinfection must be undertaken with caution.DiscussionOverall, in situ challenge testing trials are recommended once the system is operational to investigate the impact of the UV disinfection on microbial survival.ConclusionsA Screening Level Risk Assessment is a valuable starting point for assessing waterborne risks from enteric pathogens, and to identify risk drivers and research needs.", [["UV", "CHEMICAL", 83, 85], ["the UV units", "TREATMENT", 14, 26], ["effective UV dose", "TREATMENT", 73, 90], ["an approach", "TREATMENT", 109, 120], ["drinking water treatment", "TREATMENT", 153, 177], ["UV disinfection", "TREATMENT", 216, 231], ["the water column", "TREATMENT", 256, 272], ["UV disinfection", "TREATMENT", 408, 423], ["the UV disinfection", "TREATMENT", 584, 603], ["microbial survival", "TREATMENT", 607, 625], ["ConclusionsA Screening", "TEST", 626, 648], ["enteric pathogens", "PROBLEM", 736, 753], ["UV disinfection", "OBSERVATION", 216, 231], ["water column", "OBSERVATION_MODIFIER", 260, 272], ["UV disinfection", "OBSERVATION", 588, 603]]], ["Even with the simplistic box flow model applied to the NSP described, the following important lessons regarding the likely performance of the system were identified:Conclusions\uf0b7 Enteric pathogen risks associated with natural swimming pools depend upon how many swimmers are infected.", [["the simplistic box flow model", "TREATMENT", 10, 39], ["Enteric pathogen risks", "TREATMENT", 178, 200], ["infected", "OBSERVATION", 274, 282]]], ["Modelling pathogen concentration needs to account for the likelihood of one or more shedders being present;Conclusions\uf0b7 The overall performance of the filtration system was driven by the system water turnover time, and using the 11 and 4 h designed turnover time would achieve less than 1 Log 10 reduction for all reference pathogens evaluated;Conclusions\uf0b7 Natural disinfection mechanisms for NSP are poorly understood, making reliance upon them for health protection in public pools challenging.", [["Modelling pathogen concentration", "PROBLEM", 0, 32], ["the filtration system", "TREATMENT", 147, 168], ["NSP", "PROBLEM", 393, 396], ["health protection", "TREATMENT", 450, 467]]], ["Specific data is needed to better describe the fate of pathogens in natural waters; and \uf0b7 Performance of natural filtration barriers in the NSP environment are poorly understood and challenge studies of in situ systems are recommended to reduce uncertainties in the current study.", [["Specific data", "TEST", 0, 13], ["natural filtration barriers", "TREATMENT", 105, 132], ["the current study", "TEST", 262, 279]]], ["Under reporting factor 27.2 (Thomas, Murray et al. 2013) 288 (Tam, Rodrigues et al. 2012) 48.5 (Thomas, Murray et al. 2013) Mean duration of 21 (Havelaar, van 28.5 (Tu, McCaig et al.Adults ChildrenVolume of water (unintentionally) ingested 10 mL (Dufour, Behymer et al. 2017) 38 mL (Dufour, Behymer et al. 2017 )CampylobacterNorovirus Cryptosporidium Dose-response model: Exact Beta-Poisson Parameters \u03b1=0.024; \u03b2=0.011 (Teunis, van den Brandhof et al. 2005) \u03b1=0.0044; \u03b2=0.0022 (Messner, Berger et al. 2014) \u03b1=0.115; \u03b2=0.176 (Teunis, Chappell et al. 2002) Probability of illness given infection P ill 0.2 (Black, Levine et al. 1988", [["illness", "DISEASE", 570, 577], ["infection P ill", "DISEASE", 584, 599], ["Adults", "ORGANISM", 182, 188], ["Adults", "SPECIES", 182, 188], ["Mean duration", "TEST", 124, 137], ["CampylobacterNorovirus", "TEST", 312, 334], ["Parameters", "TEST", 391, 401], ["illness", "PROBLEM", 570, 577], ["infection", "PROBLEM", 584, 593], ["infection", "OBSERVATION", 584, 593]]]], "efcd4f058d2b435a17c63793904cbf85c899b982": [["INTRODUCTIONNorovirus is the commonest cause of gastrointestinal infection worldwide.", [["gastrointestinal", "ANATOMY", 48, 64], ["gastrointestinal infection", "DISEASE", 48, 74], ["gastrointestinal", "ORGAN", 48, 64], ["gastrointestinal infection", "PROBLEM", 48, 74], ["gastrointestinal", "ANATOMY", 48, 64], ["infection", "OBSERVATION", 65, 74]]], ["1 There are between two and three million cases occurring each year in the UK.", [["UK", "GENE_OR_GENE_PRODUCT", 75, 77]]], ["2 3 Norovirus commonly presents as outbreaks of diarrhoea and vomiting and are frequently reported in hospitals, care-homes, schools and cruise ships.", [["Norovirus", "DISEASE", 4, 13], ["diarrhoea", "DISEASE", 48, 57], ["vomiting", "DISEASE", 62, 70], ["Norovirus", "PROBLEM", 4, 13], ["diarrhoea", "PROBLEM", 48, 57], ["vomiting", "PROBLEM", 62, 70]]], ["4 5 Outbreaks in hospitals are disruptive, often leading to ward or bay closures, staff sickness and cancelled operations.", [["sickness", "DISEASE", 88, 96], ["cancelled operations", "TREATMENT", 101, 121]]], ["6 The cost of nosocomial outbreaks of norovirus to the National Health Service (NHS) in England was estimated at \u00a3115 million in 2002/2003.", [["norovirus", "DISEASE", 38, 47], ["norovirus", "SPECIES", 38, 47], ["norovirus", "PROBLEM", 38, 47]]], ["6 Recently the cost in one region in Scotland was estimated at \u00a31.2 million in the two norovirus seasons from 2007 to 2008.", [["norovirus", "DISEASE", 87, 96], ["cost", "OBSERVATION_MODIFIER", 15, 19], ["norovirus", "OBSERVATION", 87, 96]]], ["7 Understanding the benefits of infection control measures is challenging, because they are usually instigated as a package with several measures being implemented during an outbreak.", [["infection", "DISEASE", 32, 41], ["infection control measures", "TREATMENT", 32, 58], ["a package", "TREATMENT", 114, 123], ["several measures", "TREATMENT", 129, 145], ["infection", "OBSERVATION", 32, 41]]], ["While these interventions are based on sound infection control principles,Key messages\u25aa We have shown a clear role of spatial proximity in the transmission of norovirus in hospital outbreaks. \u25aa Patients who are in the same bay as patients who become ill have a higher probability of becoming ill compared with patients in a different bay. \u25aa Increasing barriers to movement between bays by closing affected bays promptly would be effective in preventing further spread.Strengths and limitations of this study\u25aa Provides an estimation of serial interval, and assessment of significance of patient proximity in spreading norovirus within hospitals. \u25aa Different modelling approaches showed consistent results. \u25aa A weakness is that although data collection were standardised it is often difficult to assess the accuracy of the information on patients' positions on a ward. evaluating their efficacy in trials is difficult and the published literature on norovirus outbreaks does not provide clear evidence of the effectiveness of infection control measures.", [["infection", "DISEASE", 45, 54], ["norovirus", "DISEASE", 159, 168], ["ill", "DISEASE", 292, 295], ["norovirus", "DISEASE", 617, 626], ["norovirus", "DISEASE", 948, 957], ["infection", "DISEASE", 1024, 1033], ["norovirus", "ORGANISM", 159, 168], ["Patients", "ORGANISM", 194, 202], ["patients", "ORGANISM", 230, 238], ["patients", "ORGANISM", 310, 318], ["patient", "ORGANISM", 586, 593], ["patients", "ORGANISM", 836, 844], ["norovirus", "ORGANISM", 948, 957], ["Patients", "SPECIES", 194, 202], ["patients", "SPECIES", 230, 238], ["patients", "SPECIES", 310, 318], ["patient", "SPECIES", 586, 593], ["patients", "SPECIES", 836, 844], ["these interventions", "TREATMENT", 6, 25], ["sound infection control principles", "TREATMENT", 39, 73], ["norovirus", "PROBLEM", 159, 168], ["this study", "TEST", 497, 507], ["serial interval", "TEST", 535, 550], ["assessment", "TEST", 556, 566], ["spreading norovirus", "PROBLEM", 607, 626], ["A weakness", "PROBLEM", 707, 717], ["norovirus outbreaks", "PROBLEM", 948, 967], ["infection control measures", "TREATMENT", 1024, 1050], ["infection", "OBSERVATION", 45, 54], ["clear", "OBSERVATION_MODIFIER", 104, 109], ["norovirus", "OBSERVATION", 159, 168], ["norovirus", "OBSERVATION", 617, 626], ["weakness", "OBSERVATION", 709, 717], ["infection", "OBSERVATION", 1024, 1033]]], ["5 In observational studies early ward closure has been shown to shorten the mean duration of outbreaks.", [["observational studies", "TEST", 5, 26]]], ["6 7 There is also evidence that vomiting and the resultant aerosols are important in transmitting the infection.", [["vomiting", "DISEASE", 32, 40], ["infection", "DISEASE", 102, 111], ["vomiting", "PROBLEM", 32, 40], ["the resultant aerosols", "PROBLEM", 45, 67], ["the infection", "PROBLEM", 98, 111], ["vomiting", "OBSERVATION", 32, 40], ["resultant", "OBSERVATION_MODIFIER", 49, 58], ["aerosols", "OBSERVATION", 59, 67], ["infection", "OBSERVATION", 102, 111]]], ["People exposed to vomiting events, either by being close to the person who initially vomited, or by occupying the same area sometime after the initial event, have a higher infection risk.", [["vomiting", "DISEASE", 18, 26], ["infection", "DISEASE", 172, 181], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["person", "SPECIES", 64, 70], ["vomiting events", "PROBLEM", 18, 33], ["a higher infection risk", "PROBLEM", 163, 186], ["higher", "OBSERVATION_MODIFIER", 165, 171], ["infection", "OBSERVATION", 172, 181]]], ["[8] [9] [10] [11] However, these analyses are based on single outbreaks or events that led to subsequent disease.", [["[8] [9] [10] [11]", "SIMPLE_CHEMICAL", 0, 17], ["these analyses", "TEST", 27, 41], ["subsequent disease", "PROBLEM", 94, 112], ["disease", "OBSERVATION", 105, 112]]], ["Improved understanding of how norovirus spreads in closed environments could lead to better infection control procedures.", [["norovirus", "DISEASE", 30, 39], ["infection", "DISEASE", 92, 101], ["norovirus", "ORGANISM", 30, 39], ["how norovirus", "PROBLEM", 26, 39], ["infection control procedures", "TREATMENT", 92, 120], ["norovirus", "OBSERVATION", 30, 39]]], ["The aim of our study was to assess how spatial proximity to a norovirus case is associated with risk of acquiring symptomatic norovirus gastroenteritis.", [["norovirus", "DISEASE", 62, 71], ["norovirus gastroenteritis", "DISEASE", 126, 151], ["norovirus", "ORGANISM", 62, 71], ["our study", "TEST", 11, 20], ["a norovirus case", "PROBLEM", 60, 76], ["acquiring symptomatic norovirus gastroenteritis", "PROBLEM", 104, 151], ["norovirus", "OBSERVATION", 62, 71], ["symptomatic", "OBSERVATION_MODIFIER", 114, 125], ["norovirus", "OBSERVATION", 126, 135]]], ["Our hypothesis was that patients sharing bays (small self-contained areas within wards) with patients with symptomatic norovirus infection were more likely to become infected compared with those who were in another bay or part of the affected ward.MATERIALS AND METHODS SettingWe carried out enhanced surveillance of norovirus outbreaks from all in-patient wards in five tertiary care hospitals serving two cities in England, with a combined catchment of approximately two million people.Surveillance dataWe collected data during outbreaks from individual patients on date of onset of illness, symptoms (diarrhoea and/or vomiting), last date of illness for each patient, location on the ward at the time of the patients' symptoms onset (recorded as bed number and bay number) and also the ward type.Surveillance dataFor two hospitals, information was recorded from January 2008 to November 2011 on specially designed forms that were completed by infection control staff and returned to the Health Protection Agency.", [["norovirus infection", "DISEASE", 119, 138], ["norovirus outbreaks", "DISEASE", 317, 336], ["illness", "DISEASE", 585, 592], ["diarrhoea", "DISEASE", 604, 613], ["vomiting", "DISEASE", 621, 629], ["infection", "DISEASE", 946, 955], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 93, 101], ["norovirus", "ORGANISM", 317, 326], ["patient", "ORGANISM", 349, 356], ["people", "ORGANISM", 481, 487], ["patients", "ORGANISM", 556, 564], ["patient", "ORGANISM", 662, 669], ["patients", "ORGANISM", 711, 719], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 93, 101], ["patient", "SPECIES", 349, 356], ["people", "SPECIES", 481, 487], ["patients", "SPECIES", 556, 564], ["patient", "SPECIES", 662, 669], ["patients", "SPECIES", 711, 719], ["small self-contained areas", "PROBLEM", 47, 73], ["symptomatic norovirus infection", "PROBLEM", 107, 138], ["norovirus outbreaks", "PROBLEM", 317, 336], ["Surveillance dataWe", "TEST", 488, 507], ["illness", "PROBLEM", 585, 592], ["symptoms", "PROBLEM", 594, 602], ["diarrhoea", "PROBLEM", 604, 613], ["vomiting", "PROBLEM", 621, 629], ["illness", "PROBLEM", 645, 652], ["the patients' symptoms", "PROBLEM", 707, 729], ["small", "OBSERVATION_MODIFIER", 47, 52], ["symptomatic", "OBSERVATION_MODIFIER", 107, 118], ["norovirus", "OBSERVATION", 119, 128], ["infected", "OBSERVATION", 166, 174], ["norovirus", "OBSERVATION", 317, 326]]], ["Each month, we contacted the infection control lead at these hospitals asking about suspected or laboratory confirmed norovirus outbreaks and, if any had occurred and for the forms to be completed and returned.", [["infection", "DISEASE", 29, 38], ["norovirus", "DISEASE", 118, 127], ["norovirus outbreaks", "PROBLEM", 118, 137], ["norovirus", "OBSERVATION", 118, 127]]], ["In three other hospitals the data were downloaded from a database on which infection control specialists had recorded these data items during outbreaks of norovirus occurring in the season of 2007/2008.", [["infection", "DISEASE", 75, 84], ["norovirus", "DISEASE", 155, 164], ["norovirus", "ORGANISM", 155, 164], ["a database", "TEST", 55, 65], ["norovirus", "PROBLEM", 155, 164], ["norovirus", "OBSERVATION", 155, 164]]], ["Data on outbreaks on norovirus were available from November 2007 to November 2011.Patient location during outbreaksWe obtained ward plans for two of the five hospitals, which assisted in locating patients in the ward if only part of the information on patient location was recorded in the outbreak reports.DefinitionsOutbreaks were defined as two or more cases of diarrhoea and or vomiting of infectious origin in a ward occurring within 2 days of the first case suspected or confirmed to be due to norovirus.", [["diarrhoea", "DISEASE", 364, 373], ["vomiting", "DISEASE", 381, 389], ["norovirus", "DISEASE", 499, 508], ["norovirus", "ORGANISM", 21, 30], ["patients", "ORGANISM", 196, 204], ["patient", "ORGANISM", 252, 259], ["Patient", "SPECIES", 82, 89], ["patients", "SPECIES", 196, 204], ["patient", "SPECIES", 252, 259], ["norovirus", "PROBLEM", 21, 30], ["diarrhoea", "PROBLEM", 364, 373], ["vomiting of infectious origin", "PROBLEM", 381, 410], ["norovirus", "PROBLEM", 499, 508], ["diarrhoea", "OBSERVATION", 364, 373], ["infectious", "OBSERVATION", 393, 403], ["norovirus", "OBSERVATION", 499, 508]]], ["All the hospitals in this study used PCR for detection of norovirus in stool samples.DefinitionsA bay is a small self-contained area within a ward.", [["stool samples", "ANATOMY", 71, 84], ["norovirus", "DISEASE", 58, 67], ["norovirus", "ORGANISM", 58, 67], ["stool samples", "ORGANISM_SUBSTANCE", 71, 84], ["norovirus", "SPECIES", 58, 67], ["this study", "TEST", 21, 31], ["PCR", "TEST", 37, 40], ["norovirus", "PROBLEM", 58, 67], ["stool samples", "TEST", 71, 84], ["a small self-contained area", "PROBLEM", 105, 132], ["norovirus", "OBSERVATION", 58, 67], ["small", "OBSERVATION_MODIFIER", 107, 112]]], ["Proximity was defined as patients who share a bay.Analytical frameworkThe analysis is based on a probabilistic reconstruction of chains of transmission (trees) based on the dates of illness onset for patients affected in outbreaks.", [["illness", "DISEASE", 182, 189], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 200, 208], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 200, 208], ["The analysis", "TEST", 70, 82], ["a probabilistic reconstruction of chains of transmission (trees", "TREATMENT", 95, 158], ["illness", "PROBLEM", 182, 189]]], ["It makes use of methods developed for Severe Acute Respiratory Syndrome (SARS) transmission and later applied to norovirus.", [["Acute Respiratory Syndrome (SARS) transmission", "DISEASE", 45, 91], ["norovirus", "DISEASE", 113, 122], ["norovirus", "ORGANISM", 113, 122], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 38, 78], ["methods", "TREATMENT", 16, 23], ["Severe Acute Respiratory Syndrome", "PROBLEM", 38, 71], ["SARS) transmission", "PROBLEM", 73, 91], ["norovirus", "PROBLEM", 113, 122], ["Severe", "OBSERVATION_MODIFIER", 38, 44], ["Acute", "OBSERVATION_MODIFIER", 45, 50], ["Respiratory Syndrome", "OBSERVATION", 51, 71], ["norovirus", "OBSERVATION", 113, 122]]], ["[12] [13] [14] [15] If we knew with certainty who acquired infection from whom it would be straightforward to quantify the role of proximity in norovirus outbreaks, for example, by using regression analysis.", [["infection", "DISEASE", 59, 68], ["norovirus", "DISEASE", 144, 153], ["[12] [13] [14] [15", "SIMPLE_CHEMICAL", 0, 18], ["norovirus", "ORGANISM", 144, 153], ["acquired infection", "PROBLEM", 50, 68], ["regression analysis", "TEST", 187, 206], ["infection", "OBSERVATION", 59, 68], ["norovirus", "OBSERVATION", 144, 153]]], ["However, in practice, transmission events are unobserved, so instead we consider all possible infection trees consistent with the data.", [["infection", "DISEASE", 94, 103], ["transmission events", "PROBLEM", 22, 41], ["infection trees", "PROBLEM", 94, 109]]], ["We used a previously described approach to calculate the probability, \u03c0 ij , that patient i was infected by patient j for each pair of infected patients in each outbreak based on onset times and the serial interval distribution (the serial interval is the time from onset of symptoms in case i to case j), without using proximity data.", [["patient", "ORGANISM", 82, 89], ["patient", "ORGANISM", 108, 115], ["patients", "ORGANISM", 144, 152], ["patient", "SPECIES", 82, 89], ["patient", "SPECIES", 108, 115], ["patients", "SPECIES", 144, 152], ["ij", "TREATMENT", 72, 74], ["the serial interval distribution", "PROBLEM", 195, 227], ["symptoms", "PROBLEM", 275, 283], ["ij", "ANATOMY", 72, 74], ["infected", "OBSERVATION", 135, 143], ["distribution", "OBSERVATION_MODIFIER", 215, 227]]], ["The serial interval distribution tells us the probability of durations of 0, 1, 2\u2026 days between onset in a case and onset in secondary cases infected by this case.", [["distribution", "OBSERVATION_MODIFIER", 20, 32]]], ["12 We then used the matrix of \u03c0 ij values to simulate 1000 possible infection trees for each outbreak, by assigning the infector of patient i to be patient j with probability \u03c0 ij .Analytical frameworkIn these simulations, we assumed that the case with the earliest onset time was the index case and had no infectors on the ward.", [["infection", "DISEASE", 68, 77], ["patient", "ORGANISM", 132, 139], ["patient", "ORGANISM", 148, 155], ["patient", "SPECIES", 132, 139], ["patient", "SPECIES", 148, 155], ["the matrix of \u03c0 ij values", "TREATMENT", 16, 41], ["infection trees", "PROBLEM", 68, 83], ["ij", "TREATMENT", 177, 179], ["infectors", "PROBLEM", 307, 316], ["infection", "OBSERVATION", 68, 77], ["ij", "ANATOMY", 177, 179]]], ["If more than one patient had the earliest onset date in a given outbreak, we selected the index case from these patients with equal probability in each simulation.", [["patient", "ORGANISM", 17, 24], ["patients", "ORGANISM", 112, 120], ["patient", "SPECIES", 17, 24], ["patients", "SPECIES", 112, 120]]], ["For each outbreak k, we used these 1000 simulations to produce a proximity metric, P k , defined asAnalytical frameworkwhere s ijkl is equal to 1 if patient i was infected by patient j in simulation l of outbreak k and is zero otherwise.", [["patient", "ORGANISM", 149, 156], ["patient", "ORGANISM", 175, 182], ["P k", "DNA", 83, 86], ["patient", "SPECIES", 149, 156], ["patient", "SPECIES", 175, 182], ["infected", "OBSERVATION", 163, 171]]], ["The p ijk terms measure proximity between patients i and j in outbreak k.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["The p ijk terms", "TREATMENT", 0, 15]]], ["In this application, we consider this to be a binary variable equal to 1 if patients i and j occupied the same bay at the time of first symptom onset of these patients.", [["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 159, 167]]], ["An overall proximity metric, P, is obtained by summing the P k values.", [["P", "DNA", 29, 30], ["the P k values", "TEST", 55, 69], ["overall", "OBSERVATION_MODIFIER", 3, 10], ["proximity", "OBSERVATION_MODIFIER", 11, 20]]], ["The value of P (and of P k for individual outbreaks) should be interpreted as a measure of how much transmission occurs between patients in the same bay.Analytical frameworkIf people in the same bay pose a greater risk of infecting each other this will tend to lead to larger values of the proximity metrics, P, and P k .", [["patients", "ORGANISM", 128, 136], ["people", "ORGANISM", 176, 182], ["P", "DNA", 309, 310], ["patients", "SPECIES", 128, 136], ["people", "SPECIES", 176, 182], ["infecting", "OBSERVATION", 222, 231]]], ["This distribution was derived by performing random permutations of the bays of the patients in each outbreak and calculating P k as above for each outbreak.", [["patients", "ORGANISM", 83, 91], ["P k", "DNA", 125, 128], ["patients", "SPECIES", 83, 91], ["calculating P k", "TEST", 113, 128]]], ["These values were again summed to give an overall proximity metric, S, when proximity was by assumption not an important factor.", [["These values", "TEST", 0, 12]]], ["We repeated this for 1000 random permutations of the patient bays to obtain 1000 sampled proximity metrics.", [["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60]]], ["These 1000 S values therefore represent a sample from the distribution of proximity metrics that would be expected if proximity played no role in spreading the disease during the outbreak.", [["the disease", "PROBLEM", 156, 167], ["proximity metrics", "OBSERVATION", 74, 91], ["disease", "OBSERVATION", 160, 167]]], ["By comparing the 1000 sampled values of S with the observed value P we can evaluate whether transmission is more (or less) likely to occur between patients in close proximity.", [["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155]]], ["If proximity is unimportant the observed value of P would be unlikely to be in the tails of the distribution of S. If proximity leads to increased transmission the observed value of P would tend to be greater than most of the sampled S values.", [["P", "DNA", 50, 51], ["P", "DNA", 182, 183], ["tails", "ANATOMY_MODIFIER", 83, 88], ["increased", "OBSERVATION_MODIFIER", 137, 146]]], ["If proximity leads to decreased transmission (which could occur as a result of enhanced hygiene measures, eg,) the observed value of P is likely to be smaller than most of the sampled S values.", [["P", "DNA", 133, 134], ["decreased transmission", "PROBLEM", 22, 44], ["enhanced hygiene measures", "TREATMENT", 79, 104], ["decreased", "OBSERVATION_MODIFIER", 22, 31], ["likely to be", "UNCERTAINTY", 138, 150], ["smaller", "OBSERVATION_MODIFIER", 151, 158]]], ["Formally, we can perform a two-sided hypothesis test with a null hypothesis that proximity is not important where the p value is given by the proportion of sampled S values which are the more extreme than the value observed, P.Serial intervalsA key input for constructing the transmission trees is the serial interval.", [["a two-sided hypothesis test", "TEST", 25, 52], ["a null hypothesis", "PROBLEM", 58, 75], ["the p value", "TEST", 114, 125], ["sampled S values", "TEST", 156, 172], ["more extreme", "OBSERVATION_MODIFIER", 187, 199]]], ["Our best estimate came from the observed distribution of the difference between first and second onset dates for each outbreak, and our primary analysis made use of this empirical serial interval distribution.", [["this empirical serial interval distribution", "TREATMENT", 165, 208]]], ["Often, more than one patient was ill on the first day of the outbreak, so we used the first date of illness onset in the next patient(s) for calculating the serial interval.", [["illness", "DISEASE", 100, 107], ["patient", "ORGANISM", 21, 28], ["patient", "ORGANISM", 126, 133], ["patient", "SPECIES", 21, 28], ["patient", "SPECIES", 126, 133]]], ["This gave a mean serial interval of 1.86 days (median 1 day, 95% CI 1.6 to 2.2 days, obtained by bootstrapping).Serial intervalsWe also performed sensitivity analyses using different assumptions.", [["CI", "TEST", 65, 67], ["sensitivity analyses", "TEST", 146, 166]]], ["First, we used an estimate from a study of a community outbreak of norovirus at a scouting jamboree, giving a mean serial interval of 3.6 days, with an assumed \u03b3 distribution.", [["norovirus", "DISEASE", 67, 76], ["norovirus", "ORGANISM", 67, 76], ["a study", "TEST", 32, 39], ["norovirus", "PROBLEM", 67, 76], ["norovirus", "OBSERVATION", 67, 76]]], ["These outbreaks affected 1694 patients and 456 staff.", [["patients", "ORGANISM", 30, 38], ["patients", "SPECIES", 30, 38]]], ["The average duration of the outbreaks, determined as the first date of onset to the last date of onset, was 8.9 days (median 8; range 1-40 days).", [["average", "OBSERVATION_MODIFIER", 4, 11]]], ["Outbreaks affected an average of 11.4 patients (median 11; range 1-30) and an average of 3.2 staff (median 2; range 0-20).", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["average", "OBSERVATION_MODIFIER", 22, 29]]], ["Figure 1 shows the distribution of serial intervals from the observed data and the nearest fitting \u03b3 distribution.RESULTSThe spatial modelling analysis used data from 65 outbreaks where all data (for both onset dates and position in ward when taken ill) were complete.", [["spatial modelling analysis", "TEST", 125, 151], ["all data", "TEST", 186, 194], ["distribution", "OBSERVATION_MODIFIER", 19, 31]]], ["The corresponding figures for these outbreaks were: average length of outbreak 9.5 days (median 8 days) average number of patients 11.9 (median 11) average number of affected staff 3.4 (median 2).", [["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130]]], ["The outbreaks affected various ward types, with most occurring in general medical wards (34%) and care of the elderly wards (28%).", [["various", "OBSERVATION_MODIFIER", 23, 30], ["ward types", "OBSERVATION_MODIFIER", 31, 41]]], ["Other specialties were respiratory medicine (12%), stroke/neurology wards (11%), coronary care wards (9%) and orthopaedic/trauma wards (6%).", [["coronary", "ANATOMY", 81, 89], ["stroke", "DISEASE", 51, 57], ["trauma", "DISEASE", 122, 128], ["coronary", "MULTI-TISSUE_STRUCTURE", 81, 89], ["respiratory medicine", "TREATMENT", 23, 43], ["coronary", "ANATOMY", 81, 89]]], ["The dashed line indicates the observed proximity metric (P) and the bars indicate the distribution of proximity metrics from the simulated permutations.", [["The dashed line", "TREATMENT", 0, 15], ["distribution", "OBSERVATION_MODIFIER", 86, 98], ["proximity metrics", "OBSERVATION", 102, 119], ["simulated permutations", "OBSERVATION", 129, 151]]], ["With serial intervals of less than 2 days proximity is either outside or at the extreme right of the simulated proximity metrics and the p values ranged from <0.001 for serial intervals of 0.5 days to 0.01 at a serial interval of 2 days.", [["the p values", "TEST", 133, 145], ["right", "ANATOMY_MODIFIER", 88, 93]]], ["If we increase the assumed serial interval, the proximity metric moves to within the range expected from the simulated values, and at 3 days the p value was 0.2 (figure 2).", [["the p value", "TEST", 141, 152]]], ["Using the \u03b3 probability distribution derived from a community outbreak by Heijne et al 13 (mean serial interval 3.06 days), the proportion of observed proximity values fell within the range that would be expected if proximity were not important.Proximity analysisThe results show that the proximity metric (P) was larger than would be expected by chance under the null hypothesis (that proximity is not important) up to a serial interval of 2.5 days ( p=0.05).DISCUSSIONWe have detected a strong association where patients who are in the same bay as patients who become ill have a higher probability of themselves becoming ill compared with patients in a different bay.", [["patients", "ORGANISM", 514, 522], ["patients", "ORGANISM", 550, 558], ["patients", "ORGANISM", 641, 649], ["patients", "SPECIES", 514, 522], ["patients", "SPECIES", 550, 558], ["patients", "SPECIES", 641, 649], ["Proximity analysis", "TEST", 245, 263], ["proximity values", "OBSERVATION", 151, 167], ["larger", "OBSERVATION_MODIFIER", 314, 320], ["null hypothesis", "OBSERVATION", 364, 379]]], ["In other words, transmission of norovirus infections is more likely to occur among patients sharing a bay, compared with transmission among patients in different bays.", [["norovirus infections", "DISEASE", 32, 52], ["norovirus", "ORGANISM", 32, 41], ["patients", "ORGANISM", 83, 91], ["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 83, 91], ["patients", "SPECIES", 140, 148], ["norovirus infections", "PROBLEM", 32, 52], ["norovirus", "OBSERVATION", 32, 41]]], ["While this might at first seem an obvious finding, there are competing theories about the transmission of the virus in complex healthcare settings.", [["virus", "OBSERVATION", 110, 115]]], ["For example, transmission might occur through staff transferring virus on their hands or patients touching infected surfaces with their hands when moving around the wards or the hospital.", [["hands", "ORGANISM_SUBDIVISION", 80, 85], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97]]], ["The strength of our conclusion is sensitive to the assumed serial interval distribution.", [["distribution", "OBSERVATION_MODIFIER", 75, 87]]], ["We used values derived from the dates of onset of illness in patients during outbreaks on hospital wards.", [["illness", "DISEASE", 50, 57], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["illness", "PROBLEM", 50, 57]]], ["We also performed sensitivity analysis using a serial interval distribution derived from a study of norovirus in children.", [["norovirus", "DISEASE", 100, 109], ["norovirus", "ORGANISM", 100, 109], ["children", "ORGANISM", 113, 121], ["children", "SPECIES", 113, 121], ["sensitivity analysis", "TEST", 18, 38], ["a study", "TEST", 89, 96], ["norovirus", "PROBLEM", 100, 109]]], ["Our results show that for serial intervals of less than 2 days the observed effect of proximity (sharing a bay with someone else who was ill) is highly significant ( p<0.001) and for serial intervals up to 2.5 days remained significant at the 5% level.", [["significant", "OBSERVATION_MODIFIER", 152, 163]]], ["This pattern was similar whether using the observed serial interval distribution from the outbreak data or using a parametric probability distribution.DISCUSSIONOur study has some limitations.", [["the observed serial interval distribution", "PROBLEM", 39, 80], ["DISCUSSIONOur study", "TEST", 151, 170], ["distribution", "OBSERVATION_MODIFIER", 68, 80]]], ["Although data collection were standardised it is often difficult to assess the accuracy of the date and place that patients were when they became ill.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123]]], ["Specifically, accurate information on patients' positions on a ward was available for 44% of the outbreaks.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46]]], ["The spatial analysis was undertaken on 65 outbreaks.", [["The spatial analysis", "TEST", 0, 20]]], ["In addition to the sensitivity analysis we also analysed the data by including outbreaks where onset dates of illness were complete but data on patient location were incomplete (where fewer than 10% of patient data on position was incomplete, 85 outbreaks).", [["illness", "DISEASE", 110, 117], ["patient", "ORGANISM", 144, 151], ["patient", "ORGANISM", 202, 209], ["patient", "SPECIES", 144, 151], ["patient", "SPECIES", 202, 209], ["the sensitivity analysis", "TEST", 15, 39], ["illness", "PROBLEM", 110, 117]]], ["We dealt with missing values by allocating a completely separate bay for patients with missing data on location at time of onset.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["missing data", "PROBLEM", 87, 99]]], ["This approach is conservative in that it would underestimate the impact of proximity.", [["conservative", "OBSERVATION_MODIFIER", 17, 29]]], ["Second, we removed the patients from the outbreaks if positional information was missing.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31]]], ["Despite this limitation, the additional models indicated that that the results are robust to different assumptions about missing data which is evidenced by slightly higher probabilities obtained when using records with complete information only (see online supplementary table S1 and figure S1).", [["S1", "PROTEIN", 277, 279], ["missing data", "TEST", 121, 133], ["slightly higher probabilities", "PROBLEM", 156, 185]]], ["As a check to demonstrate that the results were not an artefact of the statistical methods, we also ran the models on data where patient position was randomly assigned.", [["patient", "ORGANISM", 129, 136], ["patient", "SPECIES", 129, 136]]], ["This showed no pattern and the proximity measures were not significant for any of these models.", [["no", "UNCERTAINTY", 12, 14], ["pattern", "OBSERVATION_MODIFIER", 15, 22]]], ["In our analysis the estimation of Pk depends on outbreak size.", [["Pk", "GENE_OR_GENE_PRODUCT", 34, 36], ["Pk", "DNA", 34, 36], ["size", "OBSERVATION_MODIFIER", 57, 61]]], ["However, we are not interested in the absolute values of P, only in how the value of P calculated with real proximity data compares with the value calculated with randomly generated proximity data (based on a permutation of the bay identities) which will be affected in the same way by outbreak sizes.", [["P", "DNA", 85, 86], ["sizes", "OBSERVATION_MODIFIER", 295, 300]]], ["We also performed a sensitivity analysis, normalising Pk by dividing it by the number of branches in the transmission tree for each network.", [["Pk", "GENE_OR_GENE_PRODUCT", 54, 56], ["Pk", "DNA", 54, 56], ["a sensitivity analysis", "TEST", 18, 40], ["branches", "ANATOMY_MODIFIER", 89, 97]]], ["This gives equal weight to each outbreak and allows Pk to be interpreted as the probability that two linked cases were in the same bay.", [["Pk", "GENE_OR_GENE_PRODUCT", 52, 54]]], ["This did not change the results of the analysis; the P metric still fell well outside of the measure one would expect from the random simulations ( p=0.004, data not shown).DISCUSSIONWe used more than one approach to modelling the infection trees because of the lack of data on serial interval in norovirus outbreaks.", [["infection", "DISEASE", 231, 240], ["norovirus", "DISEASE", 297, 306], ["norovirus", "ORGANISM", 297, 306], ["P metric", "DNA", 53, 61], ["the analysis", "TEST", 35, 47], ["modelling the infection trees", "TREATMENT", 217, 246], ["norovirus outbreaks", "PROBLEM", 297, 316], ["infection", "OBSERVATION", 231, 240], ["norovirus", "OBSERVATION", 297, 306]]], ["This was a useful starting point but is unlikely to be applicable to transmission in a hospital setting.", [["unlikely to be", "UNCERTAINTY", 40, 54]]], ["The average incubation period for norovirus is considered to be between 24 and 48 h.", [["norovirus", "DISEASE", 34, 43], ["norovirus", "ORGANISM", 34, 43], ["norovirus", "SPECIES", 34, 43], ["The average incubation period", "TREATMENT", 0, 29], ["norovirus", "PROBLEM", 34, 43]]], ["1 4 In our analysis the serial intervals of up to 2.5 days is likely to be a more appropriate time period in a hospital setting, than the analysis from Heijne et al.DISCUSSIONMolecular analysis of stool samples could more definitively link outbreaks, which can help to reveal transmission networks.", [["stool samples", "ANATOMY", 197, 210], ["the analysis", "TEST", 134, 146], ["stool samples", "PROBLEM", 197, 210]]], ["18 19 For example, in this study we have assumed that each ward outbreak was distinct, that is, all cases within a ward were part of a chain of transmission, but this may not necessarily be true.", [["this study", "TEST", 22, 32], ["may not necessarily be", "UNCERTAINTY", 167, 189]]], ["It is possible for multiple introductions to occur, and some outbreaks may have spread from one ward to another.", [["possible for", "UNCERTAINTY", 6, 18]]], ["Genetic characterisation of samples from each ward during possible multiple outbreaks of norovirus would shed light on transmission events and lead to further insight about the direction of transmission, including the possibility that the virus can be moved around the hospital.DISCUSSIONOur study focused on patients rather than staff.", [["samples", "ANATOMY", 28, 35], ["norovirus", "DISEASE", 89, 98], ["samples", "CANCER", 28, 35], ["patients", "ORGANISM", 309, 317], ["patients", "SPECIES", 309, 317], ["norovirus", "SPECIES", 89, 98], ["norovirus", "PROBLEM", 89, 98], ["the virus", "PROBLEM", 235, 244], ["DISCUSSIONOur study", "TEST", 278, 297], ["possible", "UNCERTAINTY", 58, 66], ["multiple", "OBSERVATION_MODIFIER", 67, 75], ["outbreaks", "OBSERVATION", 76, 85], ["norovirus", "OBSERVATION", 89, 98]]], ["Our hypothesis was that symptomatic patients who vomit are most likely to contaminate the area close to them and other patients in their vicinity.", [["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 119, 127], ["vomit", "PROBLEM", 49, 54], ["symptomatic", "OBSERVATION_MODIFIER", 24, 35], ["most likely", "UNCERTAINTY", 59, 70]]], ["Obtaining data on staff movements is much more complicated and would only really be practical in a detailed prospective study.DISCUSSIONThe importance of spatial proximity in propagating transmission is consistent with other recent studies.", [["a detailed prospective study", "TEST", 97, 125], ["other recent studies", "TEST", 219, 239], ["spatial", "OBSERVATION_MODIFIER", 154, 161], ["proximity", "OBSERVATION_MODIFIER", 162, 171], ["consistent with", "UNCERTAINTY", 203, 218]]], ["15 20 One study which used similar methods to calculate the infection trees 15 suggests that symptomatic individuals are likely to be the drivers of outbreaks of norovirus in hospital settings.", [["infection", "DISEASE", 60, 69], ["norovirus", "DISEASE", 162, 171], ["individuals", "ORGANISM", 105, 116], ["One study", "TEST", 6, 15], ["similar methods", "TREATMENT", 27, 42], ["the infection trees", "PROBLEM", 56, 75], ["symptomatic individuals", "PROBLEM", 93, 116], ["norovirus", "PROBLEM", 162, 171], ["infection", "OBSERVATION", 60, 69]]], ["Furthermore, the effective reproductive number was significantly higher for symptomatic patients compared with that for symptomatic staff.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96]]], ["Norovirus transmission between people in close contact during sport, both within and between teams, has also been shown to occur 21 as well as airborne transmission through explosive vomiting.", [["Norovirus", "DISEASE", 0, 9], ["vomiting", "DISEASE", 183, 191], ["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37], ["explosive vomiting", "PROBLEM", 173, 191]]], ["22 One study demonstrated that successive staff working on an aircraft in which a member of the public had vomited also became sick.", [["One study", "TEST", 3, 12], ["sick", "PROBLEM", 127, 131]]], ["11 Norovirus has a low infectious dose 4 23 24 shedding virus occurs during episodes of vomiting, where the virus can become aerosolised and expose others in the vicinity.", [["Norovirus", "DISEASE", 3, 12], ["vomiting", "DISEASE", 88, 96], ["Norovirus", "PROBLEM", 3, 12], ["shedding virus", "PROBLEM", 47, 61], ["vomiting", "PROBLEM", 88, 96], ["the virus", "PROBLEM", 104, 113], ["low", "OBSERVATION_MODIFIER", 19, 22], ["infectious", "OBSERVATION_MODIFIER", 23, 33]]], ["Therefore, closing the bay quickly, preventing movement to and from that bay and immediately paying attention to cleaning areas nearby to initial vomiting events are likely to be effective in preventing further spread.", [["vomiting", "DISEASE", 146, 154], ["initial vomiting events", "PROBLEM", 138, 161], ["further spread", "PROBLEM", 203, 217], ["likely to be", "UNCERTAINTY", 166, 178]]], ["The index of suspicion for patients who become ill should be high and implementing infection control interventions should not be delayed until the results of sampling are received, because this would increase morbidity and prolong the outbreak.", [["infection", "DISEASE", 83, 92], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["ill", "PROBLEM", 47, 50], ["infection control interventions", "TREATMENT", 83, 114], ["infection", "OBSERVATION", 83, 92]]], ["New guidelines on controlling outbreaks of norovirus in hospitals and care homes recently released in the UK 25 move away from the need to close wards and operate on a 'manage within bays' principle.", [["norovirus", "DISEASE", 43, 52], ["norovirus", "ORGANISM", 43, 52], ["norovirus", "PROBLEM", 43, 52], ["norovirus", "OBSERVATION", 43, 52]]], ["Our study has shown that patients in proximity to symptomatic patients are at increased risk of becoming infected by these patients.CONCLUSIONSWe have shown a clear role of spatial proximity in the transmission of norovirus in hospital outbreaks.", [["norovirus", "DISEASE", 214, 223], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 123, 131], ["norovirus", "ORGANISM", 214, 223], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 123, 131], ["Our study", "TEST", 0, 9], ["norovirus", "PROBLEM", 214, 223], ["symptomatic", "OBSERVATION_MODIFIER", 50, 61], ["infected", "OBSERVATION", 105, 113], ["clear", "OBSERVATION", 159, 164], ["spatial", "OBSERVATION_MODIFIER", 173, 180], ["proximity", "OBSERVATION_MODIFIER", 181, 190], ["norovirus", "OBSERVATION", 214, 223]]]], "fba94b826a13817ca7f5eb8659dcb49c0a9d271f": [["EditorialSARS-CoV-2 as a causative agent of idiopathic interstitial pneumonia and interstitial pneumonia associated with collagen vascular disorders Keywords:SARS-CoV-2 COVID-19Methylprednisolone Idiopathic interstitial pneumonia Autoimmune interstitial pneumonia Fluid accumulation in the lungs due to coronavirus disease (COVID-19)-associated pneumonia is a result of inflammation caused by the secretion of inflammatory chemokines such as tumor necrosis factor (TNF-a), released by cells of the immune system.", [["interstitial", "ANATOMY", 55, 67], ["interstitial", "ANATOMY", 82, 94], ["vascular", "ANATOMY", 130, 138], ["lungs", "ANATOMY", 290, 295], ["cells", "ANATOMY", 485, 490], ["immune system", "ANATOMY", 498, 511], ["idiopathic interstitial pneumonia", "DISEASE", 44, 77], ["interstitial pneumonia", "DISEASE", 82, 104], ["collagen vascular disorders", "DISEASE", 121, 148], ["SARS-CoV-2 COVID-19Methylprednisolone", "CHEMICAL", 158, 195], ["interstitial pneumonia", "DISEASE", 207, 229], ["interstitial pneumonia", "DISEASE", 241, 263], ["coronavirus disease", "DISEASE", 303, 322], ["COVID-19)", "CHEMICAL", 324, 333], ["pneumonia", "DISEASE", 345, 354], ["inflammation", "DISEASE", 370, 382], ["tumor necrosis", "DISEASE", 442, 456], ["collagen", "GENE_OR_GENE_PRODUCT", 121, 129], ["vascular", "MULTI-TISSUE_STRUCTURE", 130, 138], ["lungs", "ORGAN", 290, 295], ["coronavirus", "ORGANISM", 303, 314], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 442, 463], ["TNF-a", "GENE_OR_GENE_PRODUCT", 465, 470], ["cells", "CELL", 485, 490], ["immune system", "ANATOMICAL_SYSTEM", 498, 511], ["inflammatory chemokines", "PROTEIN", 410, 433], ["tumor necrosis factor", "PROTEIN", 442, 463], ["TNF", "PROTEIN", 465, 468], ["EditorialSARS", "TEST", 0, 13], ["idiopathic interstitial pneumonia", "PROBLEM", 44, 77], ["interstitial pneumonia", "PROBLEM", 82, 104], ["collagen vascular disorders", "PROBLEM", 121, 148], ["SARS", "TEST", 158, 162], ["CoV", "TEST", 163, 166], ["COVID", "TEST", 169, 174], ["Idiopathic interstitial pneumonia", "PROBLEM", 196, 229], ["Autoimmune interstitial pneumonia", "PROBLEM", 230, 263], ["Fluid accumulation in the lungs", "PROBLEM", 264, 295], ["coronavirus disease", "PROBLEM", 303, 322], ["COVID", "TEST", 324, 329], ["associated pneumonia", "PROBLEM", 334, 354], ["inflammation", "PROBLEM", 370, 382], ["inflammatory chemokines", "PROBLEM", 410, 433], ["tumor necrosis factor", "PROBLEM", 442, 463], ["idiopathic", "OBSERVATION_MODIFIER", 44, 54], ["interstitial", "ANATOMY_MODIFIER", 55, 67], ["pneumonia", "OBSERVATION", 68, 77], ["interstitial", "ANATOMY_MODIFIER", 82, 94], ["pneumonia", "OBSERVATION", 95, 104], ["collagen", "OBSERVATION", 121, 129], ["vascular", "ANATOMY", 130, 138], ["interstitial", "ANATOMY_MODIFIER", 207, 219], ["pneumonia", "OBSERVATION", 220, 229], ["Autoimmune", "OBSERVATION_MODIFIER", 230, 240], ["interstitial", "OBSERVATION_MODIFIER", 241, 253], ["pneumonia", "OBSERVATION", 254, 263], ["Fluid accumulation", "OBSERVATION", 264, 282], ["lungs", "ANATOMY", 290, 295], ["coronavirus disease", "OBSERVATION", 303, 322], ["pneumonia", "OBSERVATION", 345, 354], ["inflammation", "OBSERVATION", 370, 382], ["inflammatory", "OBSERVATION_MODIFIER", 410, 422], ["tumor", "OBSERVATION_MODIFIER", 442, 447], ["necrosis", "OBSERVATION", 448, 456]]], ["This can eventually lead to acute respiratory distress syndrome (ARDS), which is the primary cause of mortality in COVID-19 patients.", [["respiratory", "ANATOMY", 34, 45], ["acute respiratory distress syndrome", "DISEASE", 28, 63], ["ARDS", "DISEASE", 65, 69], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["acute respiratory distress syndrome", "PROBLEM", 28, 63], ["ARDS", "PROBLEM", 65, 69], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["respiratory distress", "OBSERVATION", 34, 54], ["ARDS", "OBSERVATION", 65, 69]]], ["Examination of pathological specimens collected from patients with ARDS frequently reveals diffuse alveolar damage.", [["specimens", "ANATOMY", 28, 37], ["alveolar", "ANATOMY", 99, 107], ["ARDS", "DISEASE", 67, 71], ["alveolar damage", "DISEASE", 99, 114], ["specimens", "CANCER", 28, 37], ["patients", "ORGANISM", 53, 61], ["alveolar", "TISSUE", 99, 107], ["patients", "SPECIES", 53, 61], ["Examination of pathological specimens", "TEST", 0, 37], ["ARDS", "PROBLEM", 67, 71], ["diffuse alveolar damage", "PROBLEM", 91, 114], ["diffuse", "OBSERVATION_MODIFIER", 91, 98], ["alveolar damage", "OBSERVATION", 99, 114]]], ["Moreover, laboratory studies have demonstrated both alveolar epithelial and lung endothelial injury, resulting in accumulation of protein-rich inflammatory edematous fluid in the alveolar space [1] .SARS-CoV-2 COVID-19Murohashi et al. presented 11 cases wherein severe COVID-19-related pneumonia was treated with favipiravir and methylprednisolone [2] .", [["alveolar epithelial", "ANATOMY", 52, 71], ["lung endothelial", "ANATOMY", 76, 92], ["edematous fluid", "ANATOMY", 156, 171], ["alveolar space", "ANATOMY", 179, 193], ["SARS", "DISEASE", 199, 203], ["COVID-19", "CHEMICAL", 269, 277], ["pneumonia", "DISEASE", 286, 295], ["favipiravir", "CHEMICAL", 313, 324], ["methylprednisolone", "CHEMICAL", 329, 347], ["favipiravir", "CHEMICAL", 313, 324], ["methylprednisolone", "CHEMICAL", 329, 347], ["alveolar epithelial", "TISSUE", 52, 71], ["lung endothelial", "TISSUE", 76, 92], ["favipiravir", "SIMPLE_CHEMICAL", 313, 324], ["methylprednisolone", "SIMPLE_CHEMICAL", 329, 347], ["laboratory studies", "TEST", 10, 28], ["alveolar epithelial and lung endothelial injury", "PROBLEM", 52, 99], ["accumulation of protein-rich inflammatory edematous fluid in the alveolar space", "PROBLEM", 114, 193], ["SARS", "TEST", 199, 203], ["CoV", "TEST", 204, 207], ["severe COVID", "PROBLEM", 262, 274], ["pneumonia", "PROBLEM", 286, 295], ["favipiravir", "TREATMENT", 313, 324], ["methylprednisolone", "TREATMENT", 329, 347], ["alveolar", "ANATOMY_MODIFIER", 52, 60], ["epithelial", "ANATOMY_MODIFIER", 61, 71], ["lung", "ANATOMY", 76, 80], ["endothelial injury", "OBSERVATION", 81, 99], ["accumulation", "OBSERVATION_MODIFIER", 114, 126], ["rich", "OBSERVATION_MODIFIER", 138, 142], ["inflammatory", "OBSERVATION_MODIFIER", 143, 155], ["edematous", "OBSERVATION_MODIFIER", 156, 165], ["fluid", "OBSERVATION", 166, 171], ["alveolar", "ANATOMY_MODIFIER", 179, 187], ["pneumonia", "OBSERVATION", 286, 295]]], ["They concluded that early-stage treatment using a combination of favipiravir and methylprednisolone could prevent the need for ventilatory support [2] .", [["favipiravir", "CHEMICAL", 65, 76], ["methylprednisolone", "CHEMICAL", 81, 99], ["favipiravir", "CHEMICAL", 65, 76], ["methylprednisolone", "CHEMICAL", 81, 99], ["favipiravir", "SIMPLE_CHEMICAL", 65, 76], ["methylprednisolone", "SIMPLE_CHEMICAL", 81, 99], ["early-stage treatment", "TREATMENT", 20, 41], ["favipiravir", "TREATMENT", 65, 76], ["methylprednisolone", "TREATMENT", 81, 99], ["ventilatory support", "TREATMENT", 127, 146]]], ["Although there is currently no cure for COVID-19, clinical trials are underway to determine potential treatments using existing drugs.", [["COVID", "TEST", 40, 45], ["existing drugs", "TREATMENT", 119, 133]]], ["Researchers conducting the Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, currently underway in the UK, announced that dexamethasone had shown considerable potential in significantly improving the outcomes for COVID-19 patients receiving respiratory support [3] .SARS-CoV-2 COVID-19I was further impressed with the findings reported in the article by Murohashi et al. [2] , particularly regarding the radiological features of case 10.", [["respiratory", "ANATOMY", 251, 262], ["dexamethasone", "CHEMICAL", 132, 145], ["SARS", "DISEASE", 276, 280], ["COVID-19", "CHEMICAL", 52, 60], ["dexamethasone", "CHEMICAL", 132, 145], ["dexamethasone", "SIMPLE_CHEMICAL", 132, 145], ["patients", "ORGANISM", 232, 240], ["SARS-CoV-2 COVID-19I", "DNA", 276, 296], ["patients", "SPECIES", 232, 240], ["COVID", "TEST", 52, 57], ["dexamethasone", "TREATMENT", 132, 145], ["COVID", "TEST", 223, 228], ["respiratory support", "TREATMENT", 251, 270], ["SARS", "TEST", 276, 280], ["CoV", "TEST", 281, 284]]], ["Before December 2019, we were not aware of the clinical features and radiological findings of COVID-19 patients.", [["COVID", "DISEASE", 94, 99], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["COVID", "TEST", 94, 99]]], ["Without this knowledge, I would have diagnosed case 10 as nonspecific interstitial pneumonia (NSIP) [4] or autoimmune interstitial pneumonia (AIIP) [5] .SARS-CoV-2 COVID-19From a case series we conducted at the University of the Ryukyus Hospital, I present the cases of three patients whose chest computed tomography (CT) images are shown in Fig. 1 .", [["interstitial pneumonia", "DISEASE", 70, 92], ["NSIP", "DISEASE", 94, 98], ["autoimmune interstitial pneumonia", "DISEASE", 107, 140], ["AIIP", "DISEASE", 142, 146], ["SARS", "DISEASE", 153, 157], ["patients", "ORGANISM", 276, 284], ["patients", "SPECIES", 276, 284], ["nonspecific interstitial pneumonia (NSIP)", "PROBLEM", 58, 99], ["autoimmune interstitial pneumonia", "PROBLEM", 107, 140], ["SARS", "TEST", 153, 157], ["chest computed tomography", "TEST", 291, 316], ["CT) images", "TEST", 318, 328], ["nonspecific", "OBSERVATION_MODIFIER", 58, 69], ["interstitial", "OBSERVATION_MODIFIER", 70, 82], ["pneumonia", "OBSERVATION", 83, 92], ["NSIP", "OBSERVATION", 94, 98], ["autoimmune", "OBSERVATION_MODIFIER", 107, 117], ["interstitial", "ANATOMY_MODIFIER", 118, 130], ["pneumonia", "OBSERVATION", 131, 140], ["chest", "ANATOMY", 291, 296]]], ["Chest CT findings of case 1 demonstrated typical pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on days 1 and 3 after admission; however, on day 9, they indicated organizing pneumonia (OP).", [["pneumonia", "DISEASE", 49, 58], ["acute respiratory syndrome coronavirus", "DISEASE", 76, 114], ["pneumonia", "DISEASE", 208, 217], ["OP", "DISEASE", 219, 221], ["severe acute respiratory syndrome coronavirus", "SPECIES", 69, 114], ["SARS-CoV-2", "SPECIES", 118, 128], ["Chest CT", "TEST", 0, 8], ["typical pneumonia", "PROBLEM", 41, 58], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 69, 114], ["SARS-CoV", "TEST", 118, 126], ["organizing pneumonia", "PROBLEM", 197, 217], ["typical", "OBSERVATION_MODIFIER", 41, 48], ["pneumonia", "OBSERVATION", 49, 58], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["respiratory syndrome", "OBSERVATION", 82, 102], ["organizing", "OBSERVATION_MODIFIER", 197, 207], ["pneumonia", "OBSERVATION", 208, 217]]], ["Similarly, chest CT findings of case 2 demonstrated typical pneumonia caused by SARS-CoV-2 on day 1.", [["chest", "ANATOMY", 11, 16], ["pneumonia", "DISEASE", 60, 69], ["SARS", "DISEASE", 80, 84], ["SARS-CoV", "SPECIES", 80, 88], ["chest CT", "TEST", 11, 19], ["typical pneumonia", "PROBLEM", 52, 69], ["SARS", "PROBLEM", 80, 84], ["chest", "ANATOMY", 11, 16], ["typical", "OBSERVATION_MODIFIER", 52, 59], ["pneumonia", "OBSERVATION", 60, 69]]], ["However, on day 7, they indicated possible NSIP or AIIP, which closely resembled findings of case 10 in the article by Murohashi et al. [2] .", [["NSIP", "DISEASE", 43, 47], ["NSIP", "PROBLEM", 43, 47], ["possible", "UNCERTAINTY", 34, 42], ["NSIP", "OBSERVATION", 43, 47]]], ["Chest CT findings of case 3 showed a pattern of \"radiographic negative for pulmonary edema\", indicative of OP or chronic eosinophilic pneumonia.", [["pulmonary", "ANATOMY", 75, 84], ["pulmonary edema", "DISEASE", 75, 90], ["OP", "DISEASE", 107, 109], ["pneumonia", "DISEASE", 134, 143], ["pulmonary", "ORGAN", 75, 84], ["Chest CT", "TEST", 0, 8], ["pulmonary edema", "PROBLEM", 75, 90], ["OP", "PROBLEM", 107, 109], ["chronic eosinophilic pneumonia", "PROBLEM", 113, 143], ["pulmonary", "ANATOMY", 75, 84], ["edema", "OBSERVATION", 85, 90], ["indicative of", "UNCERTAINTY", 93, 106], ["OP", "OBSERVATION_MODIFIER", 107, 109], ["chronic", "OBSERVATION_MODIFIER", 113, 120], ["eosinophilic", "OBSERVATION_MODIFIER", 121, 133], ["pneumonia", "OBSERVATION", 134, 143]]], ["Because these conditions were diagnosed as COVID-19-associated pneumonia, pathological evaluation was not performed.", [["COVID-19", "CHEMICAL", 43, 51], ["pneumonia", "DISEASE", 63, 72], ["COVID", "TEST", 43, 48], ["pneumonia", "PROBLEM", 63, 72], ["pathological evaluation", "TEST", 74, 97], ["pneumonia", "OBSERVATION", 63, 72]]], ["However, previously reported pathological findings of COVID-19-associated pneumonia have demonstrated variations from those of OP, interstitial pneumonia/fibrosis, and diffuse alveolar damage [6, 7] .", [["interstitial", "ANATOMY", 131, 143], ["alveolar", "ANATOMY", 176, 184], ["COVID-19", "CHEMICAL", 54, 62], ["pneumonia", "DISEASE", 74, 83], ["OP", "DISEASE", 127, 129], ["interstitial pneumonia", "DISEASE", 131, 153], ["fibrosis", "DISEASE", 154, 162], ["alveolar damage", "DISEASE", 176, 191], ["COVID-19", "SIMPLE_CHEMICAL", 54, 62], ["alveolar", "MULTI-TISSUE_STRUCTURE", 176, 184], ["COVID", "TEST", 54, 59], ["pneumonia", "PROBLEM", 74, 83], ["OP", "PROBLEM", 127, 129], ["interstitial pneumonia", "PROBLEM", 131, 153], ["fibrosis", "PROBLEM", 154, 162], ["diffuse alveolar damage", "PROBLEM", 168, 191], ["pneumonia", "OBSERVATION", 74, 83], ["interstitial", "ANATOMY_MODIFIER", 131, 143], ["pneumonia", "OBSERVATION", 144, 153], ["fibrosis", "OBSERVATION", 154, 162], ["diffuse", "OBSERVATION_MODIFIER", 168, 175], ["alveolar damage", "OBSERVATION", 176, 191]]], ["Additionally, several reports have described the similarity between pneumonia caused by SARS-CoV-2 and interstitial pneumonia DOI of original article: https://doi.org/10.1016/j.resinv.2020.08.", [["pneumonia", "DISEASE", 68, 77], ["SARS", "DISEASE", 88, 92], ["interstitial pneumonia", "DISEASE", 103, 125], ["DOI", "CHEMICAL", 126, 129], ["DOI", "CHEMICAL", 126, 129], ["SARS-CoV-2", "ORGANISM", 88, 98], ["SARS-CoV", "SPECIES", 88, 96], ["pneumonia", "PROBLEM", 68, 77], ["SARS", "PROBLEM", 88, 92], ["CoV", "TEST", 93, 96], ["interstitial pneumonia", "PROBLEM", 103, 125], ["pneumonia", "OBSERVATION", 68, 77], ["interstitial", "ANATOMY_MODIFIER", 103, 115], ["pneumonia", "OBSERVATION", 116, 125]]], ["001.SARS-CoV-2 COVID-19Available online at www.sciencedirect.com Respiratory Investigation j ou rnal h ome pag e: www.elsevier.com/loca te/re sinv r e s p i r a t o r y i n v e s t i g a t i o n x x x ( x x x x ) x x x Please cite this article as: Fujita J, SARS-CoV-2 as a causative agent of idiopathic interstitial pneumonia and interstitial pneumonia associated with collagen vascular disorders, Respiratory Investigation, https://doi.org/10.1016/j.resinv.2020.09.002 associated with collagen vascular diseases (IP-CVD) [8, 9] .", [["interstitial", "ANATOMY", 304, 316], ["interstitial", "ANATOMY", 331, 343], ["vascular", "ANATOMY", 379, 387], ["vascular", "ANATOMY", 496, 504], ["idiopathic interstitial pneumonia", "DISEASE", 293, 326], ["interstitial pneumonia", "DISEASE", 331, 353], ["collagen vascular disorders", "DISEASE", 370, 397], ["collagen vascular diseases", "DISEASE", 487, 513], ["CVD", "DISEASE", 518, 521], ["SARS-CoV-2", "ORGANISM", 258, 268], ["collagen", "GENE_OR_GENE_PRODUCT", 370, 378], ["vascular", "MULTI-TISSUE_STRUCTURE", 379, 387], ["collagen", "GENE_OR_GENE_PRODUCT", 487, 495], ["vascular", "MULTI-TISSUE_STRUCTURE", 496, 504], ["SARS", "TEST", 4, 8], ["CoV", "TEST", 9, 12], ["Respiratory Investigation", "TEST", 65, 90], ["idiopathic interstitial pneumonia", "PROBLEM", 293, 326], ["interstitial pneumonia", "PROBLEM", 331, 353], ["collagen vascular disorders", "PROBLEM", 370, 397], ["Respiratory Investigation", "TEST", 399, 424], ["collagen vascular diseases", "PROBLEM", 487, 513], ["x x x", "OBSERVATION_MODIFIER", 213, 218], ["idiopathic", "OBSERVATION_MODIFIER", 293, 303], ["interstitial", "ANATOMY_MODIFIER", 304, 316], ["pneumonia", "OBSERVATION", 317, 326], ["interstitial", "ANATOMY_MODIFIER", 331, 343], ["pneumonia", "OBSERVATION", 344, 353], ["collagen", "OBSERVATION", 370, 378], ["vascular", "ANATOMY", 379, 387], ["vascular", "ANATOMY", 496, 504], ["diseases", "OBSERVATION", 505, 513]]], ["Furthermore, Megremis et al. identified three immunogenic linear epitopes with high sequence identity to SARS-CoV-2 proteins in patients with dermatomyositis [10] .SARS-CoV-2 COVID-19Because pneumonia caused by SARS-CoV-2 is similar to idiopathic interstitial pneumonia (IIP) and IP-CVD, I would diagnose these conditions as OP, NSIP, or AIIP, and definitively choose steroid therapy for treatment.", [["dermatomyositis", "DISEASE", 142, 157], ["SARS", "DISEASE", 164, 168], ["pneumonia", "DISEASE", 191, 200], ["SARS", "DISEASE", 211, 215], ["idiopathic interstitial pneumonia", "DISEASE", 236, 269], ["IIP", "DISEASE", 271, 274], ["CVD", "DISEASE", 283, 286], ["NSIP", "DISEASE", 329, 333], ["AIIP", "DISEASE", 338, 342], ["steroid", "CHEMICAL", 368, 375], ["steroid", "CHEMICAL", 368, 375], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 105, 115], ["patients", "ORGANISM", 128, 136], ["SARS-CoV-2 COVID-19Because", "ORGANISM", 164, 190], ["SARS-CoV-2", "ORGANISM", 211, 221], ["steroid", "SIMPLE_CHEMICAL", 368, 375], ["immunogenic linear epitopes", "PROTEIN", 46, 73], ["SARS-CoV-2 proteins", "PROTEIN", 105, 124], ["patients", "SPECIES", 128, 136], ["SARS-CoV", "SPECIES", 105, 113], ["SARS-CoV-2", "SPECIES", 211, 221], ["three immunogenic linear epitopes", "PROBLEM", 40, 73], ["high sequence identity", "PROBLEM", 79, 101], ["SARS", "PROBLEM", 105, 109], ["CoV", "TEST", 110, 113], ["dermatomyositis", "PROBLEM", 142, 157], ["SARS", "TEST", 164, 168], ["CoV", "TEST", 169, 172], ["pneumonia", "PROBLEM", 191, 200], ["SARS", "PROBLEM", 211, 215], ["idiopathic interstitial pneumonia", "PROBLEM", 236, 269], ["CVD", "PROBLEM", 283, 286], ["OP", "TEST", 325, 327], ["NSIP", "PROBLEM", 329, 333], ["AIIP", "TREATMENT", 338, 342], ["steroid therapy", "TREATMENT", 368, 383], ["treatment", "TREATMENT", 388, 397], ["dermatomyositis", "OBSERVATION", 142, 157], ["pneumonia", "OBSERVATION", 191, 200], ["idiopathic", "OBSERVATION_MODIFIER", 236, 246], ["interstitial", "ANATOMY_MODIFIER", 247, 259], ["pneumonia", "OBSERVATION", 260, 269]]], ["In addition, SARS-CoV-2 might provide clues to the pathogenesis of IIP or IP-CVD.", [["IIP", "DISEASE", 67, 70], ["CVD", "DISEASE", 77, 80], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "PROBLEM", 13, 17], ["CVD", "PROBLEM", 77, 80]]], ["Despite the uncertainty surrounding the many pathogenetic aspects of COVID-19-related pneumonia, we are probably observing a model for other forms of IIP or IP-CVD [9, 10] .", [["COVID-19", "CHEMICAL", 69, 77], ["pneumonia", "DISEASE", 86, 95], ["IIP", "DISEASE", 150, 153], ["CVD", "DISEASE", 160, 163], ["COVID-19-related pneumonia", "PROBLEM", 69, 95], ["many", "OBSERVATION_MODIFIER", 40, 44], ["pathogenetic", "OBSERVATION_MODIFIER", 45, 57], ["pneumonia", "OBSERVATION", 86, 95]]], ["The large amount of data derived from studies on COVID-19 could assist in understanding the pathogenesis of IIP or IP-CVD and developing new therapeutic strategies.Conflict of InterestThe author declares no conflict of interest.", [["IIP", "DISEASE", 108, 111], ["CVD", "DISEASE", 118, 121], ["COVID-19", "CHEMICAL", 49, 57], ["COVID-19", "GENE_OR_GENE_PRODUCT", 49, 57], ["COVID", "TEST", 49, 54], ["CVD", "PROBLEM", 118, 121], ["new therapeutic strategies", "TREATMENT", 137, 163], ["large", "OBSERVATION_MODIFIER", 4, 9], ["amount", "OBSERVATION_MODIFIER", 10, 16], ["new", "OBSERVATION_MODIFIER", 137, 140]]]], "dc04003527af4f6d52e5d0ec2ee7b541afa71aee": [["The novel coronavirus (COVID-19) pandemic is the defining global health crisis of our time and the greatest threat we have faced during this century.", [["coronavirus", "ORGANISM", 10, 21], ["COVID-19", "ORGANISM", 23, 31], ["The novel coronavirus", "TEST", 0, 21], ["COVID", "TEST", 23, 28], ["pandemic", "PROBLEM", 33, 41], ["coronavirus", "OBSERVATION", 10, 21], ["global", "OBSERVATION_MODIFIER", 58, 64], ["health crisis", "OBSERVATION", 65, 78]]], ["As a highly contagious virus, the infection emerged in China in January 2020 [1] and rapidly spread globally; with the most affected regions being the USA, Europe, Republic of Korea and Iran.", [["infection", "DISEASE", 34, 43], ["a highly contagious virus", "PROBLEM", 3, 28], ["the infection", "PROBLEM", 30, 43], ["contagious", "OBSERVATION_MODIFIER", 12, 22], ["virus", "OBSERVATION", 23, 28], ["infection", "OBSERVATION", 34, 43]]], ["According to the World Health Organizations\u00b4 (WHO) data, in April 2020, one million of the population has been infected with more than 50 000 deaths [2] .", [["deaths", "DISEASE", 142, 148]]], ["To date, in the absence of any specific treatment, our knowledge about this disease remains very limited and is subject to rapid change.", [["this disease", "PROBLEM", 71, 83]]], ["Cancer is considered a risk factor for COVID-19 infection (1%) [3] , with very few cases reported in hematology-Oncology, but with no data related to bone marrow transplant.", [["Cancer", "ANATOMY", 0, 6], ["bone marrow", "ANATOMY", 150, 161], ["Cancer", "DISEASE", 0, 6], ["infection", "DISEASE", 48, 57], ["Cancer", "CANCER", 0, 6], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 150, 161], ["COVID-19", "SPECIES", 39, 47], ["Cancer", "PROBLEM", 0, 6], ["COVID-19 infection", "PROBLEM", 39, 57], ["bone marrow transplant", "TREATMENT", 150, 172], ["bone marrow", "ANATOMY", 150, 161], ["transplant", "OBSERVATION", 162, 172]]], ["This virus represents a serious danger for patients with hematologic malignancies scheduled for bone marrow transplant due to myeloablative conditioning and immunosuppressive treatments.", [["hematologic malignancies", "ANATOMY", 57, 81], ["bone marrow", "ANATOMY", 96, 107], ["hematologic malignancies", "DISEASE", 57, 81], ["patients", "ORGANISM", 43, 51], ["hematologic malignancies", "CANCER", 57, 81], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 96, 107], ["patients", "SPECIES", 43, 51], ["hematologic malignancies", "PROBLEM", 57, 81], ["bone marrow transplant", "TREATMENT", 96, 118], ["myeloablative conditioning", "TREATMENT", 126, 152], ["immunosuppressive treatments", "TREATMENT", 157, 185]]], ["People receiving chemotherapy with compromised immune systems and complications after stem cell transplant have an increased risk for infection [4] .", [["stem cell", "ANATOMY", 86, 95], ["infection", "DISEASE", 134, 143], ["People", "ORGANISM", 0, 6], ["stem cell", "CELL", 86, 95], ["People", "SPECIES", 0, 6], ["chemotherapy", "TREATMENT", 17, 29], ["compromised immune systems", "PROBLEM", 35, 61], ["complications", "PROBLEM", 66, 79], ["stem cell transplant", "TREATMENT", 86, 106], ["infection", "PROBLEM", 134, 143], ["stem cell transplant", "OBSERVATION", 86, 106], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["infection", "OBSERVATION", 134, 143]]], ["During a bone marrow transplant, pulmonary complications are frequent and associated to death [5] .", [["bone marrow", "ANATOMY", 9, 20], ["pulmonary", "ANATOMY", 33, 42], ["pulmonary complications", "DISEASE", 33, 56], ["death", "DISEASE", 88, 93], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 9, 20], ["pulmonary", "ORGAN", 33, 42], ["a bone marrow transplant", "TREATMENT", 7, 31], ["pulmonary complications", "PROBLEM", 33, 56], ["bone marrow", "ANATOMY", 9, 20], ["transplant", "OBSERVATION", 21, 31], ["pulmonary", "ANATOMY", 33, 42], ["complications", "OBSERVATION", 43, 56]]], ["COVID-19 infection may complicate clinical symptoms with higher risk of respiratory distress [6] , and this situation could be even more critical depending on factors of co-morbidity such as age, cardiovascular, liver and kidney diseases [7] .", [["respiratory", "ANATOMY", 72, 83], ["cardiovascular", "ANATOMY", 196, 210], ["liver", "ANATOMY", 212, 217], ["kidney", "ANATOMY", 222, 228], ["COVID-19", "CHEMICAL", 0, 8], ["infection", "DISEASE", 9, 18], ["respiratory distress", "DISEASE", 72, 92], ["cardiovascular, liver and kidney diseases", "DISEASE", 196, 237], ["liver", "ORGAN", 212, 217], ["kidney", "ORGAN", 222, 228], ["COVID-19 infection", "PROBLEM", 0, 18], ["clinical symptoms", "PROBLEM", 34, 51], ["respiratory distress", "PROBLEM", 72, 92], ["co-morbidity", "PROBLEM", 170, 182], ["cardiovascular, liver and kidney diseases", "PROBLEM", 196, 237], ["infection", "OBSERVATION", 9, 18], ["respiratory distress", "OBSERVATION", 72, 92], ["liver", "ANATOMY", 212, 217], ["kidney", "ANATOMY", 222, 228], ["diseases", "OBSERVATION", 229, 237]]], ["In addition to the virulence of the infection, restrictive government measures cause many obstacles and difficulties for the transplant course: 1) blood transfusion is vital for transplant patients; the number of blood donors decreases drastically with population confinement, 2) drug manufacturing and available medicines are compromised, 3) the allogenic stem cell transplant with donors on international files becomes very difficult to access because of the international borders shut down, 4) Management of unstable patients requires an intensive care unit with mechanical ventilation, however, depending on the pandemic level and the healthcare system in each country, hospital beds might be lacking.", [["blood", "ANATOMY", 147, 152], ["blood", "ANATOMY", 213, 218], ["stem cell", "ANATOMY", 357, 366], ["infection", "DISEASE", 36, 45], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["patients", "ORGANISM", 189, 197], ["blood", "ORGANISM_SUBSTANCE", 213, 218], ["stem cell", "CELL", 357, 366], ["donors", "ORGANISM", 383, 389], ["patients", "ORGANISM", 520, 528], ["patients", "SPECIES", 189, 197], ["patients", "SPECIES", 520, 528], ["the infection", "PROBLEM", 32, 45], ["restrictive government measures", "TREATMENT", 47, 78], ["blood transfusion", "TREATMENT", 147, 164], ["transplant patients", "TREATMENT", 178, 197], ["blood donors", "TREATMENT", 213, 225], ["drug manufacturing", "TREATMENT", 280, 298], ["available medicines", "TREATMENT", 303, 322], ["the allogenic stem cell transplant", "TREATMENT", 343, 377], ["mechanical ventilation", "TREATMENT", 566, 588], ["infection", "OBSERVATION", 36, 45], ["restrictive", "OBSERVATION_MODIFIER", 47, 58], ["allogenic stem cell transplant", "OBSERVATION", 347, 377], ["unstable", "OBSERVATION_MODIFIER", 511, 519], ["mechanical ventilation", "OBSERVATION", 566, 588]]], ["Therefore, the management of patients transplanted during a pandemic is very complex.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37]]], ["To overcome this crisis, some recommendations and emergency measures have been developed by scientific societies like the European Society for Blood and Bone Marrow Transplantation [8, 9] .", [["Blood", "ANATOMY", 143, 148], ["Bone Marrow", "ANATOMY", 153, 164], ["Blood", "ORGANISM_SUBSTANCE", 143, 148], ["Bone Marrow", "MULTI-TISSUE_STRUCTURE", 153, 164], ["this crisis", "PROBLEM", 12, 23], ["emergency measures", "TREATMENT", 50, 68], ["Blood and Bone Marrow Transplantation", "TREATMENT", 143, 180], ["Bone Marrow", "ANATOMY", 153, 164]]], ["Their guidelines are established according to the coronavirus high contagion rate in Europe.", [["coronavirus high contagion", "DISEASE", 50, 76], ["coronavirus", "ORGANISM", 50, 61]]], ["The most important messages are the postponement of any low-risk non-urgent transplant, and freezing rich grafts if mobilization is already scheduled.", [["grafts", "ANATOMY", 106, 112], ["grafts", "TISSUE", 106, 112], ["non-urgent transplant", "TREATMENT", 65, 86], ["freezing rich grafts", "TREATMENT", 92, 112], ["transplant", "OBSERVATION", 76, 86]]], ["Currently, virus detection has become mandatory before any transplant process, among donors as well as recipients for allogenic stem cell transplant using throat-swab specimens for PCR test.", [["stem cell", "ANATOMY", 128, 137], ["throat-swab specimens", "ANATOMY", 155, 176], ["donors", "ORGANISM", 85, 91], ["recipients", "ORGANISM", 103, 113], ["allogenic stem cell", "CELL", 118, 137], ["throat", "ORGANISM", 155, 161], ["virus detection", "TEST", 11, 26], ["any transplant process", "TREATMENT", 55, 77], ["allogenic stem cell transplant", "TREATMENT", 118, 148], ["throat-swab specimens", "TEST", 155, 176], ["PCR test", "TEST", 181, 189], ["allogenic stem cell transplant", "OBSERVATION", 118, 148]]], ["During the transplant period, detection must be carried out before any symptom like fever, cough or chest imaging abnormalities.", [["chest", "ANATOMY", 100, 105], ["fever", "DISEASE", 84, 89], ["cough", "DISEASE", 91, 96], ["any symptom", "PROBLEM", 67, 78], ["fever", "PROBLEM", 84, 89], ["cough", "PROBLEM", 91, 96], ["chest imaging abnormalities", "PROBLEM", 100, 127], ["chest", "ANATOMY", 100, 105]]], ["Prevention procedures remain a very useful mean to avoid infection, and the WHO recommendations must be diligently followed by healthcare staff, patients and donors.", [["infection", "DISEASE", 57, 66], ["patients", "ORGANISM", 145, 153], ["donors", "ORGANISM", 158, 164], ["patients", "SPECIES", 145, 153], ["Prevention procedures", "TREATMENT", 0, 21], ["infection", "PROBLEM", 57, 66], ["infection", "OBSERVATION", 57, 66]]], ["It is vital to be very careful with hygiene routines, including hand washing, use of protective mask, alcohol-containing hand sanitizers, and limited visits.", [["hand", "ANATOMY", 64, 68], ["hand", "ANATOMY", 121, 125], ["alcohol", "CHEMICAL", 102, 109], ["alcohol", "CHEMICAL", 102, 109], ["hand", "ORGANISM_SUBDIVISION", 64, 68], ["alcohol", "SIMPLE_CHEMICAL", 102, 109], ["hand", "ORGANISM_SUBDIVISION", 121, 125], ["hygiene routines", "TREATMENT", 36, 52], ["hand washing", "TREATMENT", 64, 76], ["protective mask", "TREATMENT", 85, 100]]], ["In Morocco, the situation is less critical than in Europe, with a record of 1184 confirmed cases with 90 deaths [10] .", [["deaths", "DISEASE", 105, 111], ["less", "OBSERVATION_MODIFIER", 29, 33], ["critical", "OBSERVATION_MODIFIER", 34, 42]]], ["The government has adopted containment measures very early but the contagion is still gaining ground, and to ensure the safety of our transplanted patients, our hematology centers have adopted actions based on the European recommendations.", [["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["containment measures", "TREATMENT", 27, 47]]], ["In the Table 1 , we summarize the main practical steps that can be taken to reduce the risk to our vulnerable patients during bone marrow transplant [8] .ConclusionThe situation is critical all over the world and restrictive measures will affect bone marrow transplantation as the COVID-19 is spreading.", [["bone marrow", "ANATOMY", 126, 137], ["bone marrow", "ANATOMY", 246, 257], ["patients", "ORGANISM", 110, 118], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 126, 137], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 246, 257], ["patients", "SPECIES", 110, 118], ["bone marrow transplant", "TREATMENT", 126, 148], ["restrictive measures", "TREATMENT", 213, 233], ["bone marrow transplantation", "TREATMENT", 246, 273], ["the COVID", "TEST", 277, 286], ["spreading", "OBSERVATION_MODIFIER", 293, 302]]], ["It is necessary to carefully follow all international recommendations; Morocco has therefore taken emergency measures to minimize the impact of COVID-19 on transplant activity.", [["COVID-19", "CHEMICAL", 144, 152], ["COVID-19", "CHEMICAL", 144, 152], ["emergency measures", "TREATMENT", 99, 117], ["COVID", "TEST", 144, 149], ["transplant activity", "TREATMENT", 156, 175]]]], "592d11a47d474665bd6c02301fb915ac5f250e75": [["recorded in 188 countries/regions around the globe [1] .", [["globe", "ANATOMY", 45, 50]]], ["With a drastic spike in the number of infected cases occasioned by uncontrollable local community transmission globally including Africa; it is glaring that the outbreak has taken a new turn and ushered into a novel phase [2, 3] .", [["a drastic spike", "PROBLEM", 5, 20], ["Africa", "PROBLEM", 130, 136], ["drastic", "OBSERVATION_MODIFIER", 7, 14], ["spike", "OBSERVATION_MODIFIER", 15, 20], ["infected", "OBSERVATION", 38, 46], ["uncontrollable", "OBSERVATION_MODIFIER", 67, 81], ["local", "OBSERVATION_MODIFIER", 82, 87], ["community", "OBSERVATION_MODIFIER", 88, 97]]], ["Africa recorded its first case of the viral disease in Egypt on 14 February 2020.", [["viral disease", "DISEASE", 38, 51], ["the viral disease", "PROBLEM", 34, 51], ["viral disease", "OBSERVATION", 38, 51]]], ["Since then, the virus has continued to rise swiftly and infiltrated the entire continent according to the WHO [4] .", [["the virus", "PROBLEM", 12, 21], ["virus", "OBSERVATION", 16, 21]]], ["The realities surrounding the COVID-19 outbreak in Africa is that the disease is not a mere threat, rather it can be likened to a war, and one that must be won.", [["the disease", "PROBLEM", 66, 77], ["disease", "OBSERVATION", 70, 77]]], ["With the present state of preparedness and interventions among several African countries, can the continent successfully win the fight against COVID-19?", [["COVID-19", "CHEMICAL", 143, 151], ["interventions", "TREATMENT", 43, 56], ["COVID", "TEST", 143, 148]]]], "cd2f584c21a2bc13a089348c021044609e55dc06": [["IntroductionColorectal cancer (CRC) is the third most frequent cancer observed worldwide [1] , with 40,990 new cases expected for 2020 in Brazil [2] .", [["IntroductionColorectal cancer", "ANATOMY", 0, 29], ["CRC", "ANATOMY", 31, 34], ["cancer", "ANATOMY", 63, 69], ["IntroductionColorectal cancer", "DISEASE", 0, 29], ["CRC", "DISEASE", 31, 34], ["cancer", "DISEASE", 63, 69], ["IntroductionColorectal cancer", "CANCER", 0, 29], ["CRC", "CANCER", 31, 34], ["cancer", "CANCER", 63, 69], ["IntroductionColorectal cancer (CRC", "PROBLEM", 0, 34], ["cancer", "OBSERVATION", 23, 29], ["cancer", "OBSERVATION", 63, 69]]], ["Conventional therapy for patients with CRC is based on total or partial colectomy, usually followed by neoadjuvant or adjuvant chemotherapy [3] with a fluoropyrimidine, oxaliplatin, irinotecan and/or taxanes [4] .", [["CRC", "ANATOMY", 39, 42], ["CRC", "DISEASE", 39, 42], ["fluoropyrimidine", "CHEMICAL", 151, 167], ["oxaliplatin", "CHEMICAL", 169, 180], ["irinotecan", "CHEMICAL", 182, 192], ["taxanes", "CHEMICAL", 200, 207], ["fluoropyrimidine", "CHEMICAL", 151, 167], ["oxaliplatin", "CHEMICAL", 169, 180], ["irinotecan", "CHEMICAL", 182, 192], ["taxanes", "CHEMICAL", 200, 207], ["patients", "ORGANISM", 25, 33], ["CRC", "CANCER", 39, 42], ["fluoropyrimidine", "SIMPLE_CHEMICAL", 151, 167], ["oxaliplatin", "SIMPLE_CHEMICAL", 169, 180], ["irinotecan", "SIMPLE_CHEMICAL", 182, 192], ["taxanes", "SIMPLE_CHEMICAL", 200, 207], ["patients", "SPECIES", 25, 33], ["Conventional therapy", "TREATMENT", 0, 20], ["CRC", "PROBLEM", 39, 42], ["total or partial colectomy", "TREATMENT", 55, 81], ["neoadjuvant", "TREATMENT", 103, 114], ["adjuvant chemotherapy", "TREATMENT", 118, 139], ["a fluoropyrimidine", "TREATMENT", 149, 167], ["oxaliplatin", "TREATMENT", 169, 180], ["irinotecan", "TREATMENT", 182, 192], ["taxanes", "TREATMENT", 200, 207], ["CRC", "OBSERVATION", 39, 42], ["colectomy", "OBSERVATION", 72, 81]]], ["The success of chemotherapy is often complicated by metastases and relapsing disease associated with the development of drug resistance [5] .", [["metastases", "ANATOMY", 52, 62], ["metastases", "DISEASE", 52, 62], ["chemotherapy", "TREATMENT", 15, 27], ["metastases", "PROBLEM", 52, 62], ["relapsing disease", "PROBLEM", 67, 84], ["drug resistance", "PROBLEM", 120, 135], ["chemotherapy", "OBSERVATION", 15, 27], ["metastases", "OBSERVATION", 52, 62], ["relapsing", "OBSERVATION_MODIFIER", 67, 76], ["drug resistance", "OBSERVATION", 120, 135]]], ["One of the mechanisms responsible for drug resistance is autophagy, a selective cellular degradation process in which cytosolic proteins and organelles are sequestered into double-membrane autophagosomes that fuse with lysosome for the recycling of macromolecules [6, 7] .", [["cellular", "ANATOMY", 80, 88], ["cytosolic", "ANATOMY", 118, 127], ["organelles", "ANATOMY", 141, 151], ["membrane autophagosomes", "ANATOMY", 180, 203], ["lysosome", "ANATOMY", 219, 227], ["cellular", "CELL", 80, 88], ["organelles", "CELLULAR_COMPONENT", 141, 151], ["membrane autophagosomes", "CELLULAR_COMPONENT", 180, 203], ["lysosome", "CELLULAR_COMPONENT", 219, 227], ["cytosolic proteins", "PROTEIN", 118, 136], ["drug resistance", "PROBLEM", 38, 53], ["autophagy", "PROBLEM", 57, 66], ["a selective cellular degradation process", "PROBLEM", 68, 108], ["cytosolic proteins", "TEST", 118, 136], ["double-membrane autophagosomes", "TREATMENT", 173, 203], ["the recycling of macromolecules", "TREATMENT", 232, 263], ["responsible for", "UNCERTAINTY", 22, 37], ["drug resistance", "OBSERVATION", 38, 53], ["selective", "OBSERVATION_MODIFIER", 70, 79], ["cellular", "OBSERVATION_MODIFIER", 80, 88], ["degradation", "OBSERVATION", 89, 100]]], ["This process is also triggered to generate amino acids, nucleotides, and fatty acids under conditions of nutrient deprivation [8] .", [["amino acids", "CHEMICAL", 43, 54], ["fatty acids", "CHEMICAL", 73, 84], ["amino acids", "CHEMICAL", 43, 54], ["nucleotides", "CHEMICAL", 56, 67], ["fatty acids", "CHEMICAL", 73, 84], ["amino acids", "AMINO_ACID", 43, 54], ["fatty acids", "SIMPLE_CHEMICAL", 73, 84], ["amino acids", "TREATMENT", 43, 54], ["nucleotides", "TREATMENT", 56, 67], ["fatty acids", "TREATMENT", 73, 84], ["nutrient deprivation", "TREATMENT", 105, 125]]], ["Other types of stress can also trigger autophagy, such as genomic stress, https://doi.org/10.1016/j.intimp.2020.106495 Received 6 March 2020; Received in revised form 3 April 2020; Accepted 6 April 2020 endoplasmic reticulum stress, intracellular infections, and exposure to drugs [9] .IntroductionWe have previously observed that certain chemotherapeutic agents at ultra-low concentrations can modulate signaling pathways and induce cytokines, such as IL-12, IL-10, IL-4, and TNF-\u03b1 [10] , without inducing apoptosis.", [["endoplasmic reticulum", "ANATOMY", 203, 224], ["intracellular", "ANATOMY", 233, 246], ["infections", "DISEASE", 247, 257], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 203, 224], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 233, 246], ["IL-12", "GENE_OR_GENE_PRODUCT", 453, 458], ["IL-10", "GENE_OR_GENE_PRODUCT", 460, 465], ["IL-4", "GENE_OR_GENE_PRODUCT", 467, 471], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 477, 482], ["cytokines", "PROTEIN", 434, 443], ["TNF", "PROTEIN", 477, 480], ["autophagy", "PROBLEM", 39, 48], ["genomic stress", "PROBLEM", 58, 72], ["endoplasmic reticulum stress", "PROBLEM", 203, 231], ["intracellular infections", "PROBLEM", 233, 257], ["drugs", "TREATMENT", 275, 280], ["certain chemotherapeutic agents", "TREATMENT", 331, 362], ["ultra-low concentrations", "TREATMENT", 366, 390], ["cytokines", "TEST", 434, 443], ["IL", "TEST", 453, 455], ["IL", "TEST", 460, 462], ["IL", "TEST", 467, 469], ["TNF", "TEST", 477, 480], ["inducing apoptosis", "PROBLEM", 498, 516], ["reticulum stress", "OBSERVATION", 215, 231], ["intracellular infections", "OBSERVATION", 233, 257], ["without", "UNCERTAINTY", 490, 497], ["apoptosis", "OBSERVATION", 507, 516]]], ["Treatment of HCT-116 colorectal cancer cells with a nontoxic concentration of paclitaxel alters the expression of several genes, especially those responsible for the synthesis of heat shock proteins, components of the antigen processing machinery (APM) and tumor-associated antigens [11] .", [["HCT-116 colorectal cancer cells", "ANATOMY", 13, 44], ["tumor", "ANATOMY", 257, 262], ["HCT-116", "CHEMICAL", 13, 20], ["colorectal cancer", "DISEASE", 21, 38], ["paclitaxel", "CHEMICAL", 78, 88], ["tumor", "DISEASE", 257, 262], ["paclitaxel", "CHEMICAL", 78, 88], ["HCT-116 colorectal cancer cells", "CELL", 13, 44], ["paclitaxel", "SIMPLE_CHEMICAL", 78, 88], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 179, 198], ["APM", "GENE_OR_GENE_PRODUCT", 248, 251], ["tumor", "CANCER", 257, 262], ["HCT-116 colorectal cancer cells", "CELL_LINE", 13, 44], ["heat shock proteins", "PROTEIN", 179, 198], ["antigen processing machinery", "PROTEIN", 218, 246], ["APM", "PROTEIN", 248, 251], ["tumor-associated antigens", "PROTEIN", 257, 282], ["HCT", "TEST", 13, 16], ["colorectal cancer cells", "PROBLEM", 21, 44], ["a nontoxic concentration of paclitaxel", "TREATMENT", 50, 88], ["heat shock proteins", "PROBLEM", 179, 198], ["tumor-associated antigens", "PROBLEM", 257, 282], ["colorectal cancer cells", "OBSERVATION", 21, 44]]], ["The increased immunogenicity of tumor cells induced by drug exposure is dependent on the onset of socalled immunogenic cell death, with increased expression of danger signals (e.g., danger-associated molecular patterns; DAMPs) such as calreticulin, heat shock proteins, ATP, and high mobility group box 1 (HMGB-1) [12] [13] [14] [15] [16] .", [["tumor cells", "ANATOMY", 32, 43], ["cell", "ANATOMY", 119, 123], ["tumor", "DISEASE", 32, 37], ["death", "DISEASE", 124, 129], ["ATP", "CHEMICAL", 270, 273], ["ATP", "CHEMICAL", 270, 273], ["tumor cells", "CELL", 32, 43], ["cell", "CELL", 119, 123], ["danger-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 182, 218], ["DAMPs", "GENE_OR_GENE_PRODUCT", 220, 225], ["calreticulin", "GENE_OR_GENE_PRODUCT", 235, 247], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 249, 268], ["ATP", "SIMPLE_CHEMICAL", 270, 273], ["high mobility group box 1", "GENE_OR_GENE_PRODUCT", 279, 304], ["HMGB-1) [12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 306, 338], ["tumor cells", "CELL_TYPE", 32, 43], ["danger-associated molecular patterns", "PROTEIN", 182, 218], ["DAMPs", "PROTEIN", 220, 225], ["calreticulin", "PROTEIN", 235, 247], ["heat shock proteins", "PROTEIN", 249, 268], ["high mobility group box 1 (HMGB-1", "PROTEIN", 279, 312], ["The increased immunogenicity of tumor cells", "PROBLEM", 0, 43], ["drug exposure", "PROBLEM", 55, 68], ["socalled immunogenic cell death", "PROBLEM", 98, 129], ["increased expression of danger signals", "PROBLEM", 136, 174], ["DAMPs", "PROBLEM", 220, 225], ["calreticulin, heat shock proteins", "PROBLEM", 235, 268], ["ATP", "PROBLEM", 270, 273], ["high mobility group box", "PROBLEM", 279, 302], ["HMGB", "TEST", 306, 310], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["immunogenicity", "OBSERVATION_MODIFIER", 14, 28], ["tumor cells", "OBSERVATION", 32, 43], ["drug exposure", "OBSERVATION", 55, 68], ["immunogenic cell death", "OBSERVATION", 107, 129], ["increased", "OBSERVATION_MODIFIER", 136, 145]]], ["Consistent with this notion, we also observed that exposing HCT-116 cells to a nontoxic concentration of paclitaxel or doxorubicin causes transcriptional alterations in several genes associated with the expression of tumor antigens [17] .", [["HCT-116 cells", "ANATOMY", 60, 73], ["tumor", "ANATOMY", 217, 222], ["paclitaxel", "CHEMICAL", 105, 115], ["doxorubicin", "CHEMICAL", 119, 130], ["tumor", "DISEASE", 217, 222], ["paclitaxel", "CHEMICAL", 105, 115], ["doxorubicin", "CHEMICAL", 119, 130], ["HCT-116 cells", "CELL", 60, 73], ["paclitaxel", "SIMPLE_CHEMICAL", 105, 115], ["doxorubicin", "SIMPLE_CHEMICAL", 119, 130], ["tumor", "CANCER", 217, 222], ["HCT-116 cells", "CELL_LINE", 60, 73], ["tumor antigens", "PROTEIN", 217, 231], ["HCT", "TEST", 60, 63], ["paclitaxel", "TREATMENT", 105, 115], ["doxorubicin", "TREATMENT", 119, 130], ["transcriptional alterations", "PROBLEM", 138, 165], ["tumor antigens", "PROBLEM", 217, 231], ["transcriptional alterations", "OBSERVATION", 138, 165], ["tumor", "OBSERVATION", 217, 222]]], ["In addition, dendritic cells (DCs) sensitized with the lysate of HCT-116 cells that were previously treated with low concentrations of paclitaxel induced cytotoxic T lymphocytes (CTLs) with higher lytic potential than did the DCs sensitized with untreated tumor cells [17] .IntroductionMore recently, combining antineoplastic agents with autophagy blockers as a therapeutic approach for treating cancer patients has been proposed.", [["dendritic cells", "ANATOMY", 13, 28], ["DCs", "ANATOMY", 30, 33], ["lysate", "ANATOMY", 55, 61], ["HCT-116 cells", "ANATOMY", 65, 78], ["cytotoxic T lymphocytes", "ANATOMY", 154, 177], ["CTLs", "ANATOMY", 179, 183], ["DCs", "ANATOMY", 226, 229], ["tumor cells", "ANATOMY", 256, 267], ["antineoplastic", "ANATOMY", 311, 325], ["cancer", "ANATOMY", 396, 402], ["paclitaxel", "CHEMICAL", 135, 145], ["tumor", "DISEASE", 256, 261], ["cancer", "DISEASE", 396, 402], ["paclitaxel", "CHEMICAL", 135, 145], ["dendritic cells", "CELL", 13, 28], ["DCs", "CELL", 30, 33], ["HCT-116 cells", "CELL", 65, 78], ["paclitaxel", "SIMPLE_CHEMICAL", 135, 145], ["cytotoxic T lymphocytes", "CELL", 154, 177], ["CTLs", "CELL", 179, 183], ["DCs", "CELL", 226, 229], ["tumor cells", "CELL", 256, 267], ["cancer", "CANCER", 396, 402], ["patients", "ORGANISM", 403, 411], ["dendritic cells", "CELL_TYPE", 13, 28], ["DCs", "CELL_TYPE", 30, 33], ["HCT-116 cells", "CELL_LINE", 65, 78], ["cytotoxic T lymphocytes", "CELL_TYPE", 154, 177], ["CTLs", "CELL_TYPE", 179, 183], ["DCs", "CELL_TYPE", 226, 229], ["untreated tumor cells", "CELL_TYPE", 246, 267], ["patients", "SPECIES", 403, 411], ["dendritic cells", "PROBLEM", 13, 28], ["HCT", "TEST", 65, 68], ["paclitaxel", "TREATMENT", 135, 145], ["cytotoxic T lymphocytes", "PROBLEM", 154, 177], ["untreated tumor cells", "PROBLEM", 246, 267], ["combining antineoplastic agents", "TREATMENT", 301, 332], ["autophagy blockers", "TREATMENT", 338, 356], ["a therapeutic approach", "TREATMENT", 360, 382], ["treating cancer", "PROBLEM", 387, 402], ["dendritic cells", "OBSERVATION", 13, 28], ["low concentrations", "OBSERVATION_MODIFIER", 113, 131], ["cytotoxic T lymphocytes", "OBSERVATION", 154, 177], ["tumor cells", "OBSERVATION", 256, 267], ["cancer", "OBSERVATION", 396, 402]]], ["Exposing human colorectal cancer cells to 5-fluorouracil (5-FU) enhances autophagy in a considerable portion of these cells [18] .", [["colorectal cancer cells", "ANATOMY", 15, 38], ["cells", "ANATOMY", 118, 123], ["colorectal cancer", "DISEASE", 15, 32], ["5-fluorouracil", "CHEMICAL", 42, 56], ["5-FU", "CHEMICAL", 58, 62], ["5-fluorouracil", "CHEMICAL", 42, 56], ["5-FU", "CHEMICAL", 58, 62], ["human", "ORGANISM", 9, 14], ["colorectal cancer cells", "CELL", 15, 38], ["5-fluorouracil", "SIMPLE_CHEMICAL", 42, 56], ["5-FU", "SIMPLE_CHEMICAL", 58, 62], ["cells", "CELL", 118, 123], ["human colorectal cancer cells", "CELL_TYPE", 9, 38], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["Exposing human colorectal cancer cells", "PROBLEM", 0, 38], ["fluorouracil", "TREATMENT", 44, 56], ["autophagy", "PROBLEM", 73, 82], ["colorectal cancer", "OBSERVATION", 15, 32]]], ["Exposure of these cells to the antimalarial drugs chloroquine (CQ), hydroxychloroquine, or mefloquine (quinolones) reduces autophagy and increases the susceptibility of cells to chemotherapy [19] .", [["cells", "ANATOMY", 18, 23], ["cells", "ANATOMY", 169, 174], ["chloroquine", "CHEMICAL", 50, 61], ["CQ", "CHEMICAL", 63, 65], ["hydroxychloroquine", "CHEMICAL", 68, 86], ["mefloquine", "CHEMICAL", 91, 101], ["quinolones", "CHEMICAL", 103, 113], ["chloroquine", "CHEMICAL", 50, 61], ["CQ", "CHEMICAL", 63, 65], ["hydroxychloroquine", "CHEMICAL", 68, 86], ["mefloquine", "CHEMICAL", 91, 101], ["quinolones", "CHEMICAL", 103, 113], ["cells", "CELL", 18, 23], ["chloroquine", "SIMPLE_CHEMICAL", 50, 61], ["CQ", "SIMPLE_CHEMICAL", 63, 65], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 68, 86], ["mefloquine", "SIMPLE_CHEMICAL", 91, 101], ["quinolones", "SIMPLE_CHEMICAL", 103, 113], ["cells", "CELL", 169, 174], ["the antimalarial drugs chloroquine", "TREATMENT", 27, 61], ["hydroxychloroquine", "TREATMENT", 68, 86], ["mefloquine (quinolones", "TREATMENT", 91, 113], ["autophagy", "PROBLEM", 123, 132], ["chemotherapy", "TREATMENT", 178, 190]]], ["Quinolones function as weak bases that passively diffuse into the lysosomes where they are protonated and prevented from leaving this vesicle.", [["lysosomes", "ANATOMY", 66, 75], ["vesicle", "ANATOMY", 134, 141], ["Quinolones", "CHEMICAL", 0, 10], ["Quinolones", "CHEMICAL", 0, 10], ["Quinolones", "SIMPLE_CHEMICAL", 0, 10], ["lysosomes", "CELLULAR_COMPONENT", 66, 75], ["vesicle", "CELLULAR_COMPONENT", 134, 141], ["Quinolones", "TREATMENT", 0, 10], ["weak bases", "PROBLEM", 23, 33], ["diffuse", "OBSERVATION_MODIFIER", 49, 56]]], ["Their presence increases the lysosome pH, interrupting its functions and preventing the end of autophagy [20, 21] .", [["lysosome", "ANATOMY", 29, 37], ["lysosome", "CELLULAR_COMPONENT", 29, 37], ["the lysosome pH", "PROBLEM", 25, 40], ["increases", "OBSERVATION_MODIFIER", 15, 24], ["lysosome pH", "OBSERVATION", 29, 40]]], ["As anti-inflammatory drugs, quinolones have been used to treat some autoimmune diseases [22] .", [["quinolones", "CHEMICAL", 28, 38], ["autoimmune diseases", "DISEASE", 68, 87], ["quinolones", "CHEMICAL", 28, 38], ["quinolones", "SIMPLE_CHEMICAL", 28, 38], ["anti-inflammatory drugs", "TREATMENT", 3, 26], ["quinolones", "TREATMENT", 28, 38], ["some autoimmune diseases", "PROBLEM", 63, 87]]], ["Currently, there are a number of clinical trials and experimental studies focusing on the feasibility of using CQ and hydroxychloroquine against SARS-CoV-2 (COVID-19) [23, 24] .", [["CQ", "CHEMICAL", 111, 113], ["hydroxychloroquine", "CHEMICAL", 118, 136], ["SARS", "DISEASE", 145, 149], ["CQ", "CHEMICAL", 111, 113], ["hydroxychloroquine", "CHEMICAL", 118, 136], ["CQ", "SIMPLE_CHEMICAL", 111, 113], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 118, 136], ["SARS-CoV", "SPECIES", 145, 153], ["clinical trials", "TREATMENT", 33, 48], ["experimental studies", "TEST", 53, 73], ["CQ", "TREATMENT", 111, 113], ["hydroxychloroquine", "TREATMENT", 118, 136], ["SARS", "TEST", 145, 149], ["CoV", "TEST", 150, 153], ["COVID", "TEST", 157, 162]]], ["In addition, the combination of CQ and antineoplastic drugs enhances the clinical response in patients with breast [25] and kidney cancer [26] , showing a synergistic effect on the activation of mTOR (mammalian target of rapamycin), inhibiting autophagy, and thus increasing tumor cell death.", [["antineoplastic", "ANATOMY", 39, 53], ["breast", "ANATOMY", 108, 114], ["kidney cancer", "ANATOMY", 124, 137], ["tumor cell", "ANATOMY", 275, 285], ["CQ", "CHEMICAL", 32, 34], ["breast [25] and kidney cancer", "DISEASE", 108, 137], ["rapamycin", "CHEMICAL", 221, 230], ["tumor", "DISEASE", 275, 280], ["death", "DISEASE", 286, 291], ["CQ", "CHEMICAL", 32, 34], ["rapamycin", "CHEMICAL", 221, 230], ["CQ", "SIMPLE_CHEMICAL", 32, 34], ["patients", "ORGANISM", 94, 102], ["breast", "ORGANISM_SUBDIVISION", 108, 114], ["kidney cancer", "CANCER", 124, 137], ["mTOR", "GENE_OR_GENE_PRODUCT", 195, 199], ["mammalian target of rapamycin", "GENE_OR_GENE_PRODUCT", 201, 230], ["tumor cell", "CELL", 275, 285], ["mTOR", "PROTEIN", 195, 199], ["mammalian target of rapamycin", "PROTEIN", 201, 230], ["patients", "SPECIES", 94, 102], ["CQ", "PROBLEM", 32, 34], ["antineoplastic drugs", "TREATMENT", 39, 59], ["kidney cancer", "PROBLEM", 124, 137], ["a synergistic effect", "PROBLEM", 153, 173], ["mTOR", "TREATMENT", 195, 199], ["rapamycin", "TREATMENT", 221, 230], ["inhibiting autophagy", "PROBLEM", 233, 253], ["increasing tumor cell death", "PROBLEM", 264, 291], ["breast", "ANATOMY", 108, 114], ["kidney", "ANATOMY", 124, 130], ["cancer", "OBSERVATION", 131, 137], ["increasing", "OBSERVATION_MODIFIER", 264, 274], ["tumor cell death", "OBSERVATION", 275, 291]]], ["No studies on the induction of autophagy in tumor cells treated with ultra-low doses of chemotherapeutic agents are available, and little is known about the effect of this phenomenon on the immunogenicity of tumor cells.", [["tumor cells", "ANATOMY", 44, 55], ["tumor cells", "ANATOMY", 208, 219], ["tumor", "DISEASE", 44, 49], ["tumor", "DISEASE", 208, 213], ["tumor cells", "CELL", 44, 55], ["tumor cells", "CELL", 208, 219], ["tumor cells", "CELL_TYPE", 44, 55], ["tumor cells", "CELL_TYPE", 208, 219], ["tumor cells", "PROBLEM", 44, 55], ["ultra", "TEST", 69, 74], ["chemotherapeutic agents", "TREATMENT", 88, 111], ["this phenomenon", "PROBLEM", 167, 182], ["tumor cells", "PROBLEM", 208, 219], ["tumor cells", "OBSERVATION", 208, 219]]], ["Furthermore, there are no reports on the effects of using CQ combined with other drugs on the functions of immunocompetent cells such as lymphocytes or DCs.IntroductionIn the present study, we tested the hypothesis that the application of CQ in combination with low concentrations of 5-FU blocks autophagy in tumor cells and promotes DC maturation, increasing their ability to enhance T lymphocyte cytotoxic granule expression.IntroductionWe found that exposing HCT-116 cells to this combination induced transcriptional changes, and DCs treated with HCT-116 lysate showed an improved ability to stimulate the proliferation of allogeneic T cells and to enhance the generation of cytotoxic CD8+ T cells.", [["cells", "ANATOMY", 123, 128], ["lymphocytes", "ANATOMY", 137, 148], ["DCs", "ANATOMY", 152, 155], ["tumor cells", "ANATOMY", 309, 320], ["DC", "ANATOMY", 334, 336], ["T lymphocyte", "ANATOMY", 385, 397], ["granule", "ANATOMY", 408, 415], ["HCT-116 cells", "ANATOMY", 462, 475], ["DCs", "ANATOMY", 533, 536], ["HCT-116 lysate", "ANATOMY", 550, 564], ["T cells", "ANATOMY", 637, 644], ["cytotoxic CD8+ T cells", "ANATOMY", 678, 700], ["CQ", "CHEMICAL", 58, 60], ["CQ", "CHEMICAL", 239, 241], ["5-FU", "CHEMICAL", 284, 288], ["tumor", "DISEASE", 309, 314], ["HCT-116", "CHEMICAL", 550, 557], ["CQ", "CHEMICAL", 58, 60], ["CQ", "CHEMICAL", 239, 241], ["5-FU", "CHEMICAL", 284, 288], ["CQ", "SIMPLE_CHEMICAL", 58, 60], ["cells", "CELL", 123, 128], ["lymphocytes", "CELL", 137, 148], ["DCs", "CELL", 152, 155], ["CQ", "SIMPLE_CHEMICAL", 239, 241], ["5-FU", "SIMPLE_CHEMICAL", 284, 288], ["tumor cells", "CELL", 309, 320], ["DC", "CELL", 334, 336], ["T lymphocyte", "CELL", 385, 397], ["HCT-116 cells", "CELL", 462, 475], ["DCs", "CELL", 533, 536], ["HCT-116 lysate", "CELL", 550, 564], ["T cells", "CELL", 637, 644], ["CD8", "GENE_OR_GENE_PRODUCT", 688, 691], ["immunocompetent cells", "CELL_TYPE", 107, 128], ["lymphocytes", "CELL_TYPE", 137, 148], ["DCs", "CELL_TYPE", 152, 155], ["tumor cells", "CELL_TYPE", 309, 320], ["DC", "CELL_TYPE", 334, 336], ["HCT-116 cells", "CELL_LINE", 462, 475], ["DCs", "CELL_TYPE", 533, 536], ["allogeneic T cells", "CELL_TYPE", 626, 644], ["cytotoxic CD8+ T cells", "CELL_TYPE", 678, 700], ["CQ", "TREATMENT", 58, 60], ["other drugs", "TREATMENT", 75, 86], ["immunocompetent cells", "PROBLEM", 107, 128], ["lymphocytes", "PROBLEM", 137, 148], ["DCs", "PROBLEM", 152, 155], ["the present study", "TEST", 171, 188], ["the application of CQ", "TREATMENT", 220, 241], ["5-FU blocks autophagy", "TREATMENT", 284, 305], ["tumor cells", "PROBLEM", 309, 320], ["HCT", "TEST", 462, 465], ["transcriptional changes", "PROBLEM", 504, 527], ["HCT", "TEST", 550, 553], ["lysate", "TEST", 558, 564], ["allogeneic T cells", "TREATMENT", 626, 644], ["cytotoxic CD8+ T cells", "PROBLEM", 678, 700], ["tumor cells", "OBSERVATION", 309, 320], ["lymphocyte", "OBSERVATION", 387, 397], ["cytotoxic granule expression", "OBSERVATION", 398, 426], ["cytotoxic CD8", "OBSERVATION", 678, 691]]], ["These results lead us to conclude that antigenic and transcriptional changes induced in tumor cells by the combination of CQ and low concentrations of 5-FU can be used as a basis for developing better DC-based antitumor reactive T cells.Culture and treatments of colorectal cancer HCT-116 cellsThe human colon cancer cell line HCT-116 was authenticated by DNA STR profiling using the GenePrint 10 commercial system (Promega, Madison, WI, USA) at the Viral Carcinogenesis and Cancer Biology Research Group, Institute of Biotechnology (IBTEC), Sao Paulo State University (UNESP).", [["tumor cells", "ANATOMY", 88, 99], ["DC", "ANATOMY", 201, 203], ["antitumor", "ANATOMY", 210, 219], ["T cells", "ANATOMY", 229, 236], ["colorectal cancer HCT-116 cells", "ANATOMY", 263, 294], ["colon cancer cell line HCT-116", "ANATOMY", 304, 334], ["tumor", "DISEASE", 88, 93], ["CQ", "CHEMICAL", 122, 124], ["5-FU", "CHEMICAL", 151, 155], ["colorectal cancer", "DISEASE", 263, 280], ["colon cancer", "DISEASE", 304, 316], ["Viral Carcinogenesis", "DISEASE", 450, 470], ["Cancer", "DISEASE", 475, 481], ["5-FU", "CHEMICAL", 151, 155], ["tumor cells", "CELL", 88, 99], ["CQ", "SIMPLE_CHEMICAL", 122, 124], ["5-FU", "SIMPLE_CHEMICAL", 151, 155], ["DC", "CELL", 201, 203], ["antitumor reactive T cells", "CELL", 210, 236], ["colorectal cancer HCT-116 cells", "CELL", 263, 294], ["human", "ORGANISM", 298, 303], ["colon cancer cell line HCT-116", "CELL", 304, 334], ["DNA", "CELLULAR_COMPONENT", 356, 359], ["tumor cells", "CELL_TYPE", 88, 99], ["DC", "CELL_TYPE", 201, 203], ["antitumor reactive T cells", "CELL_TYPE", 210, 236], ["colorectal cancer HCT-116 cells", "CELL_LINE", 263, 294], ["human colon cancer cell line HCT-116", "CELL_LINE", 298, 334], ["human", "SPECIES", 298, 303], ["human", "SPECIES", 298, 303], ["antigenic and transcriptional changes", "PROBLEM", 39, 76], ["tumor cells", "PROBLEM", 88, 99], ["CQ and low concentrations of 5-FU", "TREATMENT", 122, 155], ["Culture", "TEST", 237, 244], ["colorectal cancer", "PROBLEM", 263, 280], ["HCT", "TEST", 281, 284], ["cells", "TEST", 289, 294], ["The human colon cancer", "PROBLEM", 294, 316], ["HCT", "TEST", 327, 330], ["DNA STR profiling", "TEST", 356, 373], ["tumor cells", "OBSERVATION", 88, 99], ["reactive T cells", "OBSERVATION", 220, 236], ["colorectal", "ANATOMY", 263, 273], ["cancer", "OBSERVATION", 274, 280], ["colon", "ANATOMY", 304, 309], ["cancer", "OBSERVATION", 310, 316], ["Viral Carcinogenesis", "OBSERVATION", 450, 470]]], ["These cells were authenticated as mycoplasma-free and were cultured in 150 cm 2 culture bottles in RMPI-1640 medium (Gibco) supplemented with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 10 mM HEPES, and 1% antibiotics/antimycotics solution (Life Technologies).", [["cells", "ANATOMY", 6, 11], ["RMPI-1640", "CHEMICAL", 99, 108], ["L-glutamine", "CHEMICAL", 156, 167], ["sodium pyruvate", "CHEMICAL", 174, 189], ["amino acids", "CHEMICAL", 211, 222], ["L-glutamine", "CHEMICAL", 156, 167], ["sodium pyruvate", "CHEMICAL", 174, 189], ["amino acids", "CHEMICAL", 211, 222], ["HEPES", "CHEMICAL", 230, 235], ["cells", "CELL", 6, 11], ["FBS", "ORGANISM_SUBSTANCE", 146, 149], ["L-glutamine", "SIMPLE_CHEMICAL", 156, 167], ["sodium pyruvate", "SIMPLE_CHEMICAL", 174, 189], ["amino acids", "AMINO_ACID", 211, 222], ["These cells", "TEST", 0, 11], ["mycoplasma", "PROBLEM", 34, 44], ["RMPI", "TEST", 99, 103], ["2 mM L-glutamine", "TREATMENT", 151, 167], ["1 mM sodium pyruvate", "TREATMENT", 169, 189], ["mM nonessential amino acids", "TREATMENT", 195, 222], ["10 mM HEPES", "TREATMENT", 224, 235], ["1% antibiotics/antimycotics solution", "TREATMENT", 241, 277]]], ["The cells were cultured at 37\u02daC under a 5% CO 2 atmosphere.", [["cells", "ANATOMY", 4, 9], ["CO", "CHEMICAL", 43, 45], ["cells", "CELL", 4, 9], ["a 5% CO 2 atmosphere", "TREATMENT", 38, 58]]], ["After 24 h of culturing, the cells were treated with 80 \u00b5M CQ for 18 h, and then the minimum effective concentration of 5-fluorouracil (20 \u00b5M) (Eurofarma) was added and the cells were cultured for a further 24 h.", [["cells", "ANATOMY", 29, 34], ["cells", "ANATOMY", 173, 178], ["CQ", "CHEMICAL", 59, 61], ["5-fluorouracil", "CHEMICAL", 120, 134], ["Eurofarma", "CHEMICAL", 144, 153], ["CQ", "CHEMICAL", 59, 61], ["5-fluorouracil", "CHEMICAL", 120, 134], ["cells", "CELL", 29, 34], ["CQ", "SIMPLE_CHEMICAL", 59, 61], ["5-fluorouracil", "SIMPLE_CHEMICAL", 120, 134], ["Eurofarma", "SIMPLE_CHEMICAL", 144, 153], ["cells", "CELL", 173, 178], ["culturing", "TEST", 14, 23], ["fluorouracil (20 \u00b5M) (Eurofarma)", "TREATMENT", 122, 154], ["the cells", "PROBLEM", 169, 178]]], ["The cells were then detached with trypsin and washed before subsequent analysis or were cryopreserved for the further preparation of cell lysates.", [["cells", "ANATOMY", 4, 9], ["cell lysates", "ANATOMY", 133, 145], ["cells", "CELL", 4, 9], ["trypsin", "GENE_OR_GENE_PRODUCT", 34, 41], ["cell lysates", "ORGANISM_SUBSTANCE", 133, 145], ["trypsin", "PROTEIN", 34, 41], ["trypsin", "TREATMENT", 34, 41], ["subsequent analysis", "TEST", 60, 79], ["cell lysates", "TREATMENT", 133, 145], ["cell lysates", "OBSERVATION", 133, 145]]], ["The CQ and 5-FU concentrations and the incubation times were previously determined by MTT-based cytotoxicity assay.", [["CQ", "CHEMICAL", 4, 6], ["5-FU", "CHEMICAL", 11, 15], ["MTT", "CHEMICAL", 86, 89], ["CQ", "CHEMICAL", 4, 6], ["5-FU", "CHEMICAL", 11, 15], ["MTT", "CHEMICAL", 86, 89], ["CQ", "SIMPLE_CHEMICAL", 4, 6], ["5-FU", "SIMPLE_CHEMICAL", 11, 15], ["The CQ", "TEST", 0, 6], ["5-FU concentrations", "TREATMENT", 11, 30], ["MTT-based cytotoxicity assay", "TEST", 86, 114]]], ["For this, 2x10 3 cells were plated in 96-well flat-bottomed culture plates and incubated with variable concentrations of CQ (80 to 200 \u00b5M) and 5-FU (0.06 to 100 \u00b5M).", [["2x10 3 cells", "ANATOMY", 10, 22], ["CQ", "CHEMICAL", 121, 123], ["5-FU", "CHEMICAL", 143, 147], ["CQ", "CHEMICAL", 121, 123], ["5-FU", "CHEMICAL", 143, 147], ["2x10 3 cells", "CELL", 10, 22], ["CQ", "SIMPLE_CHEMICAL", 121, 123], ["5-FU", "SIMPLE_CHEMICAL", 143, 147], ["2x10 3 cells", "CELL_LINE", 10, 22], ["bottomed culture plates", "TEST", 51, 74], ["CQ", "TEST", 121, 123]]], ["Increased optical density due to formazan reduction was read by a spectrophotometer to evaluate the toxic effect of the drug concentrations.Analysis of cell viability and deathThe concentration of HCT-116 cells was adjusted to 10 5 cells/mL and cultured overnight in a 24-well plate.", [["cell", "ANATOMY", 152, 156], ["HCT-116 cells", "ANATOMY", 197, 210], ["cells", "ANATOMY", 232, 237], ["formazan", "CHEMICAL", 33, 41], ["death", "DISEASE", 171, 176], ["HCT-116", "CHEMICAL", 197, 204], ["formazan", "CHEMICAL", 33, 41], ["formazan", "SIMPLE_CHEMICAL", 33, 41], ["cell", "CELL", 152, 156], ["HCT-116 cells", "CELL", 197, 210], ["HCT-116 cells", "CELL_LINE", 197, 210], ["Increased optical density", "PROBLEM", 0, 25], ["formazan reduction", "TREATMENT", 33, 51], ["a spectrophotometer", "TEST", 64, 83], ["the drug concentrations", "PROBLEM", 116, 139], ["cell viability", "PROBLEM", 152, 166], ["death", "PROBLEM", 171, 176], ["HCT", "TEST", 197, 200], ["cells", "TEST", 205, 210], ["optical density", "OBSERVATION", 10, 25], ["toxic", "OBSERVATION_MODIFIER", 100, 105], ["cell viability", "OBSERVATION", 152, 166]]], ["The cells were treated with CQ overnight, followed by exposure to 5-FU for 24 h.", [["cells", "ANATOMY", 4, 9], ["CQ", "CHEMICAL", 28, 30], ["5-FU", "CHEMICAL", 66, 70], ["CQ", "CHEMICAL", 28, 30], ["5-FU", "CHEMICAL", 66, 70], ["cells", "CELL", 4, 9], ["CQ", "SIMPLE_CHEMICAL", 28, 30], ["5-FU", "SIMPLE_CHEMICAL", 66, 70]]], ["As a positive control of cell death, cells were heated at 59\u00b0C for 20 min.", [["cell", "ANATOMY", 25, 29], ["cells", "ANATOMY", 37, 42], ["death", "DISEASE", 30, 35], ["cell", "CELL", 25, 29], ["cells", "CELL", 37, 42], ["cell death", "PROBLEM", 25, 35], ["cell death", "OBSERVATION", 25, 35]]], ["The cells were detached by trypsinization and centrifuged at 1200 rpm for 10 min.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9]]], ["The pellet was suspended in 100 \u00b5l of cold PBS and centrifuged at 10,000 rpm for 30 sec.", [["pellet", "ANATOMY", 4, 10], ["cold PBS", "TREATMENT", 38, 46], ["pellet", "OBSERVATION", 4, 10]]], ["The cell pellet was resuspended in 100 \u03bcl of annexin buffer solution and incubated with annexin V at room temperature and protected from light.", [["cell pellet", "ANATOMY", 4, 15], ["annexin V", "CHEMICAL", 88, 97], ["cell", "CELL", 4, 8], ["annexin", "GENE_OR_GENE_PRODUCT", 45, 52], ["annexin V", "GENE_OR_GENE_PRODUCT", 88, 97], ["The cell pellet", "TREATMENT", 0, 15], ["annexin buffer solution", "TREATMENT", 45, 68], ["annexin V", "TREATMENT", 88, 97], ["cell pellet", "OBSERVATION", 4, 15]]], ["After incubation, 200 \u03bcl of the annexin buffer was added.", [["annexin", "GENE_OR_GENE_PRODUCT", 32, 39], ["the annexin buffer", "TREATMENT", 28, 46]]], ["Finally, the cells were stained with 7-aminoactinomycin D (7AAD) to assess viability and were analyzed by flow cytometry.HCT-116 lysateCryopreserved aliquots were thawed in a 37\u00b0C water bath for 3 min and then quickly refrozen in liquid nitrogen for 3 min (freeze/thaw cycle).", [["cells", "ANATOMY", 13, 18], ["7-aminoactinomycin D", "CHEMICAL", 37, 57], ["7-aminoactinomycin D", "CHEMICAL", 37, 57], ["7AAD", "CHEMICAL", 59, 63], ["nitrogen", "CHEMICAL", 237, 245], ["cells", "CELL", 13, 18], ["7-aminoactinomycin D", "SIMPLE_CHEMICAL", 37, 57], ["7AAD", "SIMPLE_CHEMICAL", 59, 63], ["HCT-116", "CELL", 121, 128], ["flow cytometry", "TEST", 106, 120], ["HCT", "TEST", 121, 124], ["lysateCryopreserved aliquots", "TREATMENT", 129, 157], ["a 37\u00b0C water bath", "TREATMENT", 173, 190], ["liquid nitrogen", "TREATMENT", 230, 245]]], ["The samples were then centrifuged at 14,000 rpm for 15 min, and the supernatant was treated with 70 \u03bcl/mL of protease inhibitor (Halt \u2122 Protease Inhibitor Cocktail ThermoFisher), followed by storage at \u221280\u00b0C. The total protein was quantified using a ThermoFisher BCA Protein Assay Kit, and samples were aliquoted (100 \u03bcg protein) and stored at \u221280\u00b0C.Western blotBriefly, 40 \u03bcg of cell lysate proteins derived from each of the four treatment groups (WT, CQ, 5-FU, and 5-FU + CQ) were diluted in gel electrophoresis sample buffer and heated at 95\u00b0C for 10 min.", [["samples", "ANATOMY", 4, 11], ["supernatant", "ANATOMY", 68, 79], ["samples", "ANATOMY", 290, 297], ["cell lysate", "ANATOMY", 380, 391], ["CQ", "CHEMICAL", 453, 455], ["5-FU", "CHEMICAL", 457, 461], ["5-FU", "CHEMICAL", 467, 471], ["CQ", "CHEMICAL", 474, 476], ["5-FU", "CHEMICAL", 457, 461], ["5-FU", "CHEMICAL", 467, 471], ["cell lysate", "CELL", 380, 391], ["CQ", "SIMPLE_CHEMICAL", 453, 455], ["5-FU", "SIMPLE_CHEMICAL", 457, 461], ["5-FU + CQ", "SIMPLE_CHEMICAL", 467, 476], ["cell lysate proteins", "PROTEIN", 380, 400], ["The samples", "TEST", 0, 11], ["protease inhibitor", "TREATMENT", 109, 127], ["Halt \u2122 Protease Inhibitor Cocktail ThermoFisher", "TREATMENT", 129, 176], ["The total protein", "TEST", 209, 226], ["samples", "TEST", 290, 297], ["cell lysate proteins", "TREATMENT", 380, 400], ["WT", "TEST", 449, 451], ["CQ", "TEST", 453, 455], ["gel electrophoresis sample buffer", "TREATMENT", 494, 527]]], ["The proteins were separated on a polyacrylamide gel and then transferred to a polyvinylidene difluoride membrane.", [["polyacrylamide", "CHEMICAL", 33, 47], ["polyvinylidene", "CHEMICAL", 78, 92], ["difluoride", "CHEMICAL", 93, 103], ["membrane", "CELLULAR_COMPONENT", 104, 112], ["a polyacrylamide gel", "TREATMENT", 31, 51], ["a polyvinylidene difluoride membrane", "TREATMENT", 76, 112]]], ["Nonspecific binding of proteins was blocked by incubating the membranes in 5% low-fat milk in PBS-Tween buffer for 1 h at room temperature.", [["membranes", "ANATOMY", 62, 71], ["fat milk", "ANATOMY", 82, 90], ["membranes", "CELLULAR_COMPONENT", 62, 71], ["fat milk", "ORGANISM_SUBSTANCE", 82, 90], ["Nonspecific binding of proteins", "PROBLEM", 0, 31]]], ["The membranes were subsequently incubated overnight with antigen-specific primary antibodies for autophagy markers: LC3-II (#2775 s Cell Signaling Technologies) and SQSTM1 (#pm045 MBL Intern.", [["membranes", "ANATOMY", 4, 13], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["LC3-II", "GENE_OR_GENE_PRODUCT", 116, 122], ["primary antibodies", "PROTEIN", 74, 92], ["autophagy markers", "PROTEIN", 97, 114], ["LC3-II", "PROTEIN", 116, 122], ["SQSTM1", "PROTEIN", 165, 171], ["#pm045 MBL Intern", "PROTEIN", 173, 190], ["antigen", "TEST", 57, 64], ["autophagy markers", "TEST", 97, 114], ["LC3", "TEST", 116, 119]]], ["Corp.); secondary anti-rabbit (#A0545 Sigma) and anti-mouse (#A9044 Sigma) antibodies were applied, respectively.", [["secondary anti-rabbit", "PROTEIN", 8, 29], ["#A0545 Sigma", "PROTEIN", 31, 43], ["anti-mouse (#A9044 Sigma) antibodies", "PROTEIN", 49, 85], ["anti-rabbit", "SPECIES", 18, 29], ["anti-mouse", "SPECIES", 49, 59], ["secondary anti-rabbit (#A0545 Sigma)", "TREATMENT", 8, 44], ["anti-mouse (#A9044 Sigma) antibodies", "TREATMENT", 49, 85]]], ["GAPDH (#g8795 Sigma) was used as a housekeeping gene.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["#g8795 Sigma", "GENE_OR_GENE_PRODUCT", 7, 19], ["GAPDH", "PROTEIN", 0, 5], ["#g8795 Sigma", "PROTEIN", 7, 19], ["housekeeping gene", "DNA", 35, 52]]], ["The membranes were washed with PBS-Tween buffer for 30 min and developed with enhanced chemoluminescence immunoreactive reagent and read on a UVITEC Cambridge photodocumentation system.Ultrastructural analysis by transmission electron microscopyApproximately 10 6 cells were cultured overnight in a 6-well culture plate and were treated with CQ and 5-FU according to the abovementioned protocol .", [["membranes", "ANATOMY", 4, 13], ["cells", "ANATOMY", 264, 269], ["CQ", "CHEMICAL", 342, 344], ["5-FU", "CHEMICAL", 349, 353], ["Tween", "CHEMICAL", 35, 40], ["CQ", "CHEMICAL", 342, 344], ["5-FU", "CHEMICAL", 349, 353], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["cells", "CELL", 264, 269], ["CQ", "SIMPLE_CHEMICAL", 342, 344], ["5-FU", "SIMPLE_CHEMICAL", 349, 353], ["PBS-Tween buffer", "TREATMENT", 31, 47], ["enhanced chemoluminescence immunoreactive reagent", "TREATMENT", 78, 127], ["a UVITEC Cambridge photodocumentation system", "TREATMENT", 140, 184], ["Ultrastructural analysis", "TEST", 185, 209], ["CQ", "TREATMENT", 342, 344], ["the abovementioned protocol", "TEST", 367, 394]]], ["After incubation, cell monolayers were trypsinized, and the collected cells were centrifuged for 10 min at 1,200 rpm at 20\u00b0C. The samples were fixed in 1 mL of Karnovsky's solution, postfixed in 1% osmium tetroxide in 0.1 M phosphate buffer at pH 7.3, incubated in 0.5% uranyl acetate in aqueous solution; dehydrated in a gradient series of acetone solutions, and embedded in Araldite glue.", [["cell monolayers", "ANATOMY", 18, 33], ["cells", "ANATOMY", 70, 75], ["samples", "ANATOMY", 130, 137], ["osmium tetroxide", "CHEMICAL", 198, 214], ["phosphate", "CHEMICAL", 224, 233], ["uranyl acetate", "CHEMICAL", 270, 284], ["osmium tetroxide", "CHEMICAL", 198, 214], ["phosphate", "CHEMICAL", 224, 233], ["uranyl acetate", "CHEMICAL", 270, 284], ["acetone", "CHEMICAL", 341, 348], ["cell monolayers", "CELL", 18, 33], ["cells", "CELL", 70, 75], ["osmium tetroxide", "SIMPLE_CHEMICAL", 198, 214], ["uranyl acetate", "SIMPLE_CHEMICAL", 270, 284], ["acetone", "SIMPLE_CHEMICAL", 341, 348], ["Araldite glue", "SIMPLE_CHEMICAL", 376, 389], ["cell monolayers", "TEST", 18, 33], ["The samples", "TEST", 126, 137], ["Karnovsky's solution", "TREATMENT", 160, 180], ["1% osmium tetroxide", "TREATMENT", 195, 214], ["phosphate buffer", "TREATMENT", 224, 240], ["pH", "TEST", 244, 246], ["0.5% uranyl acetate in aqueous solution", "TREATMENT", 265, 304], ["a gradient series of acetone solutions", "TREATMENT", 320, 358], ["Araldite glue", "TREATMENT", 376, 389], ["cell monolayers", "OBSERVATION", 18, 33], ["Araldite glue", "OBSERVATION", 376, 389]]], ["The ultrafine sections (50 nm) were contrasted with saturated uranyl acetate and lead citrate solutions and observed using a Tecnai Spirit (FEI Company) electron microscope at 80 kV.Human monocyte-derived dendritic cellsDCs were differentiated in vitro from the peripheral blood adherent mononuclear cells (PBMCs) of six healthy donors.", [["ultrafine sections", "ANATOMY", 4, 22], ["monocyte", "ANATOMY", 188, 196], ["dendritic cellsDCs", "ANATOMY", 205, 223], ["peripheral blood adherent mononuclear cells", "ANATOMY", 262, 305], ["PBMCs", "ANATOMY", 307, 312], ["uranyl acetate", "CHEMICAL", 62, 76], ["citrate", "CHEMICAL", 86, 93], ["uranyl acetate", "CHEMICAL", 62, 76], ["citrate", "CHEMICAL", 86, 93], ["ultrafine sections", "MULTI-TISSUE_STRUCTURE", 4, 22], ["uranyl acetate", "SIMPLE_CHEMICAL", 62, 76], ["lead citrate solutions", "SIMPLE_CHEMICAL", 81, 103], ["Human", "ORGANISM", 182, 187], ["monocyte", "CELL", 188, 196], ["dendritic cellsDCs", "CELL", 205, 223], ["peripheral blood adherent mononuclear cells", "CELL", 262, 305], ["PBMCs", "CELL", 307, 312], ["donors", "ORGANISM", 329, 335], ["Human monocyte-derived dendritic cellsDCs", "CELL_LINE", 182, 223], ["peripheral blood adherent mononuclear cells", "CELL_TYPE", 262, 305], ["PBMCs", "CELL_TYPE", 307, 312], ["Human", "SPECIES", 182, 187], ["Human", "SPECIES", 182, 187], ["The ultrafine sections", "TREATMENT", 0, 22], ["saturated uranyl acetate", "TREATMENT", 52, 76], ["lead citrate solutions", "TREATMENT", 81, 103], ["Human monocyte", "TEST", 182, 196], ["dendritic cellsDCs", "PROBLEM", 205, 223], ["the peripheral blood adherent mononuclear cells", "TREATMENT", 258, 305], ["peripheral", "ANATOMY_MODIFIER", 262, 272], ["blood", "ANATOMY", 273, 278], ["adherent mononuclear cells", "OBSERVATION", 279, 305]]], ["The PBMCs were obtained by centrifugation through a Ficoll-isopaque gradient, suspended in AIM-V culture medium (Invitrogen), and seeded in 6-well culture plates (1x10 6 /per well).", [["PBMCs", "ANATOMY", 4, 9], ["PBMCs", "CELL", 4, 9], ["PBMCs", "CELL_TYPE", 4, 9], ["The PBMCs", "TEST", 0, 9], ["a Ficoll-isopaque gradient", "TREATMENT", 50, 76]]], ["After incubating for 1 h at 37\u02daC, nonadherent cells were removed and adherent monocytes were cultured in complete culture medium containing 80 ng/ml recombinant human GM-CSF and IL-4 (PeproTech) for 5 days.", [["cells", "ANATOMY", 46, 51], ["monocytes", "ANATOMY", 78, 87], ["GM", "CHEMICAL", 167, 169], ["cells", "CELL", 46, 51], ["monocytes", "CELL", 78, 87], ["human", "ORGANISM", 161, 166], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 167, 173], ["IL-4", "GENE_OR_GENE_PRODUCT", 178, 182], ["PeproTech", "GENE_OR_GENE_PRODUCT", 184, 193], ["nonadherent cells", "CELL_TYPE", 34, 51], ["adherent monocytes", "CELL_TYPE", 69, 87], ["recombinant human GM-CSF and IL-4", "PROTEIN", 149, 182], ["PeproTech", "PROTEIN", 184, 193], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 161, 166], ["nonadherent cells", "TREATMENT", 34, 51], ["adherent monocytes", "TEST", 69, 87], ["IL", "TEST", 178, 180], ["adherent monocytes", "OBSERVATION", 69, 87]]], ["They were then treated with HCT-116 lysate (100 \u00b5g per 10 6 DCs) and kept in culture for an additional 48 h.", [["HCT-116 lysate", "ANATOMY", 28, 42], ["DCs", "ANATOMY", 60, 63], ["HCT-116", "CHEMICAL", 28, 35], ["HCT-116 lysate", "CELL", 28, 42], ["DCs", "CELL", 60, 63], ["DCs", "CELL_TYPE", 60, 63], ["HCT", "TEST", 28, 31], ["culture", "TEST", 77, 84]]], ["Immature DCs were submitted to seven different culture conditions: DCs (untreated immature DCs); WT (DCs exposed to the lysate of untreated HCT-116 cells); CQ (DCs exposed to the lysate of HCT-116 cells that were pretreated with 80 \u00b5M of CQ), 5-FU (DCs exposed to the lysate of HCT-116 cells that were pretreated with 20 \u00b5M of 5-FU), and 5-FU + CQ (DCs exposed to the lysate of HCT-116 cells that were pretreated with 20 \u00b5M of 5-FU and 80 \u00b5M of CQ).", [["DCs", "ANATOMY", 9, 12], ["DCs", "ANATOMY", 67, 70], ["DCs", "ANATOMY", 91, 94], ["DCs", "ANATOMY", 101, 104], ["lysate", "ANATOMY", 120, 126], ["HCT-116 cells", "ANATOMY", 140, 153], ["DCs", "ANATOMY", 160, 163], ["lysate", "ANATOMY", 179, 185], ["HCT-116 cells", "ANATOMY", 189, 202], ["DCs", "ANATOMY", 249, 252], ["lysate", "ANATOMY", 268, 274], ["HCT-116 cells", "ANATOMY", 278, 291], ["DCs", "ANATOMY", 349, 352], ["lysate", "ANATOMY", 368, 374], ["HCT-116 cells", "ANATOMY", 378, 391], ["CQ", "CHEMICAL", 156, 158], ["HCT-116", "CHEMICAL", 189, 196], ["CQ", "CHEMICAL", 238, 240], ["5-FU", "CHEMICAL", 243, 247], ["HCT-116", "CHEMICAL", 278, 285], ["5-FU", "CHEMICAL", 327, 331], ["5-FU", "CHEMICAL", 338, 342], ["CQ", "CHEMICAL", 345, 347], ["HCT-116", "CHEMICAL", 378, 385], ["5-FU", "CHEMICAL", 427, 431], ["CQ", "CHEMICAL", 445, 447], ["5-FU", "CHEMICAL", 243, 247], ["5-FU", "CHEMICAL", 327, 331], ["5-FU", "CHEMICAL", 338, 342], ["5-FU", "CHEMICAL", 427, 431], ["DCs", "CELL", 9, 12], ["DCs", "CELL", 67, 70], ["DCs", "CELL", 91, 94], ["DCs", "CELL", 101, 104], ["HCT-116 cells", "CELL", 140, 153], ["CQ", "CELL", 156, 158], ["DCs", "CELL", 160, 163], ["HCT-116 cells", "CELL", 189, 202], ["CQ", "SIMPLE_CHEMICAL", 238, 240], ["5-FU", "SIMPLE_CHEMICAL", 243, 247], ["DCs", "CELL", 249, 252], ["HCT-116 cells", "CELL", 278, 291], ["5-FU", "SIMPLE_CHEMICAL", 327, 331], ["5-FU", "SIMPLE_CHEMICAL", 338, 342], ["CQ", "SIMPLE_CHEMICAL", 345, 347], ["DCs", "CELL", 349, 352], ["HCT-116 cells", "CELL", 378, 391], ["5-FU", "SIMPLE_CHEMICAL", 427, 431], ["CQ", "SIMPLE_CHEMICAL", 445, 447], ["DCs", "CELL_TYPE", 9, 12], ["DCs", "CELL_TYPE", 67, 70], ["untreated immature DCs", "CELL_TYPE", 72, 94], ["DCs", "CELL_TYPE", 101, 104], ["untreated HCT-116 cells", "CELL_LINE", 130, 153], ["DCs", "CELL_TYPE", 160, 163], ["HCT-116 cells", "CELL_LINE", 189, 202], ["DCs", "CELL_TYPE", 249, 252], ["HCT-116 cells", "CELL_LINE", 278, 291], ["DCs", "CELL_TYPE", 349, 352], ["HCT-116 cells", "CELL_LINE", 378, 391], ["Immature DCs", "PROBLEM", 0, 12], ["WT", "TEST", 97, 99], ["the lysate", "TEST", 116, 126], ["untreated HCT", "TEST", 130, 143], ["CQ", "TEST", 156, 158], ["HCT", "TEST", 189, 192], ["cells", "TEST", 197, 202], ["HCT", "TEST", 278, 281], ["HCT", "TEST", 378, 381]]], ["All procedures involving both normal and transformed human cells were approved by the Ethics Committee of the Botucatu School of Medicine -UNESP (CEP # 2.258.145).DC phenotypingThe lysate-exposed and control DCs were incubated with fluorescent monoclonal antibodies for 30 min and washed with PBS containing 0.1% bovine serum albumin (BSA) and 0.1% sodium azide.", [["cells", "ANATOMY", 59, 64], ["DC", "ANATOMY", 163, 165], ["lysate", "ANATOMY", 181, 187], ["DCs", "ANATOMY", 208, 211], ["serum", "ANATOMY", 320, 325], ["sodium azide", "CHEMICAL", 349, 361], ["sodium azide", "CHEMICAL", 349, 361], ["human", "ORGANISM", 53, 58], ["cells", "CELL", 59, 64], ["DCs", "CELL", 208, 211], ["bovine", "ORGANISM", 313, 319], ["serum", "ORGANISM_SUBSTANCE", 320, 325], ["albumin", "SIMPLE_CHEMICAL", 326, 333], ["BSA", "SIMPLE_CHEMICAL", 335, 338], ["sodium azide", "SIMPLE_CHEMICAL", 349, 361], ["transformed human cells", "CELL_LINE", 41, 64], ["DC", "CELL_TYPE", 163, 165], ["DCs", "CELL_TYPE", 208, 211], ["fluorescent monoclonal antibodies", "PROTEIN", 232, 265], ["human", "SPECIES", 53, 58], ["bovine", "SPECIES", 313, 319], ["human", "SPECIES", 53, 58], ["All procedures", "TREATMENT", 0, 14], ["The lysate", "TREATMENT", 177, 187], ["fluorescent monoclonal antibodies", "TEST", 232, 265], ["PBS", "TREATMENT", 293, 296], ["0.1% bovine serum albumin (BSA)", "TREATMENT", 308, 339], ["0.1% sodium azide", "TREATMENT", 344, 361]]], ["The DCs were incubated with labeled antibodies (HLA-DR-PE, CD11c-APC, CD83-PE-Cy7, CD80-APC-H7, and CD86-FITC (BD Biosciences) for 20 min at 4\u00b0C and then washed with PBS-BSA.", [["DCs", "ANATOMY", 4, 7], ["FITC", "CHEMICAL", 105, 109], ["DCs", "CELL", 4, 7], ["HLA-DR-PE", "GENE_OR_GENE_PRODUCT", 48, 57], ["CD11c-APC", "GENE_OR_GENE_PRODUCT", 59, 68], ["CD83", "GENE_OR_GENE_PRODUCT", 70, 74], ["CD80", "GENE_OR_GENE_PRODUCT", 83, 87], ["APC-H7", "GENE_OR_GENE_PRODUCT", 88, 94], ["CD86-FITC", "GENE_OR_GENE_PRODUCT", 100, 109], ["C", "SIMPLE_CHEMICAL", 143, 144], ["PBS-BSA", "SIMPLE_CHEMICAL", 166, 173], ["DCs", "CELL_TYPE", 4, 7], ["labeled antibodies", "PROTEIN", 28, 46], ["HLA", "PROTEIN", 48, 51], ["DR", "PROTEIN", 52, 54], ["PE", "PROTEIN", 55, 57], ["CD11c", "PROTEIN", 59, 64], ["APC", "PROTEIN", 65, 68], ["CD83", "PROTEIN", 70, 74], ["PE", "PROTEIN", 75, 77], ["Cy7", "PROTEIN", 78, 81], ["CD80", "PROTEIN", 83, 87], ["APC", "PROTEIN", 88, 91], ["H7", "PROTEIN", 92, 94], ["CD86", "PROTEIN", 100, 104], ["FITC", "PROTEIN", 105, 109], ["BD Biosciences", "PROTEIN", 111, 125], ["labeled antibodies", "TEST", 28, 46], ["HLA", "TEST", 48, 51], ["PE", "PROBLEM", 55, 57], ["CD11c", "TEST", 59, 64], ["APC", "TEST", 65, 68], ["CD83", "TEST", 70, 74], ["PE", "TEST", 75, 77], ["Cy7", "TEST", 78, 81], ["CD80", "TEST", 83, 87], ["APC", "TEST", 88, 91], ["H7", "PROBLEM", 92, 94], ["CD86", "TEST", 100, 104], ["PBS-BSA", "TREATMENT", 166, 173], ["PE", "OBSERVATION", 55, 57], ["CD11c", "ANATOMY", 59, 64], ["PE", "OBSERVATION", 75, 77], ["BSA", "ANATOMY", 170, 173]]], ["The cells were suspended in 100 \u00b5l of PBS-BSA, and the samples were read in a FACSCanto II cytometer (Becton-Dickinson) and analyzed using FlowJo, version 7.2.4.Mixed lymphocyte reaction assay (MLR)The functional activity of DCs was first evaluated through their ability to stimulate the proliferation of normal allogeneic T lymphocytes.", [["cells", "ANATOMY", 4, 9], ["samples", "ANATOMY", 55, 62], ["lymphocyte", "ANATOMY", 167, 177], ["DCs", "ANATOMY", 225, 228], ["T lymphocytes", "ANATOMY", 323, 336], ["cells", "CELL", 4, 9], ["PBS-BSA", "SIMPLE_CHEMICAL", 38, 45], ["lymphocyte", "CELL", 167, 177], ["DCs", "CELL", 225, 228], ["T lymphocytes", "CELL", 323, 336], ["DCs", "CELL_TYPE", 225, 228], ["normal allogeneic T lymphocytes", "CELL_TYPE", 305, 336], ["PBS-BSA", "TEST", 38, 45], ["the samples", "TEST", 51, 62], ["FlowJo", "TEST", 139, 145], ["version", "TEST", 147, 154], ["Mixed lymphocyte reaction assay", "PROBLEM", 161, 192], ["lymphocyte reaction", "OBSERVATION", 167, 186], ["allogeneic T lymphocytes", "OBSERVATION", 312, 336]]], ["DCs from six different donors were cocultured with allogeneic T lymphocytes (previously marked with carboxyfluorescein succinyl ester (CFSE)) in flat-bottomed 96-well plates in a 1:10 (10 4 :10 5 ) DCs: lymphocyte ratio.", [["DCs", "ANATOMY", 0, 3], ["T lymphocytes", "ANATOMY", 62, 75], ["DCs", "ANATOMY", 198, 201], ["lymphocyte", "ANATOMY", 203, 213], ["carboxyfluorescein succinyl ester", "CHEMICAL", 100, 133], ["CFSE", "CHEMICAL", 135, 139], ["carboxyfluorescein succinyl ester", "CHEMICAL", 100, 133], ["CFSE", "CHEMICAL", 135, 139], ["DCs", "CELL", 0, 3], ["donors", "ORGANISM", 23, 29], ["T lymphocytes", "CELL", 62, 75], ["carboxyfluorescein succinyl ester", "SIMPLE_CHEMICAL", 100, 133], ["CFSE", "SIMPLE_CHEMICAL", 135, 139], ["DCs", "CELL", 198, 201], ["lymphocyte", "CELL", 203, 213], ["DCs", "CELL_TYPE", 0, 3], ["allogeneic T lymphocytes", "CELL_TYPE", 51, 75], ["DCs", "CELL_TYPE", 198, 201], ["allogeneic T lymphocytes", "PROBLEM", 51, 75], ["carboxyfluorescein succinyl ester", "TREATMENT", 100, 133], ["lymphocyte ratio", "TEST", 203, 219]]], ["Cells were harvested five days later, and the lymphocyte proliferation was analyzed by flow cytometry based on the dilution of CFSE in the replicant cells.", [["Cells", "ANATOMY", 0, 5], ["lymphocyte", "ANATOMY", 46, 56], ["replicant cells", "ANATOMY", 139, 154], ["CFSE", "CHEMICAL", 127, 131], ["CFSE", "CHEMICAL", 127, 131], ["Cells", "CELL", 0, 5], ["lymphocyte", "CELL", 46, 56], ["CFSE", "SIMPLE_CHEMICAL", 127, 131], ["replicant cells", "CELL", 139, 154], ["replicant cells", "CELL_LINE", 139, 154], ["the lymphocyte proliferation", "TEST", 42, 70], ["flow cytometry", "TEST", 87, 101], ["the dilution", "TEST", 111, 123], ["lymphocyte proliferation", "OBSERVATION", 46, 70], ["replicant cells", "OBSERVATION", 139, 154]]], ["We also analyzed the expression of PD-1 and CD69 on CD3+ cells using anti-PD-1-PE and CD69-APC-H7 (BD Pharmingen).IFN-\u03b3 and IL-10 detectionSupernatants of the MLR assay were collected and preserved at \u221280\u02daC. These samples were analyzed for the in vitro synthesis of IFN-\u03b3 and IL-10 using an ELISA kit according to the manufacturer's instructions (R&D Systems).Generation of cytolytic T lymphocytes and antitumor cytotoxicity assayTo generate specific antitumor T cells, DCs were cocultured with an autologous T lymphocyte-rich suspension in a 1:10 DC:lymphocyte ratio (10 4 :10 5 ) in complete culture medium supplemented with IL-7 (5 ng/ml) and IL-2 (40 IU/ml).", [["CD3+ cells", "ANATOMY", 52, 62], ["samples", "ANATOMY", 214, 221], ["T lymphocytes", "ANATOMY", 384, 397], ["antitumor", "ANATOMY", 402, 411], ["antitumor T cells", "ANATOMY", 451, 468], ["DCs", "ANATOMY", 470, 473], ["T lymphocyte", "ANATOMY", 509, 521], ["DC", "ANATOMY", 548, 550], ["lymphocyte", "ANATOMY", 551, 561], ["PD-1", "GENE_OR_GENE_PRODUCT", 35, 39], ["CD69", "GENE_OR_GENE_PRODUCT", 44, 48], ["CD3", "GENE_OR_GENE_PRODUCT", 52, 55], ["anti-PD-1-PE", "GENE_OR_GENE_PRODUCT", 69, 81], ["CD69", "GENE_OR_GENE_PRODUCT", 86, 90], ["APC-H7", "GENE_OR_GENE_PRODUCT", 91, 97], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 114, 119], ["IL-10", "GENE_OR_GENE_PRODUCT", 124, 129], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 266, 271], ["IL-10", "GENE_OR_GENE_PRODUCT", 276, 281], ["T lymphocytes", "CELL", 384, 397], ["antitumor", "CANCER", 402, 411], ["antitumor T cells", "CELL", 451, 468], ["DCs", "CELL", 470, 473], ["T lymphocyte", "CELL", 509, 521], ["lymphocyte", "CELL", 551, 561], ["IL-7", "GENE_OR_GENE_PRODUCT", 627, 631], ["IL-2", "GENE_OR_GENE_PRODUCT", 646, 650], ["PD-1", "PROTEIN", 35, 39], ["CD69", "PROTEIN", 44, 48], ["CD3", "PROTEIN", 52, 55], ["CD69", "PROTEIN", 86, 90], ["APC", "PROTEIN", 91, 94], ["H7", "PROTEIN", 95, 97], ["BD Pharmingen", "PROTEIN", 99, 112], ["IFN", "PROTEIN", 114, 117], ["IFN", "PROTEIN", 266, 269], ["\u03b3", "PROTEIN", 270, 271], ["IL", "PROTEIN", 276, 278], ["cytolytic T lymphocytes", "CELL_TYPE", 374, 397], ["antitumor T cells", "CELL_TYPE", 451, 468], ["DCs", "CELL_TYPE", 470, 473], ["autologous T lymphocyte", "CELL_TYPE", 498, 521], ["1:10 DC", "CELL_TYPE", 543, 550], ["IL", "PROTEIN", 627, 629], ["PD", "TEST", 35, 37], ["CD69", "TEST", 44, 48], ["CD3", "TEST", 52, 55], ["cells", "TEST", 57, 62], ["anti-PD", "TEST", 69, 76], ["PE", "PROBLEM", 79, 81], ["CD69", "TEST", 86, 90], ["APC", "TEST", 91, 94], ["IFN", "TEST", 114, 117], ["IL", "TEST", 124, 126], ["the MLR assay", "TEST", 155, 168], ["These samples", "TEST", 208, 221], ["IFN", "TEST", 266, 269], ["IL", "TREATMENT", 276, 278], ["an ELISA kit", "TREATMENT", 288, 300], ["cytolytic T lymphocytes", "PROBLEM", 374, 397], ["antitumor cytotoxicity", "PROBLEM", 402, 424], ["specific antitumor T cells", "PROBLEM", 442, 468], ["an autologous T lymphocyte", "TREATMENT", 495, 521], ["lymphocyte ratio", "TEST", 551, 567], ["complete culture medium", "TEST", 585, 608], ["IL", "TEST", 627, 629], ["IL", "TEST", 646, 648], ["PE", "OBSERVATION", 79, 81], ["cytolytic T lymphocytes", "OBSERVATION", 374, 397]]], ["The culture was pulsed with IL-2 every two days for 14 days.", [["IL-2", "GENE_OR_GENE_PRODUCT", 28, 32], ["IL", "PROTEIN", 28, 30], ["The culture", "TEST", 0, 11], ["IL", "TREATMENT", 28, 30]]], ["On day 14, the lymphocytes were harvested and evaluated for their cytotoxic activity against HCT-116 target cells.", [["lymphocytes", "ANATOMY", 15, 26], ["HCT-116 target cells", "ANATOMY", 93, 113], ["lymphocytes", "CELL", 15, 26], ["HCT-116 target cells", "CELL", 93, 113], ["lymphocytes", "CELL_TYPE", 15, 26], ["HCT-116 target cells", "CELL_LINE", 93, 113], ["their cytotoxic activity", "TEST", 60, 84], ["HCT", "TEST", 93, 96], ["lymphocytes", "ANATOMY", 15, 26]]], ["A lymphocytotoxicity assay was performed by adding the in vitro-generated lymphocytes to HCT-116 monolayer cells in different effector: target ratios (15:1, 7.5:1 and 3.25:1).", [["lymphocytes", "ANATOMY", 74, 85], ["HCT-116 monolayer cells", "ANATOMY", 89, 112], ["lymphocytes", "CELL", 74, 85], ["HCT-116 monolayer cells", "CELL", 89, 112], ["lymphocytes", "CELL_TYPE", 74, 85], ["HCT-116 monolayer cells", "CELL_LINE", 89, 112], ["A lymphocytotoxicity assay", "TEST", 0, 26], ["HCT", "TEST", 89, 92], ["monolayer cells", "TEST", 97, 112], ["target ratios", "TEST", 136, 149]]], ["Anti-CD107a-APC was added to these cocultures and incubated for 5 h at 37\u02daC in an atmosphere containing 5% CO 2 .", [["Anti-CD107a", "CHEMICAL", 0, 11], ["APC", "CHEMICAL", 12, 15], ["CO 2", "CHEMICAL", 107, 111], ["Anti-CD107a-APC", "GENE_OR_GENE_PRODUCT", 0, 15], ["Anti-CD107a", "PROTEIN", 0, 11], ["APC", "CELL_TYPE", 12, 15], ["Anti-CD107a", "TREATMENT", 0, 11], ["APC", "TREATMENT", 12, 15], ["these cocultures", "TEST", 29, 45]]], ["The cells were then harvested and washed with 0.1% BSA in PBS and treated with the Cytofix/CytoPerm kit (BD Pharmingen).", [["cells", "ANATOMY", 4, 9], ["BSA", "CHEMICAL", 51, 54], ["cells", "CELL", 4, 9], ["BSA", "SIMPLE_CHEMICAL", 51, 54], ["Pharmingen", "GENE_OR_GENE_PRODUCT", 108, 118], ["CytoPerm kit", "PROTEIN", 91, 103], ["BD Pharmingen", "PROTEIN", 105, 118], ["0.1% BSA in PBS", "TREATMENT", 46, 61], ["the Cytofix/CytoPerm kit (BD Pharmingen", "TREATMENT", 79, 118]]], ["Finally, the cells were labeled with anti-perforin-Alexa 488 and anti-granzyme-PE antibodies and analyzed by flow cytometry.Tumor cell transcriptionTo investigate how treatment with the combination of CQ and 5-FU changes tumor cell gene expression, we performed a transcription analysis of these cells.", [["cells", "ANATOMY", 13, 18], ["Tumor cell", "ANATOMY", 124, 134], ["tumor cell", "ANATOMY", 221, 231], ["cells", "ANATOMY", 296, 301], ["CQ", "CHEMICAL", 201, 203], ["5-FU", "CHEMICAL", 208, 212], ["tumor", "DISEASE", 221, 226], ["anti-perforin-Alexa 488", "CHEMICAL", 37, 60], ["CQ", "CHEMICAL", 201, 203], ["5-FU", "CHEMICAL", 208, 212], ["cells", "CELL", 13, 18], ["anti-perforin", "SIMPLE_CHEMICAL", 37, 50], ["Alexa 488", "SIMPLE_CHEMICAL", 51, 60], ["anti-granzyme-PE antibodies", "GENE_OR_GENE_PRODUCT", 65, 92], ["Tumor cell", "CELL", 124, 134], ["CQ", "SIMPLE_CHEMICAL", 201, 203], ["5-FU", "SIMPLE_CHEMICAL", 208, 212], ["tumor cell", "CELL", 221, 231], ["cells", "CELL", 296, 301], ["anti-perforin", "PROTEIN", 37, 50], ["Alexa 488", "PROTEIN", 51, 60], ["anti-granzyme", "PROTEIN", 65, 78], ["PE antibodies", "PROTEIN", 79, 92], ["anti-perforin-Alexa", "TREATMENT", 37, 56], ["anti-granzyme", "TEST", 65, 78], ["PE antibodies", "PROBLEM", 79, 92], ["flow cytometry", "TEST", 109, 123], ["Tumor cell transcriptionTo", "TREATMENT", 124, 150], ["treatment", "TREATMENT", 167, 176], ["CQ", "PROBLEM", 201, 203], ["5-FU changes tumor cell gene expression", "TREATMENT", 208, 247], ["a transcription analysis", "TEST", 262, 286], ["PE", "OBSERVATION", 79, 81], ["tumor cell", "OBSERVATION", 221, 231]]], ["Total RNA was extracted using a QIAGEN RNeasy Plus Micro Kit.", [["Total RNA", "TREATMENT", 0, 9], ["a QIAGEN RNeasy Plus Micro Kit", "TREATMENT", 30, 60]]], ["RNA was quantified using an RNA HS Assay Kit (Invitrogen) and a QBIT\u00ae system.", [["RNA", "RNA", 0, 3], ["a QBIT\u00ae system", "TREATMENT", 62, 76]]], ["The quality of RNA was analyzed using an Agilent RNA 6000 chip in a Bioanalyzer 2100 system.", [["an Agilent RNA", "TREATMENT", 38, 52]]], ["Only samples with an RNA integrity number higher than 8.0 (optimal quality) were processed.Tumor cell transcriptionAll indications and steps of the Sure Select Strand-Specific RNA Library Preparation Kit were followed, and the dsDNA libraries of each treatment group with the adapters and index were analyzed on the Illumina Miseq platform.", [["samples", "ANATOMY", 5, 12], ["Tumor cell", "ANATOMY", 91, 101], ["samples", "CANCER", 5, 12], ["Tumor cell", "CELL", 91, 101], ["Kit", "GENE_OR_GENE_PRODUCT", 200, 203], ["dsDNA libraries", "DNA", 227, 242], ["an RNA integrity", "TEST", 18, 34], ["Tumor cell transcription", "PROBLEM", 91, 115], ["Kit", "TEST", 200, 203], ["the dsDNA libraries of each treatment group", "TREATMENT", 223, 266], ["index", "TEST", 289, 294], ["RNA integrity", "OBSERVATION", 21, 34], ["cell transcription", "OBSERVATION", 97, 115]]], ["After obtaining the data, the reads were assembled based on the sequences of each transcript of interest using the CLC Genomics Workbench program.", [["the data", "TEST", 16, 24]]], ["The effect of the treatments on gene expression was evaluated by comparing the fold change in RNA expression of the samples with that of the untreated control.Statistical analysisHomogeneity of variance was accessed by the Bartlett test, and the data were analyzed by analysis of variance (ANOVA) followed by the Tukey-Kramer test for multiple comparisons.", [["samples", "ANATOMY", 116, 123], ["the treatments", "TREATMENT", 14, 28], ["gene expression", "TREATMENT", 32, 47], ["the fold change", "PROBLEM", 75, 90], ["the untreated control", "TREATMENT", 137, 158], ["Statistical analysis", "TEST", 159, 179], ["the Bartlett test", "TEST", 219, 236], ["the data", "TEST", 242, 250], ["multiple comparisons", "TEST", 335, 355]]], ["Differences were considered significant when the error probability was less than or equal to 5% (p \u2264 0.05).Combination of chloroquine and 5-FU blocks autophagyWe first verified whether the working concentrations of CQ and 5-FU were able to block autophagy.", [["chloroquine", "CHEMICAL", 122, 133], ["5-FU", "CHEMICAL", 138, 142], ["CQ", "CHEMICAL", 215, 217], ["5-FU", "CHEMICAL", 222, 226], ["chloroquine", "CHEMICAL", 122, 133], ["5-FU", "CHEMICAL", 138, 142], ["CQ", "CHEMICAL", 215, 217], ["5-FU", "CHEMICAL", 222, 226], ["chloroquine", "SIMPLE_CHEMICAL", 122, 133], ["5-FU", "SIMPLE_CHEMICAL", 138, 142], ["CQ", "SIMPLE_CHEMICAL", 215, 217], ["5-FU", "SIMPLE_CHEMICAL", 222, 226], ["the error probability", "TEST", 45, 66], ["chloroquine", "TREATMENT", 122, 133], ["FU blocks autophagy", "TREATMENT", 140, 159], ["CQ", "TEST", 215, 217]]], ["Proteins extracted from untreated tumor cells (WT) or cells treated with either chloroquine (80 \u00b5M) or 5fluorouracil (20 \u00b5M) or those treated with the combination of drugs (5-FU + CQ) were analyzed by western blot to evaluate the accumulation of LC3-II and SQSTM1 (both autophagic markers).", [["Proteins", "ANATOMY", 0, 8], ["tumor cells", "ANATOMY", 34, 45], ["cells", "ANATOMY", 54, 59], ["tumor", "DISEASE", 34, 39], ["chloroquine", "CHEMICAL", 80, 91], ["5fluorouracil", "CHEMICAL", 103, 116], ["5-FU", "CHEMICAL", 173, 177], ["CQ", "CHEMICAL", 180, 182], ["chloroquine", "CHEMICAL", 80, 91], ["5fluorouracil", "CHEMICAL", 103, 116], ["5-FU", "CHEMICAL", 173, 177], ["CQ", "CHEMICAL", 180, 182], ["tumor cells", "CELL", 34, 45], ["WT", "CELL", 47, 49], ["cells", "CELL", 54, 59], ["chloroquine", "SIMPLE_CHEMICAL", 80, 91], ["5fluorouracil", "SIMPLE_CHEMICAL", 103, 116], ["5-FU", "SIMPLE_CHEMICAL", 173, 177], ["CQ", "SIMPLE_CHEMICAL", 180, 182], ["LC3-II", "GENE_OR_GENE_PRODUCT", 246, 252], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 257, 263], ["untreated tumor cells", "CELL_TYPE", 24, 45], ["LC3-II", "PROTEIN", 246, 252], ["SQSTM1", "PROTEIN", 257, 263], ["autophagic markers", "PROTEIN", 270, 288], ["Proteins", "TEST", 0, 8], ["untreated tumor cells", "PROBLEM", 24, 45], ["chloroquine", "TREATMENT", 80, 91], ["5fluorouracil", "TREATMENT", 103, 116], ["drugs", "TREATMENT", 166, 171], ["untreated", "OBSERVATION_MODIFIER", 24, 33], ["tumor cells", "OBSERVATION", 34, 45], ["autophagic markers", "OBSERVATION", 270, 288]]], ["We observed slightly increased LC3-II expression when treating with CQ alone, while the combination of CQ and 5-FU resulted in higher LC3-II expression.", [["CQ", "CHEMICAL", 68, 70], ["CQ", "CHEMICAL", 103, 105], ["5-FU", "CHEMICAL", 110, 114], ["CQ", "CHEMICAL", 68, 70], ["CQ", "CHEMICAL", 103, 105], ["5-FU", "CHEMICAL", 110, 114], ["LC3-II", "GENE_OR_GENE_PRODUCT", 31, 37], ["CQ", "SIMPLE_CHEMICAL", 68, 70], ["CQ", "SIMPLE_CHEMICAL", 103, 105], ["5-FU", "SIMPLE_CHEMICAL", 110, 114], ["LC3-II", "GENE_OR_GENE_PRODUCT", 134, 140], ["LC3", "PROTEIN", 31, 34], ["LC3", "PROTEIN", 134, 137], ["slightly increased LC3-II expression", "PROBLEM", 12, 48], ["CQ", "TREATMENT", 68, 70], ["CQ", "TEST", 103, 105], ["slightly", "OBSERVATION_MODIFIER", 12, 20], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["LC3", "OBSERVATION_MODIFIER", 31, 34], ["-II", "OBSERVATION_MODIFIER", 34, 37], ["expression", "OBSERVATION_MODIFIER", 38, 48], ["higher", "OBSERVATION_MODIFIER", 127, 133], ["LC3", "OBSERVATION", 134, 137], ["II expression", "OBSERVATION", 138, 151]]], ["Interestingly, treatment with 5-FU alone induced a slight increase of LC3-II expression, indicating the induction of autophagy, as confirmed by the lower intensity of SQSTM1 in this group (Fig. 1A) .Ultrastructural changes induced by 5-FU and CQ in HCT-116 cellsTo reinforce the cytometric results of the induction and inhibition of autophagy and the induction of apoptosis, we used transmission electron microscopy to analyze the cells under different treatments.", [["HCT-116 cells", "ANATOMY", 249, 262], ["cells", "ANATOMY", 431, 436], ["5-FU", "CHEMICAL", 30, 34], ["5-FU", "CHEMICAL", 234, 238], ["CQ", "CHEMICAL", 243, 245], ["HCT-116", "CHEMICAL", 249, 256], ["5-FU", "CHEMICAL", 30, 34], ["5-FU", "CHEMICAL", 234, 238], ["5-FU", "SIMPLE_CHEMICAL", 30, 34], ["LC3-II", "GENE_OR_GENE_PRODUCT", 70, 76], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 167, 173], ["5-FU", "SIMPLE_CHEMICAL", 234, 238], ["CQ", "SIMPLE_CHEMICAL", 243, 245], ["HCT-116 cells", "CELL", 249, 262], ["cells", "CELL", 431, 436], ["LC3", "PROTEIN", 70, 73], ["SQSTM1", "PROTEIN", 167, 173], ["HCT-116 cells", "CELL_LINE", 249, 262], ["autophagy", "PROBLEM", 117, 126], ["Ultrastructural changes", "PROBLEM", 199, 222], ["CQ", "TEST", 243, 245], ["HCT", "TEST", 249, 252], ["the induction", "TREATMENT", 301, 314], ["autophagy", "TREATMENT", 333, 342], ["apoptosis", "PROBLEM", 364, 373], ["transmission electron microscopy", "TEST", 383, 415], ["different treatments", "TREATMENT", 443, 463], ["slight", "OBSERVATION_MODIFIER", 51, 57], ["increase", "OBSERVATION_MODIFIER", 58, 66], ["II expression", "OBSERVATION_MODIFIER", 74, 87], ["lower intensity", "OBSERVATION_MODIFIER", 148, 163], ["SQSTM1", "OBSERVATION", 167, 173]]], ["Cells treated with 5-FU showed double-membrane vesicles (autophagosomes) and single-membrane vesicles containing degraded material (autophagolysosomes) in the cytoplasm (Fig. 1D ).", [["Cells", "ANATOMY", 0, 5], ["membrane vesicles", "ANATOMY", 38, 55], ["autophagosomes", "ANATOMY", 57, 71], ["membrane vesicles", "ANATOMY", 84, 101], ["autophagolysosomes", "ANATOMY", 132, 150], ["cytoplasm", "ANATOMY", 159, 168], ["5-FU", "CHEMICAL", 19, 23], ["5-FU", "CHEMICAL", 19, 23], ["Cells", "CELL", 0, 5], ["5-FU", "SIMPLE_CHEMICAL", 19, 23], ["membrane vesicles", "CELLULAR_COMPONENT", 38, 55], ["autophagosomes", "CELLULAR_COMPONENT", 57, 71], ["membrane vesicles", "CELLULAR_COMPONENT", 84, 101], ["cytoplasm", "ORGANISM_SUBSTANCE", 159, 168], ["autophagosomes", "CELL_TYPE", 57, 71], ["double-membrane vesicles", "PROBLEM", 31, 55], ["single-membrane vesicles", "PROBLEM", 77, 101], ["membrane vesicles", "ANATOMY", 38, 55], ["membrane vesicles", "ANATOMY", 84, 101]]], ["By contrast, the control cells showed a very small number of autophagosomes containing flocculated and degraded material in addition to containing mitochondria and some rough endoplasmic reticulum cisterns (Fig. 1B) .", [["cells", "ANATOMY", 25, 30], ["autophagosomes", "ANATOMY", 61, 75], ["mitochondria", "ANATOMY", 147, 159], ["endoplasmic reticulum cisterns", "ANATOMY", 175, 205], ["cells", "CELL", 25, 30], ["autophagosomes", "CELLULAR_COMPONENT", 61, 75], ["mitochondria", "CELLULAR_COMPONENT", 147, 159], ["endoplasmic reticulum cisterns", "CELLULAR_COMPONENT", 175, 205], ["the control cells", "TEST", 13, 30], ["a very small number of autophagosomes containing flocculated and degraded material", "PROBLEM", 38, 120], ["very", "OBSERVATION_MODIFIER", 40, 44], ["small", "OBSERVATION_MODIFIER", 45, 50], ["number", "OBSERVATION_MODIFIER", 51, 57], ["autophagosomes", "OBSERVATION", 61, 75], ["flocculated", "OBSERVATION_MODIFIER", 87, 98], ["degraded material", "OBSERVATION", 103, 120], ["mitochondria", "ANATOMY", 147, 159], ["some", "OBSERVATION_MODIFIER", 164, 168], ["rough", "OBSERVATION_MODIFIER", 169, 174], ["endoplasmic", "OBSERVATION_MODIFIER", 175, 186], ["reticulum cisterns", "OBSERVATION", 187, 205]]], ["In the 5-FU + CQ combined treatment, the size of autophagosomes appeared to increase within the cytoplasm, and these vesicles exhibited different filler contents.", [["autophagosomes", "ANATOMY", 49, 63], ["cytoplasm", "ANATOMY", 96, 105], ["vesicles", "ANATOMY", 117, 125], ["5-FU", "CHEMICAL", 7, 11], ["CQ", "CHEMICAL", 14, 16], ["5-FU", "CHEMICAL", 7, 11], ["CQ", "CHEMICAL", 14, 16], ["5-FU", "SIMPLE_CHEMICAL", 7, 11], ["CQ", "SIMPLE_CHEMICAL", 14, 16], ["autophagosomes", "CELLULAR_COMPONENT", 49, 63], ["cytoplasm", "ORGANISM_SUBSTANCE", 96, 105], ["vesicles", "CELLULAR_COMPONENT", 117, 125], ["CQ combined treatment", "TREATMENT", 14, 35], ["autophagosomes", "PROBLEM", 49, 63], ["size", "OBSERVATION_MODIFIER", 41, 45], ["autophagosomes", "OBSERVATION", 49, 63], ["increase", "OBSERVATION_MODIFIER", 76, 84], ["cytoplasm", "OBSERVATION_MODIFIER", 96, 105], ["different", "OBSERVATION_MODIFIER", 136, 145], ["filler contents", "OBSERVATION", 146, 161]]], ["Some vesicles had heterogeneous electrondense material inside them, and others showed myelin figures and electron-lucent degraded material, indicating that some autophagosomes were not engaged in the digestion process and that the process of digestion was blocked.", [["vesicles", "ANATOMY", 5, 13], ["myelin", "ANATOMY", 86, 92], ["autophagosomes", "ANATOMY", 161, 175], ["vesicles", "CELLULAR_COMPONENT", 5, 13], ["electron", "SIMPLE_CHEMICAL", 105, 113], ["autophagosomes", "CELLULAR_COMPONENT", 161, 175], ["Some vesicles", "PROBLEM", 0, 13], ["heterogeneous electrondense material", "PROBLEM", 18, 54], ["myelin figures", "PROBLEM", 86, 100], ["lucent degraded material", "PROBLEM", 114, 138], ["some autophagosomes", "PROBLEM", 156, 175], ["vesicles", "ANATOMY", 5, 13], ["heterogeneous", "OBSERVATION_MODIFIER", 18, 31], ["electrondense material", "OBSERVATION", 32, 54], ["myelin figures", "OBSERVATION", 86, 100], ["lucent", "OBSERVATION_MODIFIER", 114, 120], ["autophagosomes", "OBSERVATION", 161, 175]]], ["There was a clear accumulation of autophagosomes containing undigested organelles, demonstrating the failure or inhibition of autophagolysosome formation (Fig. 1E ).", [["autophagosomes", "ANATOMY", 34, 48], ["organelles", "ANATOMY", 71, 81], ["autophagolysosome", "ANATOMY", 126, 143], ["autophagosomes", "CELLULAR_COMPONENT", 34, 48], ["organelles", "CELLULAR_COMPONENT", 71, 81], ["autophagolysosome", "SIMPLE_CHEMICAL", 126, 143], ["a clear accumulation of autophagosomes", "PROBLEM", 10, 48], ["undigested organelles", "PROBLEM", 60, 81], ["the failure", "PROBLEM", 97, 108], ["inhibition of autophagolysosome formation", "PROBLEM", 112, 153], ["clear", "OBSERVATION_MODIFIER", 12, 17], ["accumulation", "OBSERVATION_MODIFIER", 18, 30], ["autophagosomes", "OBSERVATION", 34, 48], ["undigested organelles", "OBSERVATION", 60, 81], ["failure", "OBSERVATION", 101, 108]]], ["This finding is in agreement with previous studies [27] [28] [29] [30] .", [["[27] [28] [29] [30]", "SIMPLE_CHEMICAL", 51, 70], ["previous studies", "TEST", 34, 50]]], ["Table 1 shows the number of HCT-116 cells after incubation with CQ, 5-FU or the combination of both drugs (five independent assays).", [["HCT-116 cells", "ANATOMY", 28, 41], ["HCT-116", "CHEMICAL", 28, 35], ["CQ", "CHEMICAL", 64, 66], ["5-FU", "CHEMICAL", 68, 72], ["CQ", "CHEMICAL", 64, 66], ["5-FU", "CHEMICAL", 68, 72], ["HCT-116 cells", "CELL", 28, 41], ["CQ", "SIMPLE_CHEMICAL", 64, 66], ["5-FU", "SIMPLE_CHEMICAL", 68, 72], ["HCT-116 cells", "CELL_LINE", 28, 41], ["HCT", "TEST", 28, 31], ["incubation", "TEST", 48, 58], ["CQ", "TEST", 64, 66], ["both drugs", "TREATMENT", 95, 105]]], ["While CQ alone had a discrete effect on cell growth, 5-FU reduced the number of cells to approximately 50% of the control culture.", [["cell", "ANATOMY", 40, 44], ["cells", "ANATOMY", 80, 85], ["CQ", "CHEMICAL", 6, 8], ["5-FU", "CHEMICAL", 53, 57], ["CQ", "CHEMICAL", 6, 8], ["5-FU", "CHEMICAL", 53, 57], ["CQ", "SIMPLE_CHEMICAL", 6, 8], ["cell", "CELL", 40, 44], ["5-FU", "SIMPLE_CHEMICAL", 53, 57], ["cells", "CELL", 80, 85], ["a discrete effect on cell growth", "PROBLEM", 19, 51], ["the control culture", "TEST", 110, 129], ["cell", "OBSERVATION", 40, 44], ["growth", "OBSERVATION_MODIFIER", 45, 51]]], ["The Each column refers to an independent assay (cultured on different days).Enhanced cytotoxic action of 5-FU by inhibiting autophagy with chloroquinecombination of 5-FU and CQ strongly inhibited cell growth in the cultures.", [["cell", "ANATOMY", 196, 200], ["cultures", "ANATOMY", 215, 223], ["5-FU", "CHEMICAL", 105, 109], ["chloroquinecombination", "CHEMICAL", 139, 161], ["5-FU", "CHEMICAL", 165, 169], ["CQ", "CHEMICAL", 174, 176], ["5-FU", "CHEMICAL", 105, 109], ["5-FU", "CHEMICAL", 165, 169], ["CQ", "CHEMICAL", 174, 176], ["5-FU", "SIMPLE_CHEMICAL", 105, 109], ["chloroquinecombination", "SIMPLE_CHEMICAL", 139, 161], ["5-FU", "SIMPLE_CHEMICAL", 165, 169], ["CQ", "SIMPLE_CHEMICAL", 174, 176], ["cell", "CELL", 196, 200], ["Enhanced cytotoxic action", "TEST", 76, 101], ["chloroquinecombination", "TEST", 139, 161], ["CQ strongly inhibited cell growth", "PROBLEM", 174, 207], ["the cultures", "TEST", 211, 223], ["cytotoxic", "OBSERVATION_MODIFIER", 85, 94], ["inhibited cell", "OBSERVATION", 186, 200], ["growth", "OBSERVATION_MODIFIER", 201, 207]]], ["Fig. 2 shows that early apoptosis (annexin V+) was the predominant type of cell death induced by the treatments.", [["cell", "ANATOMY", 75, 79], ["death", "DISEASE", 80, 85], ["annexin V", "GENE_OR_GENE_PRODUCT", 35, 44], ["cell", "CELL", 75, 79], ["annexin V", "PROTEIN", 35, 44], ["early apoptosis", "PROBLEM", 18, 33], ["cell death", "PROBLEM", 75, 85], ["the treatments", "TREATMENT", 97, 111], ["early", "OBSERVATION_MODIFIER", 18, 23], ["apoptosis", "OBSERVATION_MODIFIER", 24, 33], ["cell death", "OBSERVATION", 75, 85]]], ["5-FU alone (Fig. 2D ) increased by four times the annexin V labeling compared to the control (Fig. 2B) , while its combination with CQ increased early apoptosis in ten times compared with the same control (Fig. 2E) , and around twice compared with 5-FU alone.", [["5-FU", "CHEMICAL", 0, 4], ["CQ", "CHEMICAL", 132, 134], ["5-FU", "CHEMICAL", 248, 252], ["5-FU", "CHEMICAL", 0, 4], ["CQ", "CHEMICAL", 132, 134], ["5-FU", "CHEMICAL", 248, 252], ["5-FU", "SIMPLE_CHEMICAL", 0, 4], ["annexin V", "GENE_OR_GENE_PRODUCT", 50, 59], ["CQ", "SIMPLE_CHEMICAL", 132, 134], ["5-FU", "SIMPLE_CHEMICAL", 248, 252], ["annexin V", "PROTEIN", 50, 59], ["the annexin V labeling", "TREATMENT", 46, 68], ["CQ increased early apoptosis", "PROBLEM", 132, 160], ["increased", "OBSERVATION_MODIFIER", 135, 144], ["early", "OBSERVATION_MODIFIER", 145, 150], ["apoptosis", "OBSERVATION_MODIFIER", 151, 160], ["ten times", "OBSERVATION_MODIFIER", 164, 173]]], ["Fig. 3 illustrates the effect of the HCT-116 lysates on the DC phenotype, highlighting the overall increase in the percentage of cells expressing maturation or activation markers CD83, CD80, CD86, and HLA-DR.", [["HCT-116 lysates", "ANATOMY", 37, 52], ["DC", "ANATOMY", 60, 62], ["cells", "ANATOMY", 129, 134], ["HCT-116", "CHEMICAL", 37, 44], ["HCT-116 lysates", "CELL", 37, 52], ["DC", "CELL", 60, 62], ["cells", "CELL", 129, 134], ["CD83", "GENE_OR_GENE_PRODUCT", 179, 183], ["CD80", "GENE_OR_GENE_PRODUCT", 185, 189], ["CD86", "GENE_OR_GENE_PRODUCT", 191, 195], ["DC", "CELL_TYPE", 60, 62], ["activation markers", "PROTEIN", 160, 178], ["CD83", "PROTEIN", 179, 183], ["CD80", "PROTEIN", 185, 189], ["CD86", "PROTEIN", 191, 195], ["HLA", "PROTEIN", 201, 204], ["the HCT", "TEST", 33, 40], ["the DC phenotype", "TEST", 56, 72], ["activation markers", "TEST", 160, 178], ["CD83", "TEST", 179, 183], ["CD80", "TEST", 185, 189], ["CD86", "TEST", 191, 195], ["HLA", "TEST", 201, 204], ["increase", "OBSERVATION_MODIFIER", 99, 107]]], ["The percentage of cells expressing the CD83 marker increased from 74 \u00b1 3.4% in WT to more than 90% in the groups exposed to 5-FU + CQ.", [["cells", "ANATOMY", 18, 23], ["5-FU", "CHEMICAL", 124, 128], ["CQ", "CHEMICAL", 131, 133], ["5-FU", "CHEMICAL", 124, 128], ["CQ", "CHEMICAL", 131, 133], ["cells", "CELL", 18, 23], ["CD83", "GENE_OR_GENE_PRODUCT", 39, 43], ["5-FU", "SIMPLE_CHEMICAL", 124, 128], ["CQ", "SIMPLE_CHEMICAL", 131, 133], ["CD83", "PROTEIN", 39, 43], ["the CD83 marker", "TEST", 35, 50], ["WT", "TEST", 79, 81]]], ["Cell markers associated with DC maturation (CD80, CD86, and HLA-DR) increased from 53.5 \u00b1 2.7%; 74.5 \u00b1 1.2%, and 65.9 \u00b1 3.2% in the WT control to 63.7 \u00b1 5.1%; 92.7 \u00b1 1.5%, respectively, and to 68.7 \u00b1 2.5%, 93.5 \u00b1 1.12% and 86.3 \u00b1 2.4% in cells treated with 5-FU + CQ, respectively.", [["Cell", "ANATOMY", 0, 4], ["DC", "ANATOMY", 29, 31], ["cells", "ANATOMY", 238, 243], ["5-FU", "CHEMICAL", 257, 261], ["CQ", "CHEMICAL", 264, 266], ["5-FU", "CHEMICAL", 257, 261], ["Cell", "CELL", 0, 4], ["DC", "CELL", 29, 31], ["CD80", "GENE_OR_GENE_PRODUCT", 44, 48], ["CD86", "GENE_OR_GENE_PRODUCT", 50, 54], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 60, 66], ["cells", "CELL", 238, 243], ["5-FU", "SIMPLE_CHEMICAL", 257, 261], ["CQ", "SIMPLE_CHEMICAL", 264, 266], ["DC", "CELL_TYPE", 29, 31], ["CD80", "PROTEIN", 44, 48], ["CD86", "PROTEIN", 50, 54], ["HLA", "PROTEIN", 60, 63], ["Cell markers", "TEST", 0, 12], ["DC maturation", "TEST", 29, 42], ["CD80", "TEST", 44, 48], ["CD86", "TEST", 50, 54], ["HLA", "TEST", 60, 63], ["the WT control", "TEST", 128, 142], ["cells", "TEST", 238, 243]]], ["Although treating HCT-116 cells with CQ or 5-FU alone increase the immunogenic effect on DCs, this effect was not as intense as seen in the drug combination.DCs sensitized with lysates from HCT-116 cells pretreated with CQ and 5-FU showed an enhanced allogeneic responseGiven the effect of HCT-116 lysates on the maturation and activation of DCs from healthy individuals, we analyzed whether phenotypic changes were accompanied by changes in DC function.", [["HCT-116 cells", "ANATOMY", 18, 31], ["DCs", "ANATOMY", 89, 92], ["DCs", "ANATOMY", 157, 160], ["lysates", "ANATOMY", 177, 184], ["HCT-116 cells", "ANATOMY", 190, 203], ["HCT-116 lysates", "ANATOMY", 290, 305], ["DCs", "ANATOMY", 342, 345], ["DC", "ANATOMY", 442, 444], ["HCT-116", "CHEMICAL", 18, 25], ["CQ", "CHEMICAL", 37, 39], ["5-FU", "CHEMICAL", 43, 47], ["CQ", "CHEMICAL", 220, 222], ["5-FU", "CHEMICAL", 227, 231], ["HCT-116", "CHEMICAL", 290, 297], ["CQ", "CHEMICAL", 37, 39], ["5-FU", "CHEMICAL", 43, 47], ["CQ", "CHEMICAL", 220, 222], ["5-FU", "CHEMICAL", 227, 231], ["HCT-116 cells", "CELL", 18, 31], ["CQ", "SIMPLE_CHEMICAL", 37, 39], ["5-FU", "SIMPLE_CHEMICAL", 43, 47], ["DCs", "CELL", 89, 92], ["DCs", "CELL", 157, 160], ["lysates", "ORGANISM_SUBSTANCE", 177, 184], ["HCT-116 cells", "CELL", 190, 203], ["CQ", "SIMPLE_CHEMICAL", 220, 222], ["5-FU", "SIMPLE_CHEMICAL", 227, 231], ["HCT-116 lysates", "CELL", 290, 305], ["DCs", "CELL", 342, 345], ["DC", "CELL", 442, 444], ["HCT-116 cells", "CELL_LINE", 18, 31], ["DCs", "CELL_TYPE", 89, 92], ["DCs", "CELL_TYPE", 157, 160], ["HCT-116 cells", "CELL_LINE", 190, 203], ["DCs", "CELL_TYPE", 342, 345], ["DC", "CELL_TYPE", 442, 444], ["HCT", "TEST", 18, 21], ["CQ", "TEST", 37, 39], ["the immunogenic effect", "PROBLEM", 63, 85], ["DCs", "TREATMENT", 89, 92], ["lysates", "TEST", 177, 184], ["HCT", "TEST", 190, 193], ["CQ", "TEST", 220, 222], ["an enhanced allogeneic response", "PROBLEM", 239, 270], ["HCT", "TEST", 290, 293], ["phenotypic changes", "PROBLEM", 392, 410], ["changes in DC function", "PROBLEM", 431, 453], ["allogeneic response", "OBSERVATION", 251, 270]]], ["The MLR assay was used to evaluate the effect of HCT-116 lysates on the ability of DCs to induce an allogeneic response.", [["HCT-116 lysates", "ANATOMY", 49, 64], ["DCs", "ANATOMY", 83, 86], ["HCT-116", "CHEMICAL", 49, 56], ["HCT-116 lysates", "CELL", 49, 64], ["DCs", "CELL", 83, 86], ["DCs", "CELL_TYPE", 83, 86], ["The MLR assay", "TEST", 0, 13], ["HCT", "TEST", 49, 52], ["DCs", "TREATMENT", 83, 86], ["allogeneic response", "OBSERVATION", 100, 119]]], ["This study was performed only with the combination of CQ and 5-FU, which presented the most relevant phenotypic changes.", [["CQ", "CHEMICAL", 54, 56], ["5-FU", "CHEMICAL", 61, 65], ["CQ", "CHEMICAL", 54, 56], ["5-FU", "CHEMICAL", 61, 65], ["CQ", "SIMPLE_CHEMICAL", 54, 56], ["5-FU", "SIMPLE_CHEMICAL", 61, 65], ["This study", "TEST", 0, 10], ["CQ", "TEST", 54, 56], ["most relevant", "OBSERVATION_MODIFIER", 87, 100], ["phenotypic", "OBSERVATION", 101, 111]]], ["Fig. 4A shows the proliferative response of total CD3 lymphocytes, while Fig. 4B and C show the proliferation of CD4+ and CD8+ cells, respectively.", [["CD3 lymphocytes", "ANATOMY", 50, 65], ["CD4+", "ANATOMY", 113, 117], ["CD8+ cells", "ANATOMY", 122, 132], ["CD3 lymphocytes", "CELL", 50, 65], ["4B", "GENE_OR_GENE_PRODUCT", 78, 80], ["C", "CELL", 85, 86], ["CD4", "GENE_OR_GENE_PRODUCT", 113, 116], ["CD8", "GENE_OR_GENE_PRODUCT", 122, 125], ["CD3 lymphocytes", "CELL_TYPE", 50, 65], ["CD4", "PROTEIN", 113, 116], ["CD8", "PROTEIN", 122, 125], ["total CD3 lymphocytes", "PROBLEM", 44, 65], ["4B and C", "TEST", 78, 86], ["CD4", "TEST", 113, 116], ["proliferative", "OBSERVATION_MODIFIER", 18, 31], ["total CD3 lymphocytes", "OBSERVATION", 44, 65], ["proliferation", "OBSERVATION_MODIFIER", 96, 109], ["CD8+ cells", "OBSERVATION", 122, 132]]], ["Although the exposure of HCT-116 cells to CQ alone increased the DC maturation compared to WT, this effect was not as intense as the drug combination.", [["HCT-116 cells", "ANATOMY", 25, 38], ["DC", "ANATOMY", 65, 67], ["HCT-116", "CHEMICAL", 25, 32], ["CQ", "CHEMICAL", 42, 44], ["CQ", "CHEMICAL", 42, 44], ["HCT-116 cells", "CELL", 25, 38], ["CQ", "SIMPLE_CHEMICAL", 42, 44], ["DC", "CELL", 65, 67], ["HCT-116 cells", "CELL_LINE", 25, 38], ["DC", "CELL_TYPE", 65, 67], ["HCT", "TEST", 25, 28], ["CQ", "TEST", 42, 44], ["the DC maturation", "TREATMENT", 61, 78], ["WT", "TEST", 91, 93]]], ["Our results showed a marked effect on the proliferation of CD4+ T lymphocytes when DCs were sensitized with lysates from HCT-116 cells that were pretreated with 20 \u03bcM 5-FU + CQ.DCs sensitized with lysates from HCT-116 cells pretreated with CQ and 5-FU showed an enhanced allogeneic response3.6.", [["CD4+ T lymphocytes", "ANATOMY", 59, 77], ["DCs", "ANATOMY", 83, 86], ["lysates", "ANATOMY", 108, 115], ["HCT-116 cells", "ANATOMY", 121, 134], ["lysates", "ANATOMY", 197, 204], ["HCT-116 cells", "ANATOMY", 210, 223], ["5-FU", "CHEMICAL", 167, 171], ["CQ.DCs", "CHEMICAL", 174, 180], ["CQ", "CHEMICAL", 240, 242], ["5-FU", "CHEMICAL", 247, 251], ["5-FU", "CHEMICAL", 167, 171], ["CQ", "CHEMICAL", 240, 242], ["5-FU", "CHEMICAL", 247, 251], ["CD4", "GENE_OR_GENE_PRODUCT", 59, 62], ["DCs", "CELL", 83, 86], ["lysates", "ORGANISM_SUBSTANCE", 108, 115], ["HCT-116 cells", "CELL", 121, 134], ["5-FU", "SIMPLE_CHEMICAL", 167, 171], ["CQ.DCs", "SIMPLE_CHEMICAL", 174, 180], ["lysates", "ORGANISM_SUBSTANCE", 197, 204], ["HCT-116 cells", "CELL", 210, 223], ["CQ", "SIMPLE_CHEMICAL", 240, 242], ["5-FU", "SIMPLE_CHEMICAL", 247, 251], ["CD4", "PROTEIN", 59, 62], ["T lymphocytes", "CELL_TYPE", 64, 77], ["DCs", "CELL_TYPE", 83, 86], ["HCT-116 cells", "CELL_LINE", 121, 134], ["HCT-116 cells", "CELL_LINE", 210, 223], ["HCT-116", "SPECIES", 121, 128], ["a marked effect", "PROBLEM", 19, 34], ["CD4+ T lymphocytes", "PROBLEM", 59, 77], ["lysates", "TEST", 108, 115], ["HCT", "TEST", 121, 124], ["lysates", "TEST", 197, 204], ["HCT", "TEST", 210, 213], ["CQ", "TEST", 240, 242], ["marked", "OBSERVATION_MODIFIER", 21, 27], ["effect", "OBSERVATION_MODIFIER", 28, 34]]], ["Lymphocytes responding to allogeneic stimulation showed an activated cell profile CD69, a marker of activated T lymphocytes, and PD-1, the checkpoint ligand of PD-L1 expressed by tumor cells, were assessed on DCstimulated T cells.", [["Lymphocytes", "ANATOMY", 0, 11], ["cell", "ANATOMY", 69, 73], ["T lymphocytes", "ANATOMY", 110, 123], ["tumor cells", "ANATOMY", 179, 190], ["DCstimulated T cells", "ANATOMY", 209, 229], ["tumor", "DISEASE", 179, 184], ["Lymphocytes", "CELL", 0, 11], ["cell", "CELL", 69, 73], ["CD69", "GENE_OR_GENE_PRODUCT", 82, 86], ["T lymphocytes", "CELL", 110, 123], ["PD-1", "GENE_OR_GENE_PRODUCT", 129, 133], ["PD-L1", "GENE_OR_GENE_PRODUCT", 160, 165], ["tumor cells", "CELL", 179, 190], ["DCstimulated T cells", "CELL", 209, 229], ["Lymphocytes", "CELL_TYPE", 0, 11], ["CD69", "PROTEIN", 82, 86], ["activated T lymphocytes", "CELL_TYPE", 100, 123], ["PD-L1", "PROTEIN", 160, 165], ["tumor cells", "CELL_TYPE", 179, 190], ["DCstimulated T cells", "CELL_LINE", 209, 229], ["Lymphocytes", "PROBLEM", 0, 11], ["allogeneic stimulation", "TEST", 26, 48], ["an activated cell profile CD69", "PROBLEM", 56, 86], ["activated T lymphocytes", "TEST", 100, 123], ["PD", "TEST", 129, 131], ["the checkpoint ligand", "TEST", 135, 156], ["PD", "TEST", 160, 162], ["tumor cells", "PROBLEM", 179, 190], ["activated cell", "OBSERVATION", 59, 73], ["L1", "ANATOMY", 163, 165], ["tumor cells", "OBSERVATION", 179, 190]]], ["Fig. 4D -G indicates that lymphocytes generated through exposure to DC 5-FU + CQ had a high frequency of CD69+ expression, both among CD4+ T lymphocytes (30.7 \u00b1 2.7%) and CD8+ lymphocytes (41.6 \u00b1 3.2% and 42.5 \u00b1 2.9%, respectively).", [["lymphocytes", "ANATOMY", 26, 37], ["DC", "ANATOMY", 68, 70], ["CD4+ T lymphocytes", "ANATOMY", 134, 152], ["CD8+ lymphocytes", "ANATOMY", 171, 187], ["5-FU", "CHEMICAL", 71, 75], ["CQ", "CHEMICAL", 78, 80], ["5-FU", "CHEMICAL", 71, 75], ["lymphocytes", "CELL", 26, 37], ["5-FU", "SIMPLE_CHEMICAL", 71, 75], ["CQ", "SIMPLE_CHEMICAL", 78, 80], ["CD69", "GENE_OR_GENE_PRODUCT", 105, 109], ["CD4", "GENE_OR_GENE_PRODUCT", 134, 137], ["CD8", "GENE_OR_GENE_PRODUCT", 171, 174], ["lymphocytes", "CELL_TYPE", 26, 37], ["DC", "CELL_TYPE", 68, 70], ["CD69", "PROTEIN", 105, 109], ["CD4", "PROTEIN", 134, 137], ["T lymphocytes", "CELL_TYPE", 139, 152], ["CD8+ lymphocytes", "CELL_TYPE", 171, 187], ["lymphocytes", "PROBLEM", 26, 37], ["DC", "TEST", 68, 70], ["FU", "TEST", 73, 75], ["CD69", "TEST", 105, 109], ["CD4", "TEST", 134, 137], ["lymphocytes", "TEST", 141, 152], ["\u00b1", "TEST", 159, 160], ["CD8", "TEST", 171, 174], ["lymphocytes", "TEST", 176, 187], ["lymphocytes", "ANATOMY", 176, 187]]], ["In contrast, the expression of the regulatory marker PD-1 was lower in these lymphocytes, especially in CD4+ cells (5-FU + CQ: 16.5 \u00b1 1.3%).HCT-116 treated with 5-FU + CQ showed an increased ability to induce a Th1 responseAs shown in Fig. 4H , DCs exposed to the lysates of HCT-116 cells that were treated with 5-FU + CQ had an increased ability to induce the production of IFN-\u03b3 via allogeneic lymphocytes.", [["lymphocytes", "ANATOMY", 77, 88], ["CD4+ cells", "ANATOMY", 104, 114], ["HCT-116", "ANATOMY", 140, 147], ["DCs", "ANATOMY", 245, 248], ["lysates", "ANATOMY", 264, 271], ["HCT-116 cells", "ANATOMY", 275, 288], ["lymphocytes", "ANATOMY", 396, 407], ["5-FU", "CHEMICAL", 116, 120], ["CQ", "CHEMICAL", 123, 125], ["HCT-116", "CHEMICAL", 140, 147], ["5-FU", "CHEMICAL", 161, 165], ["CQ", "CHEMICAL", 168, 170], ["HCT-116", "CHEMICAL", 275, 282], ["5-FU", "CHEMICAL", 312, 316], ["CQ", "CHEMICAL", 319, 321], ["5-FU", "CHEMICAL", 116, 120], ["5-FU", "CHEMICAL", 161, 165], ["CQ", "CHEMICAL", 168, 170], ["5-FU", "CHEMICAL", 312, 316], ["CQ", "CHEMICAL", 319, 321], ["PD-1", "GENE_OR_GENE_PRODUCT", 53, 57], ["lymphocytes", "CELL", 77, 88], ["CD4", "GENE_OR_GENE_PRODUCT", 104, 107], ["HCT-116", "CELL", 140, 147], ["5-FU", "SIMPLE_CHEMICAL", 161, 165], ["CQ", "SIMPLE_CHEMICAL", 168, 170], ["DCs", "CELL", 245, 248], ["lysates", "ORGANISM_SUBSTANCE", 264, 271], ["HCT-116 cells", "CELL", 275, 288], ["5-FU", "SIMPLE_CHEMICAL", 312, 316], ["CQ", "SIMPLE_CHEMICAL", 319, 321], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 375, 380], ["lymphocytes", "CELL", 396, 407], ["lymphocytes", "CELL_TYPE", 77, 88], ["CD4+ cells", "CELL_TYPE", 104, 114], ["DCs", "CELL_TYPE", 245, 248], ["HCT-116 cells", "CELL_LINE", 275, 288], ["IFN-\u03b3", "PROTEIN", 375, 380], ["allogeneic lymphocytes", "CELL_TYPE", 385, 407], ["the regulatory marker PD", "TEST", 31, 55], ["FU", "TEST", 118, 120], ["CQ", "TEST", 123, 125], ["HCT", "TEST", 140, 143], ["FU + CQ", "TEST", 163, 170], ["an increased ability", "PROBLEM", 178, 198], ["HCT", "TEST", 275, 278], ["an increased ability", "PROBLEM", 326, 346], ["IFN", "TEST", 375, 378], ["allogeneic lymphocytes", "PROBLEM", 385, 407], ["lymphocytes", "ANATOMY", 77, 88], ["Fig", "OBSERVATION", 235, 238], ["allogeneic lymphocytes", "OBSERVATION", 385, 407]]], ["The levels of IFN-\u03b3 increased from 171.1 \u00b1 11.4 pg/ml (WT) to 195.7 \u00b1 16.5 pg/ml (CQ) and 389.3 \u00b1 19.8 pg/ml (5-FU + CQ).", [["CQ", "CHEMICAL", 82, 84], ["5-FU", "CHEMICAL", 110, 114], ["5-FU", "CHEMICAL", 110, 114], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 14, 19], ["IFN", "PROTEIN", 14, 17], ["The levels", "TEST", 0, 10], ["IFN", "TEST", 14, 17], ["WT", "TEST", 55, 57], ["CQ", "TEST", 82, 84], ["pg", "TEST", 103, 105], ["FU", "TEST", 112, 114]]], ["Conversely, Fig. 4I shows that DC exposure to the lysates decreased the ability of DC-stimulated T cells to secrete IL-10, reducing the levels from 46.8 \u00b1 6.3 pg/ml (WT) to 28.7 \u00b1 7.2 pg/ml (CQ) and 8.2 \u00b1 3.7 pg/ml (5-FU + CQ).Dcs treated with lysate enhanced the in vitro generation of CTLsOur analysis of cytotoxic T lymphocytes was restricted to the expression of perforin and granzyme B molecules.", [["DC", "ANATOMY", 31, 33], ["lysates", "ANATOMY", 50, 57], ["DC", "ANATOMY", 83, 85], ["T cells", "ANATOMY", 97, 104], ["Dcs", "ANATOMY", 227, 230], ["lysate", "ANATOMY", 244, 250], ["cytotoxic T lymphocytes", "ANATOMY", 307, 330], ["CQ", "CHEMICAL", 191, 193], ["5-FU", "CHEMICAL", 216, 220], ["CQ", "CHEMICAL", 223, 225], ["Dcs", "CHEMICAL", 227, 230], ["5-FU", "CHEMICAL", 216, 220], ["lysates", "ORGANISM_SUBSTANCE", 50, 57], ["DC", "CELL", 83, 85], ["T cells", "CELL", 97, 104], ["IL-10", "GENE_OR_GENE_PRODUCT", 116, 121], ["CQ", "SIMPLE_CHEMICAL", 223, 225], ["Dcs", "SIMPLE_CHEMICAL", 227, 230], ["cytotoxic T lymphocytes", "CELL", 307, 330], ["perforin", "GENE_OR_GENE_PRODUCT", 367, 375], ["granzyme B molecules", "GENE_OR_GENE_PRODUCT", 380, 400], ["DC", "CELL_TYPE", 31, 33], ["DC", "CELL_TYPE", 83, 85], ["T cells", "CELL_TYPE", 97, 104], ["IL", "PROTEIN", 116, 118], ["Dcs", "CELL_LINE", 227, 230], ["CTLsOur", "PROTEIN", 287, 294], ["cytotoxic T lymphocytes", "CELL_TYPE", 307, 330], ["perforin", "PROTEIN", 367, 375], ["granzyme B molecules", "PROTEIN", 380, 400], ["the lysates", "PROBLEM", 46, 57], ["secrete IL", "TEST", 108, 118], ["the levels", "TEST", 132, 142], ["WT", "TEST", 166, 168], ["CQ", "TEST", 191, 193], ["pg", "TEST", 209, 211], ["lysate", "TREATMENT", 244, 250], ["CTLsOur analysis", "TEST", 287, 303], ["cytotoxic T lymphocytes", "PROBLEM", 307, 330], ["cytotoxic T lymphocytes", "OBSERVATION", 307, 330]]], ["We tested the efficiency of HCT-116 lysate-treated DCs to generate autologous tumor-reactive T cells.", [["HCT-116 lysate", "ANATOMY", 28, 42], ["DCs", "ANATOMY", 51, 54], ["tumor-reactive T cells", "ANATOMY", 78, 100], ["HCT-116", "CHEMICAL", 28, 35], ["tumor", "DISEASE", 78, 83], ["HCT-116 lysate", "CELL", 28, 42], ["DCs", "CELL", 51, 54], ["tumor-reactive T cells", "CELL", 78, 100], ["HCT-116 lysate-treated DCs", "CELL_LINE", 28, 54], ["autologous tumor-reactive T cells", "CELL_TYPE", 67, 100], ["HCT", "TEST", 28, 31], ["lysate", "TEST", 36, 42], ["autologous tumor", "PROBLEM", 67, 83], ["reactive T cells", "PROBLEM", 84, 100], ["autologous tumor", "OBSERVATION", 67, 83], ["reactive T cells", "OBSERVATION", 84, 100]]], ["We found that lymphocytes cultured with DCs exposed to lysates of HCT-116 cells treated with 5-FU + CQ induced the generation of lymphocytes with higher levels of perforin and granzyme B than in those cultured with control DCs (Fig. 5) .", [["lymphocytes", "ANATOMY", 14, 25], ["DCs", "ANATOMY", 40, 43], ["lysates", "ANATOMY", 55, 62], ["HCT-116 cells", "ANATOMY", 66, 79], ["lymphocytes", "ANATOMY", 129, 140], ["DCs", "ANATOMY", 223, 226], ["HCT-116", "CHEMICAL", 66, 73], ["5-FU", "CHEMICAL", 93, 97], ["CQ", "CHEMICAL", 100, 102], ["5-FU", "CHEMICAL", 93, 97], ["CQ", "CHEMICAL", 100, 102], ["lymphocytes", "CELL", 14, 25], ["DCs", "CELL", 40, 43], ["lysates", "ORGANISM_SUBSTANCE", 55, 62], ["HCT-116 cells", "CELL", 66, 79], ["5-FU", "SIMPLE_CHEMICAL", 93, 97], ["CQ", "SIMPLE_CHEMICAL", 100, 102], ["lymphocytes", "CELL", 129, 140], ["perforin", "GENE_OR_GENE_PRODUCT", 163, 171], ["granzyme B", "GENE_OR_GENE_PRODUCT", 176, 186], ["DCs", "CELL", 223, 226], ["lymphocytes", "CELL_TYPE", 14, 25], ["DCs", "CELL_TYPE", 40, 43], ["HCT-116 cells", "CELL_LINE", 66, 79], ["lymphocytes", "CELL_TYPE", 129, 140], ["perforin", "PROTEIN", 163, 171], ["granzyme B", "PROTEIN", 176, 186], ["DCs", "CELL_TYPE", 223, 226], ["lymphocytes", "PROBLEM", 14, 25], ["lysates", "TEST", 55, 62], ["HCT", "TEST", 66, 69], ["cells", "TEST", 74, 79], ["the generation of lymphocytes", "PROBLEM", 111, 140], ["perforin and granzyme B", "TREATMENT", 163, 186], ["lymphocytes", "OBSERVATION", 14, 25]]], ["No differences were observed upon labeling with anti-CD107a (data not shown).Transcriptional changes associated with autophagy blockadeTo better understand the increase of DC maturation associated with blocking autophagy, we evaluated HCT-116 cells treated with 5-FU, CQ and their combination.", [["DC", "ANATOMY", 172, 174], ["HCT-116 cells", "ANATOMY", 235, 248], ["5-FU", "CHEMICAL", 262, 266], ["CQ", "CHEMICAL", 268, 270], ["5-FU", "CHEMICAL", 262, 266], ["CQ", "CHEMICAL", 268, 270], ["anti-CD107a", "GENE_OR_GENE_PRODUCT", 48, 59], ["DC", "CELL", 172, 174], ["HCT-116 cells", "CELL", 235, 248], ["5-FU", "SIMPLE_CHEMICAL", 262, 266], ["CQ", "SIMPLE_CHEMICAL", 268, 270], ["anti-CD107a", "PROTEIN", 48, 59], ["DC", "CELL_TYPE", 172, 174], ["HCT-116 cells", "CELL_LINE", 235, 248], ["Transcriptional changes", "PROBLEM", 77, 100], ["autophagy blockade", "TREATMENT", 117, 135], ["DC maturation", "TREATMENT", 172, 185], ["blocking autophagy", "PROBLEM", 202, 220], ["HCT", "TEST", 235, 238], ["5-FU", "TREATMENT", 262, 266], ["CQ", "TREATMENT", 268, 270], ["autophagy blockade", "OBSERVATION", 117, 135]]], ["The gene fold change was used to identify significant differences in gene expression among the groups ( Table 2) .", [["The gene fold change", "PROBLEM", 0, 20], ["fold", "OBSERVATION_MODIFIER", 9, 13], ["change", "OBSERVATION", 14, 20]]], ["CQ-treated cells showed a modest increase in the expression of the autophagy genes ATGs, SQSTM1, MAP1LC3B, and ULK1 and a considerable decrease in genes related to tumor progression (BNIP3, BNIP3L, FOSL2, HES1, LAMB3, LOXL2, NDRG1, P4HA1, and PIK3R2), as well as a decrease in nominal tumor antigens (members of the CEA family).", [["cells", "ANATOMY", 11, 16], ["tumor", "ANATOMY", 164, 169], ["tumor", "ANATOMY", 285, 290], ["CQ", "CHEMICAL", 0, 2], ["tumor", "DISEASE", 164, 169], ["tumor", "DISEASE", 285, 290], ["CQ", "CHEMICAL", 0, 2], ["CQ", "SIMPLE_CHEMICAL", 0, 2], ["cells", "CELL", 11, 16], ["ATGs", "GENE_OR_GENE_PRODUCT", 83, 87], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 89, 95], ["MAP1LC3B", "GENE_OR_GENE_PRODUCT", 97, 105], ["ULK1", "GENE_OR_GENE_PRODUCT", 111, 115], ["tumor", "CANCER", 164, 169], ["BNIP3", "GENE_OR_GENE_PRODUCT", 183, 188], ["BNIP3L", "GENE_OR_GENE_PRODUCT", 190, 196], ["FOSL2", "GENE_OR_GENE_PRODUCT", 198, 203], ["HES1", "GENE_OR_GENE_PRODUCT", 205, 209], ["LAMB3", "GENE_OR_GENE_PRODUCT", 211, 216], ["LOXL2", "GENE_OR_GENE_PRODUCT", 218, 223], ["NDRG1", "GENE_OR_GENE_PRODUCT", 225, 230], ["P4HA1", "GENE_OR_GENE_PRODUCT", 232, 237], ["PIK3R2", "GENE_OR_GENE_PRODUCT", 243, 249], ["tumor antigens", "GENE_OR_GENE_PRODUCT", 285, 299], ["CEA", "GENE_OR_GENE_PRODUCT", 316, 319], ["CQ-treated cells", "CELL_LINE", 0, 16], ["autophagy genes", "DNA", 67, 82], ["ATGs", "DNA", 83, 87], ["SQSTM1", "DNA", 89, 95], ["MAP1LC3B", "DNA", 97, 105], ["ULK1", "DNA", 111, 115], ["BNIP3", "PROTEIN", 183, 188], ["BNIP3L", "PROTEIN", 190, 196], ["FOSL2", "DNA", 198, 203], ["HES1", "DNA", 205, 209], ["LAMB3", "DNA", 211, 216], ["LOXL2", "DNA", 218, 223], ["NDRG1", "DNA", 225, 230], ["P4HA1", "DNA", 232, 237], ["PIK3R2", "DNA", 243, 249], ["nominal tumor antigens", "PROTEIN", 277, 299], ["CEA family", "PROTEIN", 316, 326], ["CQ", "TEST", 0, 2], ["the autophagy genes ATGs", "PROBLEM", 63, 87], ["SQSTM1", "TEST", 89, 95], ["MAP1LC3B", "TEST", 97, 105], ["ULK1", "TEST", 111, 115], ["a considerable decrease in genes", "PROBLEM", 120, 152], ["tumor progression", "PROBLEM", 164, 181], ["BNIP3", "TEST", 183, 188], ["BNIP3L", "TEST", 190, 196], ["FOSL2", "TEST", 198, 203], ["HES1", "TEST", 205, 209], ["LAMB3", "TEST", 211, 216], ["LOXL2", "TEST", 218, 223], ["NDRG1", "TEST", 225, 230], ["P4HA1", "TEST", 232, 237], ["a decrease in nominal tumor antigens", "PROBLEM", 263, 299], ["modest", "OBSERVATION_MODIFIER", 26, 32], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["considerable", "OBSERVATION_MODIFIER", 122, 134], ["decrease", "OBSERVATION_MODIFIER", 135, 143], ["tumor", "OBSERVATION", 164, 169], ["decrease", "OBSERVATION_MODIFIER", 265, 273], ["tumor", "OBSERVATION", 285, 290]]], ["Treatment with 5-FU induced an increase in autophagy genes.", [["5-FU", "CHEMICAL", 15, 19], ["5-FU", "CHEMICAL", 15, 19], ["5-FU", "SIMPLE_CHEMICAL", 15, 19], ["autophagy genes", "DNA", 43, 58], ["an increase in autophagy genes", "PROBLEM", 28, 58], ["increase", "OBSERVATION_MODIFIER", 31, 39], ["autophagy genes", "OBSERVATION", 43, 58]]], ["In contrast with the CQ group, we did not observe such an intense decrease in the genes related to tumor progression, while the expression of CEA genes was increased.", [["tumor", "ANATOMY", 99, 104], ["CQ", "CHEMICAL", 21, 23], ["tumor", "DISEASE", 99, 104], ["CQ", "SIMPLE_CHEMICAL", 21, 23], ["tumor", "CANCER", 99, 104], ["CEA", "GENE_OR_GENE_PRODUCT", 142, 145], ["CEA genes", "DNA", 142, 151], ["an intense decrease in the genes", "PROBLEM", 55, 87], ["tumor progression", "PROBLEM", 99, 116], ["CEA genes", "PROBLEM", 142, 151], ["intense", "OBSERVATION_MODIFIER", 58, 65], ["decrease", "OBSERVATION", 66, 74], ["tumor", "OBSERVATION", 99, 104], ["CEA genes", "OBSERVATION", 142, 151], ["increased", "OBSERVATION_MODIFIER", 156, 165]]], ["Cells treated with 5-FU + CQ showed an increased expression of autophagy genes, as well as an increase in genes of the CEA family.", [["Cells", "ANATOMY", 0, 5], ["5-FU", "CHEMICAL", 19, 23], ["CQ", "CHEMICAL", 26, 28], ["5-FU", "CHEMICAL", 19, 23], ["Cells", "CELL", 0, 5], ["5-FU", "SIMPLE_CHEMICAL", 19, 23], ["CQ", "SIMPLE_CHEMICAL", 26, 28], ["CEA", "GENE_OR_GENE_PRODUCT", 119, 122], ["autophagy genes", "DNA", 63, 78], ["CEA family", "PROTEIN", 119, 129], ["FU + CQ", "TEST", 21, 28], ["an increased expression of autophagy genes", "PROBLEM", 36, 78], ["increased", "OBSERVATION_MODIFIER", 39, 48], ["autophagy genes", "OBSERVATION", 63, 78], ["increase", "OBSERVATION_MODIFIER", 94, 102], ["CEA", "ANATOMY", 119, 122]]], ["Unlike the 5-FU group, the expression of genes associated with tumor progression was decreased.DiscussionThe development of resistance to antitumor agents is one of the primary challenges of modern cancer therapy.", [["tumor", "ANATOMY", 63, 68], ["antitumor", "ANATOMY", 138, 147], ["cancer", "ANATOMY", 198, 204], ["5-FU", "CHEMICAL", 11, 15], ["tumor", "DISEASE", 63, 68], ["cancer", "DISEASE", 198, 204], ["5-FU", "CHEMICAL", 11, 15], ["5-FU", "SIMPLE_CHEMICAL", 11, 15], ["tumor", "CANCER", 63, 68], ["antitumor", "CANCER", 138, 147], ["cancer", "CANCER", 198, 204], ["tumor progression", "PROBLEM", 63, 80], ["antitumor agents", "TREATMENT", 138, 154], ["modern cancer therapy", "TREATMENT", 191, 212], ["tumor", "OBSERVATION", 63, 68], ["decreased", "OBSERVATION_MODIFIER", 85, 94], ["cancer", "OBSERVATION", 198, 204]]], ["Here, we investigated the effects of treating tumor cells with a combination of 5-FU and CQ.", [["tumor cells", "ANATOMY", 46, 57], ["tumor", "DISEASE", 46, 51], ["5-FU", "CHEMICAL", 80, 84], ["CQ", "CHEMICAL", 89, 91], ["5-FU", "CHEMICAL", 80, 84], ["CQ", "CHEMICAL", 89, 91], ["tumor cells", "CELL", 46, 57], ["5-FU", "SIMPLE_CHEMICAL", 80, 84], ["CQ", "SIMPLE_CHEMICAL", 89, 91], ["tumor cells", "CELL_TYPE", 46, 57], ["tumor cells", "PROBLEM", 46, 57], ["tumor cells", "OBSERVATION", 46, 57]]], ["The concentration of 20 \u03bcM 5-FU was chosen because it was the lowest concentration capable of inhibiting tumor growth and may, therefore, represent a suitable in vitro model of the metronomic dose used in the Fig. 3 .", [["tumor", "ANATOMY", 105, 110], ["5-FU", "CHEMICAL", 27, 31], ["tumor", "DISEASE", 105, 110], ["5-FU", "CHEMICAL", 27, 31], ["5-FU", "SIMPLE_CHEMICAL", 27, 31], ["tumor", "CANCER", 105, 110], ["The concentration of 20 \u03bcM", "TREATMENT", 0, 26], ["inhibiting tumor growth", "PROBLEM", 94, 117], ["the metronomic dose", "TREATMENT", 177, 196], ["tumor", "OBSERVATION", 105, 110]]], ["Lysates of HCT-116 exposed to 5-FU + CQ increase DC maturation and activation.", [["Lysates", "ANATOMY", 0, 7], ["HCT-116", "ANATOMY", 11, 18], ["DC", "ANATOMY", 49, 51], ["HCT-116", "CHEMICAL", 11, 18], ["5-FU", "CHEMICAL", 30, 34], ["CQ", "CHEMICAL", 37, 39], ["5-FU", "CHEMICAL", 30, 34], ["CQ", "CHEMICAL", 37, 39], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["HCT-116", "CELL", 11, 18], ["5-FU", "SIMPLE_CHEMICAL", 30, 34], ["CQ", "SIMPLE_CHEMICAL", 37, 39], ["DC", "CELL", 49, 51], ["HCT-116", "CELL_LINE", 11, 18], ["DC", "CELL_TYPE", 49, 51], ["Lysates", "TEST", 0, 7], ["HCT", "TEST", 11, 14], ["FU", "TEST", 32, 34], ["DC maturation", "TREATMENT", 49, 62]]], ["DCs from six healthy donors were exposed to the lysates of HCT-116 cells previously treated with the minimal effective concentrations of 5-FU or its combination with CQ (5-FU + CQ).", [["DCs", "ANATOMY", 0, 3], ["lysates", "ANATOMY", 48, 55], ["HCT-116 cells", "ANATOMY", 59, 72], ["HCT-116", "CHEMICAL", 59, 66], ["5-FU", "CHEMICAL", 137, 141], ["CQ", "CHEMICAL", 166, 168], ["5-FU", "CHEMICAL", 170, 174], ["CQ", "CHEMICAL", 177, 179], ["5-FU", "CHEMICAL", 137, 141], ["CQ", "CHEMICAL", 166, 168], ["5-FU", "CHEMICAL", 170, 174], ["CQ", "CHEMICAL", 177, 179], ["DCs", "CELL", 0, 3], ["donors", "ORGANISM", 21, 27], ["lysates", "ORGANISM_SUBSTANCE", 48, 55], ["HCT-116 cells", "CELL", 59, 72], ["5-FU", "SIMPLE_CHEMICAL", 137, 141], ["CQ", "SIMPLE_CHEMICAL", 166, 168], ["5-FU", "SIMPLE_CHEMICAL", 170, 174], ["CQ", "SIMPLE_CHEMICAL", 177, 179], ["DCs", "CELL_TYPE", 0, 3], ["HCT-116 cells", "CELL_LINE", 59, 72], ["HCT", "TEST", 59, 62], ["CQ", "TEST", 166, 168]]], ["WT refers to DCs pulsed with the lysate of untreated HCT-116 cells, and CTRL refers to unstimulated DCs.", [["DCs", "ANATOMY", 13, 16], ["lysate", "ANATOMY", 33, 39], ["HCT-116 cells", "ANATOMY", 53, 66], ["DCs", "ANATOMY", 100, 103], ["DCs", "CELL", 13, 16], ["HCT-116 cells", "CELL", 53, 66], ["DCs", "CELL", 100, 103], ["DCs", "CELL_TYPE", 13, 16], ["HCT-116 cells", "CELL_LINE", 53, 66], ["unstimulated DCs", "CELL_TYPE", 87, 103], ["the lysate", "TEST", 29, 39], ["untreated HCT", "TEST", 43, 56], ["cells", "TEST", 61, 66], ["CTRL", "TEST", 72, 76]]], ["Scatter plots illustrate the percentages of DCs (CD11c+) that co-express the markers CD83 (A), HLA-DR (B), CD80 (C), and CD86 (D).", [["DCs", "ANATOMY", 44, 47], ["DCs", "CELL", 44, 47], ["CD11c", "GENE_OR_GENE_PRODUCT", 49, 54], ["CD83", "GENE_OR_GENE_PRODUCT", 85, 89], ["A", "GENE_OR_GENE_PRODUCT", 91, 92], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 95, 101], ["B", "GENE_OR_GENE_PRODUCT", 103, 104], ["CD80 (C)", "GENE_OR_GENE_PRODUCT", 107, 115], ["CD86", "GENE_OR_GENE_PRODUCT", 121, 125], ["DCs", "CELL_TYPE", 44, 47], ["CD11c", "PROTEIN", 49, 54], ["CD83", "PROTEIN", 85, 89], ["A", "PROTEIN", 91, 92], ["HLA", "PROTEIN", 95, 98], ["DR", "PROTEIN", 99, 101], ["B", "PROTEIN", 103, 104], ["CD80", "PROTEIN", 107, 111], ["C", "PROTEIN", 113, 114], ["CD86", "PROTEIN", 121, 125], ["Scatter plots", "TEST", 0, 13], ["the markers CD83", "TEST", 73, 89], ["HLA", "TEST", 95, 98], ["CD80", "TEST", 107, 111]]], ["The mean and standard deviation of the six individual donors was analyzed by ANOVA. * p \u2264 0.05; ** p \u2264 0.01; *** p \u2264 0.005. clinic [31] .", [["donors", "ORGANISM", 54, 60], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Although CQ has previously been applied in combination with several antineoplastic agents, a study using low concentrations of the drug has not yet been reported.DiscussionIncreased LC3-II and SQSTM1 levels are currently used as suitable markers of effective autophagy inhibition.", [["antineoplastic", "ANATOMY", 68, 82], ["CQ", "CHEMICAL", 9, 11], ["CQ", "SIMPLE_CHEMICAL", 9, 11], ["LC3-II", "GENE_OR_GENE_PRODUCT", 182, 188], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 193, 199], ["LC3", "PROTEIN", 182, 185], ["SQSTM1", "PROTEIN", 193, 199], ["CQ", "PROBLEM", 9, 11], ["several antineoplastic agents", "TREATMENT", 60, 89], ["a study", "TEST", 91, 98], ["the drug", "TREATMENT", 127, 135], ["SQSTM1 levels", "TEST", 193, 206], ["effective autophagy inhibition", "TREATMENT", 249, 279]]], ["When autophagy is blocked by CQ, LC3-II accumulates [32] .", [["CQ", "CHEMICAL", 29, 31], ["LC3-II", "CHEMICAL", 33, 39], ["CQ", "SIMPLE_CHEMICAL", 29, 31], ["LC3-II", "GENE_OR_GENE_PRODUCT", 33, 39], ["LC3-II", "PROTEIN", 33, 39]]], ["SQSTM1 binds to ubiquitinated proteins, especially LC3-II, forming part of the autophagosome wall.", [["autophagosome wall", "ANATOMY", 79, 97], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 0, 6], ["LC3-II", "GENE_OR_GENE_PRODUCT", 51, 57], ["autophagosome wall", "CELLULAR_COMPONENT", 79, 97], ["SQSTM1", "PROTEIN", 0, 6], ["ubiquitinated proteins", "PROTEIN", 16, 38], ["LC3-II", "PROTEIN", 51, 57], ["ubiquitinated proteins", "TEST", 16, 38], ["ubiquitinated proteins", "OBSERVATION", 16, 38], ["autophagosome", "OBSERVATION", 79, 92], ["wall", "ANATOMY_MODIFIER", 93, 97]]], ["Thus, if autophagy is enhanced, SQSTM1 is degraded.", [["SQSTM1", "GENE_OR_GENE_PRODUCT", 32, 38], ["SQSTM1", "PROTEIN", 32, 38], ["autophagy", "PROBLEM", 9, 18], ["SQSTM1", "TEST", 32, 38]]], ["Inhibiting autophagy promotes the accumulation of SQSTM1, as well as LC3-II [33] .", [["SQSTM1", "GENE_OR_GENE_PRODUCT", 50, 56], ["LC3-II", "GENE_OR_GENE_PRODUCT", 69, 75], ["SQSTM1", "PROTEIN", 50, 56], ["LC3", "PROTEIN", 69, 72], ["the accumulation of SQSTM1", "PROBLEM", 30, 56], ["accumulation", "OBSERVATION_MODIFIER", 34, 46], ["SQSTM1", "OBSERVATION", 50, 56]]], ["Low concentrations of 5-FU increased autophagy in HCT-116 cells, while CQ was able to inhibit the process, as evidenced by the accumulation of LC3-II.", [["HCT-116 cells", "ANATOMY", 50, 63], ["5-FU", "CHEMICAL", 22, 26], ["CQ", "CHEMICAL", 71, 73], ["5-FU", "CHEMICAL", 22, 26], ["CQ", "CHEMICAL", 71, 73], ["5-FU", "SIMPLE_CHEMICAL", 22, 26], ["HCT-116 cells", "CELL", 50, 63], ["CQ", "SIMPLE_CHEMICAL", 71, 73], ["LC3-II.", "GENE_OR_GENE_PRODUCT", 143, 150], ["HCT-116 cells", "CELL_LINE", 50, 63], ["LC3", "PROTEIN", 143, 146], ["HCT-116", "SPECIES", 50, 57], ["Low concentrations", "PROBLEM", 0, 18], ["FU increased autophagy", "PROBLEM", 24, 46], ["HCT", "TEST", 50, 53], ["CQ", "TEST", 71, 73]]], ["The analysis of SQSTM1 expression is consistent with constitutive autophagy in HCT-116 cells [34] .DiscussionAutophagy induction by 5-FU was also confirmed by transcriptome analysis that showed an increase in expression of the autophagy-associated genes ATGs, SQSTM1, MAP1LC3B, BECN1, and ULK1.", [["HCT-116 cells", "ANATOMY", 79, 92], ["5-FU", "CHEMICAL", 132, 136], ["5-FU", "CHEMICAL", 132, 136], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 16, 22], ["HCT-116 cells", "CELL", 79, 92], ["5-FU", "SIMPLE_CHEMICAL", 132, 136], ["ATGs", "GENE_OR_GENE_PRODUCT", 254, 258], ["SQSTM1", "GENE_OR_GENE_PRODUCT", 260, 266], ["MAP1LC3B", "GENE_OR_GENE_PRODUCT", 268, 276], ["BECN1", "GENE_OR_GENE_PRODUCT", 278, 283], ["ULK1", "GENE_OR_GENE_PRODUCT", 289, 293], ["SQSTM1", "DNA", 16, 22], ["HCT-116 cells", "CELL_LINE", 79, 92], ["autophagy-associated genes", "DNA", 227, 253], ["ATGs", "DNA", 254, 258], ["SQSTM1", "DNA", 260, 266], ["MAP1LC3B", "DNA", 268, 276], ["BECN1", "DNA", 278, 283], ["ULK1", "DNA", 289, 293], ["The analysis", "TEST", 0, 12], ["SQSTM1 expression", "PROBLEM", 16, 33], ["constitutive autophagy", "PROBLEM", 53, 75], ["HCT", "TEST", 79, 82], ["cells", "TEST", 87, 92], ["transcriptome analysis", "TEST", 159, 181], ["the autophagy", "PROBLEM", 223, 236], ["SQSTM1", "TEST", 260, 266], ["MAP1LC3B", "TEST", 268, 276], ["BECN1", "TEST", 278, 283], ["ULK1", "TEST", 289, 293], ["SQSTM1 expression", "OBSERVATION", 16, 33], ["consistent with", "UNCERTAINTY", 37, 52], ["constitutive autophagy", "OBSERVATION", 53, 75], ["increase", "OBSERVATION_MODIFIER", 197, 205]]], ["Their expression was enhanced when applying the combination of 5-FU + CQ.", [["5-FU", "CHEMICAL", 63, 67], ["CQ", "CHEMICAL", 70, 72], ["5-FU", "CHEMICAL", 63, 67], ["CQ", "CHEMICAL", 70, 72], ["5-FU", "SIMPLE_CHEMICAL", 63, 67], ["CQ", "SIMPLE_CHEMICAL", 70, 72]]], ["The increased expression of LC3B and BECN1 under stress conditions is consistent with previous reports [35, 36] .DiscussionUltrastructural analysis revealed that the untreated control cells had negligible expression of autophagosomes and autophagolysosomes, while those treated with CQ showed increased numbers of Fig. 4 .", [["cells", "ANATOMY", 184, 189], ["autophagosomes", "ANATOMY", 219, 233], ["autophagolysosomes", "ANATOMY", 238, 256], ["CQ", "CHEMICAL", 283, 285], ["LC3B", "GENE_OR_GENE_PRODUCT", 28, 32], ["BECN1", "GENE_OR_GENE_PRODUCT", 37, 42], ["cells", "CELL", 184, 189], ["autophagosomes", "CELLULAR_COMPONENT", 219, 233], ["CQ", "SIMPLE_CHEMICAL", 283, 285], ["LC3B", "PROTEIN", 28, 32], ["BECN1", "PROTEIN", 37, 42], ["autophagosomes", "CELL_TYPE", 219, 233], ["BECN1 under stress conditions", "PROBLEM", 37, 66], ["Ultrastructural analysis", "TEST", 123, 147], ["the untreated control cells", "PROBLEM", 162, 189], ["autophagosomes", "PROBLEM", 219, 233], ["autophagolysosomes", "PROBLEM", 238, 256], ["CQ", "PROBLEM", 283, 285], ["increased numbers of Fig", "PROBLEM", 293, 317], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["increased", "OBSERVATION_MODIFIER", 293, 302], ["numbers", "OBSERVATION_MODIFIER", 303, 310]]], ["Improved DC antigen-presenting function induced by lysates of HCT-116 treated with 5-FU + CQ.", [["DC", "ANATOMY", 9, 11], ["lysates", "ANATOMY", 51, 58], ["HCT-116", "ANATOMY", 62, 69], ["HCT-116", "CHEMICAL", 62, 69], ["5-FU", "CHEMICAL", 83, 87], ["CQ", "CHEMICAL", 90, 92], ["5-FU", "CHEMICAL", 83, 87], ["CQ", "CHEMICAL", 90, 92], ["lysates", "ORGANISM_SUBSTANCE", 51, 58], ["HCT-116", "CELL", 62, 69], ["5-FU", "SIMPLE_CHEMICAL", 83, 87], ["CQ", "SIMPLE_CHEMICAL", 90, 92], ["HCT-116", "CELL_LINE", 62, 69], ["HCT", "TEST", 62, 65]]], ["DCs were exposed to HCT-116 lysates and cocultured with allogeneic lymphocytes for 5 days.", [["DCs", "ANATOMY", 0, 3], ["HCT-116 lysates", "ANATOMY", 20, 35], ["lymphocytes", "ANATOMY", 67, 78], ["HCT-116", "CHEMICAL", 20, 27], ["DCs", "CELL", 0, 3], ["HCT-116 lysates", "CELL", 20, 35], ["lymphocytes", "CELL", 67, 78], ["DCs", "CELL_TYPE", 0, 3], ["allogeneic lymphocytes", "CELL_TYPE", 56, 78], ["HCT", "TEST", 20, 23], ["lysates", "TEST", 28, 35], ["allogeneic lymphocytes", "TREATMENT", 56, 78]]], ["Growing total lymphocytes (CD3+ cells) were quantified by flow cytometry (A), as were CD4+ and CD8+ cells (B; C) (N = 9; * p \u2264 0.05; ** p \u2264 0.01).", [["lymphocytes", "ANATOMY", 14, 25], ["CD3+ cells", "ANATOMY", 27, 37], ["CD4+ and CD8+ cells", "ANATOMY", 86, 105], ["lymphocytes", "CELL", 14, 25], ["CD3", "GENE_OR_GENE_PRODUCT", 27, 30], ["CD4", "GENE_OR_GENE_PRODUCT", 86, 89], ["CD8", "GENE_OR_GENE_PRODUCT", 95, 98], ["total lymphocytes", "CELL_TYPE", 8, 25], ["CD3+ cells", "CELL_TYPE", 27, 37], ["CD4", "PROTEIN", 86, 89], ["CD8", "PROTEIN", 95, 98], ["Growing total lymphocytes", "TEST", 0, 25], ["CD3+ cells", "TEST", 27, 37], ["flow cytometry", "TEST", 58, 72], ["CD4", "TEST", 86, 89], ["CD8", "TEST", 95, 98], ["B", "TEST", 107, 108], ["C", "TEST", 110, 111], ["N", "TEST", 114, 115], ["p", "TEST", 123, 124], ["total lymphocytes", "OBSERVATION", 8, 25]]], ["The CD4+ and CD8+ T lymphocytes were further analyzed separately for the expression of CD69 (activation marker) and PD-1 (regulatory molecule) (D-G; * p \u2264 0.05; ** p \u2264 0.02).", [["CD4+ and CD8+ T lymphocytes", "ANATOMY", 4, 31], ["CD4", "GENE_OR_GENE_PRODUCT", 4, 7], ["CD8", "GENE_OR_GENE_PRODUCT", 13, 16], ["CD69", "GENE_OR_GENE_PRODUCT", 87, 91], ["PD-1", "GENE_OR_GENE_PRODUCT", 116, 120], ["D-G", "GENE_OR_GENE_PRODUCT", 144, 147], ["CD4", "PROTEIN", 4, 7], ["CD8", "PROTEIN", 13, 16], ["T lymphocytes", "CELL_TYPE", 18, 31], ["CD69", "PROTEIN", 87, 91], ["activation marker", "PROTEIN", 93, 110], ["PD-1", "PROTEIN", 116, 120], ["regulatory molecule", "PROTEIN", 122, 141], ["The CD4", "TEST", 0, 7], ["CD8", "TEST", 13, 16], ["T lymphocytes", "PROBLEM", 18, 31], ["CD69", "TEST", 87, 91], ["activation marker", "TEST", 93, 110], ["PD", "TEST", 116, 118], ["p", "TEST", 151, 152], ["\u2264", "TEST", 153, 154]]], ["MLR supernatants were collected and analyzed for the secretion of IFN-\u03b3 (H) and IL-10 (I) by ELISA (*** p \u2264 0.01).Discussionautophagosomes in the cytoplasm.", [["supernatants", "ANATOMY", 4, 16], ["cytoplasm", "ANATOMY", 146, 155], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 66, 71], ["H", "GENE_OR_GENE_PRODUCT", 73, 74], ["IL-10", "GENE_OR_GENE_PRODUCT", 80, 85], ["cytoplasm", "ORGANISM_SUBSTANCE", 146, 155], ["IFN", "PROTEIN", 66, 69], ["IL", "PROTEIN", 80, 82], ["MLR supernatants", "TEST", 0, 16], ["the secretion", "TEST", 49, 62], ["IFN", "TEST", 66, 69], ["IL", "TEST", 80, 82], ["ELISA", "TEST", 93, 98], ["cytoplasm", "ANATOMY_MODIFIER", 146, 155]]], ["Cells treated with 5-FU showed an evident increase in the number of autophagolysosomes containing degraded material, indicating the induction of autophagy and the completion of the process, consistent with prior reports [28] [29] [30] 37, 38] .", [["Cells", "ANATOMY", 0, 5], ["5-FU", "CHEMICAL", 19, 23], ["5-FU", "CHEMICAL", 19, 23], ["Cells", "CELL", 0, 5], ["5-FU", "SIMPLE_CHEMICAL", 19, 23], ["autophagolysosomes", "SIMPLE_CHEMICAL", 68, 86], ["autophagolysosomes", "PROTEIN", 68, 86], ["autophagolysosomes containing degraded material", "PROBLEM", 68, 115], ["autophagy", "PROBLEM", 145, 154], ["increase", "OBSERVATION_MODIFIER", 42, 50], ["consistent with", "UNCERTAINTY", 190, 205]]], ["The combined treatment of CQ and 20 \u00b5M 5-FU induced intense accumulation of cytoplasmic vesicles in several stages, especially autophagosomes containing undigested material.", [["cytoplasmic vesicles", "ANATOMY", 76, 96], ["autophagosomes", "ANATOMY", 127, 141], ["CQ", "CHEMICAL", 26, 28], ["5-FU", "CHEMICAL", 39, 43], ["CQ", "CHEMICAL", 26, 28], ["5-FU", "CHEMICAL", 39, 43], ["CQ", "SIMPLE_CHEMICAL", 26, 28], ["5-FU", "SIMPLE_CHEMICAL", 39, 43], ["cytoplasmic", "ORGANISM_SUBSTANCE", 76, 87], ["vesicles", "CELLULAR_COMPONENT", 88, 96], ["autophagosomes", "CELLULAR_COMPONENT", 127, 141], ["The combined treatment of CQ", "TREATMENT", 0, 28], ["20 \u00b5M", "TREATMENT", 33, 38], ["cytoplasmic vesicles", "PROBLEM", 76, 96], ["undigested material", "PROBLEM", 153, 172], ["intense", "OBSERVATION_MODIFIER", 52, 59], ["accumulation of", "OBSERVATION", 60, 75], ["cytoplasmic vesicles", "OBSERVATION", 76, 96], ["several stages", "OBSERVATION_MODIFIER", 100, 114], ["undigested material", "OBSERVATION", 153, 172]]], ["We also found cells with signs of autophagic and apoptotic death, such as cytoplasmic vacuolization, chromatin rarefaction (reduction of heterochromatic groups associated with the nuclear envelope), altered mitochondrial morphology (dilation of the cristae), and dilation of the nuclear envelope, which also agrees with previous reports [39, 40] .", [["cells", "ANATOMY", 14, 19], ["cytoplasmic", "ANATOMY", 74, 85], ["chromatin", "ANATOMY", 101, 110], ["nuclear", "ANATOMY", 180, 187], ["mitochondrial", "ANATOMY", 207, 220], ["cristae", "ANATOMY", 249, 256], ["nuclear envelope", "ANATOMY", 279, 295], ["death", "DISEASE", 59, 64], ["cells", "CELL", 14, 19], ["cytoplasmic", "ORGANISM_SUBSTANCE", 74, 85], ["chromatin", "CELLULAR_COMPONENT", 101, 110], ["nuclear", "CELLULAR_COMPONENT", 180, 187], ["mitochondrial", "CELLULAR_COMPONENT", 207, 220], ["cristae", "CELLULAR_COMPONENT", 249, 256], ["nuclear", "CELLULAR_COMPONENT", 279, 286], ["chromatin", "DNA", 101, 110], ["autophagic and apoptotic death", "PROBLEM", 34, 64], ["cytoplasmic vacuolization", "PROBLEM", 74, 99], ["chromatin rarefaction", "PROBLEM", 101, 122], ["heterochromatic groups", "PROBLEM", 137, 159], ["altered mitochondrial morphology", "PROBLEM", 199, 231], ["dilation of the nuclear envelope", "PROBLEM", 263, 295], ["autophagic", "OBSERVATION_MODIFIER", 34, 44], ["apoptotic death", "OBSERVATION", 49, 64], ["cytoplasmic vacuolization", "OBSERVATION", 74, 99], ["chromatin rarefaction", "OBSERVATION", 101, 122], ["reduction", "OBSERVATION_MODIFIER", 124, 133], ["heterochromatic groups", "OBSERVATION", 137, 159], ["mitochondrial morphology", "OBSERVATION", 207, 231], ["dilation", "OBSERVATION", 263, 271], ["nuclear envelope", "ANATOMY", 279, 295]]], ["This phenomenon was confirmed by the observation that CQ + 5-FU treatment strongly reduced cell proliferation and induced early apoptosis in tumor cells, although CQ or 5-FU alone had no apparent effect on cell viability.", [["cell", "ANATOMY", 91, 95], ["tumor cells", "ANATOMY", 141, 152], ["cell", "ANATOMY", 206, 210], ["CQ", "CHEMICAL", 54, 56], ["5-FU", "CHEMICAL", 59, 63], ["tumor", "DISEASE", 141, 146], ["CQ", "CHEMICAL", 163, 165], ["5-FU", "CHEMICAL", 169, 173], ["CQ", "CHEMICAL", 54, 56], ["5-FU", "CHEMICAL", 59, 63], ["CQ", "CHEMICAL", 163, 165], ["5-FU", "CHEMICAL", 169, 173], ["CQ", "SIMPLE_CHEMICAL", 54, 56], ["5-FU", "SIMPLE_CHEMICAL", 59, 63], ["cell", "CELL", 91, 95], ["tumor cells", "CELL", 141, 152], ["CQ", "SIMPLE_CHEMICAL", 163, 165], ["5-FU", "SIMPLE_CHEMICAL", 169, 173], ["cell", "CELL", 206, 210], ["tumor cells", "CELL_TYPE", 141, 152], ["the observation", "TEST", 33, 48], ["CQ", "TEST", 54, 56], ["FU treatment", "TREATMENT", 61, 73], ["reduced cell proliferation", "PROBLEM", 83, 109], ["early apoptosis in tumor cells", "PROBLEM", 122, 152], ["CQ", "TEST", 163, 165], ["cell viability", "PROBLEM", 206, 220], ["reduced cell proliferation", "OBSERVATION", 83, 109], ["early", "OBSERVATION_MODIFIER", 122, 127], ["apoptosis", "OBSERVATION_MODIFIER", 128, 137], ["tumor cells", "OBSERVATION", 141, 152], ["no apparent", "UNCERTAINTY", 184, 195], ["cell viability", "OBSERVATION", 206, 220]]], ["5-Fluorouracil induces apoptosis in cancer cells [41] , and the inhibition of autophagy by CQ can potentiate the cytotoxicity of 5-FU.", [["cancer cells", "ANATOMY", 36, 48], ["5-Fluorouracil", "CHEMICAL", 0, 14], ["cancer", "DISEASE", 36, 42], ["CQ", "CHEMICAL", 91, 93], ["5-FU.", "CHEMICAL", 129, 134], ["5-Fluorouracil", "CHEMICAL", 0, 14], ["CQ", "CHEMICAL", 91, 93], ["5-Fluorouracil", "SIMPLE_CHEMICAL", 0, 14], ["cancer cells", "CELL", 36, 48], ["CQ", "SIMPLE_CHEMICAL", 91, 93], ["5-FU.", "SIMPLE_CHEMICAL", 129, 134], ["cancer cells", "CELL_TYPE", 36, 48], ["Fluorouracil induces apoptosis in cancer cells", "PROBLEM", 2, 48], ["the cytotoxicity", "TEST", 109, 125], ["apoptosis", "OBSERVATION_MODIFIER", 23, 32], ["cancer cells", "OBSERVATION", 36, 48]]], ["This occurs because the accumulation of vesicles in the cytoplasm due to incomplete autophagy can cause oxidative stress and lead to cell death.", [["vesicles", "ANATOMY", 40, 48], ["cytoplasm", "ANATOMY", 56, 65], ["cell", "ANATOMY", 133, 137], ["death", "DISEASE", 138, 143], ["vesicles", "CELLULAR_COMPONENT", 40, 48], ["cytoplasm", "ORGANISM_SUBSTANCE", 56, 65], ["cell", "CELL", 133, 137], ["the accumulation of vesicles", "PROBLEM", 20, 48], ["the cytoplasm", "PROBLEM", 52, 65], ["incomplete autophagy", "PROBLEM", 73, 93], ["oxidative stress", "PROBLEM", 104, 120], ["cell death", "PROBLEM", 133, 143], ["vesicles", "OBSERVATION", 40, 48]]], ["Based on this information, we aimed to confirm whether the toxicity of low 5-FU concentrations would be enhanced by CQ.", [["toxicity", "DISEASE", 59, 67], ["5-FU", "CHEMICAL", 75, 79], ["CQ", "CHEMICAL", 116, 118], ["5-FU", "CHEMICAL", 75, 79], ["5-FU", "SIMPLE_CHEMICAL", 75, 79], ["CQ", "SIMPLE_CHEMICAL", 116, 118], ["the toxicity of low 5-FU concentrations", "PROBLEM", 55, 94]]], ["In this study, the apoptosis and cell death results showed that 5-FU + CQ increased the levels of early apoptosis even though the drug concentrations had only a negligible effect if applied alone.DiscussionAnalyzing the effects of CQ + 5-FU treatment on the immunogenicity of tumor cells revealed that DC exposure to the lysate of HCT-116 cells treated with drug enhanced the maturation of antigenpresenting cells.", [["cell", "ANATOMY", 33, 37], ["tumor cells", "ANATOMY", 276, 287], ["DC", "ANATOMY", 302, 304], ["lysate", "ANATOMY", 321, 327], ["HCT-116 cells", "ANATOMY", 331, 344], ["cells", "ANATOMY", 408, 413], ["5-FU", "CHEMICAL", 64, 68], ["CQ", "CHEMICAL", 71, 73], ["CQ", "CHEMICAL", 231, 233], ["5-FU", "CHEMICAL", 236, 240], ["tumor", "DISEASE", 276, 281], ["HCT-116", "CHEMICAL", 331, 338], ["5-FU", "CHEMICAL", 64, 68], ["CQ", "CHEMICAL", 71, 73], ["CQ", "CHEMICAL", 231, 233], ["5-FU", "CHEMICAL", 236, 240], ["cell", "CELL", 33, 37], ["5-FU", "SIMPLE_CHEMICAL", 64, 68], ["CQ", "SIMPLE_CHEMICAL", 71, 73], ["CQ", "SIMPLE_CHEMICAL", 231, 233], ["5-FU", "SIMPLE_CHEMICAL", 236, 240], ["tumor cells", "CELL", 276, 287], ["DC", "CELL", 302, 304], ["HCT-116 cells", "CELL", 331, 344], ["cells", "CELL", 408, 413], ["tumor cells", "CELL_TYPE", 276, 287], ["DC", "CELL_TYPE", 302, 304], ["HCT-116 cells", "CELL_LINE", 331, 344], ["antigenpresenting cells", "CELL_TYPE", 390, 413], ["this study", "TEST", 3, 13], ["the apoptosis", "TEST", 15, 28], ["cell death", "TEST", 33, 43], ["CQ", "PROBLEM", 71, 73], ["early apoptosis", "PROBLEM", 98, 113], ["the drug concentrations", "PROBLEM", 126, 149], ["CQ", "TEST", 231, 233], ["5-FU treatment", "TREATMENT", 236, 250], ["tumor cells", "PROBLEM", 276, 287], ["DC exposure", "PROBLEM", 302, 313], ["HCT", "TEST", 331, 334], ["drug enhanced the maturation of antigenpresenting cells", "TREATMENT", 358, 413], ["early", "OBSERVATION_MODIFIER", 98, 103], ["apoptosis", "OBSERVATION", 104, 113], ["tumor", "OBSERVATION", 276, 281]]], ["DC maturation is required for increased antigen-presenting ability and is accompanied by phenotypic changes, such as increased expression of MHC class II and co-stimulatory molecule expression.", [["DC", "ANATOMY", 0, 2], ["MHC class II", "GENE_OR_GENE_PRODUCT", 141, 153], ["DC", "CELL_TYPE", 0, 2], ["MHC class II", "PROTEIN", 141, 153], ["co-stimulatory molecule", "PROTEIN", 158, 181], ["increased antigen", "PROBLEM", 30, 47], ["phenotypic changes", "PROBLEM", 89, 107]]], ["CD40, CD80, and CD86 expression are essential for T lymphocyte stimulation [42] .", [["T lymphocyte", "ANATOMY", 50, 62], ["CD40", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD80", "GENE_OR_GENE_PRODUCT", 6, 10], ["CD86", "GENE_OR_GENE_PRODUCT", 16, 20], ["T lymphocyte", "CELL", 50, 62], ["CD40", "PROTEIN", 0, 4], ["CD80", "PROTEIN", 6, 10], ["CD86", "PROTEIN", 16, 20], ["CD40", "TEST", 0, 4], ["CD80", "TEST", 6, 10], ["CD86 expression", "TEST", 16, 31], ["T lymphocyte stimulation", "TEST", 50, 74], ["CD80", "ANATOMY", 6, 10]]], ["In addition to being a maturation marker, CD83 modulates the immune response by stimulating both naive and memory T cells [43] .", [["memory T cells", "ANATOMY", 107, 121], ["CD83", "GENE_OR_GENE_PRODUCT", 42, 46], ["memory T cells", "CELL", 107, 121], ["CD83", "PROTEIN", 42, 46], ["naive and memory T cells", "CELL_TYPE", 97, 121], ["a maturation marker", "TEST", 21, 40]]], ["CD83 expression was also enhanced by the drug combination.", [["CD83", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD83", "PROTEIN", 0, 4]]], ["Although apoptotic cell death is considered non-immunogenic or weakly immunogenic, it is possible that apoptosis induced by the blockage of autophagy results in the expression of danger signals (e.g., DAMPs) that are usually not expressed during physiological apoptosis.", [["cell", "ANATOMY", 19, 23], ["cell", "CELL", 19, 23], ["DAMPs", "GENE_OR_GENE_PRODUCT", 201, 206], ["DAMPs", "PROTEIN", 201, 206], ["apoptotic cell death", "PROBLEM", 9, 29], ["non-immunogenic", "PROBLEM", 44, 59], ["weakly immunogenic", "PROBLEM", 63, 81], ["apoptosis", "PROBLEM", 103, 112], ["the blockage of autophagy", "PROBLEM", 124, 149], ["apoptotic cell death", "OBSERVATION", 9, 29], ["apoptosis", "OBSERVATION", 260, 269]]], ["In a parallel study, we observed that exposing HCT-116 cells to low concentrations of paclitaxel induces the expression of HSP-70 and 90 (unpublished data).", [["HCT-116 cells", "ANATOMY", 47, 60], ["paclitaxel", "CHEMICAL", 86, 96], ["paclitaxel", "CHEMICAL", 86, 96], ["HCT-116 cells", "CELL", 47, 60], ["paclitaxel", "SIMPLE_CHEMICAL", 86, 96], ["HSP-70", "GENE_OR_GENE_PRODUCT", 123, 129], ["HCT-116 cells", "CELL_LINE", 47, 60], ["HSP", "PROTEIN", 123, 126], ["a parallel study", "TEST", 3, 19], ["HCT", "TEST", 47, 50], ["paclitaxel", "TREATMENT", 86, 96], ["HSP", "TEST", 123, 126]]], ["In the present study, we observed a small increase in the expression of HSP-70 but irrelevant changes in the HSP-90 and HMGB genes.", [["HSP-70", "GENE_OR_GENE_PRODUCT", 72, 78], ["HSP-90", "GENE_OR_GENE_PRODUCT", 109, 115], ["HMGB", "GENE_OR_GENE_PRODUCT", 120, 124], ["HSP", "PROTEIN", 72, 75], ["HSP-90 and HMGB genes", "DNA", 109, 130], ["a small increase", "PROBLEM", 34, 50], ["HSP", "TEST", 72, 75], ["irrelevant changes", "PROBLEM", 83, 101], ["the HSP", "TEST", 105, 112], ["HMGB genes", "PROBLEM", 120, 130], ["small", "OBSERVATION_MODIFIER", 36, 41], ["increase", "OBSERVATION_MODIFIER", 42, 50]]], ["These findings indicated that the enhanced ability to sensitize DCs is mainly due to the increased expression of the tumorassociated genes of the CEA family (CEACAM 1, 5, 6, and 7).DiscussionIn another study, we found that exposing HCT-116 cells to low doses of paclitaxel or doxorubicin increased the expression of several genes associated with enhanced tumor immunogenicity [11] .", [["DCs", "ANATOMY", 64, 67], ["HCT-116 cells", "ANATOMY", 232, 245], ["tumor", "ANATOMY", 355, 360], ["paclitaxel", "CHEMICAL", 262, 272], ["doxorubicin", "CHEMICAL", 276, 287], ["tumor", "DISEASE", 355, 360], ["paclitaxel", "CHEMICAL", 262, 272], ["doxorubicin", "CHEMICAL", 276, 287], ["DCs", "CELL", 64, 67], ["CEA", "GENE_OR_GENE_PRODUCT", 146, 149], ["CEACAM 1", "GENE_OR_GENE_PRODUCT", 158, 166], ["HCT-116 cells", "CELL", 232, 245], ["paclitaxel", "SIMPLE_CHEMICAL", 262, 272], ["doxorubicin", "SIMPLE_CHEMICAL", 276, 287], ["tumor", "CANCER", 355, 360], ["DCs", "CELL_TYPE", 64, 67], ["tumorassociated genes", "DNA", 117, 138], ["CEA family", "PROTEIN", 146, 156], ["CEACAM 1, 5, 6, and 7", "PROTEIN", 158, 179], ["HCT-116 cells", "CELL_LINE", 232, 245], ["another study", "TEST", 194, 207], ["HCT", "TEST", 232, 235], ["paclitaxel", "TREATMENT", 262, 272], ["doxorubicin", "TREATMENT", 276, 287], ["enhanced tumor immunogenicity", "PROBLEM", 346, 375], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["expression", "OBSERVATION", 99, 109], ["CEA", "ANATOMY", 146, 149], ["several genes", "OBSERVATION_MODIFIER", 316, 329], ["tumor", "OBSERVATION", 355, 360]]], ["Total RNA extracted from HCT-116 colorectal cancer cells treated with 5-FU was more immunogenic when transfected into DCs [44] .", [["HCT-116 colorectal cancer cells", "ANATOMY", 25, 56], ["DCs", "ANATOMY", 118, 121], ["HCT-116", "CHEMICAL", 25, 32], ["colorectal cancer", "DISEASE", 33, 50], ["5-FU", "CHEMICAL", 70, 74], ["5-FU", "CHEMICAL", 70, 74], ["HCT-116 colorectal cancer cells", "CELL", 25, 56], ["5-FU", "SIMPLE_CHEMICAL", 70, 74], ["DCs", "CELL", 118, 121], ["HCT-116 colorectal cancer cells", "CELL_LINE", 25, 56], ["DCs", "CELL_TYPE", 118, 121], ["HCT-116", "SPECIES", 25, 32], ["Total RNA", "TEST", 0, 9], ["HCT", "TEST", 25, 28], ["colorectal cancer cells", "PROBLEM", 33, 56], ["FU", "TREATMENT", 72, 74], ["colorectal", "ANATOMY", 33, 43], ["cancer cells", "OBSERVATION", 44, 56]]], ["Exposing tumor cells to other drugs such as paclitaxel and doxorubicin increases the expression of the antigen processing machinery via the cytosolic route, such as TAP1, tapasin, and calnexin [11] .", [["tumor cells", "ANATOMY", 9, 20], ["cytosolic", "ANATOMY", 140, 149], ["tumor", "DISEASE", 9, 14], ["paclitaxel", "CHEMICAL", 44, 54], ["doxorubicin", "CHEMICAL", 59, 70], ["paclitaxel", "CHEMICAL", 44, 54], ["doxorubicin", "CHEMICAL", 59, 70], ["tumor cells", "CELL", 9, 20], ["paclitaxel", "SIMPLE_CHEMICAL", 44, 54], ["doxorubicin", "SIMPLE_CHEMICAL", 59, 70], ["TAP1", "GENE_OR_GENE_PRODUCT", 165, 169], ["tapasin", "GENE_OR_GENE_PRODUCT", 171, 178], ["calnexin", "GENE_OR_GENE_PRODUCT", 184, 192], ["tumor cells", "CELL_TYPE", 9, 20], ["TAP1", "PROTEIN", 165, 169], ["tapasin", "PROTEIN", 171, 178], ["calnexin", "PROTEIN", 184, 192], ["Exposing tumor cells", "PROBLEM", 0, 20], ["other drugs", "TREATMENT", 24, 35], ["paclitaxel", "TREATMENT", 44, 54], ["doxorubicin", "TREATMENT", 59, 70], ["the antigen processing machinery", "TREATMENT", 99, 131], ["the cytosolic route", "TREATMENT", 136, 155], ["TAP1", "TREATMENT", 165, 169], ["tapasin", "TREATMENT", 171, 178], ["calnexin", "TREATMENT", 184, 192], ["tumor cells", "OBSERVATION", 9, 20]]], ["This view is reinforced by the observation that chemical stress triggers the cell surface expression of calreticulin (CALR) [12] , another molecule promoting the antigenic processing of tumor cells.", [["cell surface", "ANATOMY", 77, 89], ["tumor cells", "ANATOMY", 186, 197], ["tumor", "DISEASE", 186, 191], ["cell surface", "CELLULAR_COMPONENT", 77, 89], ["calreticulin", "GENE_OR_GENE_PRODUCT", 104, 116], ["CALR) [12]", "GENE_OR_GENE_PRODUCT", 118, 128], ["tumor cells", "CELL", 186, 197], ["calreticulin", "PROTEIN", 104, 116], ["CALR", "PROTEIN", 118, 122], ["tumor cells", "CELL_TYPE", 186, 197], ["chemical stress", "PROBLEM", 48, 63], ["calreticulin (CALR)", "TREATMENT", 104, 123], ["tumor cells", "PROBLEM", 186, 197], ["tumor cells", "OBSERVATION", 186, 197]]], ["Interestingly, CALR moves from the endoplasmic reticulum (where it functions as an APM component) to the cytoplasmic membrane, where it serves as a potent activating signal.", [["endoplasmic reticulum", "ANATOMY", 35, 56], ["cytoplasmic membrane", "ANATOMY", 105, 125], ["CALR", "GENE_OR_GENE_PRODUCT", 15, 19], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 35, 56], ["APM", "GENE_OR_GENE_PRODUCT", 83, 86], ["cytoplasmic membrane", "CELLULAR_COMPONENT", 105, 125], ["CALR", "PROTEIN", 15, 19], ["APM component", "PROTEIN", 83, 96], ["CALR", "OBSERVATION", 15, 19], ["endoplasmic reticulum", "ANATOMY", 35, 56], ["cytoplasmic membrane", "OBSERVATION", 105, 125]]], ["CALR, together with HMGB1, plays an important role in the phenotypic maturation of DCs, increasing HLA-DR, CD80, and CD86 expression and functional maturation, as well as enhancing the secretion of IL-12 and INF-\u03b3 [45] .DiscussionThis enhancing effect on tumor cell immunogenicity was reinforced by our demonstration that the cell lysates had a functional effect on DCs.", [["DCs", "ANATOMY", 83, 86], ["tumor cell", "ANATOMY", 255, 265], ["cell lysates", "ANATOMY", 326, 338], ["DCs", "ANATOMY", 366, 369], ["tumor", "DISEASE", 255, 260], ["CALR", "GENE_OR_GENE_PRODUCT", 0, 4], ["HMGB1", "GENE_OR_GENE_PRODUCT", 20, 25], ["DCs", "CELL", 83, 86], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 99, 105], ["CD80", "GENE_OR_GENE_PRODUCT", 107, 111], ["CD86", "GENE_OR_GENE_PRODUCT", 117, 121], ["IL-12", "GENE_OR_GENE_PRODUCT", 198, 203], ["INF-\u03b3", "GENE_OR_GENE_PRODUCT", 208, 213], ["tumor cell", "CELL", 255, 265], ["cell lysates", "CELL", 326, 338], ["DCs", "CELL", 366, 369], ["CALR", "PROTEIN", 0, 4], ["HMGB1", "PROTEIN", 20, 25], ["DCs", "CELL_TYPE", 83, 86], ["CD80", "PROTEIN", 107, 111], ["CD86", "PROTEIN", 117, 121], ["IL-12", "PROTEIN", 198, 203], ["INF", "PROTEIN", 208, 211], ["DCs", "CELL_TYPE", 366, 369], ["HMGB1", "TREATMENT", 20, 25], ["enhancing the secretion of IL", "TEST", 171, 200], ["tumor cell immunogenicity", "PROBLEM", 255, 280], ["the cell lysates", "TEST", 322, 338], ["tumor cell", "OBSERVATION", 255, 265], ["functional effect", "OBSERVATION", 345, 362]]], ["Indeed, the mixed lymphocyte reaction (MLR) allowed us to demonstrate that the phenotypic changes observed in DCs are accompanied by an improvement in their ability to stimulate allogeneic lymphocytes.", [["lymphocyte", "ANATOMY", 18, 28], ["DCs", "ANATOMY", 110, 113], ["lymphocytes", "ANATOMY", 189, 200], ["lymphocyte", "CELL", 18, 28], ["DCs", "CELL", 110, 113], ["lymphocytes", "CELL", 189, 200], ["DCs", "CELL_TYPE", 110, 113], ["allogeneic lymphocytes", "CELL_TYPE", 178, 200], ["the mixed lymphocyte reaction", "PROBLEM", 8, 37], ["the phenotypic changes", "PROBLEM", 75, 97], ["mixed", "OBSERVATION_MODIFIER", 12, 17], ["lymphocyte reaction", "OBSERVATION", 18, 37], ["phenotypic", "OBSERVATION", 79, 89], ["improvement", "OBSERVATION_MODIFIER", 136, 147], ["allogeneic lymphocytes", "OBSERVATION", 178, 200]]], ["Specifically, DCs sensitized with the lysates of HCT-116 Fig. 5 .", [["DCs", "ANATOMY", 14, 17], ["lysates", "ANATOMY", 38, 45], ["DCs", "CELL", 14, 17], ["HCT-116 Fig. 5", "CELL", 49, 63], ["DCs", "CELL_TYPE", 14, 17], ["the lysates", "TEST", 34, 45], ["HCT", "TEST", 49, 52]]], ["In vitro generation of cytotoxic T lymphocytes (CTLs) is improved by DCs exposed to lysates of HCT-116 previously treated with 5-FU + CQ.", [["cytotoxic T lymphocytes", "ANATOMY", 23, 46], ["CTLs", "ANATOMY", 48, 52], ["DCs", "ANATOMY", 69, 72], ["lysates", "ANATOMY", 84, 91], ["HCT-116", "ANATOMY", 95, 102], ["HCT-116", "CHEMICAL", 95, 102], ["5-FU", "CHEMICAL", 127, 131], ["CQ", "CHEMICAL", 134, 136], ["5-FU", "CHEMICAL", 127, 131], ["CQ", "CHEMICAL", 134, 136], ["cytotoxic T lymphocytes", "CELL", 23, 46], ["CTLs", "CELL", 48, 52], ["DCs", "CELL", 69, 72], ["lysates", "ORGANISM_SUBSTANCE", 84, 91], ["HCT-116", "CELL", 95, 102], ["5-FU", "SIMPLE_CHEMICAL", 127, 131], ["CQ", "SIMPLE_CHEMICAL", 134, 136], ["cytotoxic T lymphocytes", "CELL_TYPE", 23, 46], ["CTLs", "CELL_TYPE", 48, 52], ["DCs", "CELL_TYPE", 69, 72], ["HCT-116", "CELL_LINE", 95, 102], ["cytotoxic T lymphocytes", "PROBLEM", 23, 46], ["lysates", "TEST", 84, 91], ["HCT", "TEST", 95, 98], ["cytotoxic T lymphocytes", "OBSERVATION", 23, 46]]], ["Mean fluorescence intensity (MFI) of proliferating CD8+ cells (A) of four healthy donors at individual effector:target ratios (3.25:1, 7.5:1, and 15:1).", [["CD8+ cells", "ANATOMY", 51, 61], ["CD8", "GENE_OR_GENE_PRODUCT", 51, 54], ["donors", "ORGANISM", 82, 88], ["proliferating CD8+ cells", "CELL_TYPE", 37, 61], ["Mean fluorescence intensity", "TEST", 0, 27], ["MFI", "TEST", 29, 32], ["proliferating CD8+ cells", "PROBLEM", 37, 61], ["target ratios", "TEST", 112, 125], ["proliferating", "OBSERVATION_MODIFIER", 37, 50], ["CD8+ cells", "OBSERVATION", 51, 61]]], ["These lymphocytes showed higher expression levels of the cytotoxicity markers perforin (MFI 15:1 ratio, 5-FU + CQ > WT (p < 0.05)) and granzyme B (MFI 7.5:1 ratio, 5-FU + CQ > WT (p < 0.05); MFI 15:1 ratio, 5-FU + CQ > WT (p < 0.05)) compared to the WT control group. cells treated with 5-FU + CQ promoted the enhanced proliferation of lymphocytes in the MLR.", [["lymphocytes", "ANATOMY", 6, 17], ["cells", "ANATOMY", 268, 273], ["lymphocytes", "ANATOMY", 336, 347], ["5-FU", "CHEMICAL", 104, 108], ["5-FU", "CHEMICAL", 164, 168], ["5-FU", "CHEMICAL", 207, 211], ["5-FU", "CHEMICAL", 287, 291], ["CQ", "CHEMICAL", 294, 296], ["5-FU", "CHEMICAL", 104, 108], ["5-FU", "CHEMICAL", 164, 168], ["5-FU", "CHEMICAL", 207, 211], ["5-FU", "CHEMICAL", 287, 291], ["CQ", "CHEMICAL", 294, 296], ["lymphocytes", "CELL", 6, 17], ["perforin", "GENE_OR_GENE_PRODUCT", 78, 86], ["5-FU", "SIMPLE_CHEMICAL", 104, 108], ["CQ", "SIMPLE_CHEMICAL", 111, 113], ["granzyme B", "GENE_OR_GENE_PRODUCT", 135, 145], ["5-FU", "SIMPLE_CHEMICAL", 164, 168], ["CQ", "SIMPLE_CHEMICAL", 171, 173], ["cells", "CELL", 268, 273], ["5-FU", "SIMPLE_CHEMICAL", 287, 291], ["CQ", "SIMPLE_CHEMICAL", 294, 296], ["lymphocytes", "CELL", 336, 347], ["lymphocytes", "CELL_TYPE", 6, 17], ["cytotoxicity markers", "PROTEIN", 57, 77], ["perforin", "PROTEIN", 78, 86], ["granzyme B", "PROTEIN", 135, 145], ["lymphocytes", "CELL_TYPE", 336, 347], ["These lymphocytes", "TEST", 0, 17], ["higher expression levels", "PROBLEM", 25, 49], ["the cytotoxicity markers", "TEST", 53, 77], ["perforin", "TEST", 78, 86], ["MFI", "TEST", 88, 91], ["ratio", "TEST", 97, 102], ["FU", "TEST", 106, 108], ["CQ", "TEST", 111, 113], ["WT", "TEST", 116, 118], ["granzyme", "TEST", 135, 143], ["MFI", "TEST", 147, 150], ["ratio", "TEST", 157, 162], ["FU", "TEST", 166, 168], ["CQ", "TEST", 171, 173], ["WT", "TEST", 176, 178], ["MFI", "TEST", 191, 194], ["ratio", "TEST", 200, 205], ["FU", "TEST", 209, 211], ["CQ", "TEST", 214, 216], ["WT", "TEST", 219, 221], ["CQ", "TREATMENT", 294, 296], ["higher expression", "OBSERVATION_MODIFIER", 25, 42], ["proliferation", "OBSERVATION_MODIFIER", 319, 332], ["lymphocytes", "OBSERVATION", 336, 347]]], ["The more intense proliferative effect on CD4+ T lymphocytes is also in agreement with their ability to interact with the HLA-DR molecules expressed by DCs.", [["CD4+ T lymphocytes", "ANATOMY", 41, 59], ["DCs", "ANATOMY", 151, 154], ["CD4", "GENE_OR_GENE_PRODUCT", 41, 44], ["HLA-DR molecules", "GENE_OR_GENE_PRODUCT", 121, 137], ["DCs", "CELL", 151, 154], ["CD4", "PROTEIN", 41, 44], ["T lymphocytes", "CELL_TYPE", 46, 59], ["HLA-DR molecules", "PROTEIN", 121, 137], ["DCs", "CELL_TYPE", 151, 154], ["The more intense proliferative effect", "PROBLEM", 0, 37], ["T lymphocytes", "PROBLEM", 46, 59], ["more", "OBSERVATION_MODIFIER", 4, 8], ["intense", "OBSERVATION_MODIFIER", 9, 16], ["proliferative", "OBSERVATION_MODIFIER", 17, 30], ["effect", "OBSERVATION_MODIFIER", 31, 37]]], ["Furthermore, the increased proliferation of CD8+ T lymphocytes suggests the generation of cytotoxic T lymphocytes that are specific for tumor cells (since their proliferation was stimulated by DCs sensitized with HCT-116 lysates).", [["CD8+ T lymphocytes", "ANATOMY", 44, 62], ["T lymphocytes", "ANATOMY", 100, 113], ["tumor cells", "ANATOMY", 136, 147], ["DCs", "ANATOMY", 193, 196], ["HCT-116 lysates", "ANATOMY", 213, 228], ["tumor", "DISEASE", 136, 141], ["CD8", "GENE_OR_GENE_PRODUCT", 44, 47], ["cytotoxic T lymphocytes", "CELL", 90, 113], ["tumor cells", "CELL", 136, 147], ["DCs", "CELL", 193, 196], ["HCT-116 lysates", "CELL", 213, 228], ["CD8+ T lymphocytes", "CELL_TYPE", 44, 62], ["cytotoxic T lymphocytes", "CELL_TYPE", 90, 113], ["tumor cells", "CELL_TYPE", 136, 147], ["DCs", "CELL_TYPE", 193, 196], ["the increased proliferation of CD8+ T lymphocytes", "PROBLEM", 13, 62], ["cytotoxic T lymphocytes", "PROBLEM", 90, 113], ["tumor cells", "PROBLEM", 136, 147], ["HCT", "TEST", 213, 216], ["lysates", "TEST", 221, 228], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["proliferation", "OBSERVATION_MODIFIER", 27, 40], ["CD8+ T lymphocytes", "OBSERVATION", 44, 62], ["cytotoxic T lymphocytes", "OBSERVATION", 90, 113]]], ["Aiming to confirm that the combination of 5-FU and CQ can stimulate the proliferation of CD8+ lymphocytes, we performed a CTL assay, which, unlike the MLR, tests the ability of DCs to stimulate the proliferation of autologous CD8+ lymphocytes that target tumor cells [46] .", [["CD8+ lymphocytes", "ANATOMY", 89, 105], ["DCs", "ANATOMY", 177, 180], ["CD8+ lymphocytes", "ANATOMY", 226, 242], ["tumor cells", "ANATOMY", 255, 266], ["5-FU", "CHEMICAL", 42, 46], ["CQ", "CHEMICAL", 51, 53], ["tumor", "DISEASE", 255, 260], ["5-FU", "CHEMICAL", 42, 46], ["CQ", "CHEMICAL", 51, 53], ["5-FU", "SIMPLE_CHEMICAL", 42, 46], ["CQ", "SIMPLE_CHEMICAL", 51, 53], ["CD8", "GENE_OR_GENE_PRODUCT", 89, 92], ["DCs", "CELL", 177, 180], ["CD8", "GENE_OR_GENE_PRODUCT", 226, 229], ["tumor cells", "CELL", 255, 266], ["CD8+ lymphocytes", "CELL_TYPE", 89, 105], ["MLR", "PROTEIN", 151, 154], ["DCs", "CELL_TYPE", 177, 180], ["autologous CD8+ lymphocytes", "CELL_TYPE", 215, 242], ["tumor cells", "CELL_TYPE", 255, 266], ["5-FU and CQ", "TREATMENT", 42, 53], ["a CTL assay", "TEST", 120, 131], ["the MLR", "TEST", 147, 154], ["DCs", "TREATMENT", 177, 180], ["lymphocytes", "PROBLEM", 231, 242], ["target tumor cells", "PROBLEM", 248, 266]]], ["Our main difficulty when evaluating the direct cytotoxicity of CTLs against target cells is that HCT-116 cells are adherent, but most available assays for this purpose work well for cells in suspension and are not reliable for adherent cell types.", [["cells", "ANATOMY", 83, 88], ["HCT-116 cells", "ANATOMY", 97, 110], ["cells", "ANATOMY", 182, 187], ["cell", "ANATOMY", 236, 240], ["HCT-116", "CHEMICAL", 97, 104], ["CTLs", "CELL", 63, 67], ["cells", "CELL", 83, 88], ["HCT-116 cells", "CELL", 97, 110], ["cells", "CELL", 182, 187], ["cell", "CELL", 236, 240], ["CTLs", "CELL_TYPE", 63, 67], ["target cells", "CELL_TYPE", 76, 88], ["HCT-116 cells", "CELL_LINE", 97, 110], ["adherent cell types", "CELL_TYPE", 227, 246], ["the direct cytotoxicity of CTLs", "TEST", 36, 67], ["target cells", "PROBLEM", 76, 88], ["HCT", "TEST", 97, 100], ["cells in suspension", "TREATMENT", 182, 201], ["adherent cell types", "PROBLEM", 227, 246], ["not reliable for", "UNCERTAINTY", 210, 226], ["adherent cell types", "OBSERVATION", 227, 246]]], ["There are some chemiluminescence-based assays for this, but we were unable to acquire the appropriate kit.", [["some chemiluminescence", "TEST", 10, 32], ["some", "OBSERVATION_MODIFIER", 10, 14], ["chemiluminescence", "OBSERVATION", 15, 32]]], ["Therefore, we decided to evaluate the expression of perforin and granzyme B by CTLs challenged with tumor target cells, following the methodology proposed by Betts et al [47] .", [["CTLs", "ANATOMY", 79, 83], ["tumor target cells", "ANATOMY", 100, 118], ["tumor", "DISEASE", 100, 105], ["perforin", "GENE_OR_GENE_PRODUCT", 52, 60], ["granzyme B", "GENE_OR_GENE_PRODUCT", 65, 75], ["CTLs", "CELL", 79, 83], ["tumor target cells", "CELL", 100, 118], ["perforin", "PROTEIN", 52, 60], ["granzyme B", "PROTEIN", 65, 75], ["CTLs", "CELL_TYPE", 79, 83], ["tumor target cells", "CELL_TYPE", 100, 118], ["perforin and granzyme B", "TREATMENT", 52, 75], ["tumor target cells", "PROBLEM", 100, 118]]], ["These proteins are considered to be functional markers in cells with cytotoxic capacity [48] ; perforin polymerization perforates the target cell membrane, while granzyme B induces apoptosis [49] .", [["cells", "ANATOMY", 58, 63], ["cell membrane", "ANATOMY", 141, 154], ["granzyme B", "CHEMICAL", 162, 172], ["cells", "CELL", 58, 63], ["perforin", "GENE_OR_GENE_PRODUCT", 95, 103], ["cell membrane", "CELLULAR_COMPONENT", 141, 154], ["granzyme B", "GENE_OR_GENE_PRODUCT", 162, 172], ["perforin", "PROTEIN", 95, 103], ["granzyme B", "PROTEIN", 162, 172], ["functional markers in cells", "PROBLEM", 36, 63], ["cytotoxic capacity", "TEST", 69, 87], ["perforin polymerization", "TREATMENT", 95, 118], ["considered to be", "UNCERTAINTY", 19, 35], ["target cell membrane", "OBSERVATION", 134, 154]]], ["As expected, we found increased expression (i.e., increased mean fluorescence intensity; MFI) of both perforin and granzyme B in the CD8+ population induced by DCs sensitized with 5-FU + CQ lysate.DiscussionWe also observed that lymphocytes generated in response to sensitized DCs expressed higher levels of the 'very early antigen' CD69, which is associated with the effective stimulation of lymphocytes by antigen-presenting cells [50] .", [["CD8+ population", "ANATOMY", 133, 148], ["DCs", "ANATOMY", 160, 163], ["lysate", "ANATOMY", 190, 196], ["lymphocytes", "ANATOMY", 229, 240], ["DCs", "ANATOMY", 277, 280], ["lymphocytes", "ANATOMY", 393, 404], ["cells", "ANATOMY", 427, 432], ["5-FU", "CHEMICAL", 180, 184], ["CQ", "CHEMICAL", 187, 189], ["5-FU", "CHEMICAL", 180, 184], ["perforin", "GENE_OR_GENE_PRODUCT", 102, 110], ["granzyme B", "GENE_OR_GENE_PRODUCT", 115, 125], ["CD8", "GENE_OR_GENE_PRODUCT", 133, 136], ["DCs", "CELL", 160, 163], ["5-FU", "SIMPLE_CHEMICAL", 180, 184], ["CQ", "SIMPLE_CHEMICAL", 187, 189], ["lymphocytes", "CELL", 229, 240], ["DCs", "CELL", 277, 280], ["CD69", "GENE_OR_GENE_PRODUCT", 333, 337], ["lymphocytes", "CELL", 393, 404], ["antigen", "GENE_OR_GENE_PRODUCT", 408, 415], ["cells", "CELL", 427, 432], ["perforin", "PROTEIN", 102, 110], ["granzyme B", "PROTEIN", 115, 125], ["CD8", "PROTEIN", 133, 136], ["DCs", "CELL_TYPE", 160, 163], ["lymphocytes", "CELL_TYPE", 229, 240], ["sensitized DCs", "CELL_TYPE", 266, 280], ["CD69", "PROTEIN", 333, 337], ["lymphocytes", "CELL_TYPE", 393, 404], ["antigen-presenting cells", "CELL_TYPE", 408, 432], ["increased expression", "PROBLEM", 22, 42], ["increased mean fluorescence intensity", "PROBLEM", 50, 87], ["MFI", "TEST", 89, 92], ["CQ lysate", "TREATMENT", 187, 196], ["lymphocytes", "PROBLEM", 229, 240], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["expression", "OBSERVATION", 32, 42]]], ["Consistently, lymphocytes stimulated with DCs exposed to 5-FU + CQ lysates induced earlier and more potent T cell activation.", [["lymphocytes", "ANATOMY", 14, 25], ["DCs", "ANATOMY", 42, 45], ["lysates", "ANATOMY", 67, 74], ["T cell", "ANATOMY", 107, 113], ["5-FU", "CHEMICAL", 57, 61], ["CQ", "CHEMICAL", 64, 66], ["5-FU", "CHEMICAL", 57, 61], ["lymphocytes", "CELL", 14, 25], ["DCs", "CELL", 42, 45], ["5-FU", "SIMPLE_CHEMICAL", 57, 61], ["CQ", "SIMPLE_CHEMICAL", 64, 66], ["T cell", "CELL", 107, 113], ["lymphocytes", "CELL_TYPE", 14, 25], ["DCs", "CELL_TYPE", 42, 45], ["DCs", "TEST", 42, 45], ["CQ lysates", "TEST", 64, 74], ["more potent", "OBSERVATION_MODIFIER", 95, 106], ["T cell activation", "OBSERVATION", 107, 124]]], ["The findings also indicated that there was no selective activation of CD4+ or CD8+ T cells, since the percentage of CD69+ cells was increased in both subpopulations.", [["CD4+ or CD8+", "ANATOMY", 70, 82], ["T cells", "ANATOMY", 83, 90], ["CD69+ cells", "ANATOMY", 116, 127], ["CD4", "GENE_OR_GENE_PRODUCT", 70, 73], ["CD8", "GENE_OR_GENE_PRODUCT", 78, 81], ["T cells", "CELL", 83, 90], ["CD69", "GENE_OR_GENE_PRODUCT", 116, 120], ["CD4", "PROTEIN", 70, 73], ["CD8", "PROTEIN", 78, 81], ["T cells", "CELL_TYPE", 83, 90], ["CD69", "PROTEIN", 116, 120], ["CD4", "TEST", 70, 73], ["CD8", "PROBLEM", 78, 81], ["T cells", "TEST", 83, 90], ["CD69+ cells", "PROBLEM", 116, 127], ["CD4", "OBSERVATION", 70, 73], ["CD69+ cells", "OBSERVATION", 116, 127], ["increased", "OBSERVATION_MODIFIER", 132, 141], ["both", "OBSERVATION_MODIFIER", 145, 149], ["subpopulations", "OBSERVATION_MODIFIER", 150, 164]]], ["Accordingly, these same treatments resulted in a reduced generation of PD-1+ cells among CD4+ T lymphocytes.", [["PD-1+ cells", "ANATOMY", 71, 82], ["CD4+ T lymphocytes", "ANATOMY", 89, 107], ["PD-1", "GENE_OR_GENE_PRODUCT", 71, 75], ["CD4", "GENE_OR_GENE_PRODUCT", 89, 92], ["CD4", "PROTEIN", 89, 92], ["T lymphocytes", "CELL_TYPE", 94, 107], ["these same treatments", "TREATMENT", 13, 34], ["a reduced generation of PD", "PROBLEM", 47, 73], ["CD4", "TEST", 89, 92], ["lymphocytes", "ANATOMY", 96, 107]]], ["PD-1 is a member of the CD28 family, and its primary function is to limit clustering of the TCR and costimulatory molecules within the immunologic synapse.", [["immunologic synapse", "ANATOMY", 135, 154], ["PD-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD28", "GENE_OR_GENE_PRODUCT", 24, 28], ["TCR", "GENE_OR_GENE_PRODUCT", 92, 95], ["CD28 family", "PROTEIN", 24, 35], ["TCR", "PROTEIN", 92, 95], ["costimulatory molecules", "PROTEIN", 100, 123]]], ["PD-1 expression is increased in the T cells of patients with pancreatic cancer, lung cancer, and various leukemias and lymphomas [51] .", [["T cells", "ANATOMY", 36, 43], ["pancreatic cancer", "ANATOMY", 61, 78], ["lung cancer", "ANATOMY", 80, 91], ["leukemias", "ANATOMY", 105, 114], ["lymphomas", "ANATOMY", 119, 128], ["pancreatic cancer", "DISEASE", 61, 78], ["lung cancer", "DISEASE", 80, 91], ["leukemias", "DISEASE", 105, 114], ["lymphomas", "DISEASE", 119, 128], ["PD-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["T cells", "CELL", 36, 43], ["patients", "ORGANISM", 47, 55], ["pancreatic cancer", "CANCER", 61, 78], ["lung cancer", "CANCER", 80, 91], ["leukemias", "CANCER", 105, 114], ["lymphomas", "CANCER", 119, 128], ["T cells", "CELL_TYPE", 36, 43], ["patients", "SPECIES", 47, 55], ["PD", "TEST", 0, 2], ["pancreatic cancer", "PROBLEM", 61, 78], ["lung cancer", "PROBLEM", 80, 91], ["various leukemias", "PROBLEM", 97, 114], ["lymphomas", "PROBLEM", 119, 128], ["increased", "OBSERVATION_MODIFIER", 19, 28], ["pancreatic", "ANATOMY", 61, 71], ["cancer", "OBSERVATION", 72, 78], ["lung", "ANATOMY", 80, 84], ["cancer", "OBSERVATION", 85, 91], ["various", "OBSERVATION_MODIFIER", 97, 104], ["leukemias", "OBSERVATION", 105, 114], ["lymphomas", "OBSERVATION", 119, 128]]], ["Therefore, PD-1 expression in T cells and PD-L1 expression in tumor cells constitute a tumor escape mechanism.", [["T cells", "ANATOMY", 30, 37], ["tumor cells", "ANATOMY", 62, 73], ["tumor", "ANATOMY", 87, 92], ["tumor", "DISEASE", 62, 67], ["tumor", "DISEASE", 87, 92], ["PD-1", "GENE_OR_GENE_PRODUCT", 11, 15], ["T cells", "CELL", 30, 37], ["PD-L1", "GENE_OR_GENE_PRODUCT", 42, 47], ["tumor cells", "CELL", 62, 73], ["tumor", "CANCER", 87, 92], ["T cells", "CELL_TYPE", 30, 37], ["tumor cells", "CELL_TYPE", 62, 73], ["PD", "TEST", 11, 13], ["PD-L1 expression in tumor cells", "TREATMENT", 42, 73], ["a tumor escape mechanism", "PROBLEM", 85, 109], ["L1", "ANATOMY", 45, 47], ["tumor cells", "OBSERVATION", 62, 73], ["tumor", "OBSERVATION", 87, 92]]], ["We observed reduced PD-1 expression on the expanding lymphocytes cocultured with DCs.", [["lymphocytes", "ANATOMY", 53, 64], ["DCs", "ANATOMY", 81, 84], ["PD-1", "GENE_OR_GENE_PRODUCT", 20, 24], ["lymphocytes", "CELL", 53, 64], ["DCs", "CELL", 81, 84], ["lymphocytes", "CELL_TYPE", 53, 64], ["DCs", "CELL_TYPE", 81, 84], ["reduced PD", "PROBLEM", 12, 22], ["reduced", "OBSERVATION_MODIFIER", 12, 19], ["PD", "OBSERVATION", 20, 22], ["lymphocytes", "ANATOMY", 53, 64]]], ["This aspect is particularly interesting because the signals associated with PD-1 and PD-L1 are among the main checkpoint blockades of the antitumor response.", [["antitumor", "ANATOMY", 138, 147], ["PD-1", "GENE_OR_GENE_PRODUCT", 76, 80], ["PD-L1", "GENE_OR_GENE_PRODUCT", 85, 90], ["antitumor", "CANCER", 138, 147], ["PD", "TEST", 76, 78], ["PD-L1", "TREATMENT", 85, 90], ["L1", "ANATOMY", 88, 90], ["main", "OBSERVATION_MODIFIER", 105, 109], ["checkpoint blockades", "OBSERVATION", 110, 130], ["antitumor response", "OBSERVATION", 138, 156]]], ["Hence, in addition to the anti-CTLA-4 antibody, the anti-PD-1 antibodies [52] are mainstays of modern antitumor immunotherapy.DiscussionThe lymphocytes cultured with DCs sensitized with drug-exposed tumor cells produced higher amounts of IFN-\u03b3 than controls while showing decreased production of IL-10.", [["antitumor", "ANATOMY", 102, 111], ["lymphocytes", "ANATOMY", 140, 151], ["DCs", "ANATOMY", 166, 169], ["tumor cells", "ANATOMY", 199, 210], ["tumor", "DISEASE", 199, 204], ["anti-CTLA-4", "GENE_OR_GENE_PRODUCT", 26, 37], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 52, 61], ["antitumor", "CANCER", 102, 111], ["lymphocytes", "CELL", 140, 151], ["DCs", "CELL", 166, 169], ["tumor cells", "CELL", 199, 210], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 238, 243], ["controls", "ORGANISM", 249, 257], ["IL-10", "GENE_OR_GENE_PRODUCT", 296, 301], ["anti-CTLA-4 antibody", "PROTEIN", 26, 46], ["anti-PD-1 antibodies", "PROTEIN", 52, 72], ["lymphocytes", "CELL_TYPE", 140, 151], ["DCs", "CELL_TYPE", 166, 169], ["tumor cells", "CELL_TYPE", 199, 210], ["IFN-\u03b3", "PROTEIN", 238, 243], ["IL", "PROTEIN", 296, 298], ["the anti-CTLA", "TEST", 22, 35], ["the anti-PD", "TEST", 48, 59], ["modern antitumor immunotherapy", "TREATMENT", 95, 125], ["The lymphocytes", "TEST", 136, 151], ["drug", "TREATMENT", 186, 190], ["exposed tumor cells", "PROBLEM", 191, 210], ["IFN", "TEST", 238, 241], ["decreased production of IL", "PROBLEM", 272, 298], ["antitumor immunotherapy", "OBSERVATION", 102, 125], ["lymphocytes", "ANATOMY", 140, 151], ["tumor cells", "OBSERVATION", 199, 210], ["higher", "OBSERVATION_MODIFIER", 220, 226], ["amounts", "OBSERVATION_MODIFIER", 227, 234], ["decreased", "OBSERVATION_MODIFIER", 272, 281], ["production", "OBSERVATION_MODIFIER", 282, 292]]], ["Naive CD4+ and CD8+ lymphocytes can differentiate into specific effector T cells with different functions that are attributed, in part, to the pattern of cytokines they produce [53] .", [["CD4+ and CD8+ lymphocytes", "ANATOMY", 6, 31], ["effector T cells", "ANATOMY", 64, 80], ["CD4", "GENE_OR_GENE_PRODUCT", 6, 9], ["CD8", "GENE_OR_GENE_PRODUCT", 15, 18], ["effector T cells", "CELL", 64, 80], ["Naive CD4+ and CD8+ lymphocytes", "CELL_TYPE", 0, 31], ["effector T cells", "CELL_TYPE", 64, 80], ["cytokines", "PROTEIN", 154, 163], ["Naive CD4", "TEST", 0, 9], ["CD8", "TEST", 15, 18], ["lymphocytes", "PROBLEM", 20, 31], ["lymphocytes", "ANATOMY", 20, 31]]], ["CD4+ T cells can differentiate into Th1 cells that release IFN-\u03b3 and TNF-\u03b1 to stimulate the generation of CD8+ cells; in this way, Th1 cells are involved in the development of the antitumor immune response.", [["CD4+ T cells", "ANATOMY", 0, 12], ["Th1 cells", "ANATOMY", 36, 45], ["CD8+ cells", "ANATOMY", 106, 116], ["Th1 cells", "ANATOMY", 131, 140], ["antitumor", "ANATOMY", 180, 189], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["Th1 cells", "CELL", 36, 45], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 59, 64], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 69, 74], ["CD8", "GENE_OR_GENE_PRODUCT", 106, 109], ["Th1 cells", "CELL", 131, 140], ["antitumor", "CANCER", 180, 189], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 5, 12], ["Th1 cells", "CELL_TYPE", 36, 45], ["IFN", "PROTEIN", 59, 62], ["TNF", "PROTEIN", 69, 72], ["CD8+ cells", "CELL_TYPE", 106, 116], ["Th1 cells", "CELL_TYPE", 131, 140], ["CD4", "TEST", 0, 3], ["T cells", "PROBLEM", 5, 12], ["Th1 cells", "TEST", 36, 45], ["IFN", "TEST", 59, 62], ["TNF", "TEST", 69, 72], ["CD8+ cells", "PROBLEM", 106, 116], ["Th1 cells", "OBSERVATION", 36, 45]]], ["Interferon \u03b3 also recruits monocytes, inducing the differentiation of CD4+ T lymphocytes into Th1 lymphocytes [54, 55] .", [["monocytes", "ANATOMY", 27, 36], ["CD4+ T lymphocytes", "ANATOMY", 70, 88], ["Th1 lymphocytes", "ANATOMY", 94, 109], ["Interferon \u03b3", "GENE_OR_GENE_PRODUCT", 0, 12], ["monocytes", "CELL", 27, 36], ["CD4", "GENE_OR_GENE_PRODUCT", 70, 73], ["Interferon \u03b3", "PROTEIN", 0, 12], ["monocytes", "CELL_TYPE", 27, 36], ["CD4", "PROTEIN", 70, 73], ["T lymphocytes", "CELL_TYPE", 75, 88], ["Th1 lymphocytes", "CELL_TYPE", 94, 109], ["Interferon", "TREATMENT", 0, 10], ["monocytes", "TEST", 27, 36], ["CD4", "TEST", 70, 73], ["Th1 lymphocytes", "TEST", 94, 109], ["recruits monocytes", "OBSERVATION", 18, 36], ["Th1 lymphocytes", "ANATOMY", 94, 109]]], ["IL-10 is a DC-inhibiting cytokine that can be secreted by both Tregs and Th2, inhibiting antigen presentation, and decreasing the expression of MHC II and the co-stimulatory molecules CD80 and CD86 [56] .", [["DC", "ANATOMY", 11, 13], ["Tregs", "ANATOMY", 63, 68], ["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["DC", "CELL", 11, 13], ["Tregs", "CELL", 63, 68], ["Th2", "CELL", 73, 76], ["MHC II", "GENE_OR_GENE_PRODUCT", 144, 150], ["CD80", "GENE_OR_GENE_PRODUCT", 184, 188], ["CD86", "GENE_OR_GENE_PRODUCT", 193, 197], ["IL-10", "PROTEIN", 0, 5], ["DC-inhibiting cytokine", "PROTEIN", 11, 33], ["Tregs", "CELL_TYPE", 63, 68], ["Th2", "CELL_TYPE", 73, 76], ["MHC II", "PROTEIN", 144, 150], ["co-stimulatory molecules", "PROTEIN", 159, 183], ["CD80", "PROTEIN", 184, 188], ["CD86", "PROTEIN", 193, 197], ["a DC-inhibiting cytokine", "TREATMENT", 9, 33], ["CD86", "TEST", 193, 197]]], ["Thus, DCs under the combined treatment promoted preferential activation of Th1 lymphocytes, with little Th2 or Treg stimulation.", [["DCs", "ANATOMY", 6, 9], ["Th1 lymphocytes", "ANATOMY", 75, 90], ["Treg", "ANATOMY", 111, 115], ["DCs", "CELL", 6, 9], ["Th1 lymphocytes", "CELL", 75, 90], ["Th2", "GENE_OR_GENE_PRODUCT", 104, 107], ["Treg", "CELL", 111, 115], ["DCs", "CELL_TYPE", 6, 9], ["Th1 lymphocytes", "CELL_TYPE", 75, 90], ["the combined treatment", "TREATMENT", 16, 38], ["preferential activation of Th1 lymphocytes", "TREATMENT", 48, 90], ["Treg stimulation", "TREATMENT", 111, 127], ["Th1 lymphocytes", "OBSERVATION", 75, 90]]], ["An analysis of other cytokines, such as IL-12, IL-2, TNF, IL-4, IL-6, IL17, and IL-23, would be useful to provide a clearer view regarding how the different treatments affect the modulation of T cell subsets.", [["T cell", "ANATOMY", 193, 199], ["IL-12", "GENE_OR_GENE_PRODUCT", 40, 45], ["IL-2", "GENE_OR_GENE_PRODUCT", 47, 51], ["TNF", "GENE_OR_GENE_PRODUCT", 53, 56], ["IL-4", "GENE_OR_GENE_PRODUCT", 58, 62], ["IL-6", "GENE_OR_GENE_PRODUCT", 64, 68], ["IL17", "GENE_OR_GENE_PRODUCT", 70, 74], ["IL-23", "GENE_OR_GENE_PRODUCT", 80, 85], ["T cell", "CELL", 193, 199], ["cytokines", "PROTEIN", 21, 30], ["TNF", "PROTEIN", 53, 56], ["IL-6", "PROTEIN", 64, 68], ["IL17", "PROTEIN", 70, 74], ["IL", "PROTEIN", 80, 82], ["T cell subsets", "CELL_TYPE", 193, 207], ["An analysis", "TEST", 0, 11], ["other cytokines", "TEST", 15, 30], ["IL", "TEST", 40, 42], ["IL", "TEST", 47, 49], ["TNF", "TEST", 53, 56], ["IL", "TEST", 58, 60], ["IL", "TEST", 64, 66], ["IL", "TREATMENT", 80, 82], ["the different treatments", "TREATMENT", 143, 167], ["T cell subsets", "PROBLEM", 193, 207], ["cell subsets", "OBSERVATION", 195, 207]]], ["The quantification of these cytokines should be considered in future studies.DiscussionFinally, the evidence that the combination of 5-FU and CQ can modulate tumor cell biology, as can the corresponding HCT-116 lysate, is reinforced by the increased expression of genes of the tumor-associated CEA family (CEACAM 5, 6, and 7), as previously reported [57] , and the decreased expression of genes associated with tumor progression (BNIP3, BNIP3L, FOSL2, HES1, LAMB3, LOXL2, NDRG1, P4HA1, and PIK3R2).ConclusionTaken together, our results indicate that blocking autophagy with chloroquine increases the ability of tumor cells to mature DCs that can induce an antitumor response.", [["tumor cell", "ANATOMY", 158, 168], ["HCT-116 lysate", "ANATOMY", 203, 217], ["tumor", "ANATOMY", 277, 282], ["tumor", "ANATOMY", 411, 416], ["tumor cells", "ANATOMY", 611, 622], ["DCs", "ANATOMY", 633, 636], ["antitumor", "ANATOMY", 656, 665], ["5-FU", "CHEMICAL", 133, 137], ["CQ", "CHEMICAL", 142, 144], ["tumor", "DISEASE", 158, 163], ["tumor", "DISEASE", 277, 282], ["tumor", "DISEASE", 411, 416], ["chloroquine", "CHEMICAL", 574, 585], ["tumor", "DISEASE", 611, 616], ["5-FU", "CHEMICAL", 133, 137], ["CQ", "CHEMICAL", 142, 144], ["chloroquine", "CHEMICAL", 574, 585], ["5-FU", "SIMPLE_CHEMICAL", 133, 137], ["CQ", "SIMPLE_CHEMICAL", 142, 144], ["tumor cell", "CELL", 158, 168], ["HCT-116 lysate", "CELL", 203, 217], ["tumor", "CANCER", 277, 282], ["CEA", "GENE_OR_GENE_PRODUCT", 294, 297], ["CEACAM 5", "GENE_OR_GENE_PRODUCT", 306, 314], ["6", "GENE_OR_GENE_PRODUCT", 316, 317], ["7", "GENE_OR_GENE_PRODUCT", 323, 324], ["tumor", "CANCER", 411, 416], ["BNIP3", "GENE_OR_GENE_PRODUCT", 430, 435], ["BNIP3L", "GENE_OR_GENE_PRODUCT", 437, 443], ["FOSL2", "GENE_OR_GENE_PRODUCT", 445, 450], ["HES1", "GENE_OR_GENE_PRODUCT", 452, 456], ["LAMB3", "GENE_OR_GENE_PRODUCT", 458, 463], ["LOXL2", "GENE_OR_GENE_PRODUCT", 465, 470], ["NDRG1", "GENE_OR_GENE_PRODUCT", 472, 477], ["P4HA1", "GENE_OR_GENE_PRODUCT", 479, 484], ["PIK3R2", "GENE_OR_GENE_PRODUCT", 490, 496], ["chloroquine", "SIMPLE_CHEMICAL", 574, 585], ["tumor cells", "CELL", 611, 622], ["DCs", "CELL", 633, 636], ["antitumor", "CANCER", 656, 665], ["cytokines", "PROTEIN", 28, 37], ["CEA family", "PROTEIN", 294, 304], ["CEACAM 5, 6, and 7", "PROTEIN", 306, 324], ["BNIP3", "PROTEIN", 430, 435], ["BNIP3L", "PROTEIN", 437, 443], ["FOSL2", "PROTEIN", 445, 450], ["HES1", "PROTEIN", 452, 456], ["LAMB3", "PROTEIN", 458, 463], ["LOXL2", "PROTEIN", 465, 470], ["NDRG1", "PROTEIN", 472, 477], ["P4HA1", "PROTEIN", 479, 484], ["PIK3R2", "DNA", 490, 496], ["tumor cells", "CELL_TYPE", 611, 622], ["DCs", "CELL_TYPE", 633, 636], ["these cytokines", "TREATMENT", 22, 37], ["future studies", "TEST", 62, 76], ["the corresponding HCT", "TEST", 185, 206], ["the tumor", "PROBLEM", 273, 282], ["tumor progression", "PROBLEM", 411, 428], ["BNIP3", "TEST", 430, 435], ["BNIP3L", "TEST", 437, 443], ["FOSL2", "TEST", 445, 450], ["HES1", "TEST", 452, 456], ["LOXL2", "TEST", 465, 470], ["blocking autophagy", "PROBLEM", 550, 568], ["chloroquine", "TREATMENT", 574, 585], ["tumor cells", "PROBLEM", 611, 622], ["tumor cell", "OBSERVATION", 158, 168], ["tumor", "OBSERVATION", 277, 282], ["tumor", "OBSERVATION", 411, 416], ["tumor cells", "OBSERVATION", 611, 622]]], ["In addition, these results confirm the clinical application of this protocol for improving the in vitro stimulation of DCs, as well as the use of combined anti-autophagic agents and conventional chemotherapeutic agents for the treatment of patients with colorectal cancer.ConclusionData Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.", [["DCs", "ANATOMY", 119, 122], ["colorectal cancer", "ANATOMY", 254, 271], ["colorectal cancer", "DISEASE", 254, 271], ["DCs", "CELL", 119, 122], ["patients", "ORGANISM", 240, 248], ["colorectal cancer", "CANCER", 254, 271], ["DCs", "CELL_TYPE", 119, 122], ["patients", "SPECIES", 240, 248], ["this protocol", "TREATMENT", 63, 76], ["DCs", "TREATMENT", 119, 122], ["combined anti-autophagic agents", "TREATMENT", 146, 177], ["conventional chemotherapeutic agents", "TREATMENT", 182, 218], ["the treatment", "TREATMENT", 223, 236], ["colorectal cancer", "PROBLEM", 254, 271], ["this study", "TEST", 348, 358], ["colorectal", "ANATOMY", 254, 264], ["cancer", "OBSERVATION", 265, 271]]]], "39a7144ced64a39e54d38f82f589db2ad9513b40": [["IntroductionO'nyong nyong virus (ONNV) is an arthropod-borne virus (arbovirus) associated with a small number of large-scale epidemics.", [["arbovirus", "DISEASE", 68, 77], ["'nyong nyong virus", "ORGANISM", 13, 31], ["ONNV", "ORGANISM", 33, 37], ["arthropod-borne virus", "ORGANISM", 45, 66], ["'nyong nyong virus", "SPECIES", 13, 31], ["ONNV", "SPECIES", 33, 37], ["IntroductionO'nyong nyong virus", "PROBLEM", 0, 31], ["an arthropod-borne virus (arbovirus", "PROBLEM", 42, 77], ["large-scale epidemics", "PROBLEM", 113, 134], ["nyong virus", "OBSERVATION", 20, 31], ["small", "OBSERVATION_MODIFIER", 97, 102], ["large", "OBSERVATION_MODIFIER", 113, 118], ["-scale", "OBSERVATION_MODIFIER", 118, 124], ["epidemics", "OBSERVATION", 125, 134]]], ["One such epidemic began in 1959 in Uganda, lasted three years and affected over 2 million people [1] .", [["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96], ["epidemic", "OBSERVATION_MODIFIER", 9, 17]]], ["Serological evidence of ONNV transmission indicated circulation in Kenya until the late 1960s [2] , additional serological surveys in [1974] [1975] showed circulation in West Africa [3] , but ONNV did not cause another epidemic until 1996, when 400 people were sickened in the Rakai district in southern Uganda [4] .", [["people", "ORGANISM", 249, 255], ["people", "SPECIES", 249, 255], ["ONNV", "SPECIES", 24, 28], ["ONNV transmission", "PROBLEM", 24, 41], ["additional serological surveys", "TEST", 100, 130]]], ["The known distribution of ONNV mirrors that of the mosquito vectors that transmit the virus, Anopheles gambiae and Anopheles funestus [5] .", [["ONNV", "GENE_OR_GENE_PRODUCT", 26, 30], ["Anopheles gambiae", "ORGANISM", 93, 110], ["Anopheles funestus", "ORGANISM", 115, 133], ["ONNV", "DNA", 26, 30], ["Anopheles gambiae", "SPECIES", 93, 110], ["Anopheles funestus", "SPECIES", 115, 133], ["Anopheles gambiae", "SPECIES", 93, 110], ["Anopheles funestus", "SPECIES", 115, 133], ["ONNV mirrors", "PROBLEM", 26, 38], ["the mosquito vectors", "TREATMENT", 47, 67], ["the virus", "PROBLEM", 82, 91], ["distribution", "OBSERVATION_MODIFIER", 10, 22], ["ONNV mirrors", "OBSERVATION", 26, 38]]], ["Humans are the only currently known reservoir of ONNV [6] .", [["Humans", "ORGANISM", 0, 6]]], ["ONNV infection in humans is usually selflimiting, but does cause a low grade-fever, joint pain, lymphadenopathy, and a generalized papular or maculopapular rash [7] .IntroductionChikungunya (CHIKV) virus is a closely related alphavirus which has caused millions of cases of disease throughout countries in and surrounding the Indian Ocean since its re-emergence in 2004 [8] [9] [10] .", [["joint", "ANATOMY", 84, 89], ["papular", "ANATOMY", 131, 138], ["maculopapular", "ANATOMY", 142, 155], ["ONNV infection", "DISEASE", 0, 14], ["fever", "DISEASE", 77, 82], ["joint pain", "DISEASE", 84, 94], ["lymphadenopathy", "DISEASE", 96, 111], ["rash", "DISEASE", 156, 160], ["Chikungunya (CHIKV) virus", "DISEASE", 178, 203], ["alphavirus", "DISEASE", 225, 235], ["humans", "ORGANISM", 18, 24], ["joint", "ORGANISM_SUBDIVISION", 84, 89], ["Chikungunya (CHIKV) virus", "ORGANISM", 178, 203], ["humans", "SPECIES", 18, 24], ["ONNV", "SPECIES", 0, 4], ["humans", "SPECIES", 18, 24], ["CHIKV", "SPECIES", 191, 196], ["ONNV infection in humans", "PROBLEM", 0, 24], ["a low grade", "PROBLEM", 65, 76], ["fever", "PROBLEM", 77, 82], ["joint pain", "PROBLEM", 84, 94], ["lymphadenopathy", "PROBLEM", 96, 111], ["a generalized papular or maculopapular rash", "PROBLEM", 117, 160], ["IntroductionChikungunya (CHIKV) virus", "PROBLEM", 166, 203], ["a closely related alphavirus", "PROBLEM", 207, 235], ["disease", "PROBLEM", 274, 281], ["infection", "OBSERVATION", 5, 14], ["low grade", "OBSERVATION_MODIFIER", 67, 76], ["fever", "OBSERVATION", 77, 82], ["joint", "ANATOMY", 84, 89], ["lymphadenopathy", "OBSERVATION", 96, 111], ["generalized", "OBSERVATION_MODIFIER", 119, 130], ["papular", "OBSERVATION_MODIFIER", 131, 138], ["maculopapular", "OBSERVATION_MODIFIER", 142, 155], ["rash", "OBSERVATION", 156, 160], ["disease", "OBSERVATION", 274, 281]]], ["Additional cases occurred in travelers returning from affected areas to Asia, North America, and to Europe, where a few small epidemics have since occurred due to autochthonous transmission [11] [12] [13] [14] .", [["a few small epidemics", "PROBLEM", 114, 135]]], ["Humans are infected with CHIKV when bitten by infected Aedes aegypti or, during epidemics, Aedes albopictus mosquitoes.", [["CHIKV when bitten by infected Aedes aegypti", "DISEASE", 25, 68], ["Aedes albopictus mosquitoes", "DISEASE", 91, 118], ["Humans", "ORGANISM", 0, 6], ["CHIKV", "ORGANISM", 25, 30], ["Aedes aegypti", "ORGANISM", 55, 68], ["Aedes albopictus mosquitoes", "ORGANISM", 91, 118], ["Aedes aegypti", "SPECIES", 55, 68], ["Aedes albopictus", "SPECIES", 91, 107], ["CHIKV", "SPECIES", 25, 30], ["Aedes aegypti", "SPECIES", 55, 68], ["Aedes albopictus", "SPECIES", 91, 107], ["CHIKV", "PROBLEM", 25, 30], ["infected", "OBSERVATION", 11, 19], ["CHIKV", "OBSERVATION", 25, 30]]], ["Patients infected with CHIKV suffer from clinical symptoms similar to those infected with ONNV except that the fever is a higher, there is typically no lymphadenopathy, and the arthralgia is both incapacitating and chronic.IntroductionCHIKV and ONNV diverged from a common ancestor thousands of years ago [15] and despite their genetic similarity, ONNV and CHIKV have distinct ecologies.", [["CHIKV", "DISEASE", 23, 28], ["ONNV", "DISEASE", 90, 94], ["fever", "DISEASE", 111, 116], ["lymphadenopathy", "DISEASE", 152, 167], ["arthralgia", "DISEASE", 177, 187], ["Patients", "ORGANISM", 0, 8], ["CHIKV", "ORGANISM", 23, 28], ["CHIKV", "ORGANISM", 357, 362], ["ONNV", "DNA", 245, 249], ["Patients", "SPECIES", 0, 8], ["CHIKV", "SPECIES", 23, 28], ["ONNV", "SPECIES", 90, 94], ["ONNV", "SPECIES", 348, 352], ["CHIKV", "SPECIES", 357, 362], ["CHIKV", "PROBLEM", 23, 28], ["clinical symptoms", "PROBLEM", 41, 58], ["ONNV", "TREATMENT", 90, 94], ["the fever", "PROBLEM", 107, 116], ["lymphadenopathy", "PROBLEM", 152, 167], ["the arthralgia", "PROBLEM", 173, 187], ["CHIKV", "OBSERVATION", 23, 28], ["fever", "OBSERVATION", 111, 116], ["no", "UNCERTAINTY", 149, 151], ["lymphadenopathy", "OBSERVATION", 152, 167], ["arthralgia", "OBSERVATION", 177, 187], ["incapacitating", "OBSERVATION_MODIFIER", 196, 210], ["chronic", "OBSERVATION_MODIFIER", 215, 222]]], ["In fact, ONNV is the only alphavirus to be vectored by anopheline mosquitoes [5] while CHIKV is transmitted by culicine mosquitoes.", [["ONNV", "GENE_OR_GENE_PRODUCT", 9, 13], ["anopheline mosquitoes [5", "ORGANISM", 55, 79], ["CHIKV", "ORGANISM", 87, 92], ["culicine mosquitoes", "ORGANISM", 111, 130], ["ONNV", "SPECIES", 9, 13], ["CHIKV", "SPECIES", 87, 92], ["CHIKV", "PROBLEM", 87, 92]]], ["The differential mosquito infectivities of CHIKV and ONNV have been characterized in the laboratory where An. gambiae mosquitoes have been shown to be highly susceptible to ONNV infection and refractory to CHIKV infection [6] .", [["infection", "DISEASE", 178, 187], ["CHIKV infection", "DISEASE", 206, 221], ["CHIKV", "ORGANISM", 43, 48], ["ONNV", "GENE_OR_GENE_PRODUCT", 53, 57], ["An. gambiae mosquitoes", "ORGANISM", 106, 128], ["ONNV", "CANCER", 173, 177], ["CHIKV", "ORGANISM", 206, 211], ["An. gambiae", "SPECIES", 106, 117], ["CHIKV", "SPECIES", 43, 48], ["ONNV", "SPECIES", 53, 57], ["An. gambiae", "SPECIES", 106, 117], ["ONNV", "SPECIES", 173, 177], ["CHIKV", "SPECIES", 206, 211], ["CHIKV", "PROBLEM", 43, 48], ["An. gambiae mosquitoes", "PROBLEM", 106, 128], ["ONNV infection", "PROBLEM", 173, 187], ["CHIKV infection", "PROBLEM", 206, 221], ["differential", "OBSERVATION_MODIFIER", 4, 16], ["mosquito infectivities", "OBSERVATION", 17, 39], ["CHIKV", "OBSERVATION", 43, 48], ["infection", "OBSERVATION", 178, 187]]], ["Thus, this mosquito serves as an ideal system to examine the molecular determinants of infection using hybrids of the two viruses.IntroductionMembers of the genus Alphavirus contain a single-stranded, positive-sense RNA genome (,11.7 kb) that contains two regions, a non-structural domain making up the 59 two-thirds of the RNA and a structural domain at the 39 end making up the remaining one-third of the genome [16] .", [["infection", "DISEASE", 87, 96], ["Alphavirus", "GENE_OR_GENE_PRODUCT", 163, 173], ["positive-sense RNA genome", "DNA", 201, 226], ["non-structural domain", "PROTEIN", 267, 288], ["RNA", "RNA", 324, 327], ["structural domain", "PROTEIN", 334, 351], ["39 end", "PROTEIN", 359, 365], ["infection", "PROBLEM", 87, 96], ["hybrids", "TREATMENT", 103, 110], ["the genus Alphavirus", "PROBLEM", 153, 173], ["a non-structural domain", "PROBLEM", 265, 288], ["infection", "OBSERVATION", 87, 96], ["genus Alphavirus", "ANATOMY", 157, 173], ["RNA genome", "OBSERVATION", 216, 226], ["non-structural domain", "OBSERVATION", 267, 288], ["RNA", "ANATOMY", 324, 327]]], ["The non-structural domain encodes four viral non-structural proteins: nsP1, nsP2, nsP3, and nsP4 which are essential for replication and polyprotein processing.", [["nsP1", "GENE_OR_GENE_PRODUCT", 70, 74], ["nsP2", "GENE_OR_GENE_PRODUCT", 76, 80], ["nsP3", "GENE_OR_GENE_PRODUCT", 82, 86], ["nsP4", "GENE_OR_GENE_PRODUCT", 92, 96], ["non-structural domain", "PROTEIN", 4, 25], ["viral non-structural proteins", "PROTEIN", 39, 68], ["nsP1", "PROTEIN", 70, 74], ["nsP2", "PROTEIN", 76, 80], ["nsP3", "PROTEIN", 82, 86], ["nsP4", "PROTEIN", 92, 96], ["viral non-structural proteins", "TEST", 39, 68], ["nsP1", "TEST", 70, 74], ["nsP2", "TEST", 76, 80], ["nsP3", "TEST", 82, 86], ["nsP4", "PROBLEM", 92, 96], ["replication", "PROBLEM", 121, 132], ["polyprotein processing", "TREATMENT", 137, 159], ["non-structural domain", "OBSERVATION", 4, 25]]], ["In addition to copying the RNA genome, the non-structural proteins synthesize 26S subgenomic mRNA which is capped and polyadenylated and which ultimately produces five individual structural proteins (capsid, E3, E2, 6K, E1) [17] .", [["26S", "GENE_OR_GENE_PRODUCT", 78, 81], ["E3", "GENE_OR_GENE_PRODUCT", 208, 210], ["E2", "GENE_OR_GENE_PRODUCT", 212, 214], ["RNA genome", "DNA", 27, 37], ["non-structural proteins", "PROTEIN", 43, 66], ["26S subgenomic mRNA", "RNA", 78, 97], ["structural proteins", "PROTEIN", 179, 198], ["capsid", "PROTEIN", 200, 206], ["E3", "PROTEIN", 208, 210], ["E2", "PROTEIN", 212, 214], ["6K", "PROTEIN", 216, 218], ["E1", "PROTEIN", 220, 222], ["copying the RNA genome", "PROBLEM", 15, 37], ["the non-structural proteins synthesize 26S subgenomic mRNA", "PROBLEM", 39, 97], ["capsid", "TEST", 200, 206], ["E2", "TEST", 212, 214], ["RNA genome", "OBSERVATION", 27, 37], ["subgenomic mRNA", "OBSERVATION", 82, 97]]], ["Previous studies with chimeric alphaviruses have shown that viral components in both the structural and non-structural portions of the Venezuelan equine encephalitis genome contribute to infection phenotypes in guinea pigs [18] .", [["encephalitis", "DISEASE", 153, 165], ["infection", "DISEASE", 187, 196], ["Venezuelan equine encephalitis genome", "ORGANISM", 135, 172], ["guinea pigs", "ORGANISM", 211, 222], ["Venezuelan equine encephalitis", "SPECIES", 135, 165], ["guinea pigs", "SPECIES", 211, 222], ["Venezuelan equine encephalitis", "SPECIES", 135, 165], ["guinea pigs", "SPECIES", 211, 222], ["Previous studies", "TEST", 0, 16], ["chimeric alphaviruses", "PROBLEM", 22, 43], ["viral components", "PROBLEM", 60, 76], ["the Venezuelan equine encephalitis genome", "PROBLEM", 131, 172], ["infection phenotypes", "PROBLEM", 187, 207], ["viral", "OBSERVATION", 60, 65], ["infection", "OBSERVATION", 187, 196]]], ["Similar results were seen with chimeric eastern equine encephalitis viruses, with both structural and nonstructural proteins contributing to neurovirulence and viral tissue tropism in mice [19] .", [["tissue", "ANATOMY", 166, 172], ["encephalitis", "DISEASE", 55, 67], ["chimeric eastern equine encephalitis viruses", "ORGANISM", 31, 75], ["tissue", "TISSUE", 166, 172], ["mice", "ORGANISM", 184, 188], ["nonstructural proteins", "PROTEIN", 102, 124], ["equine encephalitis", "SPECIES", 48, 67], ["mice", "SPECIES", 184, 188], ["eastern equine encephalitis viruses", "SPECIES", 40, 75], ["mice", "SPECIES", 184, 188], ["chimeric eastern equine encephalitis viruses", "PROBLEM", 31, 75], ["both structural and nonstructural proteins", "PROBLEM", 82, 124], ["neurovirulence", "PROBLEM", 141, 155], ["viral tissue tropism", "PROBLEM", 160, 180], ["encephalitis", "OBSERVATION", 55, 67], ["nonstructural proteins", "OBSERVATION", 102, 124], ["viral tissue tropism", "OBSERVATION", 160, 180]]], ["Chimeric viruses are also useful for studying virusvector interactions as seen in a study that mapped mosquito infection determinants specifically to the E2 envelope glycoprotein region of Venezuelan equine encephalitis [20] .", [["virusvector", "ANATOMY", 46, 57], ["infection", "DISEASE", 111, 120], ["E2", "CHEMICAL", 154, 156], ["equine encephalitis", "DISEASE", 200, 219], ["Venezuelan equine encephalitis", "ORGANISM", 189, 219], ["E2 envelope glycoprotein region", "PROTEIN", 154, 185], ["Venezuelan equine encephalitis", "SPECIES", 189, 219], ["Venezuelan equine encephalitis", "SPECIES", 189, 219], ["Chimeric viruses", "PROBLEM", 0, 16], ["a study", "TEST", 82, 89], ["mosquito infection", "PROBLEM", 102, 120], ["the E2 envelope glycoprotein region", "TREATMENT", 150, 185], ["Venezuelan equine encephalitis", "PROBLEM", 189, 219], ["viruses", "OBSERVATION", 9, 16]]], ["Earlier studies using chimeric ONNV suggested that all of the viral structural proteins are necessary for ONNV to infect An. gambiae mosquitoes [21] ; however these studies used limited sample sizes and looked only at the structural regions of the genome.", [["ONNV", "GENE_OR_GENE_PRODUCT", 31, 35], ["ONNV", "GENE_OR_GENE_PRODUCT", 106, 110], ["An. gambiae mosquitoes", "ORGANISM", 121, 143], ["genome", "CELLULAR_COMPONENT", 248, 254], ["chimeric ONNV", "PROTEIN", 22, 35], ["viral structural proteins", "PROTEIN", 62, 87], ["ONNV", "PROTEIN", 106, 110], ["An. gambiae", "SPECIES", 121, 132], ["ONNV", "SPECIES", 106, 110], ["An. gambiae", "SPECIES", 121, 132], ["Earlier studies", "TEST", 0, 15], ["chimeric ONNV", "TREATMENT", 22, 35], ["the viral structural proteins", "PROBLEM", 58, 87], ["these studies", "TEST", 159, 172], ["genome", "ANATOMY", 248, 254]]], ["The current study expanded upon this earlier work to examine the contribution of each specific viral region or gene to virus-vector specificity.Infectious clone productionAll plasmid clones used in this study were designed and constructed in house.", [["clone", "CELL", 155, 160], ["viral region", "DNA", 95, 107], ["The current study", "TEST", 0, 17], ["each specific viral region", "PROBLEM", 81, 107], ["Infectious clone production", "PROBLEM", 144, 171], ["All plasmid clones", "TREATMENT", 171, 189], ["this study", "TEST", 198, 208], ["viral", "OBSERVATION", 95, 100], ["plasmid clones", "OBSERVATION", 175, 189]]], ["The full length clone pONN.AP3 was constructed from ONNV strain SG650 [5] (GenBank accession number AF079456) while pCHIK.b was constructed from CHIKV strain 37997 (GenBank accession number AY726732).", [["AP3", "GENE_OR_GENE_PRODUCT", 27, 30], ["pCHIK.b", "GENE_OR_GENE_PRODUCT", 116, 123], ["full length clone pONN", "DNA", 4, 26], ["AP3", "PROTEIN", 27, 30], ["pCHIK.b", "PROTEIN", 116, 123], ["CHIKV strain 37997", "SPECIES", 145, 163], ["CHIKV strain", "PROBLEM", 145, 157]]], ["These two full -length parental clones were used to construct 15 chimeric viruses as shown in Figures 1 and 2 .Infectious clone productionAll plasmid clones designed to evaluate structural regions of the genome were constructed in a similar fashion, with the substituted region produced from a PCR product and the backbone region produced from the parental plasmid clones described previously.", [["clones", "ANATOMY", 365, 371], ["parental clones", "CELL", 23, 38], ["clone", "CELL", 122, 127], ["clones", "CELL", 365, 371], ["PCR product", "DNA", 294, 305], ["parental plasmid clones", "CELL_LINE", 348, 371], ["full -length parental clones", "TREATMENT", 10, 38], ["Infectious clone production", "PROBLEM", 111, 138], ["All plasmid clones", "PROBLEM", 138, 156], ["a PCR product and the backbone region", "PROBLEM", 292, 329], ["the parental plasmid clones", "PROBLEM", 344, 371], ["plasmid clones", "OBSERVATION", 142, 156], ["backbone", "ANATOMY_MODIFIER", 314, 322], ["plasmid clones", "OBSERVATION", 357, 371]]], ["For example, to construct pCHIK/ONN E2, the E2 region of ONNV was amplified from parental pONN.AP3 by PCR with PFU turbo polymerase (Stratagene, La Jolla, CA).", [["E2", "CHEMICAL", 36, 38], ["E2", "CHEMICAL", 44, 46], ["pCHIK", "GENE_OR_GENE_PRODUCT", 26, 31], ["ONN E2", "GENE_OR_GENE_PRODUCT", 32, 38], ["E2", "GENE_OR_GENE_PRODUCT", 44, 46], ["ONNV", "GENE_OR_GENE_PRODUCT", 57, 61], ["AP3", "GENE_OR_GENE_PRODUCT", 95, 98], ["pCHIK", "PROTEIN", 26, 31], ["ONN E2", "PROTEIN", 32, 38], ["E2 region", "DNA", 44, 53], ["ONNV", "DNA", 57, 61], ["AP3", "PROTEIN", 95, 98], ["PFU turbo polymerase", "PROTEIN", 111, 131], ["AP3", "TEST", 95, 98], ["PCR", "TEST", 102, 105], ["PFU turbo polymerase", "TEST", 111, 131], ["Stratagene", "TEST", 133, 143], ["La Jolla", "ANATOMY", 145, 153]]], ["The ONNV amplicon and pCHIK.B were digested with the same restriction enzymes (Table 1) .", [["pCHIK", "GENE_OR_GENE_PRODUCT", 22, 27], ["B", "GENE_OR_GENE_PRODUCT", 28, 29], ["ONNV amplicon", "DNA", 4, 17], ["pCHIK", "DNA", 22, 27], ["restriction enzymes", "PROTEIN", 58, 77], ["Table 1", "PROTEIN", 79, 86], ["The ONNV amplicon", "TREATMENT", 0, 17]]], ["When necessary, appropriate restriction enzyme sites were added to pCHIK.B using a QuikChange XL site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions.", [["pCHIK", "GENE_OR_GENE_PRODUCT", 67, 72], ["B", "GENE_OR_GENE_PRODUCT", 73, 74], ["restriction enzyme sites", "DNA", 28, 52], ["pCHIK", "PROTEIN", 67, 72], ["QuikChange XL site", "DNA", 83, 101], ["appropriate restriction enzyme sites", "PROBLEM", 16, 52], ["a QuikChange XL site", "TREATMENT", 81, 101], ["directed mutagenesis kit (Stratagene)", "TREATMENT", 102, 139]]], ["Modifications were performed so that no amino acid changes were introduced and all viruses generated from constructs with introduced mutations were tested to insure they replicated in a manner comparable to the parental viruses.", [["amino acid", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 40, 50], ["amino acid", "AMINO_ACID", 40, 50], ["amino acid changes", "PROBLEM", 40, 58], ["all viruses", "PROBLEM", 79, 90], ["introduced mutations", "PROBLEM", 122, 142]]], ["Both restriction digests were run on an agarose gel at low voltage for at least 8 hours.", [["agarose", "SIMPLE_CHEMICAL", 40, 47], ["Both restriction digests", "TREATMENT", 0, 24], ["an agarose gel", "TREATMENT", 37, 51], ["low voltage", "OBSERVATION_MODIFIER", 55, 66]]], ["The doubly-digested insert and plasmid backbone were cut from the gel and purified from the agarose using the MinElute Gel Extraction Kit (Qiagen, Valencia, CA).", [["plasmid", "ANATOMY", 31, 38], ["agarose", "SIMPLE_CHEMICAL", 92, 99], ["doubly-digested insert", "DNA", 4, 26], ["The doubly-digested insert and plasmid backbone", "TREATMENT", 0, 47], ["the gel", "TREATMENT", 62, 69], ["the agarose", "TREATMENT", 88, 99], ["the MinElute Gel Extraction", "TREATMENT", 106, 133]]], ["The backbone vector was treated with Antarctic Phosphatase (NEB, Beverly, MA) to remove the 59 phosphate groups, thus preventing self-ligation of the plasmid.", [["plasmid", "ANATOMY", 150, 157], ["phosphate", "CHEMICAL", 95, 104], ["phosphate", "CHEMICAL", 95, 104], ["Antarctic Phosphatase", "PROTEIN", 37, 58], ["plasmid", "DNA", 150, 157], ["The backbone vector", "TREATMENT", 0, 19], ["Antarctic Phosphatase", "TREATMENT", 37, 58], ["NEB", "TREATMENT", 60, 63], ["the 59 phosphate groups", "TREATMENT", 88, 111], ["self-ligation of the plasmid", "TREATMENT", 129, 157]]], ["Prepared plasmid backbone and insert were ligated overnight with T4 DNA ligase (NEB) and then electroporated into XL-1 Blue electrocompetent cells (Stratagene).", [["plasmid", "ANATOMY", 9, 16], ["cells", "ANATOMY", 141, 146], ["T4 DNA ligase", "GENE_OR_GENE_PRODUCT", 65, 78], ["NEB", "GENE_OR_GENE_PRODUCT", 80, 83], ["cells", "CELL", 141, 146], ["T4 DNA ligase", "PROTEIN", 65, 78], ["NEB", "PROTEIN", 80, 83], ["XL-1 Blue electrocompetent cells", "CELL_LINE", 114, 146], ["plasmid backbone", "TREATMENT", 9, 25], ["T4 DNA ligase (NEB", "TREATMENT", 65, 83]]], ["Transformed cells were grown on YT plates with 50 mg/ml ampicillin and incubated overnight at 37uC.", [["cells", "ANATOMY", 12, 17], ["ampicillin", "CHEMICAL", 56, 66], ["ampicillin", "CHEMICAL", 56, 66], ["Transformed cells", "CELL", 0, 17], ["ampicillin", "SIMPLE_CHEMICAL", 56, 66], ["Transformed cells", "PROBLEM", 0, 17], ["YT plates", "TREATMENT", 32, 41], ["ampicillin", "TREATMENT", 56, 66]]], ["Colonies were picked and screened for confirmation of ONNV insert by PCR.", [["Colonies", "CELL", 0, 8], ["ONNV insert", "DNA", 54, 65], ["ONNV", "SPECIES", 54, 58], ["ONNV insert", "TREATMENT", 54, 65]]], ["Plasmid clones were confirmed by sequencing the entire construct.Infectious clone productionPlasmid clones designed to evaluate non-structural regions of the genome were engineered as exact gene substitutions by using a series of subclones, as described in the Protocol S1 and in Figures S1, S2, S3, S4, S5, S6.", [["clones", "ANATOMY", 8, 14], ["subclones", "ANATOMY", 230, 239], ["Plasmid clones", "CELL", 0, 14], ["clone", "CELL", 76, 81], ["Plasmid clones", "CELL", 92, 106], ["subclones", "CELL", 230, 239], ["S5", "GENE_OR_GENE_PRODUCT", 304, 306], ["S6", "GENE_OR_GENE_PRODUCT", 308, 310], ["non-structural regions", "DNA", 128, 150], ["S2, S3, S4, S5, S6", "DNA", 292, 310], ["Plasmid clones", "TREATMENT", 0, 14], ["Infectious clone productionPlasmid clones", "PROBLEM", 65, 106], ["exact gene substitutions", "PROBLEM", 184, 208], ["a series of subclones", "TREATMENT", 218, 239], ["S2", "ANATOMY", 292, 294], ["S3", "ANATOMY_MODIFIER", 296, 298], ["S4", "ANATOMY", 300, 302], ["S5", "ANATOMY", 304, 306]]], ["Briefly, CHIKV regions flanking the desired non-structural protein, and containing convenient restriction sites were amplified from pCHIK.b by PCR with PFU turbo polymerase (Stratagene).", [["CHIKV", "ORGANISM", 9, 14], ["pCHIK", "GENE_OR_GENE_PRODUCT", 132, 137], ["CHIKV regions", "DNA", 9, 22], ["non-structural protein", "PROTEIN", 44, 66], ["restriction sites", "DNA", 94, 111], ["pCHIK", "PROTEIN", 132, 137], ["PFU turbo polymerase", "PROTEIN", 152, 172], ["CHIKV", "SPECIES", 9, 14], ["CHIKV regions flanking", "PROBLEM", 9, 31], ["convenient restriction sites", "TREATMENT", 83, 111], ["PFU turbo polymerase", "TREATMENT", 152, 172], ["CHIKV", "OBSERVATION", 9, 14], ["non-structural protein", "OBSERVATION", 44, 66]]], ["Primers used for amplification added a type II restriction enzyme site to the outside of each desired insert product.", [["type II restriction enzyme site", "DNA", 39, 70], ["Primers", "TREATMENT", 0, 7], ["amplification", "TREATMENT", 17, 30], ["a type II restriction enzyme site", "TREATMENT", 37, 70]]], ["These two PCR products and a modified cloning vector, pUC19M2 were each double digested using type I enzymes exterior to the type II engineered sites.", [["pUC19M2", "GENE_OR_GENE_PRODUCT", 54, 61], ["PCR products", "DNA", 10, 22], ["modified cloning vector", "DNA", 29, 52], ["pUC19M2", "DNA", 54, 61], ["type I enzymes", "PROTEIN", 94, 108], ["type II engineered sites", "DNA", 125, 149], ["These two PCR products", "TREATMENT", 0, 22], ["a modified cloning vector", "TREATMENT", 27, 52], ["pUC", "TREATMENT", 54, 57], ["type I enzymes", "TREATMENT", 94, 108], ["engineered sites", "OBSERVATION", 133, 149]]], ["A 3-way ligation then produced the first subclone (pUC19M2 with the CHIKV sequence flanking where the desired non-structural protein sequence would subsequently be inserted).", [["subclone", "ANATOMY", 41, 49], ["pUC19M2", "CANCER", 51, 58], ["CHIKV sequence flanking", "DNA", 68, 91], ["non-structural protein sequence", "DNA", 110, 141], ["CHIKV", "SPECIES", 68, 73], ["A 3-way ligation", "TREATMENT", 0, 16], ["the CHIKV sequence flanking", "TREATMENT", 64, 91], ["the desired non-structural protein sequence", "TREATMENT", 98, 141], ["ligation", "OBSERVATION", 8, 16]]], ["The desired ONNV non-structural protein was amplified using primers which added the same type II enzyme site as was added to the PCR products.", [["ONNV", "GENE_OR_GENE_PRODUCT", 12, 16], ["ONNV non-structural protein", "PROTEIN", 12, 39], ["type II enzyme site", "DNA", 89, 108], ["The desired ONNV non-structural protein", "TREATMENT", 0, 39], ["primers", "TREATMENT", 60, 67], ["the PCR products", "TREATMENT", 125, 141], ["non-structural protein", "OBSERVATION", 17, 39]]], ["The first subclone and the ONNV PCR product were both digested with the same type II enzyme, which cuts itself out upon digestion.", [["subclone", "ANATOMY", 10, 18], ["ONNV PCR product", "PROTEIN", 27, 43], ["type II enzyme", "PROTEIN", 77, 91], ["the ONNV PCR product", "TEST", 23, 43]]], ["Ligation of the two digested products produced a second subclone (pUC19M2 with the entire and exact ONNV nonstructural protein, flanked by CHIKV sequence).", [["subclone", "ANATOMY", 56, 64], ["pUC19M2", "CANCER", 66, 73], ["ONNV nonstructural protein", "GENE_OR_GENE_PRODUCT", 100, 126], ["ONNV nonstructural protein", "PROTEIN", 100, 126], ["CHIKV", "SPECIES", 139, 144], ["Ligation", "TREATMENT", 0, 8], ["the two digested products", "TREATMENT", 12, 37], ["a second subclone (pUC19M2", "TREATMENT", 47, 73]]], ["This second subclone and pCHIK.b were then digested using the convenient restriction sites already present in the flanking CHIKV sequence.", [["subclone", "ANATOMY", 12, 20], ["pCHIK", "DNA", 25, 30], ["restriction sites", "DNA", 73, 90], ["flanking CHIKV sequence", "DNA", 114, 137], ["CHIKV", "SPECIES", 123, 128], ["the convenient restriction sites", "TREATMENT", 58, 90]]], ["Ligation of the doubly-digested pCHIK.b backbone and the insert obtained from the second subclone produced the final construct.", [["pCHIK", "PROTEIN", 32, 37], ["Ligation", "TREATMENT", 0, 8], ["the doubly-digested pCHIK", "TREATMENT", 12, 37], ["b backbone", "TREATMENT", 38, 48], ["the insert", "TREATMENT", 53, 63]]], ["Colonies were screened and verified by complete genome sequencing and plasmid DNA was prepared as described above.Rescue of virus from infectious clone templatesTemplates for in vitro transcription were generated by linearizing each full-length clone with a unique Not I restriction site present downstream of the poly (A) tail.", [["plasmid", "ANATOMY", 70, 77], ["Colonies", "CELL", 0, 8], ["DNA", "CELLULAR_COMPONENT", 78, 81], ["clone", "CELL", 245, 250], ["poly (A) tail", "GENE_OR_GENE_PRODUCT", 314, 327], ["plasmid DNA", "DNA", 70, 81], ["Not I restriction site", "DNA", 265, 287], ["poly (A) tail", "PROTEIN", 314, 327], ["plasmid DNA", "PROBLEM", 70, 81], ["Rescue of virus", "PROBLEM", 114, 129], ["infectious clone templates", "TREATMENT", 135, 161], ["virus", "OBSERVATION", 124, 129], ["infectious", "OBSERVATION", 135, 145], ["tail", "ANATOMY", 323, 327]]], ["Linearized plasmids were treated with Proteinase K (Invitrogen, Carlsbad, CA) to digest any endogenous RNases or DNases.", [["plasmids", "ANATOMY", 11, 19], ["Proteinase K", "CHEMICAL", 38, 50], ["Proteinase K", "SIMPLE_CHEMICAL", 38, 50], ["CA", "GENE_OR_GENE_PRODUCT", 74, 76], ["DNases", "GENE_OR_GENE_PRODUCT", 113, 119], ["Linearized plasmids", "DNA", 0, 19], ["endogenous RNases", "PROTEIN", 92, 109], ["DNases", "PROTEIN", 113, 119], ["Linearized plasmids", "TREATMENT", 0, 19], ["Proteinase K (Invitrogen", "TREATMENT", 38, 62], ["Carlsbad", "TREATMENT", 64, 72], ["DNases", "PROBLEM", 113, 119], ["plasmids", "OBSERVATION", 11, 19]]], ["DNA was purified using a phenolchloroform extraction followed by an ethanol precipitation.", [["phenolchloroform", "CHEMICAL", 25, 41], ["ethanol", "CHEMICAL", 68, 75], ["phenolchloroform", "CHEMICAL", 25, 41], ["ethanol", "CHEMICAL", 68, 75], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["phenolchloroform", "SIMPLE_CHEMICAL", 25, 41], ["ethanol", "SIMPLE_CHEMICAL", 68, 75], ["DNA", "PROBLEM", 0, 3], ["a phenolchloroform extraction", "TREATMENT", 23, 52], ["an ethanol precipitation", "TREATMENT", 65, 89], ["ethanol precipitation", "OBSERVATION", 68, 89]]], ["A 20 ml aliquot of linearized and treated DNA was then transcribed in vitro by incubating the DNA with 0.4 ml (100 mM) each rNTP (Promega, Madison, WI), 0.4 ml BSA (10 mg/ml) (NEB, Beverly, MA), 2 ml DTT (100 mM) (Promega, Madison, WI), 8 ml (5x) transcription buffer (Promega, Madison, WI), 1.3 ml (15 U/ml) T7 RNA polymerase (Promega, Madison, WI), and 4 ml (10 mM) Acap-structure analog (NEB, Beverly, MA) for one hour at 39uC.", [["BSA", "CHEMICAL", 160, 163], ["DTT", "CHEMICAL", 200, 203], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["DNA", "CELLULAR_COMPONENT", 94, 97], ["BSA", "SIMPLE_CHEMICAL", 160, 163], ["DTT", "SIMPLE_CHEMICAL", 200, 203], ["A 20 ml aliquot of linearized and treated DNA", "TREATMENT", 0, 45], ["rNTP (Promega, Madison, WI)", "TREATMENT", 124, 151], ["Promega, Madison, WI)", "TREATMENT", 214, 235], ["transcription buffer (Promega, Madison, WI)", "TREATMENT", 247, 290], ["Acap-structure analog (NEB", "TREATMENT", 368, 394]]], ["Transcribed RNA (10 ml) was mixed with 400 ml BHK-21 cells (1610 7 cells/ml) in a 2 mm gap cuvette (BTX:Harvard Apparatus, Inc., Holliston, MA) and electroporated twice using a BTX ElectroCell Manipulator with the following settings: 460volts, 725ohms, 75 mF [22] .", [["BHK-21 cells", "ANATOMY", 46, 58], ["cells", "ANATOMY", 67, 72], ["BTX", "CHEMICAL", 177, 180], ["BHK-21 cells", "CELL", 46, 58], ["cells", "CELL", 67, 72], ["a 2 mm gap cuvette", "TREATMENT", 80, 98], ["Harvard Apparatus", "TREATMENT", 104, 121], ["Inc., Holliston, MA", "TREATMENT", 123, 142], ["a BTX ElectroCell Manipulator", "TREATMENT", 175, 204]]], ["After electroporation, the cells were transferred to a T-25 tissue-culture flask.", [["cells", "ANATOMY", 27, 32], ["tissue", "ANATOMY", 60, 66], ["cells", "CELL", 27, 32], ["culture flask", "TEST", 67, 80]]], ["Dulbecco's Modified Eagle Medium (DMEM) with 10% by volume fetal bovine serum and 1% by volume penicillin/streptomycin was added to the flaskAuthor SummaryO'nyong nyong virus (ONNV) is unique in that it is the only alphavirus, and one of few viruses in general, to be transmitted to humans by the bite of an anopheline mosquito.", [["fetal bovine serum", "ANATOMY", 59, 77], ["penicillin", "CHEMICAL", 95, 105], ["streptomycin", "CHEMICAL", 106, 118], ["alphavirus", "DISEASE", 215, 225], ["penicillin", "CHEMICAL", 95, 105], ["streptomycin", "CHEMICAL", 106, 118], ["bovine", "ORGANISM", 65, 71], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["penicillin", "SIMPLE_CHEMICAL", 95, 105], ["streptomycin", "SIMPLE_CHEMICAL", 106, 118], ["nyong nyong virus", "ORGANISM", 157, 174], ["ONNV", "CANCER", 176, 180], ["humans", "ORGANISM", 283, 289], ["bovine", "SPECIES", 65, 71], ["humans", "SPECIES", 283, 289], ["bovine", "SPECIES", 65, 71], ["nyong nyong virus", "SPECIES", 157, 174], ["ONNV", "SPECIES", 176, 180], ["humans", "SPECIES", 283, 289], ["Dulbecco's Modified Eagle Medium (DMEM)", "TREATMENT", 0, 39], ["volume fetal bovine serum", "TEST", 52, 77], ["volume penicillin", "TREATMENT", 88, 105], ["streptomycin", "TREATMENT", 106, 118], ["few", "OBSERVATION_MODIFIER", 238, 241], ["viruses", "OBSERVATION", 242, 249]]], ["The genetics responsible for this unique vector specificity would be useful information in helping to develop antivirals, vaccines, and other methods for interrupting virus transmission.", [["antivirals", "TREATMENT", 110, 120], ["vaccines", "TREATMENT", 122, 130], ["other methods", "TREATMENT", 136, 149], ["interrupting virus transmission", "PROBLEM", 154, 185]]], ["Previous research using other arboviruses has shown that specific viral genomic regions, amino acid sequences, or even single nucleotide mutations can have a profound effect on virus growth, infection, and virulence characteristics.", [["amino acid", "CHEMICAL", 89, 99], ["nucleotide", "CHEMICAL", 126, 136], ["infection", "DISEASE", 191, 200], ["amino acid", "CHEMICAL", 89, 99], ["nucleotide", "CHEMICAL", 126, 136], ["amino acid", "AMINO_ACID", 89, 99], ["viral genomic regions", "DNA", 66, 87], ["other arboviruses", "PROBLEM", 24, 41], ["specific viral genomic regions", "PROBLEM", 57, 87], ["amino acid sequences", "TEST", 89, 109], ["single nucleotide mutations", "PROBLEM", 119, 146], ["virus growth", "PROBLEM", 177, 189], ["infection", "PROBLEM", 191, 200], ["virulence characteristics", "PROBLEM", 206, 231], ["infection", "OBSERVATION", 191, 200]]], ["Using chimeric viruses that substitute a gene from one virus with a gene from a closely related virus is a proven method of evaluating the relative contribution of each gene to a given phenotype.", [["chimeric viruses", "PROBLEM", 6, 22], ["a gene from one virus", "PROBLEM", 39, 60], ["a closely related virus", "PROBLEM", 78, 101]]], ["Our study analyzed both structural and non-structural regions of the ONNV genome using chimeric viruses and artificially infected Anopheles gambiae mosquitoes.", [["ONNV", "GENE_OR_GENE_PRODUCT", 69, 73], ["Anopheles gambiae mosquitoes", "ORGANISM", 130, 158], ["non-structural regions", "DNA", 39, 61], ["ONNV genome", "DNA", 69, 80], ["Anopheles gambiae", "SPECIES", 130, 147], ["Anopheles gambiae", "SPECIES", 130, 147], ["Our study", "TEST", 0, 9], ["chimeric viruses", "PROBLEM", 87, 103], ["artificially infected Anopheles gambiae mosquitoes", "PROBLEM", 108, 158]]], ["When ONNV non-structural protein 3 (nsP3) replaced nsP3 from chikungunya virus in one of the chimeric viruses, infection rates in An. gambiae went from 0% to 63.5%.", [["chikungunya", "DISEASE", 61, 72], ["infection", "DISEASE", 111, 120], ["ONNV non-structural protein 3", "GENE_OR_GENE_PRODUCT", 5, 34], ["nsP3", "GENE_OR_GENE_PRODUCT", 36, 40], ["nsP3", "GENE_OR_GENE_PRODUCT", 51, 55], ["chikungunya virus", "ORGANISM", 61, 78], ["An. gambiae", "ORGANISM", 130, 141], ["ONNV non-structural protein 3", "PROTEIN", 5, 34], ["nsP3", "PROTEIN", 36, 40], ["nsP3", "PROTEIN", 51, 55], ["An. gambiae", "SPECIES", 130, 141], ["chikungunya virus", "SPECIES", 61, 78], ["An. gambiae", "SPECIES", 130, 141], ["non-structural protein", "TEST", 10, 32], ["nsP3", "PROBLEM", 51, 55], ["chikungunya virus", "PROBLEM", 61, 78], ["the chimeric viruses", "PROBLEM", 89, 109], ["infection rates", "PROBLEM", 111, 126], ["An. gambiae", "TEST", 130, 141], ["chikungunya virus", "OBSERVATION", 61, 78], ["viruses", "OBSERVATION", 102, 109], ["infection", "OBSERVATION", 111, 120]]], ["No other single gene or viral region addition was able to restore infection rates.", [["infection", "DISEASE", 66, 75], ["other single gene or viral region", "PROBLEM", 3, 36], ["infection rates", "PROBLEM", 66, 81], ["viral", "OBSERVATION", 24, 29], ["infection", "OBSERVATION", 66, 75]]], ["That ONNV nsP3 is largely responsible for ONNV's unique ability to infect An. gambiae is especially interesting since the exact mechanisms and functions of this highly-variable protein remain poorly understood.Author Summarybefore incubation at 37uC.", [["ONNV", "GENE_OR_GENE_PRODUCT", 5, 9], ["nsP3", "GENE_OR_GENE_PRODUCT", 10, 14], ["ONNV", "GENE_OR_GENE_PRODUCT", 42, 46], ["An. gambiae", "ORGANISM", 74, 85], ["ONNV nsP3", "PROTEIN", 5, 14], ["ONNV", "PROTEIN", 42, 46], ["An. gambiae", "SPECIES", 74, 85], ["ONNV", "SPECIES", 5, 9], ["ONNV", "SPECIES", 42, 46], ["An. gambiae", "SPECIES", 74, 85]]], ["Tissue culture supernatant was harvested approximately 72 hours post-transfection or when cytopathic effects (CPE) were observed.", [["Tissue", "ANATOMY", 0, 6], ["supernatant", "ANATOMY", 15, 26], ["Tissue culture supernatant", "TEST", 0, 26], ["cytopathic effects", "PROBLEM", 90, 108], ["CPE", "PROBLEM", 110, 113]]], ["Supernatant was aliquoted and stored at 280uC until later use.SequencingEach time a virus was generated, the entire virus was sequenced to verify fidelity to the original sequence.", [["Supernatant", "ANATOMY", 0, 11], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["a virus", "PROBLEM", 82, 89], ["the entire virus", "PROBLEM", 105, 121]]], ["Viral RNA was extracted using QIAamp Viral RNA Mini Kit (Qiagen).", [["Viral", "ORGANISM", 0, 5], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["QIAamp", "TEST", 30, 36]]], ["Extracted RNA was then added to a reverse-transcriptase PCR reaction using the Titan One Tube RT-PCR System (Roche, Indianapolis, IN).", [["Extracted RNA", "PROBLEM", 0, 13], ["a reverse-transcriptase PCR reaction", "TREATMENT", 32, 68], ["the Titan One Tube RT", "TREATMENT", 75, 96]]], ["Complementary DNA for sequencing the 59 end of each viral genome was generated using a FirstChoice RLM-RACE Kit (Ambion, Austin, TX).", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["59 end", "DNA", 37, 43], ["viral genome", "DNA", 52, 64], ["a FirstChoice RLM", "TREATMENT", 85, 102], ["TX", "TREATMENT", 129, 131]]], ["This complementary DNA was then sequenced using virus-specific primers with the Big Dyev3.1 kit on an ABI 3130xl genetic analyzer (Applied Biosystems, Foster City, CA).", [["DNA", "CELLULAR_COMPONENT", 19, 22], ["complementary DNA", "DNA", 5, 22], ["This complementary DNA", "PROBLEM", 0, 22], ["virus", "TREATMENT", 48, 53], ["an ABI", "TEST", 99, 105]]], ["Sequence files were aligned and analyzed for sequence quality and genome coverage using Lasergene suite software (DNASTAR, Madison, WI).TitrationsVirus rescued from clones was titered by plaque assay.", [["clones", "ANATOMY", 165, 171], ["plaque", "ANATOMY", 187, 193], ["Virus", "ORGANISM", 146, 151], ["clones", "CELL", 165, 171], ["Sequence files", "TEST", 0, 14], ["sequence quality", "TEST", 45, 61], ["TitrationsVirus", "PROBLEM", 136, 151]]], ["Ten-fold virus dilutions from 10 21 to 10 27 were added to individual well of 6-well plates covered in monolayers of VERO cells.", [["monolayers", "ANATOMY", 103, 113], ["VERO cells", "ANATOMY", 117, 127], ["monolayers", "CELL", 103, 113], ["VERO cells", "CELL", 117, 127], ["VERO cells", "CELL_LINE", 117, 127], ["Ten-fold virus dilutions", "TEST", 0, 24], ["VERO cells", "PROBLEM", 117, 127], ["VERO cells", "OBSERVATION", 117, 127]]], ["Plates were incubated at 37uC, with 5% CO 2 .", [["CO 2", "CHEMICAL", 39, 43], ["Plates", "TEST", 0, 6]]], ["Cells were fixed 48-72 hours later using a solution of 40% methanol and 0.25% crystal violet in water.", [["Cells", "ANATOMY", 0, 5], ["methanol", "CHEMICAL", 59, 67], ["crystal violet", "CHEMICAL", 78, 92], ["methanol", "CHEMICAL", 59, 67], ["Cells", "CELL", 0, 5], ["methanol", "SIMPLE_CHEMICAL", 59, 67], ["crystal violet", "SIMPLE_CHEMICAL", 78, 92], ["Cells", "TEST", 0, 5], ["a solution of 40% methanol", "TREATMENT", 41, 67]]], ["Plaques were then counted and titers were calculated as plaque forming units per milliliter (PFU/ml).Mosquito infectionsThe ability of each chimeric virus to infect mosquitoes was evaluated using the G3 strain of An. gambiae, originally obtained from the National Institute of Health.", [["Plaques", "ANATOMY", 0, 7], ["plaque", "ANATOMY", 56, 62], ["Mosquito infections", "DISEASE", 101, 120], ["mosquitoes", "ORGANISM", 165, 175], ["An. gambiae", "ORGANISM", 213, 224], ["An. gambiae", "SPECIES", 213, 224], ["An. gambiae", "SPECIES", 213, 224], ["Plaques", "PROBLEM", 0, 7], ["titers", "TEST", 30, 36], ["Mosquito infections", "PROBLEM", 101, 120], ["each chimeric virus", "PROBLEM", 135, 154], ["infections", "OBSERVATION", 110, 120]]], ["This strain has been maintained as a colony in our lab with rearing conditions that include a 12:12 hour light:dark cycle in chambers maintained at 28uC with approximately 95% humidity [23] .Mosquito infectionsInfectious blood meals were prepared from equal volumes of packed, calf erythrocytes, 10% sucrose in fetal bovine serum, and 4.4-6 log 10 PFU/ml of virus.", [["colony", "ANATOMY", 37, 43], ["blood", "ANATOMY", 221, 226], ["erythrocytes", "ANATOMY", 282, 294], ["fetal bovine serum", "ANATOMY", 311, 329], ["Mosquito infections", "DISEASE", 191, 210], ["sucrose", "CHEMICAL", 300, 307], ["sucrose", "CHEMICAL", 300, 307], ["blood", "ORGANISM_SUBSTANCE", 221, 226], ["calf", "ORGANISM", 277, 281], ["erythrocytes", "ORGANISM_SUBSTANCE", 282, 294], ["sucrose", "SIMPLE_CHEMICAL", 300, 307], ["bovine", "ORGANISM", 317, 323], ["serum", "ORGANISM_SUBSTANCE", 324, 329], ["calf erythrocytes", "CELL_TYPE", 277, 294], ["calf", "SPECIES", 277, 281], ["bovine", "SPECIES", 317, 323], ["bovine", "SPECIES", 317, 323], ["Mosquito infectionsInfectious blood meals", "PROBLEM", 191, 232], ["calf erythrocytes", "TEST", 277, 294], ["fetal bovine serum", "TEST", 311, 329], ["virus", "PROBLEM", 358, 363], ["calf erythrocytes", "ANATOMY", 277, 294]]], ["Mosquitoes were allowed to feed on the warmed infectious blood meal for one hour through an artificial membrane feeder (Hemotek, Accrington, UK).", [["blood", "ANATOMY", 57, 62], ["membrane feeder", "ANATOMY", 103, 118], ["Mosquitoes", "ORGANISM", 0, 10], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["the warmed infectious blood meal", "TREATMENT", 35, 67], ["an artificial membrane feeder", "TREATMENT", 89, 118]]], ["Fully engorged females were separated and maintained for an incubation period of up to 12 days.", [["engorged", "OBSERVATION_MODIFIER", 6, 14], ["females", "OBSERVATION", 15, 22]]], ["Mosquitoes were sacrificed at days 4, 8, and 11 or 12 post-infectious-blood meal.", [["blood", "ANATOMY", 70, 75], ["Mosquitoes", "ORGANISM", 0, 10], ["blood", "ORGANISM_SUBSTANCE", 70, 75]]], ["Heads and bodies were separated into individual tubes and stored at 280uC until subsequent processing.", [["bodies", "ANATOMY", 10, 16], ["bodies", "ANATOMY_MODIFIER", 10, 16], ["tubes", "OBSERVATION", 48, 53]]], ["Infection rates were determined using Results from the 2-3 replicate feeds were combined and the titer (log 10 PFU/ml) shown is an average (for titers that were within 0.5 log 10 PFU/ml of one another).", [["Infection rates", "PROBLEM", 0, 15], ["titers", "TEST", 144, 150]]], ["Infection rate is determined using mosquito bodies while dissemination rate is derived from heads. doi:10.1371/journal.pntd.0001931.g001Mosquito infectionsindividual bodies and dissemination rates were calculated as the number of positive heads among the positive bodies.", [["heads", "ORGANISM_SUBDIVISION", 92, 97], ["Infection rate", "PROBLEM", 0, 14], ["mosquito bodies", "TREATMENT", 35, 50], ["dissemination rate", "TEST", 57, 75], ["dissemination rates", "TEST", 177, 196], ["dissemination", "OBSERVATION_MODIFIER", 177, 190], ["rates", "OBSERVATION_MODIFIER", 191, 196], ["positive heads", "OBSERVATION", 230, 244], ["positive bodies", "OBSERVATION", 255, 270]]], ["At least two replicate infectious feeds were done for each chimeric virus, with replicate feeds performed entirely independent of one another.", [["infectious feeds", "TREATMENT", 23, 39], ["each chimeric virus", "PROBLEM", 54, 73], ["replicate feeds", "TREATMENT", 80, 95], ["infectious feeds", "OBSERVATION", 23, 39]]], ["No less than 140 mosquitoes were tested for any one chimeric virus.Mosquito processingIndividual frozen mosquito bodies and heads were triturated in 300 ml of DMEM supplemented with (by volume): 10% heatinactivated fetal bovine serum, 1% penicillin/streptomycin, 0.1% gentamicin, and 0.1% Fungizone.", [["bodies", "ANATOMY", 113, 119], ["heads", "ANATOMY", 124, 129], ["fetal", "ANATOMY", 215, 220], ["serum", "ANATOMY", 228, 233], ["penicillin", "CHEMICAL", 238, 248], ["streptomycin", "CHEMICAL", 249, 261], ["gentamicin", "CHEMICAL", 268, 278], ["Fungizone", "CHEMICAL", 289, 298], ["penicillin", "CHEMICAL", 238, 248], ["streptomycin", "CHEMICAL", 249, 261], ["gentamicin", "CHEMICAL", 268, 278], ["Fungizone", "CHEMICAL", 289, 298], ["mosquitoes", "ORGANISM", 17, 27], ["heads", "ORGANISM_SUBDIVISION", 124, 129], ["bovine", "ORGANISM", 221, 227], ["serum", "ORGANISM_SUBSTANCE", 228, 233], ["penicillin", "SIMPLE_CHEMICAL", 238, 248], ["streptomycin", "SIMPLE_CHEMICAL", 249, 261], ["gentamicin", "SIMPLE_CHEMICAL", 268, 278], ["Fungizone", "SIMPLE_CHEMICAL", 289, 298], ["bovine", "SPECIES", 221, 227], ["bovine", "SPECIES", 221, 227], ["any one chimeric virus", "PROBLEM", 44, 66], ["heatinactivated fetal bovine serum", "TREATMENT", 199, 233], ["penicillin", "TREATMENT", 238, 248], ["streptomycin", "TREATMENT", 249, 261], ["gentamicin", "TREATMENT", 268, 278], ["Fungizone", "TREATMENT", 289, 298], ["virus", "OBSERVATION", 61, 66], ["frozen mosquito bodies", "OBSERVATION", 97, 119]]], ["The mosquito homogenates were passed through a 0.2 mm Gelman Acrodisc filter (Krackeler Scientific Inc., Albany, NY) to remove potential bacterial or fungal contaminates.", [["homogenates", "ANATOMY", 13, 24], ["mosquito", "ORGANISM", 4, 12], ["homogenates", "ORGANISM_SUBSTANCE", 13, 24], ["a 0.2 mm Gelman Acrodisc filter", "TREATMENT", 45, 76], ["potential bacterial or fungal contaminates", "PROBLEM", 127, 169], ["fungal contaminates", "OBSERVATION", 150, 169]]], ["Filtrate from each body or head was added to a single well of a 96-well flat-bottom tissue-culture plate, along with 50 ml of prepared BHK-21 cell suspension (approximately 4.6 log 10 cells/well).", [["body", "ANATOMY", 19, 23], ["head", "ANATOMY", 27, 31], ["tissue", "ANATOMY", 84, 90], ["BHK-21 cell", "ANATOMY", 135, 146], ["cells", "ANATOMY", 184, 189], ["Filtrate", "CHEMICAL", 0, 8], ["BHK-21", "CHEMICAL", 135, 141], ["Filtrate", "SIMPLE_CHEMICAL", 0, 8], ["body", "ORGANISM_SUBDIVISION", 19, 23], ["head", "ORGANISM_SUBDIVISION", 27, 31], ["tissue", "TISSUE", 84, 90], ["BHK-21 cell", "CELL", 135, 146], ["Filtrate", "TREATMENT", 0, 8], ["culture plate", "TEST", 91, 104], ["prepared BHK-21 cell suspension", "TREATMENT", 126, 157], ["head", "ANATOMY", 27, 31]]], ["Inoculated tissue-culture plates were incubated at 37uC for 5 days.", [["tissue", "ANATOMY", 11, 17], ["37uC", "CHEMICAL", 51, 55], ["tissue-culture plates", "CELL", 11, 32], ["culture plates", "TEST", 18, 32]]], ["Cells were observed daily for CPE due to virus replication.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["CPE", "PROBLEM", 30, 33], ["virus replication", "PROBLEM", 41, 58]]], ["Virus replication in mosquito body samples indicated that virus had infected the mosquito's midgut, while replication in the mosquito heads showed a disseminated infection.Confirmation of viral replicationTo confirm that all constructed viruses were comparably replication competent, growth curves were performed in cell culture on all rescued viruses.", [["body samples", "ANATOMY", 30, 42], ["midgut", "ANATOMY", 92, 98], ["heads", "ANATOMY", 134, 139], ["cell", "ANATOMY", 316, 320], ["infection", "DISEASE", 162, 171], ["Virus", "ORGANISM", 0, 5], ["mosquito", "ORGANISM", 21, 29], ["body samples", "ORGANISM_SUBSTANCE", 30, 42], ["midgut", "ORGAN", 92, 98], ["mosquito", "ORGANISM", 125, 133], ["heads", "ORGANISM_SUBDIVISION", 134, 139], ["cell", "CELL", 316, 320], ["Virus replication", "TREATMENT", 0, 17], ["mosquito body samples", "TEST", 21, 42], ["virus", "PROBLEM", 58, 63], ["a disseminated infection", "PROBLEM", 147, 171], ["viral replication", "TREATMENT", 188, 205], ["all constructed viruses", "PROBLEM", 221, 244], ["growth curves", "TEST", 284, 297], ["cell culture", "TEST", 316, 328], ["virus", "OBSERVATION", 58, 63], ["disseminated", "OBSERVATION_MODIFIER", 149, 161], ["infection", "OBSERVATION", 162, 171], ["viral replication", "OBSERVATION", 188, 205]]], ["Briefly, 24-well plates (Corning, Corning, NY) were seeded with Vero (African green monkey) cells.", [["green monkey) cells", "ANATOMY", 78, 97], ["green monkey) cells", "CELL", 78, 97], ["green monkey", "SPECIES", 78, 90], ["African green monkey", "SPECIES", 70, 90], ["Vero (African green monkey) cells", "TREATMENT", 64, 97]]], ["Monolayers at 90% confluency were infected with virus at a multiplicity of infection (MOI) of 0.1.", [["Monolayers", "ANATOMY", 0, 10], ["infection", "DISEASE", 75, 84], ["Monolayers", "CELL", 0, 10], ["Monolayers", "TEST", 0, 10], ["virus", "PROBLEM", 48, 53], ["infection", "PROBLEM", 75, 84], ["infection", "OBSERVATION", 75, 84]]], ["At specified times post infection, supernatant was removed from two wells for each virus and placed in a screw-cap cryovial at 270uC until titration by plaque assay.", [["supernatant", "ANATOMY", 35, 46], ["plaque", "ANATOMY", 152, 158], ["infection", "DISEASE", 24, 33], ["infection", "PROBLEM", 24, 33], ["supernatant", "TREATMENT", 35, 46], ["each virus", "PROBLEM", 78, 88], ["a screw-cap cryovial", "TREATMENT", 103, 123], ["infection", "OBSERVATION", 24, 33], ["screw", "OBSERVATION", 105, 110], ["plaque", "OBSERVATION", 152, 158]]], ["Titration results for each virus were compared at all time points by the student t-test.Confirmation of viral replicationTo confirm virus replication (and not just persistence of the input virus) within the mosquito, five females that had fed on the ONNV infectious blood meal were sacrificed every other day post-infectious feed.", [["blood", "ANATOMY", 266, 271], ["blood", "ORGANISM_SUBSTANCE", 266, 271], ["ONNV", "SPECIES", 250, 254], ["each virus", "PROBLEM", 22, 32], ["the student t-test", "TEST", 69, 87], ["viral replicationTo", "TREATMENT", 104, 123], ["virus replication", "TREATMENT", 132, 149], ["the input virus", "PROBLEM", 179, 194], ["the ONNV infectious blood meal", "TREATMENT", 246, 276]]], ["Each body and head was processed separately, as described earlier.", [["body", "ANATOMY", 5, 9], ["head", "ANATOMY", 14, 18], ["body", "ORGANISM_SUBDIVISION", 5, 9], ["head", "ORGAN", 14, 18], ["head", "ANATOMY", 14, 18]]], ["RNA was extracted from homogenized mosquitoes using QIAamp Viral RNA Mini Kit (Qiagen).", [["RNA", "RNA", 0, 3], ["QIAamp Viral RNA", "TREATMENT", 52, 68]]], ["The amount of RNA in each head and body was determined using the Quanti Tect Probe RT-PCR kit (Qiagen) and a TaqMan Real-Time PCR assay as previously described [24] , except that ONNV SG650 specific primers were used (10692 FWD-59 GCA GGG AGG CCA GGA CAG T, 10840 REV-59 GCC CCT TTT TCY TTG AGC CAG TA) .", [["head", "ANATOMY", 26, 30], ["body", "ANATOMY", 35, 39], ["head", "ORGANISM_SUBDIVISION", 26, 30], ["body", "ORGANISM_SUBDIVISION", 35, 39], ["RNA", "RNA", 14, 17], ["ONNV SG650 specific primers", "DNA", 179, 206], ["10840 REV-59 GCC CCT", "DNA", 258, 278], ["TCY TTG AGC CAG TA", "DNA", 283, 301], ["ONNV", "SPECIES", 179, 183], ["the Quanti Tect Probe RT", "TREATMENT", 61, 85], ["a TaqMan", "TEST", 107, 115], ["Time PCR assay", "TEST", 121, 135], ["FWD", "TEST", 224, 227], ["GCA", "TEST", 231, 234], ["GGG AGG", "TEST", 235, 242], ["CCA", "TEST", 243, 246], ["GGA", "TEST", 247, 250], ["CAG", "TEST", 251, 254], ["T", "TEST", 255, 256], ["REV", "TEST", 264, 267], ["GCC", "TEST", 271, 274], ["CCT", "TEST", 275, 278], ["TTT", "TEST", 279, 282], ["TCY", "TEST", 283, 286], ["TTG", "TEST", 287, 290], ["AGC CAG TA", "TEST", 291, 301], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["RNA", "OBSERVATION", 14, 17], ["head", "ANATOMY", 26, 30], ["body", "ANATOMY", 35, 39]]], ["The real-time probe was labeled with a 59 end HEX reporter dye and a 39 end BHQ1 quencher dye (10759 FWD-59 AAA GAC CAG CGG CAG GAG CAA TAC AC) and PCR results are reported here as PFU-equivalents/mosquito by comparison with known concentration standards.Statistical significanceFisher's exact probability test was employed to evaluate whether infection rates with chimeric viruses were statistically different from those with parental viruses.", [["infection", "DISEASE", 344, 353], ["BHQ1 quencher dye", "TEST", 76, 93], ["FWD", "TEST", 101, 104], ["AAA GAC CAG", "TEST", 108, 119], ["CGG", "TEST", 120, 123], ["CAG", "TEST", 124, 127], ["CAA TAC AC)", "TEST", 132, 143], ["PCR", "TEST", 148, 151], ["Statistical significanceFisher's exact probability test", "TEST", 255, 310], ["infection rates", "PROBLEM", 344, 359], ["chimeric viruses", "PROBLEM", 365, 381], ["parental viruses", "PROBLEM", 427, 443]]], ["The infection rate was defined as significantly different from parental CHIKV if the two-tailed pvalue was ,0.007.", [["infection", "DISEASE", 4, 13], ["CHIKV", "ORGANISM", 72, 77], ["CHIKV", "SPECIES", 72, 77], ["The infection rate", "PROBLEM", 0, 18], ["infection", "OBSERVATION", 4, 13]]], ["The two-tailed p-value had to be ,0.01 to be statistically different from parental ONNV infection rates.", [["infection", "DISEASE", 88, 97], ["parental ONNV infection rates", "PROBLEM", 74, 103], ["infection", "OBSERVATION", 88, 97]]], ["Both adjusted alphas were obtained using the Bonferroni correction for multiple comparisons to ensure an overall Type I error of 0.05.", [["the Bonferroni correction", "TREATMENT", 41, 66]]], ["Computations were made using freely-available software [25] .Understanding the involvement of viral elements in vector specificity is critical for eventual control of vector-borne viruses.This study built upon previously established disparate infectivity patterns for two closely related alphaviruses, CHIKV and ONNV, in An. gambiae [5, 6] and infection rates with the parental viruses generated from our full-length infectious clones were concordant with those previously reported.", [["infection", "DISEASE", 344, 353], ["alphaviruses", "ORGANISM", 288, 300], ["CHIKV", "ORGANISM", 302, 307], ["An. gambiae", "ORGANISM", 321, 332], ["clones", "CELL", 428, 434], ["viral elements", "DNA", 94, 108], ["An. gambiae", "SPECIES", 321, 332], ["CHIKV", "SPECIES", 302, 307], ["ONNV", "SPECIES", 312, 316], ["An. gambiae", "SPECIES", 321, 332], ["viral elements in vector specificity", "PROBLEM", 94, 130], ["borne viruses", "PROBLEM", 174, 187], ["This study", "TEST", 188, 198], ["two closely related alphaviruses", "PROBLEM", 268, 300], ["CHIKV", "PROBLEM", 302, 307], ["ONNV", "TREATMENT", 312, 316], ["infection rates", "PROBLEM", 344, 359], ["the parental viruses", "PROBLEM", 365, 385], ["viral elements", "OBSERVATION", 94, 108], ["infectivity", "OBSERVATION", 243, 254]]], ["By day 12, up to 91% of An. gambiae mosquitoes were infected with ONNV, whereas a maximum of only 6% were infected with CHIKV.", [["CHIKV", "DISEASE", 120, 125], ["An. gambiae mosquitoes", "ORGANISM", 24, 46], ["CHIKV", "ORGANISM", 120, 125], ["An. gambiae", "SPECIES", 24, 35], ["An. gambiae", "SPECIES", 24, 35], ["ONNV", "SPECIES", 66, 70], ["CHIKV", "SPECIES", 120, 125], ["ONNV", "TREATMENT", 66, 70], ["CHIKV", "PROBLEM", 120, 125], ["CHIKV", "OBSERVATION", 120, 125]]], ["These values are similar to previously published work [6] .", [["These values", "TEST", 0, 12]]], ["With this highly significant difference (p,0.0001) between the two viruses, characterization of individual viral gene substitutions was likely to reveal which elements were involved in mosquito infection.", [["mosquito infection", "DISEASE", 185, 203], ["viral gene substitutions", "DNA", 107, 131], ["the two viruses", "PROBLEM", 59, 74], ["individual viral gene substitutions", "PROBLEM", 96, 131], ["mosquito infection", "PROBLEM", 185, 203], ["highly", "OBSERVATION_MODIFIER", 10, 16], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["difference", "OBSERVATION", 29, 39], ["viruses", "OBSERVATION", 67, 74]]], ["Prior to initiating these experiments with chimeric viruses in An. gambiae, viral replication (and not just persistence of input virus) within both cell culture and in the mosquito was confirmed.", [["cell culture", "ANATOMY", 148, 160], ["chimeric viruses", "ORGANISM", 43, 59], ["An. gambiae", "ORGANISM", 63, 74], ["cell culture", "CELL", 148, 160], ["mosquito", "ORGANISM", 172, 180], ["An. gambiae", "SPECIES", 63, 74], ["An. gambiae", "SPECIES", 63, 74], ["these experiments", "TREATMENT", 20, 37], ["chimeric viruses", "PROBLEM", 43, 59], ["viral replication", "TREATMENT", 76, 93], ["input virus", "PROBLEM", 123, 134], ["both cell culture", "TEST", 143, 160]]], ["Cell culture growth curves of all of the chimeras were performed in Vero cells to confirm that all viruses were indeed replication competent and replicated in a manner similar to their parental viruses ( Figure 3 ).", [["Cell", "ANATOMY", 0, 4], ["Vero cells", "ANATOMY", 68, 78], ["Cell", "CELL", 0, 4], ["Vero cells", "CELL", 68, 78], ["Vero cells", "CELL_LINE", 68, 78], ["Cell culture growth curves", "TEST", 0, 26], ["the chimeras", "TEST", 37, 49], ["all viruses", "PROBLEM", 95, 106]]], ["The structural change viruses all replicated efficiently and replication was virtually identical among all chimeras sharing non-structural genes.", [["non-structural genes", "DNA", 124, 144], ["The structural change viruses", "PROBLEM", 0, 29], ["structural", "OBSERVATION_MODIFIER", 4, 14], ["change", "OBSERVATION_MODIFIER", 15, 21], ["viruses", "OBSERVATION", 22, 29], ["non-structural genes", "OBSERVATION", 124, 144]]], ["In general, those viruses with the ONNV non-structural genes grew to peak titers of 10 6.5 -10 7 pfu/ mL while those with CHIKV non-structural genes had peak titers of 10 7.5 -10 8 pfu/mL.", [["ONNV", "GENE_OR_GENE_PRODUCT", 35, 39], ["CHIKV", "ORGANISM", 122, 127], ["ONNV non-structural genes", "DNA", 35, 60], ["CHIKV non-structural genes", "DNA", 122, 148], ["CHIKV", "SPECIES", 122, 127], ["the ONNV non-structural genes", "TEST", 31, 60], ["peak titers", "TEST", 69, 80], ["CHIKV non-structural genes", "TEST", 122, 148], ["peak titers", "TEST", 153, 164], ["viruses", "OBSERVATION", 18, 25]]], ["All non-structural chimeric viruses grew similarly well, rapidly increasing in titer from 1000 pfu/mL to 10 7 -10 8.5 pfu/mL.", [["All non-structural chimeric viruses", "PROBLEM", 0, 35], ["non-structural", "OBSERVATION", 4, 18], ["chimeric viruses", "OBSERVATION", 19, 35], ["rapidly", "OBSERVATION_MODIFIER", 57, 64], ["increasing", "OBSERVATION_MODIFIER", 65, 75]]], ["No consistent statistical differences were observed among the non-structural substitution viruses.Understanding the involvement of viral elements in vector specificity is critical for eventual control of vector-borne viruses.The quantity of ONNV RNA present in individual mosquito bodies and heads through 11 days post-infectious feed adhered to the expected pattern of decrease during the extrinsic incubation period followed by a rise in virus replication at later time points as determined by qRT-PCR.", [["mosquito bodies", "ANATOMY", 272, 287], ["heads", "ANATOMY", 292, 297], ["ONNV", "GENE_OR_GENE_PRODUCT", 241, 245], ["viral elements", "DNA", 131, 145], ["ONNV RNA", "RNA", 241, 249], ["ONNV", "SPECIES", 241, 245], ["the non-structural substitution viruses", "PROBLEM", 58, 97], ["viral elements in vector specificity", "PROBLEM", 131, 167], ["borne viruses", "PROBLEM", 211, 224], ["ONNV RNA", "PROBLEM", 241, 249], ["post-infectious feed", "TREATMENT", 314, 334], ["a rise in virus replication", "PROBLEM", 430, 457], ["non-structural substitution viruses", "OBSERVATION", 62, 97], ["viral elements", "OBSERVATION", 131, 145], ["quantity", "OBSERVATION_MODIFIER", 229, 237], ["ONNV RNA", "OBSERVATION", 241, 249], ["mosquito bodies", "OBSERVATION", 272, 287], ["heads", "OBSERVATION_MODIFIER", 292, 297], ["decrease", "OBSERVATION_MODIFIER", 370, 378], ["virus replication", "OBSERVATION", 440, 457]]], ["Moreover, after 5 days post infection, the five mosquito bodies tested at each of the subsequent time points had more RNA copies than could have been initially imbibed in the blood meal indicating replication of the virus was indeed occurring (Figure 4) .Understanding the involvement of viral elements in vector specificity is critical for eventual control of vector-borne viruses.Nine unique chimeric hybrids of CHIKV and ONNV were constructed using convenient restriction enzyme sites to produce substitutions in the structural region of the viral genome and to examine the contribution of each of these specific regions to virusvector specificity (Figure 1 ).", [["blood", "ANATOMY", 175, 180], ["infection", "DISEASE", 28, 37], ["blood", "ORGANISM_SUBSTANCE", 175, 180], ["CHIKV", "ORGANISM", 414, 419], ["ONNV", "GENE_OR_GENE_PRODUCT", 424, 428], ["RNA copies", "RNA", 118, 128], ["viral elements", "DNA", 288, 302], ["ONNV", "DNA", 424, 428], ["restriction enzyme sites", "DNA", 463, 487], ["viral genome", "DNA", 545, 557], ["CHIKV", "SPECIES", 414, 419], ["ONNV", "SPECIES", 424, 428], ["infection", "PROBLEM", 28, 37], ["the five mosquito bodies", "TREATMENT", 39, 63], ["more RNA copies", "PROBLEM", 113, 128], ["the virus", "PROBLEM", 212, 221], ["viral elements in vector specificity", "PROBLEM", 288, 324], ["borne viruses", "PROBLEM", 368, 381], ["CHIKV and ONNV", "TREATMENT", 414, 428], ["convenient restriction enzyme sites", "TREATMENT", 452, 487], ["substitutions", "PROBLEM", 499, 512], ["infection", "OBSERVATION", 28, 37], ["virus", "OBSERVATION", 216, 221], ["viral elements", "OBSERVATION", 288, 302], ["viral genome", "OBSERVATION", 545, 557]]], ["Six additional non-structural chimeric viruses were also constructed using a novel type II restriction enzyme cloning strategy to examine the broader genome with respect to ONNV's unique vector specificity for An. gambiae mosquitoes (Figure 2) .Understanding the involvement of viral elements in vector specificity is critical for eventual control of vector-borne viruses.Having confirmed viral replication and infections rates of parental ONNV in An. gambiae, infection and dissemination rates with each of the 15 chimeric viruses were determined.", [["infections", "DISEASE", 411, 421], ["infection", "DISEASE", 461, 470], ["ONNV", "CANCER", 173, 177], ["An. gambiae mosquitoes", "ORGANISM", 210, 232], ["An. gambiae", "ORGANISM", 448, 459], ["ONNV", "DNA", 173, 177], ["viral elements", "DNA", 278, 292], ["An. gambiae", "SPECIES", 210, 221], ["An. gambiae", "SPECIES", 448, 459], ["An. gambiae", "SPECIES", 210, 221], ["ONNV", "SPECIES", 440, 444], ["An. gambiae", "SPECIES", 448, 459], ["Six additional non-structural chimeric viruses", "PROBLEM", 0, 46], ["a novel type II restriction enzyme cloning strategy", "TREATMENT", 75, 126], ["viral elements in vector specificity", "PROBLEM", 278, 314], ["borne viruses", "PROBLEM", 358, 371], ["viral replication", "PROBLEM", 389, 406], ["infections rates", "PROBLEM", 411, 427], ["infection", "PROBLEM", 461, 470], ["dissemination rates", "TEST", 475, 494], ["the 15 chimeric viruses", "PROBLEM", 508, 531], ["non-structural chimeric viruses", "OBSERVATION", 15, 46], ["viral elements", "OBSERVATION", 278, 292], ["viral replication", "OBSERVATION", 389, 406], ["infections", "OBSERVATION", 411, 421], ["infection", "OBSERVATION", 461, 470], ["viruses", "OBSERVATION", 524, 531]]], ["Each time a virus was generated through in vitro transcription for this study, it was sequenced completely prior to use in an infectious feed.", [["a virus", "PROBLEM", 10, 17], ["this study", "TEST", 67, 77], ["an infectious feed", "TREATMENT", 123, 141], ["infectious", "OBSERVATION", 126, 136]]], ["Mosquitoes containing replicating virus in the body, as shown by CPE analysis, were defined as being positive for viral infection.", [["body", "ANATOMY", 47, 51], ["viral infection", "DISEASE", 114, 129], ["body", "ORGANISM_SUBDIVISION", 47, 51], ["replicating virus in the body", "PROBLEM", 22, 51], ["CPE analysis", "TEST", 65, 77], ["viral infection", "PROBLEM", 114, 129], ["replicating virus", "OBSERVATION", 22, 39], ["body", "ANATOMY", 47, 51], ["infection", "OBSERVATION", 120, 129]]], ["Mosquito heads were analyzed separately from bodies to determine dissemination rates.Understanding the involvement of viral elements in vector specificity is critical for eventual control of vector-borne viruses.Each chimeric virus constructed from the parental CHIKV genome maintained a CHIKV-like infection profile (,10% infection rate), with one exception.", [["heads", "ANATOMY", 9, 14], ["CHIKV-like infection", "DISEASE", 288, 308], ["infection", "DISEASE", 323, 332], ["CHIKV", "ORGANISM", 262, 267], ["viral elements", "DNA", 118, 132], ["parental CHIKV genome", "DNA", 253, 274], ["CHIKV", "SPECIES", 262, 267], ["CHIKV", "SPECIES", 288, 293], ["dissemination rates", "TEST", 65, 84], ["viral elements in vector specificity", "PROBLEM", 118, 154], ["borne viruses", "PROBLEM", 198, 211], ["Each chimeric virus", "TREATMENT", 212, 231], ["a CHIKV-like infection profile", "PROBLEM", 286, 316], ["viral elements", "OBSERVATION", 118, 132], ["CHIKV genome", "OBSERVATION", 262, 274], ["CHIKV", "OBSERVATION", 288, 293]]], ["When allowed to feed on a blood meal containing approximately 5.5 log 10 PFU/ml of CHIK/ONN nsP3 virus, 63.5% (n = 85) of mosquitoes had replicating virus when harvested on day 8 post infection ( Figure 2) .", [["blood", "ANATOMY", 26, 31], ["infection", "DISEASE", 184, 193], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["CHIK/ONN nsP3 virus", "ORGANISM", 83, 102], ["mosquitoes", "ORGANISM", 122, 132], ["ONN nsP3 virus", "SPECIES", 88, 102], ["a blood meal", "TREATMENT", 24, 36], ["CHIK", "PROBLEM", 83, 87], ["nsP3 virus", "PROBLEM", 92, 102], ["mosquitoes", "PROBLEM", 122, 132], ["replicating virus", "PROBLEM", 137, 154], ["infection", "PROBLEM", 184, 193], ["infection", "OBSERVATION", 184, 193]]], ["None of the ONNV substitutions made to the structural regions of the CHIKV parental genome produced infection results deviating from those seen with the complete CHIKV parental genome ( Figure 1 ).", [["infection", "DISEASE", 100, 109], ["ONNV", "GENE_OR_GENE_PRODUCT", 12, 16], ["CHIKV", "ORGANISM", 69, 74], ["ONNV substitutions", "DNA", 12, 30], ["CHIKV parental genome", "DNA", 69, 90], ["CHIKV parental genome", "DNA", 162, 183], ["CHIKV", "SPECIES", 69, 74], ["CHIKV", "SPECIES", 162, 167], ["the ONNV substitutions", "TREATMENT", 8, 30], ["infection", "PROBLEM", 100, 109], ["CHIKV", "OBSERVATION", 69, 74], ["infection", "OBSERVATION", 100, 109]]], ["Three of the 5 chimeric viruses constructed from the parental ONNV genome retained ONNV-like infection rates at day 8 in An. gambiae, while the remaining two viruses showed significantly lower infection rates.", [["infection", "DISEASE", 93, 102], ["infection", "DISEASE", 193, 202], ["ONNV", "GENE_OR_GENE_PRODUCT", 62, 66], ["ONNV", "GENE_OR_GENE_PRODUCT", 83, 87], ["An. gambiae", "ORGANISM", 121, 132], ["ONNV genome", "DNA", 62, 73], ["An. gambiae", "SPECIES", 121, 132], ["ONNV", "SPECIES", 62, 66], ["An. gambiae", "SPECIES", 121, 132], ["the 5 chimeric viruses", "PROBLEM", 9, 31], ["infection rates", "PROBLEM", 93, 108], ["significantly lower infection rates", "PROBLEM", 173, 208], ["viruses", "OBSERVATION", 24, 31], ["retained", "OBSERVATION_MODIFIER", 74, 82], ["ONNV", "OBSERVATION_MODIFIER", 83, 87], ["infection", "OBSERVATION", 93, 102], ["significantly", "OBSERVATION_MODIFIER", 173, 186], ["lower", "OBSERVATION_MODIFIER", 187, 192], ["infection", "OBSERVATION", 193, 202]]], ["Only 11.1% (n = 135) of mosquitoes feeding on ONN/CHIK 39STR and 53.2% (n = 77) of ONN/CHIK 59STR were shown to be infected at day 8.", [["STR", "CHEMICAL", 94, 97], ["mosquitoes", "ORGANISM", 24, 34], ["mosquitoes feeding", "TEST", 24, 42], ["CHIK", "TEST", 50, 54], ["ONN/CHIK 59STR", "PROBLEM", 83, 97], ["infected", "OBSERVATION", 115, 123]]], ["Infection rates for mosquitoes sacrificed at days 4, 11, or 12 corroborate day 8 results (data not shown).Understanding the involvement of viral elements in vector specificity is critical for eventual control of vector-borne viruses.Dissemination rates for each of the viruses in An. gambiae was very low and all were comparable for both day 8 and day 11 samples.", [["An. gambiae", "ORGANISM", 280, 291], ["viral elements", "DNA", 139, 153], ["An. gambiae", "SPECIES", 280, 291], ["An. gambiae", "SPECIES", 280, 291], ["Infection rates", "PROBLEM", 0, 15], ["viral elements in vector specificity", "PROBLEM", 139, 175], ["borne viruses", "PROBLEM", 219, 232], ["Dissemination rates", "TEST", 233, 252], ["the viruses", "PROBLEM", 265, 276], ["An. gambiae", "TEST", 280, 291], ["viral elements", "OBSERVATION", 139, 153], ["viruses", "OBSERVATION", 269, 276]]], ["Only 5 viruses showed any dissemination (figures 1 and 2): parental ONN.AP3,Onn/Chik E2, Onn/Chik eSTR, Onn/ Chik 39nsP4-59C, Chik/Onn 39STR.", [["AP3", "GENE_OR_GENE_PRODUCT", 72, 75], ["AP3", "PROTEIN", 72, 75], ["Onn", "PROTEIN", 76, 79], ["Chik E2", "PROTEIN", 80, 87], ["Onn", "PROTEIN", 89, 92], ["Chik", "PROTEIN", 93, 97], ["eSTR", "PROTEIN", 98, 102], ["Onn", "PROTEIN", 104, 107], ["Chik", "PROTEIN", 109, 113], ["39nsP4", "PROTEIN", 114, 120], ["59C", "PROTEIN", 121, 124], ["Chik", "PROTEIN", 126, 130], ["Onn 39STR", "PROTEIN", 131, 140], ["AP3", "TEST", 72, 75], ["Chik", "PROBLEM", 126, 130], ["dissemination", "OBSERVATION", 26, 39]]], ["The rest of the viruses showed no dissemination.DiscussionA panel of 15 chimeric viruses were developed here to study specific elements of the ONNV genome and to determine which of these regions are necessary for ONNV to infect An. gambiae mosquitoes.", [["ONNV", "GENE_OR_GENE_PRODUCT", 143, 147], ["ONNV", "GENE_OR_GENE_PRODUCT", 213, 217], ["An. gambiae mosquitoes", "ORGANISM", 228, 250], ["ONNV genome", "DNA", 143, 154], ["An. gambiae", "SPECIES", 228, 239], ["ONNV", "SPECIES", 213, 217], ["An. gambiae", "SPECIES", 228, 239], ["dissemination", "PROBLEM", 34, 47], ["DiscussionA panel", "TEST", 48, 65], ["15 chimeric viruses", "PROBLEM", 69, 88], ["viruses", "OBSERVATION", 16, 23], ["no", "UNCERTAINTY", 31, 33], ["dissemination", "OBSERVATION", 34, 47]]], ["As CHIKV virus primarily infects Aedes species and ONNV primarily infects Anopheles species, these two closely related viruses provide an ideal opportunity to study these viral genetic determinants of infection.", [["infection", "DISEASE", 201, 210], ["CHIKV virus", "ORGANISM", 3, 14], ["Aedes species", "ORGANISM", 33, 46], ["ONNV", "GENE_OR_GENE_PRODUCT", 51, 55], ["Anopheles species", "ORGANISM", 74, 91], ["CHIKV virus", "SPECIES", 3, 14], ["ONNV", "SPECIES", 51, 55], ["CHIKV virus", "PROBLEM", 3, 14], ["Aedes species", "PROBLEM", 33, 46], ["Anopheles species", "PROBLEM", 74, 91], ["infection", "PROBLEM", 201, 210], ["infection", "OBSERVATION", 201, 210]]], ["This study is the first to look at the importance of ONNV non-structural proteins in An. gambiae infection.", [["An. gambiae infection", "DISEASE", 85, 106], ["ONNV", "GENE_OR_GENE_PRODUCT", 53, 57], ["An. gambiae", "ORGANISM", 85, 96], ["ONNV non-structural proteins", "PROTEIN", 53, 81], ["An. gambiae", "SPECIES", 85, 96], ["An. gambiae", "SPECIES", 85, 96], ["This study", "TEST", 0, 10], ["ONNV non-structural proteins", "PROBLEM", 53, 81], ["An. gambiae infection", "PROBLEM", 85, 106], ["infection", "OBSERVATION", 97, 106]]], ["Of the ten CHIKV-backbone chimeras constructed and tested, only the one containing ONNV nsP3 produced infection rates closer to parental ONNV than to the parental CHIKV.", [["infection", "DISEASE", 102, 111], ["CHIKV", "ORGANISM", 11, 16], ["ONNV", "GENE_OR_GENE_PRODUCT", 83, 87], ["nsP3", "GENE_OR_GENE_PRODUCT", 88, 92], ["CHIKV", "ORGANISM", 163, 168], ["ONNV nsP3", "DNA", 83, 92], ["CHIKV", "SPECIES", 11, 16], ["CHIKV", "SPECIES", 163, 168], ["the ten CHIKV-backbone chimeras", "TREATMENT", 3, 34], ["infection rates", "PROBLEM", 102, 117], ["infection", "OBSERVATION", 102, 111]]], ["The ability of ONNV nsP3 to up-regulate infection rates so substantially shows that ONNV nsP3 is the main determinant of ONNV vector specificity for An. gambiae.", [["infection", "DISEASE", 40, 49], ["ONNV nsP3", "GENE_OR_GENE_PRODUCT", 15, 24], ["ONNV nsP3", "GENE_OR_GENE_PRODUCT", 84, 93], ["ONNV", "GENE_OR_GENE_PRODUCT", 121, 125], ["An. gambiae", "ORGANISM", 149, 160], ["ONNV nsP3", "PROTEIN", 15, 24], ["ONNV nsP3", "PROTEIN", 84, 93], ["An. gambiae", "SPECIES", 149, 160], ["ONNV", "SPECIES", 15, 19], ["ONNV", "SPECIES", 84, 88], ["ONNV", "SPECIES", 121, 125], ["An. gambiae", "SPECIES", 149, 160], ["ONNV nsP3", "TREATMENT", 15, 24], ["infection rates", "PROBLEM", 40, 55], ["infection", "OBSERVATION", 40, 49]]], ["Interestingly, the reciprocal chimeric virus (full length-ONNV with the CHIKV nsP3) was not able to be rescued from cDNA in either mammalian or insect cells.", [["cells", "ANATOMY", 151, 156], ["CHIKV", "ORGANISM", 72, 77], ["nsP3", "GENE_OR_GENE_PRODUCT", 78, 82], ["insect cells", "CELL", 144, 156], ["CHIKV nsP3", "DNA", 72, 82], ["cDNA", "DNA", 116, 120], ["mammalian or insect cells", "CELL_TYPE", 131, 156], ["CHIKV", "SPECIES", 72, 77], ["the reciprocal chimeric virus", "PROBLEM", 15, 44], ["the CHIKV nsP3", "PROBLEM", 68, 82], ["insect cells", "OBSERVATION", 144, 156]]], ["This would further suggest that nsP3 plays a critical role in viral replication that is distinct in these two closely related viruses that exhibit 81% and 72% amino acid and nucleotide identity respectively in nsP3.", [["nsP3", "CHEMICAL", 32, 36], ["amino acid", "CHEMICAL", 159, 169], ["nucleotide", "CHEMICAL", 174, 184], ["amino acid", "CHEMICAL", 159, 169], ["nucleotide", "CHEMICAL", 174, 184], ["nsP3", "GENE_OR_GENE_PRODUCT", 32, 36], ["amino acid", "AMINO_ACID", 159, 169], ["nsP3", "PROTEIN", 32, 36], ["nsP3", "PROTEIN", 210, 214], ["nsP3", "PROBLEM", 32, 36], ["viral replication", "PROBLEM", 62, 79], ["amino acid", "TEST", 159, 169], ["nucleotide identity", "TEST", 174, 193], ["nsP3", "PROBLEM", 210, 214], ["viral replication", "OBSERVATION", 62, 79]]], ["That nsP3 should be found to be essential to infection is especially interesting given the fact that the precise functions of this protein are not fully defined.", [["nsP3", "CHEMICAL", 5, 9], ["infection", "DISEASE", 45, 54], ["nsP3", "GENE_OR_GENE_PRODUCT", 5, 9], ["nsP3", "PROTEIN", 5, 9], ["nsP3", "PROBLEM", 5, 9], ["infection", "PROBLEM", 45, 54], ["infection", "OBSERVATION", 45, 54]]], ["It is required for the correct formation and localization of replication complexes and does provide essential functions in both minus strand and subgenomic RNA synthesis, but specific mechanisms are not yet resolved [21] [22] [23] .DiscussionTo further add to the intrigue of this protein, it has been shown that some members of the alphavirus family actually contain inserts of foreign genetic material within nsP3.", [["[21] [22] [23]", "SIMPLE_CHEMICAL", 216, 230], ["nsP3", "GENE_OR_GENE_PRODUCT", 411, 415], ["replication complexes", "PROTEIN", 61, 82], ["subgenomic RNA", "RNA", 145, 159], ["alphavirus family", "PROTEIN", 333, 350], ["nsP3", "DNA", 411, 415], ["replication complexes", "TREATMENT", 61, 82], ["both minus strand and subgenomic RNA synthesis", "PROBLEM", 123, 169], ["foreign genetic material within nsP3", "PROBLEM", 379, 415], ["subgenomic RNA synthesis", "OBSERVATION", 145, 169], ["foreign genetic material", "OBSERVATION", 379, 403]]], ["An eight amino acid sequence from the carboxyl-terminus of CHIKV nsP3 maps to a putative zinc finger protein in Ae. aegypti, the main vertebrate vector for that virus [26] .", [["amino acid", "CHEMICAL", 9, 19], ["amino acid", "CHEMICAL", 9, 19], ["carboxyl", "CHEMICAL", 38, 46], ["zinc", "CHEMICAL", 89, 93], ["amino acid", "AMINO_ACID", 9, 19], ["CHIKV", "ORGANISM", 59, 64], ["nsP3", "GENE_OR_GENE_PRODUCT", 65, 69], ["aegypti", "ORGANISM", 116, 123], ["carboxyl-terminus", "PROTEIN", 38, 55], ["CHIKV nsP3", "PROTEIN", 59, 69], ["zinc finger protein", "PROTEIN", 89, 108], ["Ae", "PROTEIN", 112, 114], ["aegypti", "SPECIES", 116, 123], ["CHIKV", "SPECIES", 59, 64], ["aegypti", "SPECIES", 116, 123], ["An eight amino acid sequence", "TEST", 0, 28], ["the carboxyl", "TREATMENT", 34, 46], ["CHIKV nsP3 maps", "TREATMENT", 59, 74], ["a putative zinc finger protein", "TEST", 78, 108], ["aegypti", "PROBLEM", 116, 123]]], ["In Semliki Forest virus, a 7 amino acid sequence corresponds to elements found in a wide-range of cellular proteins [26] .", [["cellular", "ANATOMY", 98, 106], ["amino acid", "CHEMICAL", 29, 39], ["amino acid", "CHEMICAL", 29, 39], ["Semliki Forest virus", "ORGANISM", 3, 23], ["amino acid", "AMINO_ACID", 29, 39], ["cellular", "CELL", 98, 106], ["cellular proteins", "PROTEIN", 98, 115], ["Semliki", "SPECIES", 3, 10], ["Semliki Forest virus", "SPECIES", 3, 23], ["Semliki Forest virus", "TREATMENT", 3, 23], ["a 7 amino acid sequence", "TEST", 25, 48], ["cellular proteins", "TEST", 98, 115], ["Semliki Forest virus", "OBSERVATION", 3, 23]]], ["Numerous other examples of what may be inserts of foreign genetic material been shown by sequencing nsP3 from the following alphaviruses: CHIKV, eastern equine encephalitis virus, Semliki Forest virus, and Venezuelan equine encephalitis virus [26] .DiscussionAlphavirus nsP3 can be clearly divided into two distinct domains.", [["equine encephalitis", "DISEASE", 153, 172], ["Venezuelan equine encephalitis", "DISEASE", 206, 236], ["nsP3", "GENE_OR_GENE_PRODUCT", 100, 104], ["CHIKV", "ORGANISM", 138, 143], ["eastern equine encephalitis virus", "ORGANISM", 145, 178], ["Semliki Forest virus", "ORGANISM", 180, 200], ["Venezuelan equine encephalitis virus", "ORGANISM", 206, 242], ["Alphavirus nsP3", "GENE_OR_GENE_PRODUCT", 259, 274], ["nsP3", "PROTEIN", 100, 104], ["Alphavirus nsP3", "DNA", 259, 274], ["equine encephalitis virus", "SPECIES", 153, 178], ["Semliki Forest virus", "SPECIES", 180, 200], ["Venezuelan equine encephalitis virus", "SPECIES", 206, 242], ["CHIKV", "SPECIES", 138, 143], ["eastern equine encephalitis virus", "SPECIES", 145, 178], ["Semliki Forest virus", "SPECIES", 180, 200], ["Venezuelan equine encephalitis virus", "SPECIES", 206, 242], ["foreign genetic material", "PROBLEM", 50, 74], ["sequencing nsP3", "PROBLEM", 89, 104], ["CHIKV", "PROBLEM", 138, 143], ["eastern equine encephalitis virus", "PROBLEM", 145, 178], ["Semliki Forest virus", "PROBLEM", 180, 200], ["Venezuelan equine encephalitis virus", "TREATMENT", 206, 242], ["Alphavirus nsP3", "TREATMENT", 259, 274], ["foreign genetic material", "OBSERVATION", 50, 74], ["Semliki Forest virus", "OBSERVATION", 180, 200], ["distinct", "OBSERVATION_MODIFIER", 307, 315], ["domains", "OBSERVATION", 316, 323]]], ["The macro domain, or amino-terminal region, is highly conserved, not just among alphaviruses but also among coronaviruses, hepatitis E virus, rubella virus and even cellular proteins [27, 28] .", [["cellular", "ANATOMY", 165, 173], ["hepatitis E", "DISEASE", 123, 134], ["rubella virus", "DISEASE", 142, 155], ["amino", "CHEMICAL", 21, 26], ["coronaviruses", "ORGANISM", 108, 121], ["hepatitis E virus", "ORGANISM", 123, 140], ["rubella virus", "ORGANISM", 142, 155], ["cellular", "CELL", 165, 173], ["macro domain", "PROTEIN", 4, 16], ["amino-terminal region", "PROTEIN", 21, 42], ["cellular proteins", "PROTEIN", 165, 182], ["hepatitis E virus", "SPECIES", 123, 140], ["rubella virus", "SPECIES", 142, 155], ["hepatitis E virus", "SPECIES", 123, 140], ["rubella virus", "SPECIES", 142, 155], ["The macro domain, or amino-terminal region", "PROBLEM", 0, 42], ["alphaviruses", "PROBLEM", 80, 92], ["coronaviruses", "PROBLEM", 108, 121], ["hepatitis E virus", "PROBLEM", 123, 140], ["rubella virus", "PROBLEM", 142, 155], ["cellular proteins", "TEST", 165, 182], ["macro domain", "OBSERVATION", 4, 16], ["amino", "ANATOMY_MODIFIER", 21, 26], ["terminal", "ANATOMY_MODIFIER", 27, 35], ["region", "ANATOMY_MODIFIER", 36, 42]]], ["The carboxyl-terminus domain of the alphavirus nsP3 is highly variable in size and sequence and is devoid of any predicted secondary structure [29, 30] .", [["carboxyl", "CHEMICAL", 4, 12], ["alphavirus", "ORGANISM", 36, 46], ["nsP3", "GENE_OR_GENE_PRODUCT", 47, 51], ["carboxyl-terminus domain", "PROTEIN", 4, 28], ["alphavirus nsP3", "PROTEIN", 36, 51], ["The carboxyl-terminus domain", "TREATMENT", 0, 28], ["the alphavirus nsP3", "PROBLEM", 32, 51], ["alphavirus nsP3", "OBSERVATION", 36, 51], ["highly", "OBSERVATION_MODIFIER", 55, 61], ["variable", "OBSERVATION_MODIFIER", 62, 70], ["size", "OBSERVATION_MODIFIER", 74, 78]]], ["Chimeric viruses were constructed using the natural division between the conserved and nonconserved regions of nsP3 to engineer two additional chimeric viruses to determine if the region conferring specificity to An. gambiae could be attributed solely to either of the distinct domains within nsP3.", [["nsP3", "GENE_OR_GENE_PRODUCT", 111, 115], ["An. gambiae", "ORGANISM", 213, 224], ["nsP3", "GENE_OR_GENE_PRODUCT", 293, 297], ["conserved and nonconserved regions", "DNA", 73, 107], ["nsP3", "DNA", 111, 115], ["nsP3", "DNA", 293, 297], ["An. gambiae", "SPECIES", 213, 224], ["An. gambiae", "SPECIES", 213, 224], ["Chimeric viruses", "PROBLEM", 0, 16], ["nsP3", "PROBLEM", 111, 115], ["the distinct domains within nsP3", "PROBLEM", 265, 297], ["viruses", "OBSERVATION", 9, 16]]], ["Interestingly, the addition of just the carboxylterminus of ONNV nsP3 did produce a small, although not a statistically significant, increase in infection rates as compared with parental CHIKV in An. gambiae.DiscussionThe carboxyl-terminus of nsP3, which has been subject to rapid alteration during alphavirus evolution, may also be involved in the optimization of replication in diverse host cell types [29] .", [["cell", "ANATOMY", 393, 397], ["infection", "DISEASE", 145, 154], ["carboxyl", "CHEMICAL", 222, 230], ["ONNV nsP3", "GENE_OR_GENE_PRODUCT", 60, 69], ["CHIKV", "ORGANISM", 187, 192], ["An. gambiae", "ORGANISM", 196, 207], ["nsP3", "GENE_OR_GENE_PRODUCT", 243, 247], ["host cell", "CELL", 388, 397], ["ONNV nsP3", "PROTEIN", 60, 69], ["carboxyl-terminus", "PROTEIN", 222, 239], ["nsP3", "PROTEIN", 243, 247], ["An. gambiae", "SPECIES", 196, 207], ["CHIKV", "SPECIES", 187, 192], ["An. gambiae", "SPECIES", 196, 207], ["infection rates", "PROBLEM", 145, 160], ["The carboxyl-terminus of nsP3", "TREATMENT", 218, 247], ["rapid alteration during alphavirus evolution", "PROBLEM", 275, 319], ["small", "OBSERVATION_MODIFIER", 84, 89], ["significant", "OBSERVATION_MODIFIER", 120, 131], ["increase", "OBSERVATION_MODIFIER", 133, 141], ["infection", "OBSERVATION", 145, 154], ["rapid", "OBSERVATION_MODIFIER", 275, 280], ["alteration", "OBSERVATION", 281, 291], ["diverse", "OBSERVATION_MODIFIER", 380, 387], ["host cell", "OBSERVATION", 388, 397]]], ["Studies with Sindbis showed that deletions in the carboxyl-terminus rendered mutants defective at initiating a productive infection, generating plaques in mosquito cells at only 1-2% the efficiency of the parental virus [31] .", [["plaques", "ANATOMY", 144, 151], ["cells", "ANATOMY", 164, 169], ["infection", "DISEASE", 122, 131], ["plaques", "DISEASE", 144, 151], ["carboxyl", "CHEMICAL", 50, 58], ["Sindbis", "ORGANISM", 13, 20], ["plaques", "PATHOLOGICAL_FORMATION", 144, 151], ["mosquito cells", "CELL", 155, 169], ["carboxyl-terminus", "PROTEIN", 50, 67], ["mosquito cells", "CELL_TYPE", 155, 169], ["Studies", "TEST", 0, 7], ["Sindbis", "PROBLEM", 13, 20], ["deletions in the carboxyl", "PROBLEM", 33, 58], ["mutants defective", "PROBLEM", 77, 94], ["a productive infection", "PROBLEM", 109, 131], ["generating plaques in mosquito cells", "PROBLEM", 133, 169], ["productive", "OBSERVATION_MODIFIER", 111, 121], ["infection", "OBSERVATION", 122, 131], ["plaques", "OBSERVATION_MODIFIER", 144, 151]]], ["A recent study noted a carboxyl-terminus, proline-rich sequence motif, the PIPPPR motif, shared by many alphavirus nsP3 proteins and demonstrated that even a single mutation in this region of Semliki Forest virus or Sindbis virus greatly impaired RNA synthesis by disrupting binding with host cell amphiphysins [32] .", [["cell", "ANATOMY", 293, 297], ["proline", "CHEMICAL", 42, 49], ["carboxyl", "CHEMICAL", 23, 31], ["proline", "CHEMICAL", 42, 49], ["proline", "AMINO_ACID", 42, 49], ["PIPPPR", "GENE_OR_GENE_PRODUCT", 75, 81], ["nsP3", "GENE_OR_GENE_PRODUCT", 115, 119], ["Semliki Forest virus", "ORGANISM", 192, 212], ["Sindbis virus", "ORGANISM", 216, 229], ["cell", "CELL", 293, 297], ["carboxyl-terminus", "PROTEIN", 23, 40], ["proline-rich sequence motif", "PROTEIN", 42, 69], ["PIPPPR motif", "PROTEIN", 75, 87], ["alphavirus nsP3 proteins", "PROTEIN", 104, 128], ["Sindbis virus", "SPECIES", 216, 229], ["Semliki Forest virus", "SPECIES", 192, 212], ["Sindbis virus", "SPECIES", 216, 229], ["A recent study", "TEST", 0, 14], ["a carboxyl-terminus", "TREATMENT", 21, 40], ["proline-rich sequence motif", "TREATMENT", 42, 69], ["the PIPPPR motif", "TEST", 71, 87], ["many alphavirus nsP3 proteins", "PROBLEM", 99, 128], ["a single mutation", "PROBLEM", 156, 173], ["Semliki Forest virus", "PROBLEM", 192, 212], ["Sindbis virus", "PROBLEM", 216, 229], ["host cell amphiphysins", "PROBLEM", 288, 310], ["Semliki Forest virus", "OBSERVATION", 192, 212], ["Sindbis virus", "OBSERVATION", 216, 229], ["host cell amphiphysins", "OBSERVATION", 288, 310]]], ["It is possible that this motif also modulates ONNV vector specificity since ONNV and CHIKV do differ from one another by one amino acid in this PIPPPR region.", [["amino acid", "CHEMICAL", 125, 135], ["amino acid", "CHEMICAL", 125, 135], ["ONNV", "GENE_OR_GENE_PRODUCT", 46, 50], ["ONNV", "GENE_OR_GENE_PRODUCT", 76, 80], ["CHIKV", "ORGANISM", 85, 90], ["amino acid", "AMINO_ACID", 125, 135], ["ONNV", "PROTEIN", 76, 80], ["PIPPPR region", "PROTEIN", 144, 157], ["ONNV", "SPECIES", 76, 80], ["CHIKV", "SPECIES", 85, 90], ["CHIKV", "PROBLEM", 85, 90]]], ["Attenuated virulence and reduced rates of RNA synthesis and virus replication were also seen in vertebrate cells with Semliki Forest virus mutants lacking some portion of the carboxyl-terminus of nsP3 [33] .", [["cells", "ANATOMY", 107, 112], ["carboxyl", "CHEMICAL", 175, 183], ["cells", "CELL", 107, 112], ["Semliki Forest virus", "ORGANISM", 118, 138], ["vertebrate cells", "CELL_TYPE", 96, 112], ["carboxyl-terminus", "PROTEIN", 175, 192], ["nsP3 [33]", "PROTEIN", 196, 205], ["Semliki Forest virus", "SPECIES", 118, 138], ["Attenuated virulence", "PROBLEM", 0, 20], ["reduced rates of RNA synthesis", "PROBLEM", 25, 55], ["virus replication", "TREATMENT", 60, 77], ["vertebrate cells", "PROBLEM", 96, 112], ["Semliki Forest virus mutants", "TREATMENT", 118, 146], ["reduced", "OBSERVATION_MODIFIER", 25, 32], ["rates", "OBSERVATION_MODIFIER", 33, 38], ["RNA synthesis", "OBSERVATION", 42, 55], ["Semliki", "OBSERVATION", 118, 125], ["Forest virus", "OBSERVATION", 126, 138]]], ["Yet, studies in mammalian cell lines showed that a 34 amino acid deletion in this region of nsP3 in Venezuelan equine encephalitis had no detectable effect on replication [34] .", [["cell lines", "ANATOMY", 26, 36], ["amino acid", "CHEMICAL", 54, 64], ["encephalitis", "DISEASE", 118, 130], ["amino acid", "CHEMICAL", 54, 64], ["mammalian cell lines", "CELL", 16, 36], ["amino acid", "AMINO_ACID", 54, 64], ["nsP3", "GENE_OR_GENE_PRODUCT", 92, 96], ["Venezuelan equine encephalitis", "ORGANISM", 100, 130], ["mammalian cell lines", "CELL_LINE", 16, 36], ["nsP3", "PROTEIN", 92, 96], ["Venezuelan equine encephalitis", "SPECIES", 100, 130], ["Venezuelan equine encephalitis", "SPECIES", 100, 130], ["mammalian cell lines", "TEST", 16, 36], ["a 34 amino acid deletion", "PROBLEM", 49, 73], ["nsP3 in Venezuelan equine encephalitis", "PROBLEM", 92, 130], ["cell lines", "OBSERVATION", 26, 36]]], ["Collectively, these studies support the current finding that nsP3 can be vital for productive infection, but in a manner that is host and virus specific.DiscussionAnother interesting characteristic of the carboxyl-terminus of nsP3 is that it is phosphorylated at multiple serine and threonine residues [35, 36] .", [["nsP3", "CHEMICAL", 61, 65], ["infection", "DISEASE", 94, 103], ["threonine", "CHEMICAL", 283, 292], ["carboxyl", "CHEMICAL", 205, 213], ["serine", "CHEMICAL", 272, 278], ["threonine", "CHEMICAL", 283, 292], ["nsP3", "GENE_OR_GENE_PRODUCT", 61, 65], ["nsP3", "GENE_OR_GENE_PRODUCT", 226, 230], ["serine", "AMINO_ACID", 272, 278], ["threonine residues", "AMINO_ACID", 283, 301], ["nsP3", "PROTEIN", 61, 65], ["carboxyl-terminus", "PROTEIN", 205, 222], ["nsP3", "PROTEIN", 226, 230], ["these studies", "TEST", 14, 27], ["nsP3", "PROBLEM", 61, 65], ["productive infection", "PROBLEM", 83, 103], ["the carboxyl-terminus of nsP3", "TREATMENT", 201, 230], ["threonine residues", "TEST", 283, 301], ["infection", "OBSERVATION", 94, 103]]], ["The role of this phosphorylation is not exactly clear, except that it does seem to modulate the efficiency of minusstrand RNA synthesis [37, 38] .", [["minusstrand RNA", "RNA", 110, 125]]], ["Determination of the exact mechanisms of this modulation and the mechanisms for the host-specific effects seen with nsP3 mutants in this and other studies would be extremely valuable information and allow for design of further studies.", [["nsP3", "GENE_OR_GENE_PRODUCT", 116, 120], ["nsP3 mutants", "PROTEIN", 116, 128], ["this modulation", "PROBLEM", 41, 56], ["nsP3 mutants", "PROBLEM", 116, 128], ["other studies", "TEST", 141, 154], ["further studies", "TEST", 219, 234]]], ["Furthermore, our studies show that an intact ONNV nsP3 is required for ONNV-like infection rates, and that dividing the region either disrupts a vital interaction between the two or removes an element necessary for An. gambiae infection.DiscussionThe former seems more probable since substituting CHIKV for either half of ONNV nsP3 results in infection rates not significantly different from rates with parental CHIKV.DiscussionWhile molecular determinants residing in nsP3 did turn out to be the most dramatic finding of our study, we did also examine the structural regions of the genome.", [["infection", "DISEASE", 81, 90], ["An. gambiae infection", "DISEASE", 215, 236], ["CHIKV", "DISEASE", 297, 302], ["infection", "DISEASE", 343, 352], ["ONNV", "GENE_OR_GENE_PRODUCT", 45, 49], ["nsP3", "GENE_OR_GENE_PRODUCT", 50, 54], ["ONNV", "GENE_OR_GENE_PRODUCT", 71, 75], ["An. gambiae", "ORGANISM", 215, 226], ["CHIKV", "ORGANISM", 297, 302], ["nsP3", "GENE_OR_GENE_PRODUCT", 327, 331], ["CHIKV", "ORGANISM", 412, 417], ["nsP3", "GENE_OR_GENE_PRODUCT", 469, 473], ["genome", "CELLULAR_COMPONENT", 583, 589], ["ONNV nsP3", "PROTEIN", 45, 54], ["ONNV", "PROTEIN", 71, 75], ["ONNV nsP3", "PROTEIN", 322, 331], ["nsP3", "PROTEIN", 469, 473], ["An. gambiae", "SPECIES", 215, 226], ["An. gambiae", "SPECIES", 215, 226], ["CHIKV", "SPECIES", 297, 302], ["ONNV", "SPECIES", 322, 326], ["CHIKV", "SPECIES", 412, 417], ["our studies", "TEST", 13, 24], ["an intact ONNV nsP3", "PROBLEM", 35, 54], ["ONNV", "PROBLEM", 71, 75], ["infection rates", "PROBLEM", 81, 96], ["An. gambiae infection", "PROBLEM", 215, 236], ["substituting CHIKV", "PROBLEM", 284, 302], ["infection rates", "PROBLEM", 343, 358], ["parental CHIKV", "PROBLEM", 403, 417], ["our study", "TEST", 522, 531], ["infection", "OBSERVATION", 81, 90], ["infection", "OBSERVATION", 227, 236], ["infection", "OBSERVATION", 343, 352], ["genome", "ANATOMY", 583, 589]]], ["Previously published studies by another group had suggested that all of the viral structural proteins are necessary for ONNV to infect An. gambiae mosquitoes [21] .", [["ONNV", "GENE_OR_GENE_PRODUCT", 120, 124], ["An. gambiae mosquitoes", "ORGANISM", 135, 157], ["viral structural proteins", "PROTEIN", 76, 101], ["ONNV", "PROTEIN", 120, 124], ["An. gambiae", "SPECIES", 135, 146], ["ONNV", "SPECIES", 120, 124], ["An. gambiae", "SPECIES", 135, 146], ["Previously published studies", "TEST", 0, 28], ["the viral structural proteins", "PROBLEM", 72, 101]]], ["Our study was able to provide critical fine tuning to this conclusion.", [["Our study", "TEST", 0, 9]]], ["In our experiments with CHIKV-backbone chimeras containing various regions of the ONNV structural proteins, each maintained parental CHIKV-like infection profiles despite containing portions of the ONNV genome.", [["infection", "DISEASE", 144, 153], ["CHIKV", "ORGANISM", 24, 29], ["ONNV", "GENE_OR_GENE_PRODUCT", 82, 86], ["ONNV", "GENE_OR_GENE_PRODUCT", 198, 202], ["ONNV structural proteins", "PROTEIN", 82, 106], ["ONNV genome", "DNA", 198, 209], ["CHIKV", "SPECIES", 24, 29], ["CHIKV", "SPECIES", 133, 138], ["CHIKV-backbone chimeras", "TREATMENT", 24, 47], ["the ONNV structural proteins", "PROBLEM", 78, 106], ["parental CHIKV", "PROBLEM", 124, 138], ["infection profiles", "PROBLEM", 144, 162], ["CHIKV", "OBSERVATION", 24, 29], ["CHIKV", "OBSERVATION", 133, 138], ["infection", "OBSERVATION", 144, 153], ["ONNV genome", "OBSERVATION", 198, 209]]], ["In fact, even an intact ONNV structural region was not sufficient for infection of An. gambiae, as shown with the chimera CHIK/ONN eSTR (Figure 1 ).", [["infection", "DISEASE", 70, 79], ["An. gambiae", "ORGANISM", 83, 94], ["ONNV structural region", "DNA", 24, 46], ["chimera CHIK", "PROTEIN", 114, 126], ["ONN eSTR", "PROTEIN", 127, 135], ["Figure 1", "PROTEIN", 137, 145], ["An. gambiae", "SPECIES", 83, 94], ["An. gambiae", "SPECIES", 83, 94], ["an intact ONNV structural region", "PROBLEM", 14, 46], ["infection", "PROBLEM", 70, 79], ["the chimera CHIK", "PROBLEM", 110, 126], ["intact", "OBSERVATION", 17, 23], ["not sufficient for", "UNCERTAINTY", 51, 69], ["infection", "OBSERVATION", 70, 79]]], ["The reciprocal chimeras, substituting sections of CHIKV structural regions for the like section of ONNV structural genes, in most cases, did not greatly reduce mosquito infection rates.", [["sections", "ANATOMY", 38, 46], ["infection", "DISEASE", 169, 178], ["ONNV", "GENE_OR_GENE_PRODUCT", 99, 103], ["CHIKV structural regions", "PROTEIN", 50, 74], ["ONNV structural genes", "DNA", 99, 120], ["CHIKV", "SPECIES", 50, 55], ["The reciprocal chimeras", "TREATMENT", 0, 23], ["CHIKV structural regions", "PROBLEM", 50, 74], ["mosquito infection rates", "PROBLEM", 160, 184], ["reciprocal chimeras", "OBSERVATION", 4, 23], ["CHIKV", "OBSERVATION", 50, 55], ["infection", "OBSERVATION", 169, 178]]], ["The notable exceptions were in the chimeras that divided the ONNV structural region in half.", [["ONNV structural region", "PROTEIN", 61, 83], ["notable", "OBSERVATION_MODIFIER", 4, 11]]], ["Both ONN/CHIK 59STR and ONN/ CHIK 39STR were significantly less infectious to An. gambiae than was parental ONNV.", [["ONN", "GENE_OR_GENE_PRODUCT", 5, 8], ["CHIK", "GENE_OR_GENE_PRODUCT", 9, 13], ["ONN/ CHIK 39STR", "GENE_OR_GENE_PRODUCT", 24, 39], ["An. gambiae", "ORGANISM", 78, 89], ["ONN/CHIK 59STR and ONN/ CHIK 39STR", "DNA", 5, 39], ["An. gambiae", "SPECIES", 78, 89], ["An. gambiae", "SPECIES", 78, 89], ["ONNV", "SPECIES", 108, 112], ["CHIK", "PROBLEM", 9, 13], ["CHIK", "PROBLEM", 29, 33]]], ["However, since the reciprocal chimeras, CHIK/ONN 59STR and CHIK/ONN 39STR, did not show upregulated infection rates, the drop in infection with the chimeric viruses is likely due to disruption of one or more virus-virus or virus-host interactions.DiscussionIn alphaviruses, the extreme 39 terminus of the genome, just preceding the poly(A) tail, has a sequence which is highly conserved among all alphaviruses and which is absolutely required for efficient virus replication [39, 40] .", [["infection", "DISEASE", 100, 109], ["infection", "DISEASE", 129, 138], ["CHIK", "GENE_OR_GENE_PRODUCT", 40, 44], ["ONN", "GENE_OR_GENE_PRODUCT", 45, 48], ["CHIK", "GENE_OR_GENE_PRODUCT", 59, 63], ["virus-virus", "ORGANISM", 208, 219], ["genome", "CELLULAR_COMPONENT", 305, 311], ["poly(A) tail", "GENE_OR_GENE_PRODUCT", 332, 344], ["CHIK", "PROTEIN", 40, 44], ["ONN 59STR", "PROTEIN", 45, 54], ["CHIK", "PROTEIN", 59, 63], ["ONN 39STR", "DNA", 64, 73], ["extreme 39 terminus", "PROTEIN", 278, 297], ["poly(A) tail", "PROTEIN", 332, 344], ["virus-virus", "SPECIES", 208, 219], ["the reciprocal chimeras", "TEST", 15, 38], ["CHIK", "TEST", 40, 44], ["CHIK", "TEST", 59, 63], ["STR", "TEST", 70, 73], ["upregulated infection rates", "PROBLEM", 88, 115], ["the drop in infection", "PROBLEM", 117, 138], ["the chimeric viruses", "PROBLEM", 144, 164], ["more virus-virus", "PROBLEM", 203, 219], ["virus", "PROBLEM", 223, 228], ["a sequence", "TEST", 350, 360], ["all alphaviruses", "PROBLEM", 393, 409], ["efficient virus replication", "PROBLEM", 447, 474], ["upregulated", "OBSERVATION_MODIFIER", 88, 99], ["infection", "OBSERVATION", 100, 109], ["drop", "OBSERVATION_MODIFIER", 121, 125], ["infection", "OBSERVATION", 129, 138], ["viruses", "OBSERVATION", 157, 164], ["likely due to", "UNCERTAINTY", 168, 181], ["tail", "ANATOMY", 340, 344]]], ["This 19-nucleotide sequence is identical in CHIKV and ONNV so this could not have played a role in the decreased infection rates seen with ONN/CHIK 39STR.", [["infection", "DISEASE", 113, 122], ["CHIKV", "ORGANISM", 44, 49], ["ONNV", "CANCER", 54, 58], ["19-nucleotide sequence", "DNA", 5, 27], ["ONN", "PROTEIN", 139, 142], ["CHIK 39STR", "PROTEIN", 143, 153], ["CHIKV", "SPECIES", 44, 49], ["ONNV", "SPECIES", 54, 58], ["nucleotide sequence", "TEST", 8, 27], ["CHIKV", "PROBLEM", 44, 49], ["the decreased infection rates", "PROBLEM", 99, 128], ["CHIKV", "OBSERVATION", 44, 49], ["decreased", "OBSERVATION_MODIFIER", 103, 112], ["infection", "OBSERVATION", 113, 122]]], ["However, studies using Sindbis mutants with large deletions in the 39non-translated region (NTR) have shown that the rest of the 39 NTR is also important for virus replication in a host-specific manner [40] .", [["Sindbis mutants", "ORGANISM", 23, 38], ["NTR", "GENE_OR_GENE_PRODUCT", 132, 135], ["39non-translated region", "DNA", 67, 90], ["NTR", "DNA", 92, 95], ["39 NTR", "PROTEIN", 129, 135], ["studies", "TEST", 9, 16], ["Sindbis mutants", "TREATMENT", 23, 38], ["large deletions", "PROBLEM", 44, 59], ["virus replication", "TREATMENT", 158, 175], ["large", "OBSERVATION_MODIFIER", 44, 49], ["deletions", "OBSERVATION", 50, 59]]], ["ONNV is 156 additional nucleotides shorter in the 39NTR when compared to CHIKV; this size difference alone could result in conformational changes resulting in the inability of the virus to interact with itself or with host proteins.", [["nucleotides", "CHEMICAL", 23, 34], ["NTR", "GENE_OR_GENE_PRODUCT", 52, 55], ["CHIKV", "ORGANISM", 73, 78], ["ONNV", "DNA", 0, 4], ["39NTR", "DNA", 50, 55], ["host proteins", "PROTEIN", 218, 231], ["CHIKV", "SPECIES", 73, 78], ["additional nucleotides", "TREATMENT", 12, 34], ["CHIKV", "PROBLEM", 73, 78], ["conformational changes", "PROBLEM", 123, 145], ["the virus", "PROBLEM", 176, 185]]], ["Of note is the design of our eSTR and 39STR structural clones, which contain the indicated structural region as well as the 39 NTR from the non-parental virus ( Figure 1) ; this design is different from those previously described [21] and may suggest the possibility of multiple interactions within the proteins or gene sequences of the virus itself that may have a minor role in the overall ability of a chimeric virus to replicate within the mosquito.", [["eSTR", "GENE_OR_GENE_PRODUCT", 29, 33], ["NTR", "GENE_OR_GENE_PRODUCT", 127, 130], ["non-parental virus", "ORGANISM", 140, 158], ["eSTR and 39STR structural clones", "DNA", 29, 61], ["39 NTR", "PROTEIN", 124, 130], ["our eSTR and 39STR structural clones", "PROBLEM", 25, 61], ["multiple interactions within the proteins", "PROBLEM", 270, 311], ["the virus", "PROBLEM", 333, 342], ["a chimeric virus", "PROBLEM", 403, 419], ["clones", "OBSERVATION", 55, 61], ["may suggest the possibility of", "UNCERTAINTY", 239, 269], ["multiple", "OBSERVATION_MODIFIER", 270, 278], ["interactions", "OBSERVATION", 279, 291]]], ["It is further possible that the differences in CHIKV and ONNV conserved sequence elements [41] are sufficient to undercut RNA stability, resulting in greatly reduced mosquito infection patterns.DiscussionStudies with chimeric viruses must be viewed in the overall context of the virus' life cycle.", [["infection", "DISEASE", 175, 184], ["CHIKV", "ORGANISM", 47, 52], ["CHIKV and ONNV conserved sequence elements", "DNA", 47, 89], ["CHIKV", "SPECIES", 47, 52], ["CHIKV", "PROBLEM", 47, 52], ["greatly reduced mosquito infection patterns", "PROBLEM", 150, 193], ["chimeric viruses", "PROBLEM", 217, 233], ["further possible", "UNCERTAINTY", 6, 22], ["stability", "OBSERVATION_MODIFIER", 126, 135], ["greatly", "OBSERVATION_MODIFIER", 150, 157], ["reduced", "OBSERVATION_MODIFIER", 158, 165], ["mosquito infection", "OBSERVATION", 166, 184]]], ["When substitutions are made to construct chimeric viruses, numerous aspects of the virus-host interactions and virus-virus regulatory functions can be disrupted resulting in reduced infection rates.", [["infection", "DISEASE", 182, 191], ["virus-virus", "ORGANISM", 111, 122], ["virus-virus", "SPECIES", 111, 122], ["construct chimeric viruses", "PROBLEM", 31, 57], ["the virus", "PROBLEM", 79, 88], ["host interactions", "PROBLEM", 89, 106], ["virus-virus regulatory functions", "TREATMENT", 111, 143], ["reduced infection rates", "PROBLEM", 174, 197], ["viruses", "OBSERVATION", 50, 57], ["reduced", "OBSERVATION_MODIFIER", 174, 181], ["infection", "OBSERVATION", 182, 191]]], ["Reduced infection rates may be a direct consequence of missing the essential genomic region or may be an indirect result of disrupting an essential regulatory interaction.", [["infection", "DISEASE", 8, 17], ["Reduced infection rates", "PROBLEM", 0, 23], ["infection", "OBSERVATION", 8, 17], ["essential", "OBSERVATION_MODIFIER", 138, 147], ["regulatory interaction", "OBSERVATION", 148, 170]]], ["Conversely, when the addition of a specific region increases mosquito infection rates, we must conclude the region itself to be essential for infection.", [["mosquito infection", "DISEASE", 61, 79], ["infection", "DISEASE", 142, 151], ["a specific region", "PROBLEM", 33, 50], ["mosquito infection rates", "PROBLEM", 61, 85], ["infection", "PROBLEM", 142, 151], ["infection", "OBSERVATION", 142, 151]]], ["Interestingly, because there was such a low dissemination rate of all viruses within this study, elements involved in dissemination throughout the mosquito may be distinct from those important in initial infection.", [["infection", "DISEASE", 204, 213], ["mosquito", "ORGANISM", 147, 155], ["a low dissemination rate of all viruses", "PROBLEM", 38, 77], ["this study", "TEST", 85, 95], ["initial infection", "PROBLEM", 196, 213], ["low", "OBSERVATION_MODIFIER", 40, 43], ["viruses", "OBSERVATION", 70, 77], ["infection", "OBSERVATION", 204, 213]]], ["However, this study has shown that ONNV nsP3 is directly responsible for ONNV infection of An. gambiae.", [["infection", "DISEASE", 78, 87], ["ONNV", "GENE_OR_GENE_PRODUCT", 35, 39], ["nsP3", "GENE_OR_GENE_PRODUCT", 40, 44], ["ONNV", "GENE_OR_GENE_PRODUCT", 73, 77], ["An. gambiae", "ORGANISM", 91, 102], ["ONNV nsP3", "PROTEIN", 35, 44], ["An. gambiae", "SPECIES", 91, 102], ["ONNV", "SPECIES", 35, 39], ["ONNV", "SPECIES", 73, 77], ["An. gambiae", "SPECIES", 91, 102], ["this study", "TEST", 9, 19], ["ONNV nsP3", "PROBLEM", 35, 44], ["ONNV infection", "PROBLEM", 73, 87], ["infection", "OBSERVATION", 78, 87]]], ["There are also numerous interactions within nsP3 itself, within the two halves of the structural region, and possibly the 39 NTR which, when disrupted, can eliminate mosquito infection.", [["mosquito infection", "DISEASE", 166, 184], ["nsP3", "GENE_OR_GENE_PRODUCT", 44, 48], ["NTR", "GENE_OR_GENE_PRODUCT", 125, 128], ["nsP3", "PROTEIN", 44, 48], ["39 NTR", "PROTEIN", 122, 128], ["mosquito infection", "PROBLEM", 166, 184], ["numerous", "OBSERVATION_MODIFIER", 15, 23], ["interactions", "OBSERVATION", 24, 36], ["structural", "ANATOMY_MODIFIER", 86, 96], ["region", "ANATOMY_MODIFIER", 97, 103], ["39 NTR", "OBSERVATION_MODIFIER", 122, 128], ["infection", "OBSERVATION", 175, 184]]], ["Figure S1 Illustration of exact nsP3 substitution made to create CHIK/ONN nsP3.", [["nsP3", "GENE_OR_GENE_PRODUCT", 32, 36], ["CHIK", "GENE_OR_GENE_PRODUCT", 65, 69], ["nsP3", "DNA", 32, 36], ["CHIK", "PROTEIN", 65, 69], ["ONN nsP3", "PROTEIN", 70, 78], ["exact nsP3 substitution", "TREATMENT", 26, 49], ["nsP3", "PROBLEM", 74, 78], ["nsP3 substitution", "OBSERVATION", 32, 49]]], ["(TIFF) Figure S2 Construction of CHIKV nsP3 receiving plasmid.", [["plasmid", "ANATOMY", 54, 61], ["CHIKV", "ORGANISM", 33, 38], ["nsP3", "GENE_OR_GENE_PRODUCT", 39, 43], ["CHIKV nsP3 receiving plasmid", "DNA", 33, 61], ["CHIKV", "SPECIES", 33, 38], ["CHIKV", "PROBLEM", 33, 38], ["plasmid", "TREATMENT", 54, 61]]], ["PCR primers were designed to generate two amplicons flanking the DNA insertion sites and extend outward to include unique restriction enzyme sites and inward to include a unique type II restriction site.", [["DNA", "CELLULAR_COMPONENT", 65, 68], ["PCR primers", "DNA", 0, 11], ["DNA insertion sites", "DNA", 65, 84], ["restriction enzyme sites", "DNA", 122, 146], ["type II restriction site", "DNA", 178, 202], ["PCR primers", "TEST", 0, 11], ["two amplicons flanking the DNA insertion sites", "TREATMENT", 38, 84], ["unique restriction enzyme sites", "PROBLEM", 115, 146], ["a unique type II restriction site", "PROBLEM", 169, 202]]], ["Amplification with these primers, subsequent digestion with PciI/SacI or EcoRI/SacI, followed by a 3-part ligation produce a pUC-based vector containing CHIKV sequence flanking the site where ONNV nsP3 will later be inserted.", [["PciI", "GENE_OR_GENE_PRODUCT", 60, 64], ["SacI", "GENE_OR_GENE_PRODUCT", 65, 69], ["EcoRI", "GENE_OR_GENE_PRODUCT", 73, 78], ["SacI", "GENE_OR_GENE_PRODUCT", 79, 83], ["pUC", "GENE_OR_GENE_PRODUCT", 125, 128], ["CHIKV", "ORGANISM", 153, 158], ["nsP3", "GENE_OR_GENE_PRODUCT", 197, 201], ["PciI", "DNA", 60, 64], ["SacI", "DNA", 65, 69], ["EcoRI", "DNA", 73, 78], ["SacI", "DNA", 79, 83], ["pUC-based vector", "DNA", 125, 141], ["CHIKV sequence", "DNA", 153, 167], ["ONNV nsP3", "DNA", 192, 201], ["CHIKV", "SPECIES", 153, 158], ["these primers", "TREATMENT", 19, 32], ["PciI/SacI", "TREATMENT", 60, 69], ["EcoRI/SacI", "TREATMENT", 73, 83], ["a 3-part ligation", "TREATMENT", 97, 114], ["a pUC-based vector", "TREATMENT", 123, 141], ["CHIKV sequence flanking", "TREATMENT", 153, 176], ["ONNV nsP3", "TREATMENT", 192, 201], ["SacI", "ANATOMY", 79, 83]]], ["(TIFF) Figure S3 Amplifying ONNV nsP3.", [["ONNV nsP3", "PROTEIN", 28, 37], ["nsP3", "PROBLEM", 33, 37], ["ONNV nsP3", "OBSERVATION", 28, 37]]], ["PCR primers were designed to amplify the desired DNA insert, with the addition of type II restriction enzyme sites to the termini.", [["DNA", "CELLULAR_COMPONENT", 49, 52], ["type II restriction enzyme", "GENE_OR_GENE_PRODUCT", 82, 108], ["PCR primers", "DNA", 0, 11], ["DNA insert", "DNA", 49, 59], ["type II restriction enzyme sites", "DNA", 82, 114], ["PCR primers", "TEST", 0, 11], ["the desired DNA insert", "TREATMENT", 37, 59], ["type II restriction enzyme sites", "TREATMENT", 82, 114], ["termini", "ANATOMY_MODIFIER", 122, 129]]], ["Type II sites were oriented such that they will be removed upon later digestion.", [["Type II sites", "ANATOMY", 0, 13], ["Type II sites", "DNA", 0, 13], ["Type II sites", "PROBLEM", 0, 13]]], ["(TIFF) Figure S4 Expanded sequence of assembled CHIKV nsP3 receiving plasmid (top).", [["plasmid", "ANATOMY", 69, 76], ["CHIKV", "ORGANISM", 48, 53], ["CHIKV nsP3 receiving plasmid", "DNA", 48, 76], ["CHIKV", "SPECIES", 48, 53], ["plasmid (top)", "TREATMENT", 69, 82], ["CHIKV nsP3", "OBSERVATION", 48, 58]]], ["Termini of ONNV nsP3 amplicon (bottom).", [["ONNV nsP3 amplicon", "DNA", 11, 29], ["Termini of ONNV nsP3 amplicon", "TREATMENT", 0, 29], ["nsP3 amplicon", "OBSERVATION", 16, 29]]], ["The lines indicate the cut sites for the type II restriction enzymes.", [["lines", "CELL", 4, 9], ["type II restriction enzymes", "GENE_OR_GENE_PRODUCT", 41, 68], ["cut sites", "DNA", 23, 32], ["type II restriction enzymes", "PROTEIN", 41, 68], ["The lines", "TREATMENT", 0, 9], ["the type II restriction enzymes", "PROBLEM", 37, 68]]], ["(TIFF) Figure S5 Products produced after digestion with appropriate type II restriction enzymes.", [["type II restriction enzymes", "GENE_OR_GENE_PRODUCT", 68, 95], ["type II restriction enzymes", "PROTEIN", 68, 95]]], ["These products were ligated to build the CHIKV/ONNV nsP3 cassette plasmid.", [["CHIKV", "ORGANISM", 41, 46], ["nsP3", "GENE_OR_GENE_PRODUCT", 52, 56], ["CHIKV/ONNV nsP3 cassette plasmid", "DNA", 41, 73], ["CHIKV", "SPECIES", 41, 46], ["the CHIKV/ONNV nsP3 cassette plasmid", "TREATMENT", 37, 73]]], ["(TIFF) Figure S6 Construction of final clone, Chik/Onn nsP3.", [["Chik/Onn nsP3", "GENE_OR_GENE_PRODUCT", 46, 59], ["S6", "PROTEIN", 14, 16], ["Chik", "PROTEIN", 46, 50], ["Onn nsP3", "PROTEIN", 51, 59], ["nsP3", "PROBLEM", 55, 59]]], ["CHIKV/ONNV nsP3 cassette plasmid and pCHIK.b were digested with SpeI and AvrII.", [["CHIKV", "ORGANISM", 0, 5], ["ONNV nsP3", "GENE_OR_GENE_PRODUCT", 6, 15], ["pCHIK", "GENE_OR_GENE_PRODUCT", 37, 42], ["SpeI", "GENE_OR_GENE_PRODUCT", 64, 68], ["AvrII", "GENE_OR_GENE_PRODUCT", 73, 78], ["CHIKV/ONNV nsP3 cassette plasmid", "DNA", 0, 32], ["pCHIK", "DNA", 37, 42], ["SpeI", "DNA", 64, 68], ["AvrII", "DNA", 73, 78], ["CHIKV", "SPECIES", 0, 5], ["ONNV", "SPECIES", 6, 10], ["nsP3 cassette plasmid", "TREATMENT", 11, 32], ["SpeI", "PROBLEM", 64, 68]]], ["The resulting products were ligated to generate the final clone with the complete ONNV nsP3 gene replacing the like gene in CHIKV.(TIFF)Protocol S1 Methods for construction of gene specific clones.(TIFF)(DOCX)", [["clone", "CELL", 58, 63], ["nsP3", "GENE_OR_GENE_PRODUCT", 87, 91], ["CHIKV", "ORGANISM", 124, 129], ["clones", "CELL", 190, 196], ["ONNV nsP3 gene", "DNA", 82, 96], ["CHIKV", "SPECIES", 124, 129], ["the complete ONNV nsP3 gene", "TREATMENT", 69, 96], ["CHIKV", "PROBLEM", 124, 129], ["S1 Methods", "TREATMENT", 145, 155], ["gene specific clones", "PROBLEM", 176, 196], ["CHIKV", "OBSERVATION", 124, 129]]]], "0d0ccac85abe4fa6a8ba572d2448a596cea7696c": [["IntroductionThe recent pandemic of COVID-19 (Coronavirus Disease-2019), an emerging respiratory disease caused by the SARS-CoV-2 virus, which spread more efficiently than previous highly pathogenic coronaviruses SARS-CoV and MERS-CoV, has led to a tremendous toll of affected cases and over 56,000 fatalities in more than 180 countries since its first outbreak in late 2019 1 .", [["respiratory", "ANATOMY", 84, 95], ["COVID-19", "CHEMICAL", 35, 43], ["respiratory disease", "DISEASE", 84, 103], ["SARS", "DISEASE", 212, 216], ["COVID-19", "ORGANISM", 35, 43], ["Coronavirus Disease-2019", "ORGANISM", 45, 69], ["SARS-CoV-2 virus", "ORGANISM", 118, 134], ["coronaviruses", "ORGANISM", 198, 211], ["SARS-CoV", "ORGANISM", 212, 220], ["MERS-CoV", "ORGANISM", 225, 233], ["CoV-2 virus", "SPECIES", 123, 134], ["COVID-19", "SPECIES", 35, 43], ["SARS-CoV-2 virus", "SPECIES", 118, 134], ["SARS-CoV", "SPECIES", 212, 220], ["MERS-CoV", "SPECIES", 225, 233], ["COVID", "TEST", 35, 40], ["Coronavirus Disease", "PROBLEM", 45, 64], ["an emerging respiratory disease", "PROBLEM", 72, 103], ["the SARS", "PROBLEM", 114, 122], ["CoV-2 virus", "PROBLEM", 123, 134], ["previous highly pathogenic coronaviruses SARS", "PROBLEM", 171, 216], ["affected cases", "PROBLEM", 267, 281], ["respiratory disease", "OBSERVATION", 84, 103]]], ["Precisely due to the rapid transmission of this novel pathogen, no antiviral drugs or vaccines are available for SARS-CoV-2.IntroductionUnderstanding the molecular mechanisms that mediate SARS-CoV-2 infection is key for the rapid development of efficient preventive or therapeutic interventions against the COVID-19.", [["infection", "DISEASE", 199, 208], ["SARS-CoV-2", "ORGANISM", 113, 123], ["SARS-CoV-2", "ORGANISM", 188, 198], ["COVID-19", "DNA", 307, 315], ["SARS-CoV", "SPECIES", 113, 121], ["this novel pathogen", "PROBLEM", 43, 62], ["antiviral drugs", "TREATMENT", 67, 82], ["vaccines", "TREATMENT", 86, 94], ["CoV", "TEST", 118, 121], ["mediate SARS", "PROBLEM", 180, 192], ["CoV-2 infection", "PROBLEM", 193, 208], ["therapeutic interventions", "TREATMENT", 269, 294], ["the COVID", "TEST", 303, 312]]], ["A comprehensive description of such molecular mechanisms is represented in the corresponding disease map, that is, the fragment of the whole network of known human protein interactions that are relevant for the disease 2 .", [["human", "ORGANISM", 158, 163], ["human", "SPECIES", 158, 163], ["human", "SPECIES", 158, 163], ["such molecular mechanisms", "PROBLEM", 31, 56], ["known human protein interactions", "PROBLEM", 152, 184], ["the disease 2", "PROBLEM", 207, 220]]], ["The recent availability of a detailed catalog of viral-human protein interactions 3 has facilitated the construction of a first version of the map of human molecular pathways involved in the viral infection.", [["viral infection", "DISEASE", 191, 206], ["human", "ORGANISM", 55, 60], ["human", "ORGANISM", 150, 155], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 150, 155], ["viral-human protein interactions", "TREATMENT", 49, 81], ["the viral infection", "PROBLEM", 187, 206], ["viral infection", "OBSERVATION", 191, 206]]], ["To do so, we firstly expanded the SARS-CoV-2 virus-human interactome from existing KEGG pathways maps to obtain a subset of signaling circuits (a circuit is the sub-pathway that defines the chain of signal transduction that connects a receptor protein to an effector protein) that represent a comprehensive model of the direct and indirect interactions of the virus with the cell.", [["cell", "ANATOMY", 375, 379], ["SARS-CoV-2 virus", "ORGANISM", 34, 50], ["human", "ORGANISM", 51, 56], ["cell", "CELL", 375, 379], ["receptor protein", "PROTEIN", 235, 251], ["effector protein", "PROTEIN", 258, 274], ["human", "SPECIES", 51, 56], ["SARS-CoV-2 virus", "SPECIES", 34, 50], ["human", "SPECIES", 51, 56], ["the SARS", "PROBLEM", 30, 38], ["CoV", "TEST", 39, 42], ["existing KEGG pathways maps", "TEST", 74, 101], ["signaling circuits", "TREATMENT", 124, 142], ["a circuit", "TREATMENT", 144, 153], ["signal transduction", "TREATMENT", 199, 218], ["a receptor protein", "TREATMENT", 233, 251]]], ["In particular, we selected those signaling circuits with at least one UniProt function that fit in one of these virus-related categories: 1) Host-virus interaction, 2) inflammatory response, 3) immune activity, 4) antiviral defense, 5) endocytosis.", [["Host-virus interaction", "PROBLEM", 141, 163], ["inflammatory response", "PROBLEM", 168, 189], ["immune activity", "PROBLEM", 194, 209], ["antiviral defense, 5) endocytosis", "PROBLEM", 214, 247], ["inflammatory", "OBSERVATION_MODIFIER", 168, 180]]], ["Our model is a part of a detailed repository of SARS-CoV-2 mechanisms, the COVID-19 Disease Map, constructed by an international community, and is available at: http://doi.org/10.17881/covid19-disease-map.", [["COVID-19 Disease Map", "DNA", 75, 95], ["SARS", "TEST", 48, 52], ["the COVID", "TEST", 71, 80]]], ["Disease maps are repositories of knowledge of disease-relevant mechanisms that provide qualitative guidance for the interpretation of experimental findings.", [["Disease maps", "PROBLEM", 0, 12], ["disease", "PROBLEM", 46, 53]]], ["Actually, disease maps are the supporting foundation of different tools able to model the information contained in them in order to provide a detailed quantitative explanation for experimental results.", [["disease maps", "PROBLEM", 10, 22], ["disease", "OBSERVATION", 10, 17]]], ["In particular, mechanistic models of disease maps are becoming increasingly relevant for genomic data interpretation because they provide a natural link between omics data measurements and cell behavior and outcome, which ultimately accounts for the phenotype of the infection.", [["cell", "ANATOMY", 189, 193], ["infection", "DISEASE", 267, 276], ["cell", "CELL", 189, 193], ["disease maps", "PROBLEM", 37, 49], ["genomic data interpretation", "TEST", 89, 116], ["the infection", "PROBLEM", 263, 276], ["disease", "OBSERVATION", 37, 44], ["infection", "OBSERVATION", 267, 276]]], ["The knowledge of these links allows a better understanding of the molecular mechanisms of the viral infection and the responses to drugs.", [["viral infection", "DISEASE", 94, 109], ["the viral infection", "PROBLEM", 90, 109], ["drugs", "TREATMENT", 131, 136], ["viral", "OBSERVATION_MODIFIER", 94, 99], ["infection", "OBSERVATION", 100, 109]]], ["Basically, mechanistic models map experimental values in the context of the disease map information, which is used to point out the relevant experimental, thus revealing aspects of the molecular mechanisms behind the experiment.", [["the disease map information", "PROBLEM", 72, 99], ["disease", "OBSERVATION", 76, 83]]], ["It is important to note that this assessment is made from a systems biology perspective, in the holistic context of the disease map, and considers the functional interactions among the gene products as described in the map.", [["this assessment", "TEST", 29, 44], ["the disease map", "PROBLEM", 116, 131], ["the gene products", "TREATMENT", 181, 198], ["disease", "OBSERVATION", 120, 127]]], ["Typically, these experimental values are gene expression transcriptomic data, although other data such as proteomic, phosphoproteomic, genomic, or even methylomics, can also be used.IntroductionHowever, beyond its usefulness for the functional interpretation of experimental results, the most interesting property of mechanistic models is that they can be used to predict the effects of interventions (inhibitions or over-activation, alone or in combinations) over proteins of the map in a given condition studied 4 .", [["these experimental values", "TEST", 11, 36], ["gene expression transcriptomic data", "PROBLEM", 41, 76], ["interventions (inhibitions", "TREATMENT", 387, 413]]], ["Therefore, this opens the possibility of using these models for exploring new therapeutic options as well 5 .ResultsHere, we present the first implementation of a mechanistic model of the SARS-CoV-2 infection in a user-friendly interface.", [["SARS", "DISEASE", 188, 192], ["infection", "DISEASE", 199, 208], ["SARS-CoV", "SPECIES", 188, 196], ["new therapeutic options", "TREATMENT", 74, 97], ["the SARS", "PROBLEM", 184, 192], ["infection", "OBSERVATION", 199, 208]]], ["The mechanistic model implemented in HiPathia has been successfully used to understand the disease mechanisms behind different cancers 6 and was able to predict cancer vulnerabilities with a high precision 8 .", [["cancers", "ANATOMY", 127, 134], ["cancer", "ANATOMY", 161, 167], ["cancers", "DISEASE", 127, 134], ["cancer", "DISEASE", 161, 167], ["cancers", "CANCER", 127, 134], ["cancer", "CANCER", 161, 167], ["the disease mechanisms", "PROBLEM", 87, 109], ["different cancers", "PROBLEM", 117, 134], ["cancers", "OBSERVATION", 127, 134]]], ["The model has been implemented in a user-friendly web application that inputs normalized gene expression values (or similar proteomics or phosphoproteomic values) and can be found at http://hipathia.babelomics.org/covid19/.", [["phosphoproteomic values", "TEST", 138, 161]]], ["As an example, we carried out some analyses that involve a case-control differential signaling analysis using a gene expression experiment with lung cell lines infected with SARS-CoV-2 (GEO id: GSE147507).", [["lung cell lines", "ANATOMY", 144, 159], ["GSE147507", "CHEMICAL", 194, 203], ["lung cell lines", "CELL", 144, 159], ["SARS-CoV-2", "ORGANISM", 174, 184], ["lung cell lines", "CELL_LINE", 144, 159], ["SARS-CoV", "SPECIES", 174, 182], ["a gene expression experiment", "TREATMENT", 110, 138], ["lung cell lines", "TREATMENT", 144, 159], ["lung", "ANATOMY", 144, 148], ["cell lines", "OBSERVATION", 149, 159]]], ["The infected cells showed a differential activation pattern in circuits related to virus entrance to cell, activation of immune, inflammatory and other virus-triggered responses (see Figure 1A and Table 1 for a detailed list of differentially activated signaling circuits and Table 2 for detail on the differentially activated cell functionalities).", [["cells", "ANATOMY", 13, 18], ["cell", "ANATOMY", 101, 105], ["cell", "ANATOMY", 327, 331], ["cells", "CELL", 13, 18], ["cell", "CELL", 101, 105], ["cell", "CELL", 327, 331], ["The infected cells", "PROBLEM", 0, 18], ["a differential activation pattern in circuits", "PROBLEM", 26, 71], ["virus entrance", "PROBLEM", 83, 97], ["immune, inflammatory and other virus", "PROBLEM", 121, 157], ["activated signaling circuits", "TREATMENT", 243, 271], ["infected cells", "OBSERVATION", 4, 18], ["differential", "OBSERVATION_MODIFIER", 28, 40], ["activation pattern", "OBSERVATION", 41, 59], ["virus", "OBSERVATION", 83, 88], ["cell", "OBSERVATION", 101, 105], ["inflammatory", "OBSERVATION_MODIFIER", 129, 141]]], ["Interestingly, several of the deregulated pathways include TNF, a target gene of chloroquine, one of the drugs with promising results against COVID-19 9 .", [["chloroquine", "CHEMICAL", 81, 92], ["COVID-19 9", "CHEMICAL", 142, 152], ["chloroquine", "CHEMICAL", 81, 92], ["TNF", "GENE_OR_GENE_PRODUCT", 59, 62], ["chloroquine", "SIMPLE_CHEMICAL", 81, 92], ["TNF", "PROTEIN", 59, 62], ["TNF", "TREATMENT", 59, 62], ["chloroquine", "TREATMENT", 81, 92], ["the drugs", "TREATMENT", 101, 110], ["COVID", "TEST", 142, 147]]], ["Moreover, NF-kB signaling pathway has been highlighted in several studies as one of the main pathways responsible for COVID-19 progression 10 (Figure 1 B) .", [["NF-kB", "GENE_OR_GENE_PRODUCT", 10, 15], ["NF-kB", "PROTEIN", 10, 15], ["COVID", "TEST", 118, 123]]], ["Figure 1C depicts the heathmap of signaling activity profiles that discriminate the two classes of samples (cases and controls) compared.", [["samples", "ANATOMY", 99, 106], ["samples", "CANCER", 99, 106], ["signaling activity profiles", "PROBLEM", 34, 61]]], ["It allows estimating the effect of interventions (inhibitions or overexpression) across the signaling circuits of the model in a given condition.", [["interventions (inhibitions", "TREATMENT", 35, 61], ["overexpression", "TREATMENT", 65, 79]]], ["Figure 1D shows a simulated knockdown in protein NFKB1A and the cell functionality affected: host-virus interaction.", [["cell", "ANATOMY", 64, 68], ["NFKB1A", "GENE_OR_GENE_PRODUCT", 49, 55], ["cell", "CELL", 64, 68], ["protein NFKB1A", "PROTEIN", 41, 55], ["a simulated knockdown in protein NFKB1A", "TREATMENT", 16, 55], ["cell functionality", "OBSERVATION", 64, 82]]], ["Other options in the application allow building predictors or estimating the relevance of human mutations in the resulting infection phenotype.ResultsDespite the limitations due to the few samples available, the results of the example clearly show the usefulness of this tool for modelling the repertoire of cell responses triggered by SARS-CoV-2, and the enormous potential that it has for future COVID-19 research and discovery of therapeutic interventions.", [["cell", "ANATOMY", 308, 312], ["infection", "DISEASE", 123, 132], ["human", "ORGANISM", 90, 95], ["cell", "CELL", 308, 312], ["SARS-CoV-2", "ORGANISM", 336, 346], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 90, 95], ["SARS-CoV", "SPECIES", 336, 344], ["human mutations", "PROBLEM", 90, 105], ["the resulting infection phenotype", "PROBLEM", 109, 142], ["therapeutic interventions", "TREATMENT", 433, 458], ["infection", "OBSERVATION", 123, 132]]]], "PMC7489269": [["IntroductionIn December 2019, a novel coronavirus, identified as coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO) (Huang et al., 2020; Novel Coronavirus Pneumonia Emergency Response Epidemiology Team., 2020; Zhu et al., 2020) emerged in Wuhan, Hubei Province, China.", [["coronavirus", "DISEASE", 38, 49], ["coronavirus disease", "DISEASE", 65, 84], ["Coronavirus Pneumonia", "DISEASE", 167, 188], ["coronavirus", "ORGANISM", 38, 49], ["a novel coronavirus", "PROBLEM", 30, 49], ["coronavirus disease", "PROBLEM", 65, 84], ["COVID", "TEST", 91, 96], ["Novel Coronavirus Pneumonia", "PROBLEM", 161, 188], ["coronavirus disease", "OBSERVATION", 65, 84]]], ["This disease spread quickly and became a global pandemic (Jernigan et al., 2020).", [["This disease spread", "PROBLEM", 0, 19], ["disease", "OBSERVATION", 5, 12]]], ["Almost all nurses nationwide either joined in or were ready to fight against this pandemic in Wuhan, China.IntroductionAt the beginning of the pandemic, all of the health care workers were confronted with great challenges, such as limited knowledge about the clinical presentations and effective drugs, the rapidly increasing number of infected patients, limited medical resources, and inadequate protective supplies, among others (Peeri et al., 2020).", [["infected", "DISEASE", 336, 344], ["patients", "ORGANISM", 345, 353], ["patients", "SPECIES", 345, 353], ["effective drugs", "TREATMENT", 286, 301], ["inadequate protective supplies", "TREATMENT", 386, 416], ["infected", "OBSERVATION_MODIFIER", 336, 344]]], ["Thus, the Fangcang shelter hospitals were constructed to address the increasing number of COVID-19 patients by converting exhibition centers and stadiums into health-care facilities (Chen et al., 2020).", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107]]], ["Under these stressful situations, many health care workers inevitably suffered great stress, especially for the nurses on the frontline.", [["great stress", "PROBLEM", 79, 91]]], ["Several studies showed that the health care workers endured significant high psychological distress in the outbreak of SARS or MERS (Maunder, 2004; Nickell et al., 2004; Oh et al., 2017; Park et al., 2018), especially the nurses.(Maunder, 2004).", [["SARS", "DISEASE", 119, 123], ["MERS", "DISEASE", 127, 131], ["Several studies", "TEST", 0, 15], ["significant high psychological distress", "PROBLEM", 60, 99], ["significant", "OBSERVATION_MODIFIER", 60, 71], ["high", "OBSERVATION_MODIFIER", 72, 76], ["psychological distress", "OBSERVATION", 77, 99]]], ["However, most of these studies only evaluated the prevalence of psychiatric morbidity in a cross-sectional manner, and did not investigate the changes of psychological state in a longitudinal manner.IntroductionIn this study, we evaluated the psychological status of nurses and the risk factors in different periods of the COVID-19 pandemic, by using the Generalized Anxiety Disorder Questionnaire (GAD-7), Patient Health Questionnaire (PHQ-9), Insomnia Severity Index (ISI), and Impact of Events Scale-Revised (IES-R).", [["psychiatric", "DISEASE", 64, 75], ["Anxiety Disorder", "DISEASE", 367, 383], ["Insomnia", "DISEASE", 445, 453], ["Patient", "SPECIES", 407, 414], ["these studies", "TEST", 17, 30], ["psychiatric morbidity", "PROBLEM", 64, 85], ["this study", "TEST", 214, 224], ["the risk factors", "PROBLEM", 278, 294], ["the COVID", "TEST", 319, 328], ["the Generalized Anxiety Disorder", "PROBLEM", 351, 383], ["GAD", "TEST", 399, 402], ["PHQ", "TEST", 437, 440], ["Insomnia", "PROBLEM", 445, 453], ["Events Scale", "TEST", 490, 502]]], ["Moreover, we evaluated the psychological status of nurses from Fangcang shelter hospitals, which were among the first medical institutions worldwide that were created to fight the epidemic.Participants and study design ::: Participants and MethodsIn this study, we enrolled all the nurses from Renmin Hospital of Wuhan University.", [["Participants", "SPECIES", 189, 201], ["Participants", "SPECIES", 223, 235], ["this study", "TEST", 250, 260]]], ["All the participants completed the questionnaire and submitted their informed consent anonymously online because of the pandemic.", [["participants", "SPECIES", 8, 20], ["the pandemic", "PROBLEM", 116, 128]]], ["The questionnaire was designed to obtain the basic information of the participants, and included four psychological assessment scales using WeChat, which is the most popular social media software in China.", [["participants", "SPECIES", 70, 82], ["four psychological assessment scales", "TEST", 97, 133]]], ["We issued the questionnaires at different points during the COVID-19 outbreak in the same WeChat groups.", [["the COVID", "TEST", 56, 65]]], ["We conducted the first survey (outbreak period) from January 29 to February 2, which was the peak of the spread of COVID-19.", [["COVID", "TEST", 115, 120]]], ["We issued the second survey (stable period) from February 26 to February 28, during the stable stage of the pandemic, which was after its comprehensive prevention and control.", [["the pandemic", "PROBLEM", 104, 116], ["stable stage", "OBSERVATION_MODIFIER", 88, 100]]], ["We excluded the participants who completed their questionnaire with a duration of less than 300 seconds or more than 1 hour.", [["participants", "SPECIES", 16, 28]]], ["Finally, we selected a total of 1,330 questionnaires for analysis, including 709 questionnaires for qualified participants in the outbreak period (excluding 72 non-health care workers, 172 not from tertiary hospital, and 16 non-nurses from 972 questionnaires) and 621 questionnaires in the stable period (excluding 14 not from tertiary hospitals and 28 not nurses from 663 questionnaires).", [["participants", "SPECIES", 110, 122], ["analysis", "TEST", 57, 65], ["stable", "OBSERVATION_MODIFIER", 290, 296]]], ["The data drawn from both the outbreak and stable periods are from the same WeChat groups; however, we could not match the questionnaires to the individuals because the questionnaires were completed anonymously online.", [["The data", "TEST", 0, 8], ["stable", "OBSERVATION_MODIFIER", 42, 48]]], ["We classified all nurses from the emergency department, fever clinics, medical unit for COVID-19 patients, and Fangcang shelter hospitals as frontline nurses, while the others were classified as non-frontline nurses.", [["fever", "DISEASE", 56, 61], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105]]], ["The investigation was carried out in accordance with the latest version of the Declaration of Helsinki.", [["The investigation", "TEST", 0, 17]]], ["This study protocol was approved by the Institutional Ethics Committee of Renmin Hospital of Wuhan University.", [["This study protocol", "TEST", 0, 19]]], ["Informed consent of the participants was obtained after the nature of the procedures had been fully explained.Evaluation of Psychological status ::: Participants and MethodsWe used four questionnaire scales to evaluate the psychological status of nurses during the pandemic, which are the Patient Healthy Questionnaire (PHQ-9), Generalized Anxiety Disorder (GAD-7), Insomnia Severity Index (ISI), and Impact of Events Scale-Revised (IES-R).", [["Anxiety Disorder", "DISEASE", 340, 356], ["Insomnia", "DISEASE", 366, 374], ["participants", "ORGANISM", 24, 36], ["participants", "SPECIES", 24, 36], ["Participants", "SPECIES", 149, 161], ["Patient", "SPECIES", 289, 296], ["the procedures", "TREATMENT", 70, 84], ["PHQ", "TEST", 320, 323], ["Generalized Anxiety Disorder", "PROBLEM", 328, 356], ["GAD", "TEST", 358, 361], ["Insomnia Severity Index", "PROBLEM", 366, 389], ["Events Scale", "TEST", 411, 423]]], ["The validity and reliability of depression by the PHQ-9 scale (Cameron et al., 2008; L\u00f6we et al., 2004) and generalized anxiety by the GAD-7 scale (Spitzer et al., 2006; Swinson, 2006) were previously demonstrated.", [["depression", "DISEASE", 32, 42], ["anxiety", "DISEASE", 120, 127], ["depression", "PROBLEM", 32, 42], ["the PHQ", "TEST", 46, 53], ["generalized anxiety", "PROBLEM", 108, 127]]], ["The PHQ-9 is a single factor structure with 9 items rated from 0 (\u201calmost never\u201d) to 3 (\u201calmost always\u201d).", [["PHQ-9", "CHEMICAL", 4, 9], ["The PHQ", "TEST", 0, 7]]], ["The GAD-7 Scale consisted of 7 items; each item was scored from 0 to 3.", [["GAD", "PROTEIN", 4, 7], ["The GAD", "TEST", 0, 7]]], ["Based on the score of the scales, the severity of anxiety or depression for participants were divided into normal (0\u20134), mild (5\u20139), moderate (10\u201314), and severe (>15).", [["anxiety", "DISEASE", 50, 57], ["depression", "DISEASE", 61, 71], ["participants", "SPECIES", 76, 88], ["anxiety", "PROBLEM", 50, 57], ["depression", "PROBLEM", 61, 71], ["mild (5\u20139)", "PROBLEM", 121, 131], ["mild", "OBSERVATION_MODIFIER", 121, 125], ["moderate", "OBSERVATION_MODIFIER", 133, 141], ["severe", "OBSERVATION_MODIFIER", 155, 161]]], ["The ISI (Morin et al., 2011) is a seven-item instrument for insomnia assessment that uses a 5-point Likert scale (0 = not at all, 4 = extremely).", [["insomnia", "DISEASE", 60, 68], ["insomnia assessment", "TEST", 60, 79], ["Likert scale", "TEST", 100, 112]]], ["The insomnia status was divided into no sleep difficulties (0\u20137), mild (8\u201314), moderate (15\u201321), and severe (22\u201328) insomnia.", [["insomnia", "DISEASE", 4, 12], ["sleep difficulties", "DISEASE", 40, 58], ["insomnia", "DISEASE", 116, 124], ["The insomnia status", "PROBLEM", 0, 19], ["sleep difficulties", "PROBLEM", 40, 58], ["severe (22\u201328) insomnia", "PROBLEM", 101, 124], ["mild", "OBSERVATION_MODIFIER", 66, 70], ["moderate", "OBSERVATION_MODIFIER", 79, 87], ["severe", "OBSERVATION_MODIFIER", 101, 107]]], ["The IES-R scale (Creamer et al., 2003) assessed posttraumatic stress disorder (PTSD) symptoms based on DSM-IV criteria.", [["posttraumatic stress disorder", "DISEASE", 48, 77], ["PTSD", "DISEASE", 79, 83], ["posttraumatic stress disorder", "PROBLEM", 48, 77], ["PTSD) symptoms", "PROBLEM", 79, 93]]], ["Each item is rated using a five-point Likert scale ranging from 0 (not at all) to 4 (very much), for a total score ranging from 0 to 88.", [["Likert scale", "TEST", 38, 50], ["a total score", "TEST", 101, 114]]], ["The participants scoring more than 34 points suggests possible PTSD.Statistical analysis ::: Participants and MethodsAll statistical analyses were carried out using the IBM SPSS Statistics (Version 16) and R software (version 3.5.1).", [["PTSD", "DISEASE", 63, 67], ["participants", "SPECIES", 4, 16], ["Participants", "SPECIES", 93, 105], ["PTSD", "PROBLEM", 63, 67], ["All statistical analyses", "TEST", 117, 141]]], ["We used one-way ANOVA and Chi-square test to compare the differences of related factors among the psychological status of nurses based on the PHQ-9, GAD-7, ISI and IES-R.", [["Chi-square test", "TEST", 26, 41], ["the PHQ", "TEST", 138, 145], ["GAD", "TEST", 149, 152]]], ["We used univariable and multivariable logistic regressions to estimate the potential factors affecting the mental health of nurses.", [["multivariable logistic regressions", "TREATMENT", 24, 58]]], ["A corresponding 95% confidence interval (CI) was calculated, and the statistical significance level was set at P < 0.05.Basic characteristics of nurses ::: ResultsWe enrolled a total of 1,330 questionnaires for qualified participants, which included 709 (53.3%) from the outbreak period and 621 (46.7%) from the stable period (Table 1).", [["participants", "SPECIES", 221, 233], ["CI", "TEST", 41, 43], ["stable", "OBSERVATION_MODIFIER", 312, 318]]], ["The rates of marriage and living alone in the outbreak period were significantly lower than those in the stable period (P = 0.024 and P < 0.0001, respectively).", [["P", "TEST", 120, 121], ["stable", "OBSERVATION_MODIFIER", 105, 111]]], ["The proportion of nurses that faced suspected cases (i.e., cohabitants with cough and fatigue, etc.) during the outbreak period were significantly higher than that in the stable period (P < 0.0001).", [["cough", "DISEASE", 76, 81], ["fatigue", "DISEASE", 86, 93], ["cough", "PROBLEM", 76, 81], ["fatigue", "PROBLEM", 86, 93], ["higher", "OBSERVATION_MODIFIER", 147, 153], ["stable", "OBSERVATION_MODIFIER", 171, 177]]], ["The protective measures, which included protection training and conditions and confidence, as well as the physical condition and uncertainty of fighting against the pandemic, significantly improved in the stable period compared to the outbreak period (P < 0.0001).", [["The protective measures", "TREATMENT", 0, 23], ["protection training", "TREATMENT", 40, 59], ["the pandemic", "PROBLEM", 161, 173], ["protective", "OBSERVATION_MODIFIER", 4, 14], ["stable", "OBSERVATION_MODIFIER", 205, 211]]], ["Lastly, there was a higher proportion of nurses benefiting from some online psychological consultation in the stable period (76.7%).2.Psychological status of nurses in different periods of pandemic", [["pandemic", "PROBLEM", 189, 197], ["stable", "OBSERVATION_MODIFIER", 110, 116]]]], "4ef9dc3571f2bb74b54c59e35f001938b9464a60": [["IntroductionRecent reports reflect emerging evidence for the neurotropism of the novel SARS-CoV-2 virus; patients have been presenting with neurological symptoms with unusual clustering frequency and age-predilection including hypercoaguability leading to ischemic stroke, hemorrhagic leukoencephalopathy, and Guillain-Barre syndrome 1 .IntroductionReversible cerebral vasoconstriction syndrome (RCVS) is a clinical syndrome characterized by thunderclap headache and alternating intracranial vascular vasoconstriction and vasodilation on vessel imaging; ischemic stroke, convexity subarachnoid hemorrhage (cSAH), and intraparenchymal hemorrhage can also occur 2 .IntroductionRCVS is usually triggered by medications, post-postpartum state, or sexual activity 3 but has not been reported with COVID-19.", [["neurological", "ANATOMY", 140, 152], ["cerebral", "ANATOMY", 360, 368], ["intracranial vascular", "ANATOMY", 479, 500], ["vessel", "ANATOMY", 538, 544], ["intraparenchymal", "ANATOMY", 617, 633], ["hypercoaguability", "DISEASE", 227, 244], ["ischemic stroke", "DISEASE", 256, 271], ["hemorrhagic leukoencephalopathy", "DISEASE", 273, 304], ["Guillain-Barre syndrome", "DISEASE", 310, 333], ["cerebral vasoconstriction syndrome", "DISEASE", 360, 394], ["RCVS", "DISEASE", 396, 400], ["headache", "DISEASE", 454, 462], ["ischemic stroke", "DISEASE", 554, 569], ["subarachnoid hemorrhage", "DISEASE", 581, 604], ["cSAH", "DISEASE", 606, 610], ["intraparenchymal hemorrhage", "DISEASE", 617, 644], ["IntroductionRCVS", "DISEASE", 663, 679], ["COVID-19", "CHEMICAL", 792, 800], ["SARS-CoV-2 virus", "ORGANISM", 87, 103], ["patients", "ORGANISM", 105, 113], ["cerebral", "MULTI-TISSUE_STRUCTURE", 360, 368], ["vascular", "MULTI-TISSUE_STRUCTURE", 492, 500], ["vessel", "MULTI-TISSUE_STRUCTURE", 538, 544], ["CoV-2 virus", "SPECIES", 92, 103], ["patients", "SPECIES", 105, 113], ["SARS-CoV-2 virus", "SPECIES", 87, 103], ["Guillain-Barre syndrome 1", "SPECIES", 310, 335], ["the neurotropism", "PROBLEM", 57, 73], ["the novel SARS", "PROBLEM", 77, 91], ["CoV-2 virus", "PROBLEM", 92, 103], ["neurological symptoms", "PROBLEM", 140, 161], ["unusual clustering frequency", "PROBLEM", 167, 195], ["age-predilection", "PROBLEM", 200, 216], ["hypercoaguability", "PROBLEM", 227, 244], ["ischemic stroke", "PROBLEM", 256, 271], ["hemorrhagic leukoencephalopathy", "PROBLEM", 273, 304], ["Guillain-Barre syndrome", "PROBLEM", 310, 333], ["IntroductionReversible cerebral vasoconstriction syndrome", "PROBLEM", 337, 394], ["a clinical syndrome", "PROBLEM", 405, 424], ["thunderclap headache", "PROBLEM", 442, 462], ["alternating intracranial vascular vasoconstriction", "PROBLEM", 467, 517], ["vessel imaging", "TEST", 538, 552], ["ischemic stroke", "PROBLEM", 554, 569], ["convexity subarachnoid hemorrhage", "PROBLEM", 571, 604], ["intraparenchymal hemorrhage", "PROBLEM", 617, 644], ["medications", "TREATMENT", 704, 715], ["COVID", "TEST", 792, 797], ["ischemic", "OBSERVATION_MODIFIER", 256, 264], ["stroke", "OBSERVATION", 265, 271], ["hemorrhagic", "OBSERVATION_MODIFIER", 273, 284], ["leukoencephalopathy", "OBSERVATION", 285, 304], ["Barre syndrome", "OBSERVATION", 319, 333], ["cerebral", "ANATOMY", 360, 368], ["vasoconstriction syndrome", "OBSERVATION", 369, 394], ["thunderclap", "OBSERVATION", 442, 453], ["intracranial", "ANATOMY_MODIFIER", 479, 491], ["vascular", "ANATOMY", 492, 500], ["vasoconstriction", "OBSERVATION", 501, 517], ["vasodilation", "OBSERVATION", 522, 534], ["vessel", "ANATOMY", 538, 544], ["ischemic", "OBSERVATION_MODIFIER", 554, 562], ["stroke", "OBSERVATION", 563, 569], ["convexity", "OBSERVATION_MODIFIER", 571, 580], ["subarachnoid", "OBSERVATION_MODIFIER", 581, 593], ["hemorrhage", "OBSERVATION", 594, 604], ["intraparenchymal", "ANATOMY_MODIFIER", 617, 633], ["hemorrhage", "OBSERVATION", 634, 644]]], ["Herein we describe RCVS and extracranial dissection with concomitant SARS-CoV-2 infection.Case ReportA female nurse in her thirties with migraines presented with a few weeks of severe cough, and three days of severe thunderclap headache different than her usual migraines.", [["extracranial", "ANATOMY", 28, 40], ["SARS-CoV-2 infection", "DISEASE", 69, 89], ["migraines", "DISEASE", 137, 146], ["cough", "DISEASE", 184, 189], ["headache", "DISEASE", 228, 236], ["migraines", "DISEASE", 262, 271], ["RCVS", "CANCER", 19, 23], ["RCVS", "PROBLEM", 19, 23], ["extracranial dissection", "PROBLEM", 28, 51], ["concomitant SARS", "PROBLEM", 57, 73], ["CoV-2 infection", "PROBLEM", 74, 89], ["migraines", "PROBLEM", 137, 146], ["severe cough", "PROBLEM", 177, 189], ["severe thunderclap headache", "PROBLEM", 209, 236], ["her usual migraines", "PROBLEM", 252, 271], ["extracranial", "ANATOMY", 28, 40], ["dissection", "OBSERVATION", 41, 51], ["concomitant", "OBSERVATION_MODIFIER", 57, 68], ["SARS", "OBSERVATION", 69, 73], ["CoV", "OBSERVATION_MODIFIER", 74, 77], ["infection", "OBSERVATION", 80, 89], ["severe", "OBSERVATION_MODIFIER", 177, 183], ["cough", "OBSERVATION", 184, 189], ["severe", "OBSERVATION_MODIFIER", 209, 215], ["thunderclap", "OBSERVATION_MODIFIER", 216, 227], ["headache", "OBSERVATION", 228, 236]]], ["Nasopharyngeal swab was positive for SARS-CoV-2 on RT-PCR assay.Case ReportNon-contrast CT brain demonstrated bilateral high frontal cSAH (Image 1A).", [["Nasopharyngeal swab", "ANATOMY", 0, 19], ["brain", "ANATOMY", 91, 96], ["Nasopharyngeal swab", "ORGANISM_SUBSTANCE", 0, 19], ["brain", "ORGAN", 91, 96], ["SARS-CoV", "SPECIES", 37, 45], ["Nasopharyngeal swab", "TEST", 0, 19], ["SARS", "PROBLEM", 37, 41], ["CoV", "TEST", 42, 45], ["RT", "TEST", 51, 53], ["PCR assay", "TEST", 54, 63], ["Case ReportNon-contrast CT brain", "TEST", 64, 96], ["bilateral high frontal cSAH", "PROBLEM", 110, 137], ["brain", "ANATOMY", 91, 96], ["bilateral", "ANATOMY_MODIFIER", 110, 119], ["high", "OBSERVATION_MODIFIER", 120, 124], ["frontal", "ANATOMY_MODIFIER", 125, 132], ["cSAH", "ANATOMY", 133, 137]]], ["She had no typical triggers for RCVS on review of medications and social history.", [["RCVS", "DISEASE", 32, 36], ["RCVS", "PROBLEM", 32, 36], ["medications", "TREATMENT", 50, 61]]], ["Coagulation parameters were normal, hCG was negative, and neurologic exam was nonfocal.Case ReportDiagnostic cerebral angiogram (DSA) on admission revealed a left V2 segment vertebral artery dissection and no other abnormalities (Image 1B) which was also seen on CT angiogram (1C).", [["neurologic", "ANATOMY", 58, 68], ["cerebral", "ANATOMY", 109, 117], ["left V2 segment vertebral artery", "ANATOMY", 158, 190], ["hCG", "GENE_OR_GENE_PRODUCT", 36, 39], ["cerebral", "ORGAN", 109, 117], ["vertebral artery", "MULTI-TISSUE_STRUCTURE", 174, 190], ["Coagulation parameters", "TEST", 0, 22], ["hCG", "TEST", 36, 39], ["neurologic exam", "TEST", 58, 73], ["Case ReportDiagnostic cerebral angiogram", "TEST", 87, 127], ["DSA", "TEST", 129, 132], ["a left V2 segment vertebral artery dissection", "PROBLEM", 156, 201], ["other abnormalities", "PROBLEM", 209, 228], ["CT angiogram", "TEST", 263, 275], ["left", "ANATOMY_MODIFIER", 158, 162], ["V2", "ANATOMY_MODIFIER", 163, 165], ["segment", "ANATOMY_MODIFIER", 166, 173], ["vertebral artery", "ANATOMY", 174, 190], ["dissection", "OBSERVATION", 191, 201], ["no", "UNCERTAINTY", 206, 208]]], ["She was transferred to the COVID19 Intensive care unit and started on verapamil, levetiracetam, aspirin, and analgesics.", [["verapamil", "CHEMICAL", 70, 79], ["levetiracetam", "CHEMICAL", 81, 94], ["aspirin", "CHEMICAL", 96, 103], ["verapamil", "CHEMICAL", 70, 79], ["levetiracetam", "CHEMICAL", 81, 94], ["aspirin", "CHEMICAL", 96, 103], ["verapamil", "SIMPLE_CHEMICAL", 70, 79], ["levetiracetam", "SIMPLE_CHEMICAL", 81, 94], ["aspirin", "SIMPLE_CHEMICAL", 96, 103], ["verapamil", "TREATMENT", 70, 79], ["levetiracetam", "TREATMENT", 81, 94], ["aspirin", "TREATMENT", 96, 103], ["analgesics", "TREATMENT", 109, 119]]], ["DSA seven days after admission demonstrated bilateral mild to moderate anterior circulation vasospasm suggestive of RCVS (Image 2,3).", [["anterior circulation", "ANATOMY", 71, 91], ["vasospasm", "DISEASE", 92, 101], ["RCVS", "DISEASE", 116, 120], ["DSA", "TEST", 0, 3], ["bilateral mild to moderate anterior circulation vasospasm", "PROBLEM", 44, 101], ["RCVS", "PROBLEM", 116, 120], ["bilateral", "ANATOMY_MODIFIER", 44, 53], ["mild", "OBSERVATION_MODIFIER", 54, 58], ["moderate", "OBSERVATION_MODIFIER", 62, 70], ["anterior", "ANATOMY_MODIFIER", 71, 79], ["circulation", "ANATOMY", 80, 91], ["vasospasm", "OBSERVATION", 92, 101], ["suggestive of", "UNCERTAINTY", 102, 115], ["RCVS", "OBSERVATION", 116, 120]]], ["She was discharged home with verapamil and followup CT angiogram.ConclusionRCVS is a common cause of cSAH in young women but is generally not associated with viral infection.", [["verapamil", "CHEMICAL", 29, 38], ["ConclusionRCVS", "DISEASE", 65, 79], ["cSAH", "DISEASE", 101, 105], ["viral infection", "DISEASE", 158, 173], ["verapamil", "CHEMICAL", 29, 38], ["verapamil", "SIMPLE_CHEMICAL", 29, 38], ["cSAH", "CANCER", 101, 105], ["women", "ORGANISM", 115, 120], ["women", "SPECIES", 115, 120], ["verapamil", "TREATMENT", 29, 38], ["followup CT angiogram", "TEST", 43, 64], ["cSAH", "PROBLEM", 101, 105], ["viral infection", "PROBLEM", 158, 173], ["cSAH", "OBSERVATION", 101, 105], ["not associated with", "UNCERTAINTY", 138, 157], ["viral", "OBSERVATION_MODIFIER", 158, 163], ["infection", "OBSERVATION", 164, 173]]], ["In our patient, dissection was present on initial DSA, with multifocal vasoconstriction seen only on repeat DSA.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["dissection", "PROBLEM", 16, 26], ["initial DSA", "TEST", 42, 53], ["multifocal vasoconstriction", "PROBLEM", 60, 87], ["repeat DSA", "TEST", 101, 111], ["dissection", "OBSERVATION", 16, 26], ["multifocal", "OBSERVATION_MODIFIER", 60, 70], ["vasoconstriction", "OBSERVATION", 71, 87]]], ["In this case, she had been coughing for a week prior to the presentation, which likely precipitated the dissection, leading to subsequent RCVS and cSAH.", [["RCVS", "DISEASE", 138, 142], ["cSAH", "DISEASE", 147, 151], ["coughing", "PROBLEM", 27, 35], ["the dissection", "PROBLEM", 100, 114], ["subsequent RCVS", "PROBLEM", 127, 142], ["cSAH", "PROBLEM", 147, 151], ["coughing", "OBSERVATION", 27, 35], ["dissection", "OBSERVATION", 104, 114]]], ["Extracranial dissection associated with RCVS is uncommon but reported; dissection may lead to vasoactive substance release precipitating RCVS 4 . cSAH in RCVS is likely due to dynamic vessel wall changes, with vasoconstriction followed by vasodilation leading to reperfusion injury and hemorrhage 2 .ConclusionHowever, SARS-CoV-2 also may also induce vasoconstriction; spikes in blood pressure may lead to loss of cerebral autoregulation, which is the proposed mechanism of RCVS 5 .", [["Extracranial", "ANATOMY", 0, 12], ["vessel wall", "ANATOMY", 184, 195], ["blood", "ANATOMY", 379, 384], ["cerebral", "ANATOMY", 414, 422], ["RCVS", "DISEASE", 40, 44], ["RCVS", "DISEASE", 137, 141], ["cSAH", "DISEASE", 146, 150], ["RCVS", "DISEASE", 154, 158], ["reperfusion injury", "DISEASE", 263, 281], ["hemorrhage", "DISEASE", 286, 296], ["SARS", "DISEASE", 319, 323], ["loss of cerebral autoregulation", "DISEASE", 406, 437], ["RCVS", "DISEASE", 474, 478], ["RCVS", "CANCER", 154, 158], ["vessel wall", "MULTI-TISSUE_STRUCTURE", 184, 195], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 319, 329], ["blood", "ORGANISM_SUBSTANCE", 379, 384], ["cerebral", "ORGAN", 414, 422], ["SARS-CoV", "SPECIES", 319, 327], ["Extracranial dissection", "PROBLEM", 0, 23], ["RCVS", "PROBLEM", 40, 44], ["dissection", "PROBLEM", 71, 81], ["RCVS", "PROBLEM", 137, 141], ["cSAH", "PROBLEM", 146, 150], ["dynamic vessel wall changes", "PROBLEM", 176, 203], ["vasoconstriction", "PROBLEM", 210, 226], ["reperfusion injury", "PROBLEM", 263, 281], ["hemorrhage", "PROBLEM", 286, 296], ["ConclusionHowever", "TEST", 300, 317], ["SARS", "TEST", 319, 323], ["vasoconstriction", "PROBLEM", 351, 367], ["spikes", "PROBLEM", 369, 375], ["blood pressure", "TEST", 379, 393], ["loss of cerebral autoregulation", "PROBLEM", 406, 437], ["dissection", "OBSERVATION", 13, 23], ["dissection", "OBSERVATION", 71, 81], ["likely due to", "UNCERTAINTY", 162, 175], ["dynamic vessel", "OBSERVATION", 176, 190], ["wall", "ANATOMY_MODIFIER", 191, 195], ["vasoconstriction", "OBSERVATION", 210, 226], ["reperfusion injury", "OBSERVATION", 263, 281], ["hemorrhage", "OBSERVATION", 286, 296], ["vasoconstriction", "OBSERVATION", 351, 367], ["cerebral autoregulation", "OBSERVATION", 414, 437]]], ["In particular, SARS-CoV-2 downregulates the ACE2 receptor, which functions to reduce sympathetic tone, increases vasodilation, and exerts antihypertensive effects.ConclusionSARS-CoV-2 leads to downregulation of ACE2, which can cause overactivation of the classic renin-angiotensin axis and lead to vasoconstriction 6 .ConclusionLimitations of our case include the lack of follow-up imaging at this time, as the patient presented early in her course and had vasoconstriction on last imaging, as well as the unclear relationship between SARS-CoV-2 infection, dissection, and RCVS.", [["angiotensin", "CHEMICAL", 269, 280], ["SARS-CoV-2 infection", "DISEASE", 535, 555], ["RCVS", "DISEASE", 573, 577], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 15, 25], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 44, 57], ["ConclusionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 163, 183], ["ACE2", "GENE_OR_GENE_PRODUCT", 211, 215], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 263, 280], ["patient", "ORGANISM", 411, 418], ["CoV-2", "ORGANISM", 540, 545], ["ACE2 receptor", "PROTEIN", 44, 57], ["ACE2", "PROTEIN", 211, 215], ["renin", "PROTEIN", 263, 268], ["patient", "SPECIES", 411, 418], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "TEST", 15, 19], ["CoV", "TEST", 20, 23], ["the ACE2 receptor", "TREATMENT", 40, 57], ["sympathetic tone", "PROBLEM", 85, 101], ["increases vasodilation", "PROBLEM", 103, 125], ["antihypertensive effects", "TREATMENT", 138, 162], ["ConclusionSARS", "TEST", 163, 177], ["CoV", "TEST", 178, 181], ["downregulation of ACE2", "PROBLEM", 193, 215], ["the classic renin", "PROBLEM", 251, 268], ["angiotensin axis", "PROBLEM", 269, 285], ["vasoconstriction", "PROBLEM", 298, 314], ["follow-up imaging", "TEST", 372, 389], ["vasoconstriction", "PROBLEM", 457, 473], ["last imaging", "TEST", 477, 489], ["SARS", "PROBLEM", 535, 539], ["CoV-2 infection", "PROBLEM", 540, 555], ["dissection", "PROBLEM", 557, 567], ["RCVS", "PROBLEM", 573, 577], ["sympathetic tone", "OBSERVATION", 85, 101], ["angiotensin axis", "OBSERVATION", 269, 285], ["infection", "OBSERVATION", 546, 555], ["dissection", "OBSERVATION", 557, 567]]], ["However, the patient's RCVS2 score 7 was 10, with a score of >5 having a high specificity and sensitivity (99% and 90% respectively) for diagnosing RCVS.", [["RCVS", "DISEASE", 148, 152], ["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["the patient's RCVS2 score", "TEST", 9, 34], ["sensitivity", "TEST", 94, 105], ["diagnosing RCVS", "TEST", 137, 152]]], ["Overall, this single case report only suggests a possible association between RCVS and SARS-CoV-2 infection, and more cases with epidemiological data are needed to validate a causal relationship.ConclusionThis case also suggests the need to consider potential neurological symptoms of SARS-CoV-2 infection.Identifying DataThe patient provided written informed consent to the publication of this case report.", [["neurological", "ANATOMY", 260, 272], ["RCVS", "DISEASE", 78, 82], ["SARS-CoV-2 infection", "DISEASE", 87, 107], ["SARS-CoV-2 infection", "DISEASE", 285, 305], ["SARS-CoV-2", "ORGANISM", 87, 97], ["SARS-CoV-2", "ORGANISM", 285, 295], ["patient", "ORGANISM", 326, 333], ["patient", "SPECIES", 326, 333], ["SARS-CoV-2", "SPECIES", 87, 97], ["SARS-CoV", "SPECIES", 285, 293], ["RCVS", "PROBLEM", 78, 82], ["SARS", "PROBLEM", 87, 91], ["CoV-2 infection", "PROBLEM", 92, 107], ["epidemiological data", "TEST", 129, 149], ["potential neurological symptoms", "PROBLEM", 250, 281], ["SARS", "PROBLEM", 285, 289], ["CoV-2 infection", "PROBLEM", 290, 305], ["infection", "OBSERVATION", 98, 107], ["infection", "OBSERVATION", 296, 305]]]], "b9ae4aa4cfc963fb9d577432658d9058a3ace21f": [["The COVID-19 pandemic has been causing significant challenges across all areas of society.", [["The COVID", "TEST", 0, 9], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["challenges", "OBSERVATION_MODIFIER", 51, 61], ["across", "OBSERVATION_MODIFIER", 62, 68], ["all", "OBSERVATION_MODIFIER", 69, 72], ["areas", "OBSERVATION_MODIFIER", 73, 78], ["society", "OBSERVATION", 82, 89]]], ["By virtue of prevalent frailty and multimorbidity, care home residents remain vulnerable to COVID-19 until effective vaccines are developed (Gordon et al., 2020) .", [["frailty", "DISEASE", 23, 30], ["multimorbidity", "DISEASE", 35, 49], ["COVID", "TEST", 92, 97], ["effective vaccines", "TREATMENT", 107, 125]]], ["The current health crisis and the enforced isolation can have huge impact to the mental health of this vulnerable individuals, the majority of whom have dementia and are also at significantly increased risk of severe COVID-19.", [["dementia", "DISEASE", 153, 161], ["COVID-19", "CHEMICAL", 217, 225], ["the enforced isolation", "TREATMENT", 30, 52], ["dementia", "PROBLEM", 153, 161], ["severe COVID", "PROBLEM", 210, 222], ["dementia", "OBSERVATION", 153, 161], ["severe", "OBSERVATION_MODIFIER", 210, 216]]]], "1730a8cc6e8f4cb23da2391a3b9e49fd6f953d63": [["Influence of Asymptomatic Carriers With COVID-19 on Transplantation Resumption in WuhanXiaoen Bian, MD, Xiaoli Fan, MD, and Yanfeng Wang, MD W uhan is not only the first city to experience COVID-19 but is also among the first to emerge from the pandemic and currently has only 5 confirmed cases.", [["Transplantation", "TREATMENT", 52, 67]]], ["The existence of asymptomatic carriers poses a threat for disease resurgence and also for virus transmission through transplantation.", [["asymptomatic carriers", "PROBLEM", 17, 38], ["disease resurgence", "TREATMENT", 58, 76], ["virus transmission through transplantation", "TREATMENT", 90, 132], ["asymptomatic", "OBSERVATION_MODIFIER", 17, 29]]], ["There are 2 types of asymptomatic carrier: the first is a recessive infection, with persistent but asymptomatic viral detection over 14 days or more, but with a relatively low-infectivity risk in the general community and unknown infection transmission risk from organ donation.", [["organ", "ANATOMY", 263, 268], ["recessive infection", "DISEASE", 58, 77], ["infection", "DISEASE", 230, 239], ["organ", "ORGAN", 263, 268], ["asymptomatic carrier", "PROBLEM", 21, 41], ["a recessive infection", "PROBLEM", 56, 77], ["asymptomatic viral detection", "PROBLEM", 99, 127], ["a relatively low-infectivity risk", "PROBLEM", 159, 192], ["organ donation", "TREATMENT", 263, 277], ["2 types", "OBSERVATION_MODIFIER", 10, 17], ["asymptomatic", "OBSERVATION_MODIFIER", 21, 33], ["recessive", "OBSERVATION_MODIFIER", 58, 67], ["infection", "OBSERVATION", 68, 77], ["persistent", "OBSERVATION_MODIFIER", 84, 94], ["asymptomatic", "OBSERVATION_MODIFIER", 99, 111], ["viral", "OBSERVATION", 112, 117], ["infection", "OBSERVATION", 230, 239]]], ["The second group of asymptomatic cases are in the early stages of the incubation of the disease and become symptomatic over time but are contagious in the asymptomatic phase.Influence of Asymptomatic Carriers With COVID-19 on Transplantation Resumption in WuhanTo identify all asymptomatic carriers, Wuhan has carried out SARS-CoV-2 nucleic acid tests (NAT) for all city dwellers since May 14.", [["nucleic acid", "CHEMICAL", 333, 345], ["asymptomatic cases", "PROBLEM", 20, 38], ["the disease", "PROBLEM", 84, 95], ["symptomatic", "PROBLEM", 107, 118], ["COVID", "TEST", 214, 219], ["Transplantation", "TREATMENT", 226, 241], ["SARS", "PROBLEM", 322, 326], ["CoV", "TEST", 327, 330], ["nucleic acid tests", "TEST", 333, 351], ["asymptomatic", "OBSERVATION_MODIFIER", 20, 32], ["cases", "OBSERVATION", 33, 38], ["early stages", "OBSERVATION_MODIFIER", 50, 62], ["disease", "OBSERVATION", 88, 95], ["symptomatic", "OBSERVATION_MODIFIER", 107, 118]]], ["As of May 24, 6 574 093 NAT tests have been completed, with a total of 227 new asymptomatic carriers and 1 new confirmed case 1 .", [["NAT tests", "TEST", 24, 33], ["new asymptomatic carriers", "PROBLEM", 75, 100]]], ["The asymptomatic infection rate in Wuhan has dropped from 0.5 per 1000 people 2 to 0.03 per 1000 people.Influence of Asymptomatic Carriers With COVID-19 on Transplantation Resumption in WuhanThe outbreak of COVID-19 greatly slowed and then stopped organ donation and transplantation in Wuhan, but the decrease in the number of infections has allowed hospitals in Wuhan to carefully resume deceased donor organ donation and transplantation.Influence of Asymptomatic Carriers With COVID-19 on Transplantation Resumption in WuhanHyo-Lim Hong et al 3 and Stephen Lagana et al 4 have reported 2 cases of donor-derived transmission of COVID-19, therefore a strategy is needed to prevent donor-derived transmission from all potential asymptomatic carriers.Influence of Asymptomatic Carriers With COVID-19 on Transplantation Resumption in WuhanDue to the superficial understanding of COVID-19 and presence of asymptomatic infection in Wuhan, we instituted a protocol to prevent organ donor transmission of COVID-19.", [["organ", "ANATOMY", 248, 253], ["organ", "ANATOMY", 404, 409], ["organ", "ANATOMY", 970, 975], ["infection", "DISEASE", 17, 26], ["COVID-19", "CHEMICAL", 207, 215], ["infections", "DISEASE", 327, 337], ["COVID-19", "CHEMICAL", 629, 637], ["infection", "DISEASE", 914, 923], ["COVID-19", "CHEMICAL", 998, 1006], ["COVID-19", "CHEMICAL", 207, 215], ["COVID-19", "CHEMICAL", 998, 1006], ["people", "ORGANISM", 97, 103], ["organ", "ORGAN", 248, 253], ["organ", "ORGAN", 404, 409], ["organ", "ORGAN", 970, 975], ["people", "SPECIES", 71, 77], ["people", "SPECIES", 97, 103], ["The asymptomatic infection rate", "PROBLEM", 0, 31], ["COVID", "TEST", 144, 149], ["Transplantation", "TREATMENT", 156, 171], ["COVID", "TEST", 207, 212], ["organ donation", "TREATMENT", 248, 262], ["transplantation", "TREATMENT", 267, 282], ["deceased donor organ donation", "TREATMENT", 389, 418], ["transplantation", "TREATMENT", 423, 438], ["Asymptomatic Carriers", "PROBLEM", 452, 473], ["COVID", "TEST", 479, 484], ["Transplantation", "TREATMENT", 491, 506], ["WuhanHyo-Lim Hong et al", "TREATMENT", 521, 544], ["Stephen Lagana et al 4", "TREATMENT", 551, 573], ["donor-derived transmission of COVID", "TREATMENT", 599, 634], ["a strategy", "TREATMENT", 649, 659], ["Asymptomatic Carriers", "PROBLEM", 762, 783], ["COVID", "TEST", 789, 794], ["Transplantation", "TREATMENT", 801, 816], ["COVID", "TEST", 876, 881], ["asymptomatic infection", "PROBLEM", 901, 923], ["a protocol", "TREATMENT", 948, 958], ["organ donor transmission of COVID", "TREATMENT", 970, 1003], ["asymptomatic", "OBSERVATION_MODIFIER", 4, 16], ["infection", "OBSERVATION", 17, 26], ["decrease", "OBSERVATION_MODIFIER", 301, 309], ["infections", "OBSERVATION", 327, 337], ["asymptomatic", "OBSERVATION_MODIFIER", 901, 913], ["infection", "OBSERVATION", 914, 923]]], ["Before transplantation both deceased donors and potential recipients undergo SARS-CoV-2 NAT and antibody tests as well as CT scans, which are repeated twice, to avoid the known false negative rates of single tests in COVID-19 patients and detect patients in the early stages of developing symptomatic disease.", [["donors", "ORGANISM", 37, 43], ["recipients", "ORGANISM", 58, 68], ["patients", "ORGANISM", 226, 234], ["patients", "ORGANISM", 246, 254], ["patients", "SPECIES", 226, 234], ["patients", "SPECIES", 246, 254], ["transplantation", "TREATMENT", 7, 22], ["SARS", "TEST", 77, 81], ["CoV", "TEST", 82, 85], ["antibody tests", "TEST", 96, 110], ["CT scans", "TEST", 122, 130], ["single tests", "TEST", 201, 213], ["COVID", "TEST", 217, 222], ["developing symptomatic disease", "PROBLEM", 278, 308], ["early stages", "OBSERVATION_MODIFIER", 262, 274], ["symptomatic", "OBSERVATION_MODIFIER", 289, 300], ["disease", "OBSERVATION", 301, 308]]], ["Donors and recipients must test negative twice to be eligible for transplant.", [["Donors", "ORGANISM", 0, 6], ["recipients", "ORGANISM", 11, 21], ["recipients must test", "TEST", 11, 31], ["transplant", "TREATMENT", 66, 76]]], ["To minimize transmission caused by asymptomatic carriers, potential deceased donors are quarantined in intensive care for >7 days while being tested.", [["donors", "ORGANISM", 77, 83], ["asymptomatic carriers", "PROBLEM", 35, 56]]], ["Suspected or confirmed COVID-19 patients would be eliminated from the donation process.Influence of Asymptomatic Carriers With COVID-19 on Transplantation Resumption in WuhanFrom April 8, when Wuhan was reopened, to May 25, 43 cases of organ donation after brain death and 125 cases of organ transplant have been completed in Wuhan hospitals.", [["organ", "ANATOMY", 236, 241], ["brain", "ANATOMY", 257, 262], ["organ", "ANATOMY", 286, 291], ["brain death", "DISEASE", 257, 268], ["patients", "ORGANISM", 32, 40], ["organ", "ORGAN", 236, 241], ["brain", "ORGAN", 257, 262], ["organ", "ORGAN", 286, 291], ["patients", "SPECIES", 32, 40], ["COVID", "TEST", 23, 28], ["the donation process", "TREATMENT", 66, 86], ["COVID", "TEST", 127, 132], ["Transplantation", "TREATMENT", 139, 154], ["organ donation", "TREATMENT", 236, 250], ["brain death", "PROBLEM", 257, 268], ["organ transplant", "TREATMENT", 286, 302]]], ["There have been no cases of COVID-19 detected among organ transplant donors and recipients.", [["organ", "ANATOMY", 52, 57], ["organ", "ORGAN", 52, 57], ["donors", "ORGANISM", 69, 75], ["recipients", "ORGANISM", 80, 90], ["COVID", "TEST", 28, 33], ["no", "UNCERTAINTY", 16, 18]]], ["This protocol may serve as a complex but necessary learning model for others.", [["This protocol", "TREATMENT", 0, 13]]]], "PMC7528416": [["INTRODUCCI\u00d3NA lo largo de los \u00faltimos veinte a\u00f1os, se ha producido el aumento y una r\u00e1pida expansi\u00f3n de ciertas enfermedades infecciosas debido a la extraordinaria conectividad que define a nuestra civilizaci\u00f3n global [1].", [["a la extraordinaria conectividad", "TREATMENT", 144, 176]]], ["Algunas de ellas, el S\u00edndrome Respiratorio Agudo Severo (SARS) (2003), la gripe H1N1 (2009), el \u00c9bola (2014) o el Zika (2015) afectan especialmente a las mujeres gestantes, ya que pueden producir una p\u00e9rdida del embarazo o da\u00f1os cong\u00e9nitos graves [2,3].INTRODUCCI\u00d3NEn diciembre del 2019, emergi\u00f3 un agrupamiento de casos de neumon\u00eda en la ciudad de Wuhan (provincia de Hubei, China), con una exposici\u00f3n com\u00fan en un mercado que fue cerrado el d\u00eda 1 de enero de 2020.", [["SARS", "DISEASE", 57, 61], ["el S\u00edndrome", "TEST", 18, 29]]], ["La enfermedad causada por este nuevo virus ha sido denominada por consenso internacional COVID-19, cuyo primer caso en Espa\u00f1a se produjo en La Gomera el 31 de enero.", [["COVID", "TEST", 89, 94]]], ["Posteriormente, el 11 de marzo, la Organizaci\u00f3n Mundial de la Salud declar\u00f3 el estado de pandemia [4-7].INTRODUCCI\u00d3NDe los siete tipos de coronavirus que infectan a los humanos, tres de ellos, MERS-CoV, SARS-CoV, SARS-CoV-2, pueden generar un cuadro de s\u00edndrome respiratorio severo.", [["SARS-CoV", "DISEASE", 203, 211], ["SARS", "DISEASE", 213, 217], ["SARS-CoV", "SPECIES", 203, 211], ["SARS", "PROBLEM", 203, 207], ["SARS", "PROBLEM", 213, 217], ["CoV", "TEST", 218, 221]]], ["El primero en aparecer fue el SARS-CoV identificado en China (2003) que se extendi\u00f3 por 26 pa\u00edses y ocasion\u00f3 cerca de 8000 casos.", [["SARS-CoV identificado", "DISEASE", 30, 51]]], ["El segundo, conocido como MERS-CoV y que produc\u00eda el S\u00edndrome Respiratorio del Medio Oriente (MERS) se identific\u00f3 en Arabia Saudita en 2012 produciendo 2500 casos [6].", [["Arabia Saudita en 2012 produciendo 2500 casos", "SPECIES", 117, 162]]], ["Finalmente, el SARS-CoV-2 es el responsable de la actual pandemia en todo el mundo [8].INTRODUCCI\u00d3NLas mujeres embarazadas constituyen un grupo de especial riesgo y vulnerabilidad para las enfermedades de origen infeccioso [9], debido a tres factores: su mayor compromiso cardio-respiratorio al avanzar la edad gestacional (sobre todo en el tercer trimestre) [10], la inmunosupresi\u00f3n secundaria a la gestaci\u00f3n [11], y las limitaciones en los tratamientos por el posible da\u00f1o al feto en cada trimestre de embarazo) [12].INTRODUCCI\u00d3NHasta la fecha el virus respiratorio m\u00e1s com\u00fan que ha afectado a las mujeres embarazadas es el virus de la gripe estacional [13,14] generando mayor morbilidad y muerte durante los periodos epid\u00e9micos [10].", [["Finalmente", "TEST", 0, 10], ["el SARS", "TEST", 12, 19], ["CoV", "TEST", 20, 23], ["al avanzar la edad gestacional (sobre todo en el tercer trimestre)", "TREATMENT", 292, 358], ["la inmunosupresi\u00f3n", "TREATMENT", 365, 383], ["a la gestaci\u00f3n", "TREATMENT", 395, 409], ["y las limitaciones en los tratamientos", "TREATMENT", 416, 454], ["al feto en cada trimestre de embarazo)", "TREATMENT", 475, 513], ["INTRODUCCI\u00d3NHasta la fecha el virus respiratorio", "TEST", 519, 567]]], ["Este incremento de las complicaciones en la salud de las mujeres embarazadas, tambi\u00e9n se ha observado con los coronavirus que produjeron el SARS y el MERS [15].", [["embarazadas", "TREATMENT", 65, 76], ["tambi\u00e9n se ha observado con los coronavirus", "TREATMENT", 78, 121]]], ["En el estudio realizado por Lam et. al.[16] las mujeres embarazadas con SARS-CoV experimentaron un peor curso cl\u00ednico en comparaci\u00f3n con las mujeres no embarazadas, presentando insuficiencia renal y coagulopat\u00eda intravascular diseminada, adem\u00e1s de mayores ingresos en la Unidad de Cuidados Intensivos (UCI).", [["SARS-CoV experimentaron", "DISEASE", 72, 95], ["intravascular diseminada", "DISEASE", 212, 236], ["las mujeres embarazadas", "TREATMENT", 44, 67], ["CoV experimentaron", "TREATMENT", 77, 95], ["embarazadas", "PROBLEM", 152, 163], ["intravascular diseminada", "PROBLEM", 212, 236], ["renal", "ANATOMY", 191, 196]]], ["Tambi\u00e9n se observ\u00f3 que si la tasa de mortalidad tras infecci\u00f3n por SARS-CoV se incrementaba un 10% en la poblaci\u00f3n general, en las mujeres embarazadas lo hac\u00eda un 25% m\u00e1s [17].", [["Tambi\u00e9n", "TREATMENT", 0, 7]]], ["Tanto el SARS-CoV como el MERS-CoV han dado lugar a urgencias obst\u00e9tricas como la hemorragia preparto [18], los partos prematuros [19], el Desprendimiento Prematuro de Placenta Normalmente Inserta (DPPNI) [20] e incluso el fallecimiento de la gestante [21].INTRODUCCI\u00d3NEl SARS-CoV-2 est\u00e1 infectando a mujeres embarazadas, lo que hace interesante realizar una revisi\u00f3n exploratoria para conocer en qu\u00e9 manera las est\u00e1 afectando y si existen similitudes o diferencias entre los casos cl\u00ednicos y su evoluci\u00f3n obst\u00e9trica en las gestantes con diagn\u00f3stico confirmado de SARS-CoV, MERS-CoV y SARS-CoV-2, lo que constituye el objetivo de esta revisi\u00f3n.M\u00c9TODOSSe ha llevado a cabo una revisi\u00f3n exploratoria [22] con objeto de conocer en gestantes su sintomatolog\u00eda general asociada a las infecciones por coronavirus, sus posibles complicaciones obst\u00e9tricas y sus resultados neonatales.M\u00c9TODOSPara la elecci\u00f3n de documentos se establecieron los siguientes criterios de inclusi\u00f3n: art\u00edculos originales sin importar el idioma en el que estuvieran escritos, texto completo, poblaci\u00f3n de mujeres embarazadas, casos \u00fanicos o m\u00faltiples generados por la infecci\u00f3n viral durante el embarazo ocasionado por coronavirus (SARS-CoV, MERS-CoV y SARS-CoV-2) y calidad de la revista mediante factor de impacto publicado en la Web of Science (WoS), y excluyendo los que no cumpl\u00edan los criterios inclusivos de mujeres embarazadas y coronavirus conjuntamente.M\u00c9TODOSSe exploraron como fuentes de informaci\u00f3n las bases de datos: MEDLINE, SciELO y CUIDEN.", [["SARS-CoV", "DISEASE", 564, 572], ["por coronavirus", "DISEASE", 1184, 1199], ["SARS-CoV", "DISEASE", 1201, 1209], ["casos \u00fanicos o m\u00faltiples generados por la infecci\u00f3n viral durante el embarazo ocasionado por coronavirus (SARS-CoV, MERS-CoV y SARS-CoV", "SPECIES", 1095, 1230], ["Tanto el SARS", "TEST", 0, 13], ["el Desprendimiento Prematuro de Placenta Normalmente Inserta (DPPNI)", "TREATMENT", 136, 204], ["obst\u00e9trica", "TEST", 506, 516], ["coronavirus", "PROBLEM", 795, 806], ["viral durante", "TEST", 1147, 1160], ["coronavirus", "PROBLEM", 1188, 1199], ["MERS", "TEST", 1211, 1215], ["CoV y SARS", "PROBLEM", 1216, 1226], ["Placenta", "ANATOMY", 168, 176]]], ["Dada la situaci\u00f3n de pandemia de la COVID-19, se han puesto distintas fuentes bibliogr\u00e1ficas en acceso abierto sobre la literatura cient\u00edfica disponible sobre coronavirus, por lo que seleccionamos el recurso de Elsevier para explorarlo a trav\u00e9s de su Web de Centro de Informaci\u00f3n sobre el COVID-19 accesible en https://www.elsevier.com/connect/coronavirus-information-center.M\u00c9TODOSSe estableci\u00f3 una estrategia de b\u00fasqueda (tabla 1) utilizando combinaciones mediante operadores booleanos de OR y AND de los siguientes t\u00e9rminos controlados localizados en Desc y MeSH: \u201ccoronavirus\u201d, \u201cSARS-CoV\u201d, \u201cMERS-CoV\u201d, \u201csindrome respiratorio agudo grave\u201d, \u201csevere acute respiratory syndrome\u201d \u201csindrome respiratorio de Oriente Medio\u201d, \u201cmiddle east respiratory syndrome\u201d, \u201cembarazada\u201d y \u201cpregnant women\u201d y \u201cpregnant woman\u201d.", [["coronavirus\u201d", "DISEASE", 568, 580], ["SARS-CoV\u201d", "DISEASE", 583, 592], ["MERS-CoV\u201d", "DISEASE", 595, 604], ["acute respiratory syndrome", "DISEASE", 651, 677], ["respiratory syndrome", "DISEASE", 734, 754], ["coronavirus", "ORGANISM", 568, 579], ["women", "ORGANISM", 782, 787], ["coronavirus", "SPECIES", 568, 579], ["women", "SPECIES", 782, 787], ["woman", "SPECIES", 801, 806], ["SARS-CoV", "SPECIES", 583, 591], ["MERS-CoV", "SPECIES", 595, 603], ["COVID", "TEST", 289, 294], ["coronavirus", "PROBLEM", 568, 579], ["SARS", "PROBLEM", 583, 587], ["CoV", "TEST", 588, 591], ["MERS", "TEST", 595, 599], ["CoV", "TEST", 600, 603], ["\u201c", "TEST", 606, 607], ["sindrome", "TEST", 607, 615], ["respiratorio", "TEST", 616, 628], ["agudo", "TEST", 629, 634], ["severe acute respiratory syndrome", "PROBLEM", 644, 677], ["middle east respiratory syndrome", "PROBLEM", 722, 754], ["severe", "OBSERVATION_MODIFIER", 644, 650], ["acute", "OBSERVATION_MODIFIER", 651, 656], ["respiratory syndrome", "OBSERVATION", 657, 677], ["middle", "ANATOMY_MODIFIER", 722, 728], ["respiratory syndrome", "OBSERVATION", 734, 754]]], ["En formulario libre de las mencionadas fuentes bibliogr\u00e1ficas y en algunos casos en el campo de \u201ct\u00edtulo/abstract\u201d de MEDLINE usamos libremente los t\u00e9rminos \u201cCOVID 19\u201d, \u201cCOVID-19\u201d, \u201cCOVID19\u201d, \u201c2019-nCov\u201d, \u201c2019nCov\u201d, \u201cSARS-CoV2\u201d, \u201cSARS-CoV-2\u201d.", [["COVID", "TEST", 157, 162], ["COVID", "TEST", 169, 174], ["COVID19", "TEST", 181, 188], ["Cov", "TEST", 210, 213], ["SARS", "TEST", 217, 221], ["SARS", "TEST", 230, 234], ["CoV", "TEST", 235, 238]]], ["La b\u00fasqueda bibliogr\u00e1fica comprendi\u00f3 desde el a\u00f1o 2003 hasta la actualidad (abril 2020) y se realiz\u00f3 entre el 2 de marzo y el 14 de abril del 2020.M\u00c9TODOSPosteriormente se seleccionaron y clasificaron los estudios, as\u00ed como sus variables bibliom\u00e9tricas, de contenido y de calidad.", [["M\u00c9TODOSPosteriormente", "TREATMENT", 147, 168]]], ["Para evaluar la calidad metodol\u00f3gica, elegimos la herramienta de evaluaci\u00f3n critica de JBI para series de casos como los utilizados en el trabajo de Murad et. al.[23] en funci\u00f3n de los dominios de selecci\u00f3n, verificaci\u00f3n, causalidad e informes.", [["Para", "TEST", 0, 4]]], ["Se utiliz\u00f3 una plantilla para extraer los siguientes datos: autor, a\u00f1o de publicaci\u00f3n, pa\u00eds, tipo de dise\u00f1o de los estudios, objetivo y poblaci\u00f3n.", [["Se", "CHEMICAL", 0, 2], ["Se", "CHEMICAL", 0, 2], ["objetivo y poblaci\u00f3n", "TREATMENT", 125, 145]]], ["Los datos fueron extra\u00eddos y volcados a la plantilla por dos investigadores del equipo.", [["a la plantilla", "TREATMENT", 38, 52]]], ["Se observ\u00f3 una considerable heterogeneidad entre los estudios y factores como el sesgo de publicaci\u00f3n y el informe selectivo de los resultados que no pudieron explicarse.", [["pudieron explicarse", "PROBLEM", 150, 169]]], ["De los 70 art\u00edculos le\u00eddos a texto completo, se seleccionaron 20 art\u00edculos finales y se descart\u00f3 el resto porque no cumpl\u00edan con todos los criterios de inclusi\u00f3n, tal como se muestra en la figura 1 del PRISMA.RESULTADOSLa mayor\u00eda de los 20 art\u00edculos seleccionados proceden de China (9), seguidos de Corea (2), Arabia Saud\u00ed (2), EE.", [["a texto completo", "TREATMENT", 27, 43]]], ["La poblaci\u00f3n elegida estaba compuesta de mujeres embarazadas, aunque hay cuatro que adem\u00e1s inclu\u00edan a neonatos (tablas 2 y 3) [8, 12, 17, 18 , 20, 21, 26-39].RESULTADOSLa muestra final recogi\u00f3 casos de 102 gestantes, con una media de edad de 31,2 (DE\u00b14,5) a\u00f1os; 79 gestantes correspond\u00edan a casos de SARS-CoV-2; 14 gestantes correspond\u00edan a casos de SARS-CoV y 9 gestantes a casos de MERS-CoV.", [["MERS-CoV", "ORGANISM", 384, 392], ["MERS-CoV", "SPECIES", 384, 392], ["a neonatos (tablas", "TREATMENT", 100, 118], ["CoV", "TEST", 305, 308]]], ["La mayor\u00eda de las infecciones se detectaron durante el segundo y tercer trimestre (32 semanas \u00b110 semanas), exceptuando siete casos de SARS-CoV en los que la infecci\u00f3n se produjo durante el primer trimestre y que acabaron en un aborto espont\u00e1neo o voluntario.", [["SARS-CoV en los que la infecci\u00f3n se produjo durante el primer trimestre y que acabaron en un aborto espont\u00e1neo o voluntario", "SPECIES", 135, 258], ["semanas", "TEST", 86, 93], ["CoV en los que la infecci\u00f3n", "TREATMENT", 140, 167]]], ["En la tabla 4 se describen los datos comparativos sobre las tres enfermedades, resaltando la fiebre con un 89,5% (IC 95%: 82,696,3) y la neumon\u00eda con un 81,5% (IC 95%: 72,7-90,2) los s\u00edntomas comunes de los tres coronavirus.", [["IC", "TEST", 114, 116], ["y la neumon\u00eda con un", "TEST", 132, 152], ["IC", "TEST", 160, 162], ["los s\u00edntomas comunes de los tres coronavirus", "PROBLEM", 179, 223]]], ["Adem\u00e1s, se observ\u00f3 que la Amenaza de Parto Prematuro (APP) con un 26,6% (IC 95%: 8,9-44,2) y la ces\u00e1rea con 85,4% (IC 95%:77,5-93,3) fueron las complicaciones obst\u00e9tricas m\u00e1s frecuentes.RESULTADOSSintomatolog\u00eda general asociada a la patolog\u00eda.", [["IC", "TEST", 73, 75], ["IC", "TEST", 115, 117]]], ["Como se aprecia en la tabla 5 [8, 26-34], la fiebre en un 85,9% (n=55) de los casos y la tos en un 32,9% (n=26) fueron los s\u00edntomas m\u00e1s caracter\u00edsticos de las gestantes que enfermaron por SARS-CoV-2, resultando ocasional, la aparici\u00f3n de diarrea con un 8,9% (n=7).", [["Como se aprecia en la tabla", "TEST", 0, 27], ["la fiebre en un", "TEST", 42, 57], ["de los casos", "TEST", 71, 83], ["fueron", "TEST", 112, 118], ["los s\u00edntomas", "TEST", 119, 131], ["m\u00e1s", "TEST", 132, 135], ["caracter\u00edsticos", "TEST", 136, 151], ["enfermaron", "TEST", 173, 183], ["SARS", "TEST", 188, 192], ["CoV", "TEST", 193, 196], ["resultando ocasional", "PROBLEM", 200, 220], ["la aparici\u00f3n de diarrea", "PROBLEM", 222, 245]]], ["La neumon\u00eda fue padecida por 75,7% (n=53) de las gestantes y esta fue de car\u00e1cter leve en la mayor\u00eda de los casos, ya que solo 4,3% (n=3) de las gestantes precisaron de ventilaci\u00f3n mec\u00e1nica e ingreso en UCI.", [["La neumon\u00eda fue padecida", "TEST", 0, 24]]], ["En este \u00faltimo dato cabe destacar que en el art\u00edculo de Zhu et. al. [26] no especifica qu\u00e9 gestantes tuvieron neumon\u00eda y si alguna de ellas precis\u00f3 o no de ventilaci\u00f3n asistida.RESULTADOSEn relaci\u00f3n con el SARS-CoV (tabla 6) [17, 18, 36, 38], la fiebre y la mialgia aparecieron en el 100% (n=14) de los casos estudiados.", [["SARS-CoV", "DISEASE", 206, 214], ["especifica", "PROBLEM", 76, 86], ["la", "TEST", 243, 245]]], ["Todas las gestantes, desarrollaron neumon\u00eda y un 42,9% (n=6) precisaron recibir ventilaci\u00f3n mec\u00e1nica en UCI.RESULTADOSRespecto al MERS-CoV (tabla 7) [12, 20, 21, 36, 37, 39], destaca la fiebre en el 100% (n=9) de los casos, la tos y la disnea que se produjo en el 87,5% (n=7) como s\u00edntomas m\u00e1s caracter\u00edsticos.", [["RESULTADOSRespecto al MERS-CoV", "SPECIES", 108, 138], ["desarrollaron neumon\u00eda", "TEST", 21, 43], ["CoV (tabla", "TEST", 135, 145], ["destaca", "TEST", 175, 182], ["la", "TEST", 183, 185], ["de los casos", "TEST", 210, 222], ["la tos", "TEST", 224, 230], ["en el", "TEST", 258, 263], ["como s\u00edntomas m\u00e1s caracter\u00edsticos", "PROBLEM", 276, 309]]], ["El 100% de las gestantes estudiadas padecieron neumon\u00eda, pero solo la mitad precisaron de ventilaci\u00f3n mec\u00e1nica.RESULTADOSComplicaciones obst\u00e9tricas de las gestantes.", [["El", "TEST", 0, 2]]], ["Las complicaciones obst\u00e9tricas en las mujeres que pasaron el COVID-19 durante la gestaci\u00f3n son escasas, destacando que se produjo la APP en el 24,3% (n=18) y el Riesgo de P\u00e9rdida de Bienestar Fetal (RPBF) en un 18,9% (n=14) como urgencias obst\u00e9tricas m\u00e1s frecuentes.", [["COVID", "TEST", 61, 66], ["la APP en el", "TEST", 130, 142]]], ["De estos datos destaca que no se produjo ning\u00fan fallecimiento entres las infectadas por SARS-CoV-2.RESULTADOSRespecto al SARS-CoV, un 41,7% (n=5) tuvieron un aborto durante el primer trimestre, por ello no tenemos datos de las complicaciones obst\u00e9tricas.", [["SARS-CoV", "DISEASE", 121, 129], ["RESULTADOSRespecto al SARS-CoV", "SPECIES", 99, 129], ["RESULTADOSRespecto", "TEST", 99, 117], ["al SARS", "TEST", 118, 125], ["CoV", "TEST", 126, 129], ["un", "TEST", 131, 133]]], ["En el resto de gestantes, la infecci\u00f3n se produjo cuando a\u00fan no hab\u00edan llegado a t\u00e9rmino, por ello el 71,4% (n=5) padecieron una APP.", [["APP", "GENE_OR_GENE_PRODUCT", 129, 132], ["APP", "PROTEIN", 129, 132], ["padecieron una APP", "TEST", 114, 132]]], ["Las hemorragias preparto ocurrieron en un 57,1% (n=4) y fueron de distinto origen, una fue por Placenta Previa (PP) [36, 38] y las otras tres una Coagulaci\u00f3n Intravascular Diseminada (CID) [18, 36].", [["Las hemorragias", "TEST", 0, 15], ["ocurrieron", "TEST", 25, 35], ["Placenta Previa", "PROBLEM", 95, 110], ["y las otras tres", "TEST", 125, 141]]], ["Una de las complicaciones m\u00e1s graves que produjo la neumon\u00eda por SARS-CoV fue la co-infecci\u00f3n por sepsis y neumon\u00eda bacteriana que se produjo en el 57,1% (n=4) de las gestantes.", [["sepsis", "DISEASE", 98, 104], ["graves", "PROBLEM", 30, 36], ["SARS", "PROBLEM", 65, 69], ["sepsis", "PROBLEM", 98, 104], ["bacteriana", "TEST", 116, 126]]], ["El 21,4% (n=3) de las gestantes fallecieron.RESULTADOSEntre las diagnosticadas por MERS-CoV, destacan tres complicaciones: la hemorragia preparto que se present\u00f3 en el 22,2% (n=2), la hipertensi\u00f3n arterial previa a la infecci\u00f3n y la APP en un 11,1% (n=1) respectivamente.", [["El", "TEST", 0, 2], ["la hemorragia", "TEST", 123, 136], ["en el", "TEST", 162, 167], ["la hipertensi\u00f3n arterial previa", "PROBLEM", 181, 212], ["respectivamente", "TREATMENT", 255, 270], ["arterial", "ANATOMY", 197, 205]]], ["La hemorragia que se dio en dos gestantes, una fue por DPPNI y la otra no se especific\u00f3 [20, 35].", [["La hemorragia", "PROBLEM", 0, 13]]], ["Fallecieron el 33,3% (n=3) de las gestantes estudiadas.RESULTADOSFin de parto, resultado neonatal y transmisi\u00f3n vertical.", [["Fallecieron el 33,3", "CHEMICAL", 0, 19], ["Fallecieron el", "TREATMENT", 0, 14]]], ["Las gestantes adquirieron la infecci\u00f3n por SARS-CoV-2, durante el tercer trimestre [36 semanas (DE\u00b13)] y el 89,0% (n=66) termin\u00f3 en ces\u00e1rea.", [["CoV", "TEST", 48, 51], ["y el", "TEST", 103, 107]]], ["El 98,6% (n=73) de los neonatos tuvieron un Apgar superior a 8 tanto al minuto como a los cinco minutos de vida.", [["El", "TEST", 0, 2]]], ["Los datos de transmisi\u00f3n vertical se obtuvieron mediante el an\u00e1lisis microbiol\u00f3gico del l\u00edquido amni\u00f3tico, la sangre de cord\u00f3n umbilical o la placenta.", [["placenta", "ANATOMY", 142, 150], ["placenta", "TISSUE", 142, 150], ["amni\u00f3tico", "TEST", 96, 105], ["umbilical", "ANATOMY", 127, 136], ["la placenta", "ANATOMY", 139, 150]]], ["No se disponen de algunos datos, porque el diagnostico positivo de infecci\u00f3n materna a SARS-CoV-2 fue posterior al nacimiento o por no consentimiento paterno para la realizaci\u00f3n de las pruebas [8].", [["se disponen de algunos datos", "PROBLEM", 3, 31], ["a SARS", "PROBLEM", 85, 91]]], ["La transmisi\u00f3n del SARS-CoV-2 a trav\u00e9s de la leche materna no se produjo en ning\u00fan caso, pero solo se realiz\u00f3 el an\u00e1lisis en el 5,9% (n=6) de las pu\u00e9rperas [30] y algunas gestaciones no hab\u00edan finalizado cuando se publicaron los trabajos [29, 31].RESULTADOSRespecto al SARS-CoV, un 85,7% (n=6) de las gestantes que se infectaron durante el tercer trimestre acabaron en ces\u00e1rea.", [["SARS-CoV", "DISEASE", 269, 277], ["RESULTADOSRespecto al SARS-CoV", "SPECIES", 247, 277], ["La transmisi\u00f3n del SARS", "TEST", 0, 23], ["CoV", "TEST", 24, 27], ["RESULTADOSRespecto", "TEST", 247, 265], ["al SARS", "TEST", 266, 273], ["CoV", "TEST", 274, 277], ["un", "TEST", 279, 281]]], ["Ning\u00fan beb\u00e9 muri\u00f3, aunque un 57,1 % (n=4) tuvieron un Apgar al minuto inferior a 7, que consiguieron estabilizar a los 5 minutos (Apgar superior a 7).", [["Ning\u00fan", "TEST", 0, 6], ["muri\u00f3", "TEST", 12, 17], ["aunque", "TEST", 19, 25], ["un", "TEST", 26, 28], ["Apgar", "TEST", 54, 59], ["Apgar", "TEST", 130, 135]]], ["No se registr\u00f3 transmisi\u00f3n vertical tras el an\u00e1lisis microbiol\u00f3gico del neonato, l\u00edquido amni\u00f3tico, sangre de cord\u00f3n o placenta [17, 18].", [["placenta", "ANATOMY", 119, 127]]], ["El 55,6% (n=5) de las gestaciones termin\u00f3 mediante ces\u00e1rea.", [["El", "TEST", 0, 2]]], ["La transmisi\u00f3n vertical tampoco se constat\u00f3 en ninguno de los seis casos analizados [21, 35, 37, 39].", [["La", "TEST", 0, 2]]], ["En dos casos se analiz\u00f3 la transmisi\u00f3n a trav\u00e9s de la leche materna con resultandos negativos [35, 37, 39].DISCUSIONUn siglo despu\u00e9s de la pandemia por Influenza A/H1N1 conocida como \u201cgripe espa\u00f1ola\u201d y causante de m\u00e1s de 40 millones de fallecimientos, la pandemia por SARS-CoV2 ha emergido con una fuerza inusitada poniendo a prueba la capacidad de respuesta de los sistemas sanitarios [40], con la desventaja de que no existe por el momento disponibilidad de vacunas o tratamientos espec\u00edficos para las infecciones por coronavirus [15].DISCUSIONEra conocido que los coronavirus, SARS-CoV y MERS-CoV, causaban complicaciones graves durante el embarazo, por lo que las observaciones extra\u00eddas de los casos podr\u00edan ser \u00fatiles para la toma de decisiones cl\u00ednicas y preventivas en el nuevo SARSCoV-2.", [["SARS-CoV y", "DISEASE", 580, 590], ["coronavirus", "ORGANISM", 567, 578], ["coronavirus", "SPECIES", 567, 578], ["SARS-CoV y MERS-CoV", "SPECIES", 580, 599], ["En dos casos", "TREATMENT", 0, 12], ["Influenza", "PROBLEM", 152, 161], ["emergido", "PROBLEM", 281, 289], ["coronavirus", "PROBLEM", 567, 578], ["SARS", "PROBLEM", 580, 584], ["CoV", "PROBLEM", 596, 599], ["causaban", "PROBLEM", 601, 609], ["graves", "PROBLEM", 625, 631]]], ["En una reciente publicaci\u00f3n [42] se realiz\u00f3 a todas las mujeres en trabajo de parto un examen de detecci\u00f3n al ingreso mediante una prueba nasofar\u00edngea, resultando que la mayor\u00eda positivas a SARS-CoV-2 no presentaban ning\u00fan s\u00edntoma de la enfermedad.DISCUSIONEl monitoreo de todas las gestantes desde el inicio es importante, dado que en otras infecciones como la gripe o el SARS, estas patolog\u00edas se relacionaron con abortos espont\u00e1neos [11], Restricciones del Crecimiento Intrauterino (RCIR) [18] y APP [14].DISCUSIONEl manejo de las gestantes con SARS-CoV-2 debe correr a cargo de un equipo multidisciplinar que permita mantener el control materno-fetal y detectar el inicio de una posible APP [26, 29, 30, 43].", [["SARS", "DISEASE", 190, 194], ["a SARS", "TEST", 188, 194], ["CoV", "TEST", 195, 198], ["presentaban", "PROBLEM", 204, 215], ["estas", "TEST", 379, 384], ["Restricciones del Crecimiento Intrauterino (RCIR)", "TREATMENT", 442, 491]]], ["En esta revisi\u00f3n, una cuarta parte de las gestantes con SARS-CoV-2 desarrollaron una APP, con las siguientes consecuencias de bajo peso fetal e ingreso en neonatos [26, 28-30, 32, 33], aunque no est\u00e1n directamente relacionados con el virus sino por lo general, consecuencia de patolog\u00eda materna o RPBF.", [["CoV", "TEST", 61, 64], ["aunque", "TEST", 185, 191], ["est\u00e1n", "TEST", 195, 200], ["RPBF", "PROBLEM", 297, 301]]], ["En segundo lugar, una quinta parte documentaron anormalidades en el registro cardiotocogr\u00e1fico con RPBF [26, 30] y en el grupo de gestante a t\u00e9rmino se observ\u00f3 Rotura Prematura de Membranas [33].DISCUSIONLa sintomatolog\u00eda com\u00fan de los tres coronavirus fue la fiebre, con el SARS-CoV-2 y el SARS-CoV la aparici\u00f3n de mialgia y con el MERS-CoV la tos [30, 31].", [["coronavirus", "SPECIES", 240, 251], ["SARS-CoV-2 y el SARS-CoV la aparici\u00f3n de mialgia y con el MERS-CoV la tos", "SPECIES", 274, 347], ["con el SARS", "TEST", 267, 278], ["CoV", "TEST", 279, 282], ["CoV la aparici\u00f3n", "PROBLEM", 295, 311]]], ["La neumon\u00eda como patolog\u00eda coincidente entre los tres, fue m\u00e1s leve en el caso del SARS-CoV-2 [44].DISCUSIONEl fallo en la funci\u00f3n respiratoria, que en algunos casos precisa la intubaci\u00f3n endotraqueal e ingreso en UCI tiene implicaciones para la salud materno-fetal [45].", [["fue m\u00e1s leve", "TEST", 55, 67], ["del SARS", "TEST", 79, 87], ["CoV", "TEST", 88, 91], ["fallo", "TEST", 111, 116], ["respiratoria", "TEST", 131, 143], ["casos", "TEST", 160, 165], ["endotraqueal e ingreso", "TREATMENT", 188, 210]]], ["Con los antecedentes de los que disponemos en otros coronavirus, debemos monitorizar los casos de SARS-CoV-2, ya que la tasa de letalidad por SARS-CoV ascendi\u00f3 al 25% y para el MERS-CoV a un 27% [17, 21, 35].DISCUSIONTodas las gestantes infectadas por MERS-CoV y SARSCoV desarrollaron una neumon\u00eda, precisando ingreso en UCI la mitad de las pacientes con MERS-CoV y la totalidad de las pacientes con SARS-CoV [12, 17, 36].", [["SARS-CoV", "DISEASE", 400, 408], ["SARS-CoV ascendi\u00f3 al 25% y para el MERS-CoV", "SPECIES", 142, 185], ["SARS-CoV", "SPECIES", 400, 408], ["disponemos", "TEST", 32, 42], ["coronavirus", "PROBLEM", 52, 63], ["CoV", "TEST", 103, 106], ["CoV ascendi\u00f3", "TEST", 147, 159], ["para el MERS", "TEST", 169, 181], ["CoV a un", "TEST", 182, 190]]], ["La coinfecci\u00f3n producida en gestantes con neumon\u00eda por SARS produjo m\u00e1s mortalidad materna asociada [18].", [["La coinfecci\u00f3n", "TEST", 0, 14]]], ["Por lo tanto, la neumon\u00eda materna genera en todos los coronavirus resultados obst\u00e9tricos adversos como APP, RCIR o muerte fetal intrauterina.", [["fetal intrauterina", "DISEASE", 122, 140], ["fetal intrauterina", "PROBLEM", 122, 140]]], ["Entonces se observ\u00f3 que m\u00e1s de la mitad de las gestantes con gripe y neumon\u00eda asociadas, no llegaron a t\u00e9rmino [46].DISCUSIONEn la muestra de gestantes con SARS-CoV-2 la forma principal de fin de parto fue la ces\u00e1rea en un (89,0 %) [8, 29, 30, 33, 34] porcentaje coincidente con la muestra del SARSCoV y en menor medida con el MERS-CoV, que tuvo partos vaginales casi en la mitad de los casos [20, 21].", [["con SARS", "PROBLEM", 152, 160], ["porcentaje", "TEST", 252, 262]]], ["Este elevado porcentaje de ces\u00e1reas es motivo de preocupaci\u00f3n, ya que la mayor\u00eda son electivas y no siempre estuvieron justificadas [47].DISCUSIONLa transmisi\u00f3n vertical de la infecci\u00f3n se produjo a trav\u00e9s de la placenta intra\u00fatero o durante el desarrollo del parto.", [["vertical de la infecci\u00f3n", "PROBLEM", 161, 185]]], ["El riesgo de ingesti\u00f3n de secreciones cervicovaginales es superior en el parto vaginal, por lo que este podr\u00eda ser uno de los factores que podr\u00eda explicar la no transmisi\u00f3n al feto en los casos de COVID-19.", [["vaginal", "ANATOMY", 79, 86]]], ["En el estudio de Yu et. al. [34], la prueba de \u00e1cido nucleico en la garganta de un reci\u00e9n nacido fue positiva a las 36h del nacimiento, aunque no se especifica el modo de contagio, ya que todas las gestantes de la muestra se encontraban en el \u00faltimo trimestre.", [["encontraban en el \u00faltimo trimestre", "TREATMENT", 225, 259]]], ["Los lactantes de madres positivas a SARS-CoV-2 no estaban infectados al nacimiento, aunque solo se documentaron en 6 casos [30] y no desarrollaron la sintomatolog\u00eda caracter\u00edstica de sus madres (disnea, fiebre o mialgia) [8].", [["Los lactantes", "TEST", 0, 13], ["a SARS", "TEST", 34, 40], ["CoV", "TEST", 41, 44], ["estaban", "PROBLEM", 50, 57], ["desarrollaron la", "PROBLEM", 133, 149]]], ["Con los otros dos coronavirus, tampoco hubo constancia de infecci\u00f3n a trav\u00e9s de la lactancia materna, pero en el caso del SARS-CoV en sangre del cord\u00f3n umbilical y en leche materna aparecieron anticuerpos, lo que hace pensar en una posible inmunidad pasiva [36, 38].", [["coronavirus", "PROBLEM", 18, 29], ["CoV en sangre del cord\u00f3n", "TREATMENT", 127, 151]]], ["Sin embargo, esta inmunidad pasiva se ha documentado recientemente en un estudio con madres infectadas con SARS-CoV-2, que habla sobre la transferencia de anticuerpos (IgA) en leche materna.[50].", [["CoV", "TEST", 112, 115]]], ["La inmunidad a trav\u00e9s de la placenta (sobre todo en el tercer trimestre) y de la leche materna [51] sugiere que se podr\u00eda permitir a las mujeres infectadas el amamantamiento, manteniendo medidas de protecci\u00f3n como higiene de manos y mascarilla facial [52].DISCUSIONIndependientemente, del tipo de parto, ya sea por ces\u00e1rea o vaginal, las valoraciones del Apgar de los reci\u00e9n nacidos de madres con COVID-19, son en todos los casos superiores a 8 (al 1 min y 5 min) [27, 34].", [["a trav\u00e9s de la placenta (sobre todo en el tercer trimestre", "TREATMENT", 13, 71], ["COVID", "TEST", 397, 402], ["vaginal", "ANATOMY", 325, 332]]], ["Con los otros dos coronavirus, existen valoraciones inferiores [21].DISCUSIONLa muerte intrauterina solo se document\u00f3 en un caso de SARS-CoV-2 [29] y ning\u00fan caso de mortalidad fetal [30, 31] a diferencia del MERS-CoV en un tercio de los casos [16, 20, 29].DISCUSIONCon todo lo expuesto, existen todav\u00eda lagunas en el conocimiento sobre las consecuencias para la madre y el feto, pero los antecedentes cl\u00ednicos de otros coronavirus nos hacen pensar que existen m\u00e1s complicaciones durante la gestaci\u00f3n (APP, RCIR, hemorragias del tercer trimestre, hospitalizaciones), el parto (RPBF, ces\u00e1reas electivas y urgentes) y en el reci\u00e9n nacido (prematuridad, dificultades respiratorias al nacimiento) [26,35,53].", [["coronavirus", "ORGANISM", 18, 29], ["coronavirus", "SPECIES", 18, 29], ["coronavirus", "PROBLEM", 18, 29], ["CoV", "TEST", 137, 140], ["a diferencia del MERS", "TEST", 191, 212], ["APP", "TEST", 501, 504], ["RCIR", "TEST", 506, 510]]], ["Sin embargo, es muy alentador que las \u00faltimas revisiones muestren una evoluci\u00f3n muy favorable de las mujeres enfermas por COVID-19, con una tasa de mortalidad materna muy baja o casi nula, con un solo caso [54-56].DISCUSIONSe\u00f1alamos como limitaci\u00f3n de esta revisi\u00f3n que todos los art\u00edculos son de tipo observacional, retrospectivos de series de casos o de reporte de un caso, en los que la fuente de datos fueron las historias cl\u00ednicas, por lo que no es posible establecer relaci\u00f3n de causalidad.", [["COVID", "TEST", 122, 127]]], ["Nuestro estudio compara los tres coronavirus como la revisi\u00f3n realizada recientemente por Di Mascio et .al.", [["coronavirus", "SPECIES", 33, 44]]], ["[57], pero difiere en el mayor n\u00famero de casos analizados de SARS-CoV-2 y la muestra de los casos de MERS, los trabajos de Jeong et. al. [35] y Park et. al. [37] no han sido analizados por separado, por tratarse de la misma gestante.DISCUSIONA pesar de las limitaciones, en estos momentos de emergencia sanitaria por un nuevo agente infeccioso, este tipo de estudios (revisi\u00f3n exploratoria) [58] pueden representar la mejor evidencia disponible para informar de la pr\u00e1ctica cl\u00ednica y sus resultados orientar futuras investigaciones.DISCUSIONCon las limitaciones propias de un acontecimiento que est\u00e1 en constante evoluci\u00f3n, puede afirmarse que las gestantes infectadas por alguno de los tres coronavirus producen una neumon\u00eda con sintomatolog\u00eda muy similar, resultando m\u00e1s leve en el SARS-CoV-2.", [["CoV", "TEST", 789, 792]]]]}